



CLINICAL GUIDELINES

Head Imaging Guidelines

Effective: September 1, 2026

VERSION 2.0.2026

EviCore

By ~~EVERNORTH~~

EviCore healthcare Clinical Decision Support Tool Diagnostic Strategies: This tool addresses common symptoms and symptom complexes. Imaging requests for individuals with atypical symptoms or clinical presentations that are not specifically addressed will require physician review. Consultation with the referring physician, specialist, and/or individual's Primary Care Physician (PCP) may provide additional insight.

EviCore's Clinical Review Criteria ("CRC") and related content is made available for the limited uses of: reference; and individual use, only limited to facilitating the determination of medically necessary and appropriate clinical treatment by clinicians for specific delegated patients under their care. The CRC and related content is proprietary information of EviCore, and copyrighted to the full extent of the law. Except as expressly permitted, you may not modify, copy, reproduce, republish, upload, post, transmit, hyperlink to or from, or distribute in any way the CRC, nor may you sell, transfer, distribute, assign, lease, reproduce, or otherwise use the CRC in commerce, in a manner that competes with us or infringes upon our rights, or for any public or commercial endeavor without our prior and express written consent.

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five-digit codes, nomenclature and other data are copyright 2026 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

Table of Contents

Guideline	Page
General Guidelines (HD-1)	4
Taste and Smell Disorders (HD-2)	24
Ataxia (HD-3)	27
Mental Health Disorders and Mental Status Change (HD-4)	31
Chiari and Skull-Base Malformations (HD-5)	40
Facial Palsy (Bell's Palsy)/Hemifacial Spasm (HD-6)	49
Recurrent Laryngeal Palsy/Vocal Cord Palsy (HD-7)	55
Mild Cognitive Impairment (MCI) and Dementia (HD-8)	57
Epilepsy/Seizures (HD-9)	84
Trigeminal Neuralgia and other Centrally Mediated Facial Pain Syndromes (HD-10)	92
Headache (HD-11)	98
Cerebral Aneurysm and AVM (HD-12)	128
Head and Facial Trauma (HD-13)	143
CNS and Head Infection/Neuro-COVID-19 (HD-14)	151
Movement Disorders (HD-15)	165
Multiple Sclerosis (MS) and Related Conditions (HD-16)	171
Papilledema/Pseudotumor Cerebri (HD-17)	201
Paresthesias and/or Weakness (HD-18)	205
Pituitary, Sella, Hypothalamus (HD-19)	211
Scalp and Skull (HD-20)	226
Cerebrovascular Disease (HD-21)	232
Cerebral Vasculitis (HD-22)	253
Dizziness, Vertigo and Syncope (HD-23)	257
Other Imaging Studies (HD-24)	269
Epistaxis (HD-25)	284
Mastoid Disease or Ear Pain (HD-26)	288
Hearing Loss and Tinnitus (HD-27)	293
Neurosurgical Imaging (HD-28)	299
Sinus and Facial Imaging (HD-29)	306
Temporomandibular Joint Disease (TMJ) and Dental/Periodontal/Maxillofacial Imaging (HD-30)	313
Cranial Neuropathies (HD-31)	319
Eye Disorders and Visual Loss (HD-32)	325
Acoustic Neuroma and Other Cerebellopontine Angle Tumors (HD-33)	338
Pineal/Colloid Cysts (HD-34)	342

Arachnoid Cysts (HD-35)..... 345
Nuclear Medicine (HD-36)..... 348
Sleep-Related Imaging (HD-37).....352

General Guidelines (HD-1)

Guideline	Page
Abbreviations for Head Imaging Guidelines.....	5
General Guidelines (HD-1.0).....	8
General Guidelines – Anatomic Issues (HD-1.1).....	10
General Guidelines – Modality (HD-1.2).....	11
General Guidelines – MRI Brain (HD-1.3).....	12
General Guidelines – CT Head (HD-1.4).....	13
General Guidelines – CT and MR Angiography (CTA/CTV and MRA/MRV) (HD-1.5).....	14
General Guidelines – PET Coding Notes (HD-1.6).....	17
General Guidelines – Other Imaging Situations (HD-1.7).....	18
References (HD-1).....	21

Abbreviations for Head Imaging Guidelines

v2.0.2026

Abbreviations for Head Imaging Guidelines	
ACTH	adrenocorticotrophic hormone
AD	Alzheimer’s Disease
ADH	antidiuretic hormone
AION	arteritic ischemic optic neuritis
AVM	arteriovenous malformation
CBCT	cone-beam computerized tomography
CMV	cytomegalovirus
CSF	cerebrospinal fluid
CT	computed tomography
CTA	computed tomography angiography
DNA	deoxyribonucleic acid
DWI	diffusion weighted imaging (for MRI)
EEG	electroencephalogram
ENT	ear, nose, throat
ESR	erythrocyte sedimentation rate
FDG	fluorodeoxyglucose
FSH	follicle-stimulating hormone

Head Imaging Guidelines

Abbreviations for Head Imaging Guidelines

FTD	Frontotemporal Dementia
GCA	giant cell arteritis
GCS	Glasgow Coma Scale
HIV	human immunodeficiency virus
LH	luteinizing hormone
MMSE	mini mental status examination
MRA	magnetic resonance angiography
MRI	magnetic resonance imaging
MRN	magnetic resonance neurography
MS	multiple sclerosis
MSI	magnetic source imaging
NAION	non-arteritic ischemic optic neuritis
NPH	normal pressure hydrocephalus
PET	positron emission tomography
PML	progressive multifocal leukoencephalopathy
PNET	primitive neuro ectodermal tumor
PWI	perfusion weighted imaging (for MRI)
SAH	subarachnoid hemorrhage
SIADH	syndrome of inappropriate antidiuretic hormone secretion

Abbreviations for Head Imaging Guidelines	
SLE	systemic lupus erythematosus
TIA	transient ischemic attack
TMJ	temporomandibular joint disease
TSH	thyroid-stimulating hormone
VBI	vertebrobasilar insufficiency
VP	ventriculoperitoneal
XRT	radiation therapy

General Guidelines (HD-1.0)

HD.GG.0001.0.A

v2.0.2026

- A pertinent clinical evaluation including a detailed history, physical examination including a neurological examination since the onset or change in symptoms, and appropriate laboratory studies should be performed prior to considering the use of an advanced imaging (CT, MR, Nuclear Medicine) procedure.
 - A pertinent clinical evaluation furnished via telehealth, since the onset or change in symptoms, is treated the same as an in-person clinical evaluation.
 - An exception to a pertinent clinical evaluation can be made if the individual is undergoing a guideline-supported, scheduled follow-up imaging evaluation.
 - Scheduled follow-up of known problems such as, multiple sclerosis, tumors, or hydrocephalus, scheduled surveillance with no new symptoms, screening asymptomatic individual due to family history or otherwise meet criteria for repeat imaging, as well as appropriate laboratory studies and non-advanced imaging modalities
 - A detailed neurological exam is required prior to advanced imaging except in the following scenarios:
 - Tinnitus, TMJ, sinus or mastoid disease, ear pain, hearing loss, eye disease, pituitary disease, and epistaxis. (A pertinent clinical evaluation since onset of symptoms is still required)
 - The request is from a neurologist, neurosurgeon, neuro-ophthalmologist, endocrinologist, gynecologist, otolaryngologist, or ophthalmologist who has seen the individual since onset of symptoms, or any provider in consultation with one of the above specialists.
- Other meaningful contact (telephone call, electronic mail, or messaging) since the onset or change in symptoms, with an established individual can substitute for a face-to-face clinical evaluation
- CT Head contrast as requested (CPT® 70450 OR CPT® 70460 OR CPT® 70470) is medically necessary when MRI is contraindicated.

Health Equity Consideration

Health equity is the highest level of health for all individuals; health inequity is the avoidable difference in health status or distribution of health resources due to the social conditions in which individuals are born, grow, live, work, and age. Social determinants of health are the conditions in the environment that affect a wide range of health, functioning, and quality of life outcomes and risks. Examples include the following: safe housing, transportation, and neighborhoods; racism, discrimination, and violence;

education, job opportunities, and income; access to nutritious foods and physical activity opportunities; access to clean air and water; and language and literacy skills.

General Guidelines – Anatomic Issues

(HD-1.1)

HD.GG.0001.1.A

v2.0.2026

- If two studies using the same modality both cover the anatomic region of clinical interest, only one is generally needed, with the exception of the following scenarios:
 - CT Maxillofacial (CPT[®] 70486, CPT[®] 70487, or CPT[®] 70488) or CT Orbit/Temporal bone (CPT[®] 70480, CPT[®] 70481, or CPT[®] 70482): both cover the structures of the orbits, sinuses, and face. Two separate imaging studies are only supported if there is suspicion of simultaneous involvement of more posterior lesions, especially of the region involving the middle or inner ear.
 - Pituitary Gland: one study (either MRI Brain [CPT[®] 70553] or MRI Orbit/Face/Neck [CPT[®] 70543]) is adequate to report the imaging of the pituitary. If a previous routine MRI Brain was reported to show a possible pituitary tumor, a repeat MRI with dedicated pituitary protocol is supported.
 - Internal Auditory Canal: (IAC) MRI can be reported as a limited study with one code from the set (CPT[®] 70540, CPT[®] 70542, or CPT[®] 70543), but should not be used in conjunction with MRI Brain codes (CPT[®] 70551, CPT[®] 70552, or CPT[®] 70553) if IAC views are performed as part of the brain.
 - Mandible (jaw): CT Maxillofacial (CPT[®] 70486, CPT[®] 70487, or CPT[®] 70488) or CT Neck (CPT[®] 70490, CPT[®] 70491, or CPT[®] 70492) can be used to report imaging of the mandible. CT Neck will also image the submandibular space.
 - If MRI is medically necessary, MRI Orbit/Face/Neck (CPT[®] 70540, CPT[®] 70542, or CPT[®] 70543) can be used to report imaging of the mandible and submandibular space.
 - MRI Temporomandibular Joint(s) (TMJ) is reported as CPT[®] 70336. This code is inherently bilateral and should not be reported twice on the same date of service.

General Guidelines – Modality (HD-1.2)

HD.GG.0001.2.A

v2.0.2026

- MRI is preferable to CT for most indications. For exceptions, See **General Guidelines – CT Head (HD-1.4)**
- MRI is medically necessary for these indications following an initial CT:
 - MRI Brain without and with contrast (CPT[®] 70553) to follow-up abnormalities seen on CT Head without contrast (CPT[®] 70450) when a mass, lesion, or infection is found.
 - MRI Brain without contrast (CPT[®] 70551) or MRI Brain without and with contrast (CPT[®] 70553) to follow-up abnormalities seen on CT Head without contrast (CPT[®] 70450) when there is suspected Multiple Sclerosis or other demyelinating disease.
 - MRI Brain without contrast (CPT[®] 70551) or MRI Brain without and with contrast (CPT[®] 70553) to follow up on stroke or TIA when initial CT Head was done on emergent basis.
 - MRI Brain without contrast (CPT[®] 70551) or MRI Brain without and with contrast (CPT[®] 70553) for evaluation of new onset seizures.

Evidence Discussion (HD-1.2)

- MRI of the brain is the appropriate initial imaging study for diagnosis, characterization and surveillance of a variety of neurologic conditions, including, but not limited to: neoplastic conditions, evaluation of the brain parenchyma, meninges, ischemia and infarction, neurodegenerative disorders, hydrocephalus, demyelinating conditions, post-traumatic brain injury, inflammatory and autoimmune disorders and infectious disorders.⁹
- MRI Brain has some benefit over CT for determining age of intracranial hemorrhage, early stroke (via Diffusion imaging sequences), and detection of micro hemorrhage.^{9,35,36,37}
- MRI is also medically necessary for further characterization of abnormalities detected on other imaging tests such as CT or sonography.⁹
- Limitations to MRI include artifacts due to motion and susceptibility effects, contrast complications, contraindication due to ferromagnetic devices or implants. Additionally, severe claustrophobia may require sedation in order to complete the study.³³

General Guidelines – MRI Brain (HD-1.3)

HD.GG.0001.3.A

v2.0.2026

- MRI Brain with contrast (CPT[®] 70552) should not be ordered except to follow-up on a very recent abnormal or equivocal non-contrast MRI Brain.
- After an MRI Brain without contrast (CPT[®] 70551), a follow up MRI Brain with contrast (CPT[®] 70552) may be performed at the discretion of a neurologist, a neurosurgeon, or a neuro-ophthalmologist, or any provider in consultation with a neurologist, neurosurgeon, or neuro-ophthalmologist, and/or at the recommendation of the radiologist.
- Gadolinium is relatively contraindicated in pregnancy, MRI Brain without contrast (CPT[®] 70551) is supported.
- The AMA CPT manual does not describe nor assign any minimum or maximum number of sequences for any CT or MRI study. Both MRI and CT imaging protocols are often influenced by the individual clinical situation of the individual and additional sequences are not uncommon. There are numerous MRI sequences that are performed to evaluate specific clinical questions, and this technology is constantly undergoing development. Additional sequences, however, are still performed and coded under the routine MRI Brain CPT[®] 70551, CPT[®] 70552, or CPT[®] 70553.

General Guidelines – CT Head (HD-1.4)

HD.GG.0001.4.A

v2.0.2026

- Scenarios in which MRI is contraindicated (i.e., pacemakers, ICDs, cochlear implants, aneurysm clips, orbital metallic fragments, etc.)
- In urgent cases, CT Head, contrast as requested is medically necessary [CT Head without contrast (CPT[®] 70450) or CT Head with contrast (CPT[®] 70460) or CT Head without and with contrast (CPT[®] 70470)]
- CT Head without contrast (CPT[®] 70450) is medically necessary for:
 - Mass effect
 - Blood/blood products
 - Urgent/emergent settings due to availability and speed of CT
 - Trauma
 - Recent hemorrhage, whether traumatic or spontaneous
 - Bony structures of the head evaluations including dystrophic calcifications
 - Hydrocephalus evaluation and follow-up (some centers use limited non-contrast “fast or rapid MRI” (CPT[®] 70551) to minimize radiation exposure in children).
 - Prior to lumbar puncture in individuals
 - Evaluation of optic disc edema and/or papilledema, a non-contrast CT Head is useful to assess for space-occupying processes such as intracranial hemorrhage, mass effect, and hydrocephalus, See **Papilledema/Pseudotumor Cerebri (HD-17.1)** and **Eye Disorders and Visual Loss (HD-32.1)**

Evidence Discussion (HD-1.4)

- CT head is the preferred modality for evaluation of bony structures, acute intracranial hemorrhage, trauma, and detection of abnormalities associated with calcifications.^{35,37,38,39}
- This modality is also useful for follow up of intracranial hemorrhage, hydrocephalus shunts, and post-operative follow-up.^{35,37,38,39}
- CT head provides more rapid detection of intracranial abnormalities in urgent or emergent situations.^{38,39,40}
- CT has less motion artifact than MRI due to its faster acquisition and better spatial resolution than MRI.
- Limitations of CT include lower early detection rates for occult fracture than MRI, ionizing radiation exposure, and lower contrast resolution than MRI.

General Guidelines – CT and MR Angiography (CTA/CTV and MRA/MRV) (HD-1.5)

HD.GG.0001.5.A

v2.0.2026

Angiography imaging refers to both arterial and venous imaging. Vascular angiography is not the same imaging as diagnostic MRI.

- MRA Head is performed without contrast (CPT[®] 70544), with contrast (CPT[®] 70545), or without and with contrast (CPT[®] 70546)
- MRA Neck is performed without contrast (CPT[®] 70547), with contrast (CPT[®] 70548), or without and with contrast (CPT[®] 70549), depending on facility preference and protocols and type of scanner
- CTA Head is performed without and with contrast (CPT[®] 70496)
- CTA Neck is performed without and with contrast (CPT[®] 70498)
- CTA Head and Neck is performed without and with contrast (CPT[®] 70471). This code must be substituted when both CTA head and neck are performed together during the same session.
- CT and MR Venography (CTV and MRV) are reported with the same codes as the CTA/MRA counterpart (there is no specific code for CT/MR venography).
 - If arterial and venous CT or MR studies are both performed in the same session, only **one** CPT[®] code is used to report both procedures.
 - If an arterial CTA or MRA study has been performed and subsequently a repeat study is needed to evaluate the venous anatomy, then this study is medically necessary.
 - If a venous CTV or MRV study has been performed and subsequently a repeat study is needed to evaluate the arterial anatomy, then this study is medically necessary.
- Medically necessary indications for CTA or MRA Head and Neck vessels include, but are not limited to the following:
 - Pulsatile tinnitus
 - Hemifacial spasm if consideration for surgical decompression
 - Evaluation of stroke or TIA (see **Stroke/TIA (HD-21.1)**) including collateral assessment
 - Trigeminal neuralgia (see **Trigeminal Neuralgia and other Centrally Mediated Facial Pain Syndromes (HD-10.1)**)

- Cerebral venous sinus thrombosis (see **Cerebral Venous Sinus Thrombosis (HD-21.8)** and **Papilledema/Pseudotumor Cerebri (HD-17.1)**)
 - MRA without and with contrast is medically necessary for venous sinus thrombosis to differentiate total from subtotal occlusion.
- Aneurysm suspected with acute “thunderclap” headache syndrome and appropriate screening or evaluation of known subarachnoid hemorrhage and pseudoaneurysms (appropriate to limit CTA to include only the head to avoid unnecessary radiation to the individual)
- Non-inflammatory vasculopathy, including radiation vasculopathy
- Traumatic vascular injuries
- Vascular malformations, vascular anatomic variants, and fistulas
- Arterial dissections
- Tumors of vascular origin or involving vascular structures
- Surgical and radiation therapy localization, planning, and neuronavigation
- Evaluation for vascular intervention and follow-up including post-surgical/post-treatment vascular complications
- Intra-cranial pre-operative planning if there is concern of possible vascular involvement or risk for vascular complication from procedure
- Vasculitis and collagen vascular disease
- Eagle Syndrome - Dynamic/positional CTA to assess for vascular compression (also known as bow-hunter's syndrome) (see **Eagle Syndrome (Neck-10.3)**)
- NOTE: Evaluation of posterior circulation disease requires both neck and head MRA/CTA to visualize the entire vertebral-basilar system.
- MRA Head (CPT[®] 70544, CPT[®] 70545, or CPT[®] 70546) or CTA Head (CPT[®] 70496) is medically necessary for follow-up of aneurysm clipping or coiling procedures (see **Intracranial Cerebral Aneurysms (HD-12.1)**)
- MRA Head (CPT[®] 70544, CPT[®] 70545, or CPT[®] 70546) or CTA Head (CPT[®] 70496) **AND/OR** MRA Neck (CPT[®] 70547, CPT[®] 70548, or CPT[®] 70549) or CTA Neck (CPT[®] 70498) is medically necessary if arterial dissection is suspected, or known and re-evaluation is needed (as directed by neurologist or neurosurgeon or any provider in consultation with a neurologist or neurosurgeon)
 - There are high-risk scenarios including, but not exclusive to, fibromuscular dysplasia (FMD), Marfan disease, motor vehicle accident (MVA) with whiplash, or chiropractic manipulation.
- Other vascular imaging indications for headaches require additional information.
 - See **Stroke/TIA (HD-21.1)**, **Sudden Onset of Headache (HD-11.3)**, **New Headache Onset Older than Age 50 (HD-11.7)**, **Abnormal Blood Clotting (HD-11.9)**, **Pregnancy (HD-11.10)**, **Physical Exertion (HD-11.11)**, and **Systemic Infections (HD-11.13)**

Evidence Discussion (HD-1.5)

- Indications for cervicocerebral computed tomography angiography (CTA) of the head and neck vessels include the diagnosis, characterization and/or surveillance of a variety of vascular conditions, including, but not limited to, arterial aneurysms, dissections, ischemic stroke and transient ischemic attacks, vasculitis, traumatic vascular injuries, pulsatile tinnitus, tumors of vascular origin, and prior to surgical intervention.⁸ CTA may refer to arterial vessels (CTA) or evaluation of venous structures (CTV).⁸
- CTA may be used as the initial imaging modality or as a follow up study for characterizing known disease or assessing changes over time.⁸
- Depending on the indication, CTA may be limited to the head to avoid unnecessary radiation to the individual. Examples include surveillance of intracranial aneurysms (that are not located in the posterior circulation).⁸
- Risks of CTA include exposure to ionizing radiation; thus, magnetic resonance angiography (MRA) is available as an alternative to reduce radiation exposure. In addition, MRA is an alternative for individuals with iodinated contrast allergies or other contraindications to iodinated contrast.^{8,41}
- Magnetic resonance angiography (MRA) indications also cover a variety of vascular conditions of the head and neck, for diagnosis, characterization, and surveillance, and may be used to evaluate either arterial (MRA) or venous structures (MRV).⁴¹
- MRA, as an alternative modality, is noninvasive, and does not require iodinated contrast.⁴¹ Limitations include artifacts due to motion, slow or turbulent flow, and susceptibility effects, and claustrophobia.⁴¹ MRA may be performed without contrast or with gadolinium contrast.⁴¹ Gadolinium contrast administration is limited to those without renal impairment or known gadolinium contrast allergy.⁴¹ Additionally, MRA may not be a feasible option for those with contraindications to MRI such as incompatible pacemakers, cochlear implants, neurostimulators, or other devices.³³ In these scenarios, CTA may be the appropriate alternative.⁸

General Guidelines – PET Coding Notes (HD-1.6)

HD.GG.0001.6.A

v2.0.2026

- Metabolic Brain PET should be reported as Metabolic Brain PET (CPT[®] 78608)
- Amyloid Brain PET should be reported as limited PET (CPT[®] 78811) or limited PET/CT (CPT[®] 78814)

General Guidelines – Other Imaging Situations (HD-1.7)

HD.GG.0001.7.A

v2.0.2026

Persistent Nausea and Vomiting

Screening for Metallic Fragments Before MRI

Gender Affirming Care Head and Neck Surgical Planning

3D Rendering

Eagle Syndrome

CSF Leak with or without Headache

Evidence Discussion (HD-1.7)

Persistent Nausea and Vomiting

- Nausea and vomiting, persistent, unexplained and a negative GI evaluation: MRI Brain without contrast (CPT® 70551) or MRI Brain without and with contrast (CPT® 70553) is medically necessary

Screening for Metallic Fragments Before MRI

- Screening for metallic fragments before MRI should be done initially with plain x- ray.
 - The use of CT Orbital to rule out orbital metallic fragments prior to MRI is rarely necessary.
 - Plain x-rays are generally sufficient; x-ray detects fragments of 0.12 mm or more, and CT detects those of 0.07 mm or more.
- Plain x-ray is generally sufficient to screen for aneurysm clips

Gender Affirming Care Head and Neck Surgical Planning

- For gender affirming care procedure planning:
 - ANY or ALL the following pre-operative CT requests are medically necessary if the individual has a health plan benefit covering the gender affirming surgeries:
 - CT Maxillofacial without contrast (CPT® 70486)

- CT Orbits/Temporal bone without contrast (CPT® 70480)
- CT Neck with contrast (CPT® 70491)
- CT Head without (CPT® 70450)
- 3D rendering (CPT® 76376 or CPT® 76377)
- Pre-operative imaging is not supported if the gender affirming surgeries are not health plan covered benefits.
- Requesting providers are encouraged to confirm eligibility with the member's health plan prior to service.

3D Rendering

- CPT® 76376 (3D rendering not requiring imaging post-processing on an independent workstation) or CPT® 76377 (3D rendering requiring image post-processing on an independent workstation) is medically necessary in the following clinical scenarios:
 - Bony conditions:
 - Evaluation of congenital skull abnormalities in newborns, infants, and toddler (usually for pre-operative planning)
 - Complex joint fractures or pelvis fractures
 - Spine fractures (usually for pre-operative planning)
 - Complex facial fractures
 - Pre-operative planning for other complex surgical cases
 - Cerebral angiography: 3D rendering when performed in conjunction with conventional angiography (i.e., conventional 4 vessel cerebral angiography).
 - See **Cerebral Aneurysms (HD-12.1)**, **Arteriovenous Malformations (AVMs) and Related Lesions (HD-12.2)**, **Stroke/TIA (HD-21.1)**, and **Cerebral Vasculitis (HD-22.1)**²⁶
- 3D Rendering (CPT® 76376 or CPT® 76377) for surgical planning and surgical follow up after craniotomy when ordered by surgical specialist or any provider in consultation with a surgical specialist.
- 3D Rendering indications in pediatric head imaging are identical to those in the general imaging guidelines.
- See **3D Rendering (Preface-4.1)** in the Preface Imaging Guidelines

Eagle Syndrome

- See **Eagle Syndrome (Neck-10.3)** in the Neck Imaging Guidelines.
- See **General Guidelines - CT and MR Angiography (CTA/CTV and MRA/MRV) (HD-1.5)** for vascular imaging related to Eagle Syndrome.

CSF Leak with or without Headache

- CSF Leak with or without headache, see **Low-Pressure Headache and CSF Leak (HD-11.15)**

Evidence Discussion (HD-1.7)

Neurologic evaluation of Nausea and vomiting

- In the evaluation of persistent, unexplained nausea and vomiting, an MRI Brain is supported after a negative GI evaluation.^{2,3,4,43} Nausea and vomiting were reported as the initial symptom of a brain tumor in 5% of brain tumor cases.⁴⁴ During the time course until diagnosis, nausea and vomiting is present in 25% of brain tumor cases.⁴⁴

Screening for metallic fragments

- The American College of Radiology White Paper on MR safety advised that all individuals who have a history of orbit trauma by a potential ferromagnetic foreign body for which they sought medical attention are to have their orbits cleared by either a plain x-ray orbit films (2 views) or by a radiologist's review and assessment of a prior CT or MR images obtained since the suspected traumatic event.^{42,46} Screening for the presence of a metallic aneurysm clips with plain films of the skull is also recommended.⁴⁶ Although CT is more sensitive than plain films, the radiation dose is greatly increased.⁴²

3D Rendering

- 3-D/rotational angiography, as part of cerebral angiography, is also useful for radiation dose reduction during diagnostic and interventional neuroradiology procedures.²²

Gender affirming head and neck surgeries

- As the field has evolved, more centers are using frontal sinus setback as 90% of individuals require frontal bone osteotomy and setback, based on their frontal bone anatomy.^{31,32} For individuals requiring bony manipulation, a fine-cut, non-contrast craniofacial CT scan from the vertex to the hyoid bone is used to map the bony framework.^{31,32} Virtual surgical planning improves efficiency, safety, and accuracy for frontal sinus setback and mandibular angle reduction surgeries.⁴⁵ CT Neck is medically necessary for laryngoplasty surgeries.⁶

References (HD-1)

v2.0.2026

1. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance of Computed Tomography (CT) of the extracranial head and neck. 2021; Available at: <https://gravitas.acr.org/PPTS/>
2. Hornby PJ. Central neurocircuitry associated with emesis. *The American Journal of Medicine*. 2001;111(8):106-112. doi:10.1016/s0002-9343(01)00849-x
3. Shosha E, Dubey D, Palace J, et al. Area postrema syndrome. *Neurology*. 2018;91(17). doi:10.1212/wnl.0000000000006392
4. Singh P, Yoon SS, Kuo B. Nausea: a review of pathophysiology and therapeutics. *Therapeutic Advances in Gastroenterology*. 2015;9(1):98-112. doi:10.1177/1756283x15618131
5. Gutkowski P, Rot S, Fritsch M, Meier U, Gözl L, Lemcke J. Secondary deterioration in patients with normal pressure hydrocephalus after ventriculoperitoneal shunt placement: a proposed algorithm of treatment. *Fluids and Barriers of the CNS*. 2020;17(1). doi:10.1186/s12987-020-00180-w
6. Capitán L, Santamaría JG, Simon D, et al. Facial Gender Confirmation Surgery. *Plastic and Reconstructive Surgery*. 2020;145(4). doi:10.1097/prs.0000000000006686
7. Hatcher-Martin JM, et al. Telemedicine in Neurology. Telemedicine Work Group of the American Academy of Neurology update. *Neurology*. 2020;94:30-38. doi:10.1212/WNL.0000000000008708
8. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance and interpretation of cervicocerebral Computed Tomography Angiography (CTA). 2020; Available at: <https://gravitas.acr.org/PPTS/>
9. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance and interpretation of Magnetic Resonance Imaging (MRI) of the brain. 2024; Available at: <https://gravitas.acr.org/PPTS/>
10. Expert Panel on Neurologic Imaging; Kennedy TA, Corey AS, et al. ACR Appropriateness Criteria® Orbits Vision and Visual Loss. *J Am Coll Radiol*. 2018;15(5S):S116-S131. doi:10.1016/j.jacr.2018.03.023
11. Ederies A, Demchuk A, Chia T, Gladstone DJ, Dowlatabadi D, Bendavid G, Wong K, Symons SP, Aviv RI. Postcontrast CT extravasation is associated with hematoma expansion in CTA spot negative patients. *Stroke*. 2009 May;40(5):1672-6. doi: 10.1161/STROKEAHA.108.541201
12. Chuang WC, Short JH, McKinney AM, Anker L, Knoll B, McKinney ZJ. Reversible left hemispheric ischemia secondary to carotid compression in Eagle syndrome: surgical and CT angiographic correlation. *AJNR Am J Neuroradiol*. 2007;28:143-5
13. Chou DW, Tejani N, Kleinberger A, Shih C. Initial Facial Feminization Surgery Experience in a Multicenter Integrated Health Care System. *Otolaryngology-Head and Neck Surgery*. 2020;163(4):737-742. doi:10.1177/0194599820924635
14. Raffaini M, Perello R, Tremolada C, Agostini T. Evolution of Full Facial Feminization Surgery. *Journal of Craniofacial Surgery*. 2019;30(5):1419-1424. doi:10.1097/scs.0000000000005221
15. Eggerstedt M, Hong YS, Wakefield CJ, Westrick J, Smith RM, Revenaugh PC. Setbacks in Forehead Feminization Cranioplasty: A Systematic Review of Complications and Patient-Reported Outcomes. *Aesthetic Plastic Surgery*. 2020;44(3):743-749. doi:10.1007/s00266-020-01664-8
16. Spiegel JH. Facial Feminization for the Transgender Patient. *Journal of Craniofacial Surgery*. 2019;30(5):1399-1402. doi:10.1097/scs.0000000000005645
17. Callen AL, Badiie RK, Phelps A, Potigailo V, Wang E, Lee S, Talbott J, Glastonbury C, Pomerantz JH, Narvid J. Facial Feminization Surgery: Key CT Findings for Preoperative Planning and Postoperative Evaluation. *AJR*. 2020 Dec 30 [published online]. Accepted manuscript. doi:10.2214/AJR.20.25228
18. James SE, Herman JL, Rankin S, Keisling M, Mottet L, Anafi M. (2016). The Report of the 2015 U.S. Transgender Survey. Washington, DC: National Center for Transgender Equality
19. Spiegel JH. Gender affirming and aesthetic cranioplasty: what's new?. *Curr Opin Otolaryngol Head Neck Surg*. 2020, 28:201-205. doi:10.1097/MOO.0000000000000640
20. Pasternak JJ and Abcejo AS. Anesthesia and the brain after concussion. *Curr Opin Anesthesiol*. 2020, 33:639-645. doi:10.1097/ACO.0000000000000906
21. American College of Radiology. ACR-ASNR-SNIS-SPR Practice Parameter for the performance of cervicocerebral Magnetic Resonance Angiography (MRA). 2020; Available at: <https://gravitas.acr.org/PPTS/>

22. American College of Radiology. ACR-ASNR-SIR-SNIS Practice Parameter for the Performance of diagnostic cervicocerebral catheter angiography in adults. 2021; Available at: <https://gravitas.acr.org/PPTS/>
23. Expert Panel on Neurologic Imaging, Whitehead MT, Cardenas AM, et al. ACR Appropriateness Criteria® Headache. *J Am Coll Radiol*. 2019;16(11S):S364-S377. doi:10.1016/j.jacr.2019.05.030
24. Expert Panel on Neurological Imaging: Luttrull MD, Boulter DJ, et al. ACR Appropriateness Criteria® Acute Mental Status Change, Delirium, and New Onset Psychosis. *J Am Coll Radiol*. 2019;16(5S):S26-S37. doi:10.1016/j.jacr.2019.02.024
25. Expert Panel on Neurological Imaging: Ledbetter LN, Burns J, et al. ACR Appropriateness Criteria® Cerebrovascular Diseases-Aneurysm, Vascular Malformation, and Subarachnoid Hemorrhage. *J Am Coll Radiol*. 2021;18(11S):S283-S304. doi:10.1016/j.jacr.2021.08.012
26. Expert Panel on Neurological Imaging, Rath TJ, Policeni B, et al. ACR Appropriateness Criteria® Cranial Neuropathy: 2022 Update. *J Am Coll Radiol*. 2022;19(11S):S266-S303. doi:10.1016/j.jacr.2022.09.021
27. Badhey, A et al. Eagle syndrome: A comprehensive review. *Clin Neurol Neurosurg*. 2017 159:34-38. doi:10.1016/j.clineuro.2017.04.021
28. Jalisi S, Jamal B, Grillone G. Surgical management of long-standing eagle's syndrome. *Annals of Maxillofacial Surgery*. 2017;7(2):232. doi:10.4103/ams.ams_53_17
29. Tillema JM. Imaging of Central Nervous System Demyelinating Disorders. *Continuum (Minneapolis)*. 2023;29(1):292-323. doi:10.1212/CON.0000000000001246
30. American College of Radiology. ACR Manual on Contrast Media. 2024; Available at: <https://www.acr.org/>
31. Dang BN, Hu AC, Bertrand AA, et al. Evaluation and treatment of facial feminization surgery: part I. forehead, orbits, eyebrows, eyes, and nose. *Arch Plast Surg*. 2021;48(5):503-510. doi:10.5999/aps.2021.00199
32. Louis M, Travieso R, Oles N, Coon D. Narrative review of facial gender surgery: approaches and techniques for the frontal sinus and upper third of the face. *Ann Transl Med*. 2021;9(7):606. doi:10.21037/atm-20-6432
33. Expert Panel on MR Safety, Kanal E, Barkovich AJ, et al. ACR guidance document on MR safe practices: 2013. *J Magn Reson Imaging*. 2013;37(3):501-530. doi:10.1002/jmri.24011
34. American College of Radiology. ACR practice parameter for performing and interpreting magnetic resonance imaging (MRI). 2022; Available at: <https://gravitas.acr.org/PPTS/>
35. Kubal WS. Updated imaging of traumatic brain injury. *Radiologic clinics of North America*. 2012;50(1):15.
36. Burgess RE, Kidwell CS. Use of MRI in the assessment of patients with stroke. *Curr Neurol Neurosci Rep*. 2011;11(1):28-34. doi:10.1007/s11910-010-0150-2
37. Kidwell CS, Chalela JA, Saver JL, et al. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. *JAMA*. 2004;292(15):1823-1830
38. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance of Computed Tomography (CT) of the Head. 2020; Available at: <https://gravitas.acr.org/PPTS/>
39. Expert Panel on Neurological Imaging, Shih RY, Burns J, et al. ACR Appropriateness Criteria® Head Trauma: 2021 Update. *J Am Coll Radiol*. 2021;18(5S):S13-S36. doi:10.1016/j.jacr.2021.01.006
40. Barnes PD. Imaging of nonaccidental injury and the mimics: issues and controversies in the era of evidence-based medicine. *Radiol Clin North Am*. 2011;49:205-29
- 41.
42. Bailey W, Robinson L. Screening for intra-orbital metallic foreign bodies prior to MRI: Review of the evidence. *Radiography (Lond)*. 2007;13(1):72-80. doi:10.1016/j.radi.2005.09.006
43. Johns T, Lawrence E. Evaluation and Treatment of Nausea and Vomiting in Adults. *Am Fam Physician*. 2024;109(5):417-425.
44. Alther B, Mylius V, Weller M, Gantenbein A. From first symptoms to diagnosis: Initial clinical presentation of primary brain tumors. *Clinical and Translational Neuroscience*. 2020;4(2). doi:10.1177/2514183X20968368
45. Gray R, Nguyen K, Lee JC, et al. Osseous Transformation with Facial Feminization Surgery: Improved Anatomical Accuracy with Virtual Planning. *Plast Reconstr Surg*. 2019;144(5):1159-1168. doi:10.1097/PRS.00000000000006166
46. Kanal E, Borgstede JP, Barkovich AJ, et al. American College of Radiology White Paper on MR Safety. *AJR Am J Roentgenol*. 2002;178(6):1335-1347. doi:10.2214/ajr.178.6.1781335
47. Pannell JS, Corey AS, Shih RY, et al. ACR Appropriateness Criteria® Cerebrovascular Diseases-Stroke and Stroke-Related Conditions. Available at <https://acsearch.acr.org/docs/3149012/Narrative/>. American College of Radiology. New 2023

48. Bookwalter CA, McDonald RJ, Packard AT, Little JT, McDonald JS, Watson RE. Contrast Media in Pregnant and Lactating Patients, From the AJR Special Series on Contrast Media. *AJR Am J Roentgenol*. 2025;224(4):e2431415. doi:10.2214/AJR.24.31415
49. American Medical Association. CPT—Current Procedural Terminology. American Medical Association.. Published 2026. Copyright 1995 – 2026

Taste and Smell Disorders (HD-2)

Guideline	Page
Taste and Smell Disorders (HD-2.1).....	25
References (HD-2).....	26

Taste and Smell Disorders (HD-2.1)

HD.TS.0002.1.A

v2.0.2026

- MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without and with contrast (CPT[®] 70551) **AND/OR** MRI Orbit/Face/Neck without (CPT[®] 70540) or MRI Orbit/Face/Neck without and with contrast (CPT[®] 70543) is medically necessary with unexplained unilateral or bilateral anosmia (inability to perceive odor) or dysgeusia (complete or partial loss of taste)
- CT Maxillofacial (CPT[®] 70486, CPT[®] 70487 or CPT[®] 70488) is medically necessary initially if sinus or facial bone disorders are suspected
- For individuals who test positive for SARS-CoV-2 (see: **Neuro-COVID-19 and Sars-CoV-2 Vaccines (HD-14.2)** and **Stroke/TIA (HD-21.1)**)

Evidence Discussion (HD-2.1)

- Initial imaging of the olfactory nerve and pathway for unexplained unilateral or bilateral anosmia or for dysgeusia should utilize MRI brain and/or MRI orbits, face and neck.^{1,6} These imaging studies are supported by clinical evidence for the identification and characterization of a potential cranial nerve lesion.^{1,6}
- CT of the sinuses and face may be superior to identify fractures, inflammatory sinus disease, and other bony lesions in some cases.¹

References (HD-2)

v2.0.2026

1. Expert Panel on Neurological Imaging, Rath TJ, Policeni B, et al. ACR Appropriateness Criteria® Cranial Neuropathy: 2022 Update. *J Am Coll Radiol*. 2022;19(11S):S266-S303. doi:10.1016/j.jacr.2022.09.021
2. DeVere R. Disorders of Taste and Smell. *Continuum (Minneap Minn)*. 2017;23(2, Selected Topics in Outpatient Neurology):421-446. doi:10.1212/CON.0000000000000463
3. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance of Computed Tomography (CT) of the extracranial head and neck. 2021; Available at: <https://gravitas.acr.org/PPTS>
4. Politi LS, Salsano E, Grimaldi M. Magnetic Resonance Imaging Alteration of the Brain in a Patient With Coronavirus Disease 2019 (COVID-19) and Anosmia. *JAMA Neurology*. 2020. doi:10.1001/jamaneurol.2020.2125
5. Soler ZM, Patel ZM, Turner JH, Holbrook EH. A primer on viral-associated olfactory loss in the era of COVID-19. *International Forum of Allergy Rhinology*. 2020;10(7):814-820. doi:10.1002/alr.22578
6. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance and interpretation of Magnetic Resonance Imaging (MRI) of the brain. 2024; Available at: <https://gravitas.acr.org/PPTS/>

Ataxia (HD-3)

Guideline	Page
Ataxia (HD-3.1).....	28
References (HD-3).....	30

Ataxia (HD-3.1)

HD.AX.0003.1.A

v2.0.2026

- Common manifestations include poor coordination, an abnormal (including wide-based) gait, abnormal finger to nose testing, abnormal rapid alternating movements, abnormal eye movements, and/or difficulty with navigation of stairs and around corners.
- MRI Brain without contrast (CPT® 70551) **OR** MRI Brain without and with contrast (CPT® 70553) is medically necessary in all individuals with ataxia:
 - MRI Cervical without contrast or without and with contrast (CPT® 72141 or CPT® 72156) **AND/OR** MRI Thoracic without contrast or without and with contrast (CPT® 72146 or CPT® 72157) **AND/OR** MRI Lumbar Spine without contrast or without and with contrast (CPT® 72148 or CPT® 72158) may be added if spinal disease is suspected
 - If these symptoms are acute and stroke is suspected, see **Stroke/TIA (HD-21.1)**
 - If MS is suspected, see **Multiple Sclerosis (MS) (HD-16.1)**
 - CT Head without contrast (CPT® 70450) **AND/OR** CT Orbit/Temporal Bone without contrast (CPT® 70480) is medically necessary in addition if these symptoms are acute following head trauma, (see also: **Head Trauma (HD-13.1)**)
- If brain tumor is suspected, see **Primary Central Nervous System Tumors (ONC-2.1)** in the Oncology Imaging Guidelines.
- For suspected Normal Pressure Hydrocephalus, see **Normal Pressure Hydrocephalus (NPH) (HD-8.4)**

Background and Supporting Information

- In general, MRI is preferred over CT, unless there is a history of acute trauma or contraindication to MRI. For all other causes, MRI provides better visualization of the cerebellum and posterior fossa.

Evidence Discussion (HD-3.1)

- MRI Brain is the preferred initial imaging modality for evaluation of ataxia when a central nervous system cause is suspected.^{1,4} MRI of the spinal cord, to include the cervical and thoracic spine, may also be added if clinically indicated.^{1,5}
- CT head is not recommended for the initial evaluation of non-traumatic ataxia due to inferior soft tissue resolution when compared to MRI Brain. In addition, MRI Brain provides better visualization of the cerebellum and posterior fossa and is more sensitive for the detection of posterior fossa infarcts.¹

- In general, MRI is preferred over CT, unless there is a history of acute trauma or a contraindication to MRI.¹

References (HD-3)

v2.0.2026

1. Wang LL, Thompson TA, Shih RY, et al. ACR Appropriateness Criteria® Dizziness and Ataxia. Available at <https://acsearch.acr.org/docs/69477/Narrative/>. American College of Radiology. Revised 2023.
2. Graff-Radford NR, Jones DT. Normal Pressure Hydrocephalus. *CONTINUUM: Lifelong Learning in Neurology*. 2019;25(1):165-186. doi:10.1212/con.0000000000000689
3. Ashizawa T, Xia G. Ataxia. *CONTINUUM: Lifelong Learning in Neurology*. 2016;22(4):1208-1226. doi:10.1212/con.0000000000000362
4. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance and interpretation of Magnetic Resonance Imaging (MRI) of the brain. 2024; Available at: <https://gravitas.acr.org/PPTS/>
5. Expert Panel on Neurologic Imaging.; Juliano AF, Policeni B, et al. ACR Appropriateness Criteria® Ataxia. *J Am Coll Radiol*. 2019;16(5S):S44-S56. doi:10.1016/j.jacr.2019.02.021

Mental Health Disorders and Mental Status Change (HD-4)

Guideline	Page
Autism Spectrum Disorders (HD-4.0).....	32
Mental Health Related Disorders (HD-4.1).....	33
Mental Status Change (HD-4.2).....	35
References (HD-4).....	39

Autism Spectrum Disorders (HD-4.0)

HD.BD.0004.0.A

v2.0.2026

- This group of diagnoses, including Asperger syndrome, is classified as pervasive development disorders (PDD). These diagnoses are established on clinical criteria, and no imaging study can confirm the diagnosis.
- Comprehensive evaluation for autism might include history, physical exam, audiology evaluation, speech, language, and communication assessment, cognitive and behavioral assessments, and academic assessment.
 - MRI Brain without and with contrast (CPT® 70553) **OR** MRI Brain without contrast (CPT® 70551) is medically necessary for **ANY** of the following:
 - New or worsening cognitive decline or focal neurologic findings documented on a pertinent physical
 - PET imaging is considered not medically necessary in the evaluation of individuals with autism spectrum disorders.

Evidence Discussion (HD-4.0)

- While the diagnosis of Autism Spectrum Disorder is based on behavioral signs and symptoms, MRI Brain without and with contrast is medically necessary for new or worsening focal neurological findings and/or loss of developmental milestones and/or regression. In these clinical situations, advanced imaging may be used to adjust an individual's treatment plan, without which their development may continue to regress.⁴
- PET is considered not currently medically necessary in the evaluation of individuals with autism spectrum disorder PET imaging in this scenario would unnecessarily expose individuals to radiation and provide no clinical utility related to autism spectrum disorder.⁵

Mental Health Related Disorders (HD-4.1)

HD.BD.0004.1.A

v2.0.2026

- Mental health diagnoses, to include Attention Deficit Hyperactivity Disorder (ADHD), do not routinely require advanced imaging.
- MRI Brain without contrast (CPT[®] 70551) **OR** MRI Brain without and with contrast (CPT[®] 70553) **OR** CT Head without contrast (CPT[®] 70450) is medically necessary for the exceptions listed below:
 - Acute mental status change, disturbance in consciousness or arousal state
 - Psychotic disorders (including schizophrenia), bipolar disorder and related disorders in the following clinical presentations:
 - Acute psychosis
 - Late onset over age 40
 - Presentation of acute psychiatric symptoms with comorbid serious medical illness
 - Non-auditory hallucinations (e.g., visual, tactile, olfactory) with no known etiology
 - Nonresponse to adequate medication trials
 - Symptoms of an organic brain disorder (e.g., focal deficits, severe headache, or seizures)
- Prior to electroconvulsive therapy (ECT) treatment, the following are medically necessary to screen for intracranial disease: MRI Brain without contrast (CPT[®] 70551) **OR** CT Head without contrast (CPT[®] 70450)
- Deep Brain Stimulation Therapy for psychiatric disorders is considered not medically necessary, except for medically refractory Obsessive Compulsive Disorder (OCD).
 - Medically necessary imaging prior to Deep Brain Stimulation (DBS) therapy for medically refractory Obsessive Compulsive Disorder (OCD):
 - MRI Brain without contrast (CPT[®] 70551) **OR** MRI Brain without and with contrast (CPT[®] 70553) **AND/OR** unlisted CT procedure code (CPT[®] 76497)

Evidence Discussion (HD-4.1)

- There is no role for advanced imaging in mental health workup (including ADHD). Unnecessary imaging has detrimental effects in that it provides no positive impact on outcomes/management and does expose individuals to unnecessary radiation, contrast, and financial strain.
- It would be appropriate to utilize Advanced imaging (CT or MRI) in the following conditions.
 - Acute mental status change, disturbance in consciousness or arousal state²

- Psychiatric disorders with the following clinical presentations²:
 - Acute psychosis
 - Late onset over age 40
 - Presentation of acute psychiatric symptoms with comorbid serious medical illness
 - Non-auditory hallucinations of unknown etiology
 - Nonresponse to adequate medication trials
 - Symptoms of an organic brain disorder (e.g., focal deficits, severe headache, or seizures)
- Advanced imaging may be medically necessary for electroconvulsive therapy clearance and prior to deep brain stimulation for medically refractory obsessive compulsive disorder.¹⁰

Mental Status Change (HD-4.2)

HD.BD.0004.2.A

v2.0.2026

After a detailed history, which includes onset, duration, and timeframe (i.e., constant vs intermittent) **AND** bedside neurologic exam that includes a mental status evaluation providing a description of the level of alertness, other characteristics and/or cognitive testing, the following are medically necessary:

Indication	Medically Necessary Imaging
Acute or worsening mental status change, initial or repeat imaging	- CT Head without contrast (CPT® 70450) OR - If setting is urgent, CT Head contrast as requested (CPT® 70450 OR CPT® 70460 OR CPT® 70470) OR - If MRI is contraindicated, CT Head contrast as requested (CPT® 70450 OR CPT® 70460 OR CPT® 70470) <i>CT Head permitted even with prior MRI Brain imaging</i> OR - MRI Brain without contrast (CPT® 70551) OR - MRI Brain without and with contrast (CPT® 70553) <i>MRI Brain permitted even with prior head CT imaging</i>

Indication	Medically Necessary Imaging
*Presence of any Red Flag, including: • Sudden language, focal motor, or sensory deficit – <u>Stroke/TIA (HD-21.1)</u> • Headache – <u>Headaches with Red Flags (HD-11.2)</u> • Hypertensive urgency – <u>Stroke/TIA (HD-21.1)</u> and <u>Sudden Onset of Headache (HD-11.3)</u> • Fever/tachycardia, possible meningitis, or other CNS infection – <u>CNS and Head Infection (HD-14.1)</u> • COVID-19 – <u>Neuro-COVID-19 and Sars-CoV-2 Vaccines (HD-14.2)</u> • Coagulopathy or anticoagulant use- <u>Abnormal Blood Clotting (HD-11.9)</u> • Pregnancy or post-partum – <u>Pregnancy (HD-11.10)</u> • Known malignancy – <u>Low Grade Gliomas (ONC-2.2)</u>, <u>High Grade Gliomas (ONC-2.3)</u> and <u>Brain Metastases (ONC-31.3)</u> • Trauma- <u>Head Trauma (HD-13.1)</u> • Non-auditory hallucinations – <u>Mental Health Related Disorders (HD-4.1)</u> • Suspected increased intracranial pressure – <u>Papilledema/Pseudotumor Cerebri (HD-17.1)</u> and <u>Hydrocephalus Shunts (HD-11.14)</u> • Seizure/suspected seizure – <u>Epilepsy/ Seizures (HD-9.1)</u>	*See relevant guideline

Background and Supporting Information

This section refers to acute/subacute mental status change, which generally involves signs and symptoms which begin over minutes to days, and includes changes in behavior and alertness, agitation, and/or confusion – as opposed to chronic, progressive cognitive decline, as in dementia.

Acute mental status change or encephalopathy is characterized by changes in behavior or alertness, agitation, confusion, as opposed to chronic, progressive cognitive decline, such as dementia related disorders.

Delirium and psychosis are defined as follows:

- Delirium is a disorder of acute onset involving deficits in attention, awareness, and cognition that fluctuate in severity over time. These are often associated with psychomotor disturbance, altered sleep cycle, and emotional variability. These disturbances may be hyperactive (restlessness, agitation) or hypoactive (psychomotor retardation, lethargy) and there may be accompanying fever and/or autonomic symptoms (tachycardia, sweating), depending on the underlying cause.
- Psychosis is a disorder of impaired reality, characterized by hallucinations, delusions, or both, without insight into their pathologic nature. It may be associated with disorganized behavior, thought blocking, illogicality, tangentiality, perseveration, and/or neologisms.

The purpose of the initial assessment is to characterize the etiology. This may include toxic/metabolic (e.g., hypoglycemic, drug exposures), structural (e.g., trauma, stroke, hypoxic-ischemic, hydrocephalus, tumor), paroxysmal (e.g., seizure, psychiatric), and inflammatory (e.g., infectious, autoimmune).

Of note, even a seemingly mild, reversible brain insult superimposed upon a chronic pathophysiologic process may cause a sudden mental status change, and head imaging may or may not be necessary, depending on the provider's pre-test suspicion of a significant new diagnosis.

Vagal Nerve Stimulators (VNS), which are FDA approved for treatment of depression, are included among potential treatments, which also include medication trials.

Evidence Discussion (HD-4.2)

- Advanced brain imaging is supported for acute onset of mental status change, or worsening symptoms in the setting of a known intracranial process with MRI Brain with or without a previous CT Head.¹
- Advanced imaging supported for mental status change with precipitating factors including suspected seizure, COVID related symptoms, head trauma, stroke, mass, or known malignancy, suspected increased intracranial pressure, intracranial infection, hypertensive emergency, presence of coagulopathy, pregnancy and postpartum period, associated headache.²
- According to the ACR, advantages of MRI for altered mental state include: 1) higher sensitivity for detection of ischemia, encephalitis, subtle cases of SAH; and 2) enhancement of pathology compared with CT. The disadvantages of MRI in this clinical scenario are the same as with MRI in general, including individual

inconvenience (longer examination time), imaging quality is susceptible to individuals' movements, and implanted devices that are not MRI safe.²

References (HD-4)

v2.0.2026

1. Uzelac A. Imaging of Altered Mental Status. *Radiologic Clinics of North America*. 2020;58(1):187-197. doi:10.1016/j.rcl.2019.08.002
2. Soares BP, Shih RY, Utukuri PS, et al. ACR Appropriateness Criteria® Altered Mental Status, Coma, Delirium, and Psychosis. Available at <https://acsearch.acr.org/docs/3102409/Narrative/>. American College of Radiology. New 2024
3. Andrea S, Papirny M, Raedler T. Brain Imaging in Adolescents and Young Adults With First-Episode Psychosis. *The Journal of Clinical Psychiatry*. 2019;80(6). doi:10.4088/jcp.18m12665
4. Baker E, and Jeste SS. Diagnosis and Management of Autism Spectrum Disorder in the Era of Genomics. *Pediatric Clinics of North America*. 2015;62(3):607-618. doi:10.1016/j.pcl.2015.03.003
5. Zürcher NR, Bhanot A, McDougale CJ, Hooker JM. A systematic review of molecular imaging (PET and SPECT) in autism spectrum disorder: Current state and future research opportunities. *Neuroscience & Biobehavioral Reviews*. 2015;52:56-73. doi:10.1016/j.neubiorev. 2015.02.002.
6. Julayanont P, Suryadevara U. Psychosis. *Continuum (Minneapolis)*. 2021;27(6):1682-1711. doi:10.1212/CON.0000000000001013
7. Keepers GA. American Psychiatric Association. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia / Guideline Writing Group, Systematic Review Group, Committee on Practice Guidelines. 3rd edition. American Psychiatric Association; 2021
8. Rapinesi C, Kotzalidis GD, Ferracuti S, Sani G, Girardi P, Del Casale A. Brain Stimulation in Obsessive-Compulsive Disorder (OCD): A Systematic Review. *Curr Neuropsychopharmacol*. 2019;17(8):787-807. doi: 10.2174/1570159X17666190409142555. PMID: 30963971; PMCID: PMC7059162.
9. Ali SA, Mathur N, Malhotra AK, Braga RJ. Electroconvulsive Therapy and Schizophrenia: A Systematic Review. *Mol Neuropsychiatry*. 2019 Apr;5(2):75-83. doi: 10.1159/000497376. Epub 2019 Apr 2. PMID: 31192220; PMCID: PMC6528094.
10. Staudt MD, Pouratian N, Miller JP, et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines for Deep Brain Stimulation for Obsessive-Compulsive Disorder: Update of the 2014 Guidelines. *Neurosurgery*. 2021;88(4):710-712. doi:10.1093/neuros/nyaa596
11. Pereira-Sanchez V, Castellanos FX. Neuroimaging in attention-deficit/hyperactivity disorder. *Curr Opin Psychiatry*. 2021;34(2):105-111. doi:10.1097/YCO.0000000000000669
12. Expert Panel on MR Safety, Kanal E, Barkovich AJ, et al. ACR guidance document on MR safe practices: 2013. *J Magn Reson Imaging*. 2013;37(3):501-530. doi:10.1002/jmri.24011

Chiari and Skull-Base Malformations (HD-5)

Guideline	Page
Chiari Malformations (HD-5.1).....	41
Chiari II Malformations (Arnold Chiari Malformation) (HD-5.2).....	43
Chiari III and IV Malformations (HD-5.3).....	44
Basilar Impression/Basilar Invagination (HD-5.4).....	45
Platybasia (HD-5.5).....	46
Evidence Discussion (HD-5).....	47
References (HD-5).....	48

Chiari Malformations (HD-5.1)

HD.CM.0005.1.A

v2.0.2026

Indication	Medically Necessary Imaging
Initial evaluation for suspected or known Chiari malformations	- MRI Brain without contrast (CPT[®] 70551) or MRI Brain without and with contrast (CPT[®] 70553) AND/OR - MRI Cervical Spine without contrast (CPT[®] 72141) or MRI Cervical Spine without and with contrast (CPT[®] 72156) AND/OR - MRI Thoracic Spine without contrast (CPT[®] 72146) or MRI Thoracic Spine without and with contrast (CPT[®] 72157) AND/OR - MRI Lumbar Spine without contrast (CPT[®] 72148) or MRI Lumbar Spine without and with contrast (CPT[®] 72158)
Repeat imaging for one of the following: - New or worsening signs or symptoms - Surgical procedure is actively being considered - At the discretion of or in consultation with a neurologist and/or neurosurgeon coordinating the individual's care	- MRI Brain without contrast (CPT[®] 70551) or MRI Brain without and with contrast (CPT[®] 70553) AND/OR - MRI Cervical Spine without contrast (CPT[®] 72141) or MRI Cervical Spine without and with contrast (CPT[®] 72156) AND/OR - MRI Thoracic Spine without contrast (CPT[®] 72146) or MRI Thoracic Spine without and with contrast (CPT[®] 72157) AND/OR - MRI Lumbar Spine without contrast (CPT[®] 72148) or MRI Lumbar Spine without and with contrast (CPT[®] 72158)

- Familial screening is NOT medically necessary for Chiari Malformations.
- For CSF flow imaging, see **CSF Flow Imaging (HD-24.4)**

Background and Supporting Information

Chiari I malformations involve caudal displacement or herniation of the cerebellar tonsils. Chiari I may be associated with syringomyelia and rarely with hydrocephalus. Most cases are asymptomatic and discovered incidentally on a head scan performed for another indication. When symptoms are present, they are usually nonspecific but can include headache, lower cranial nerve palsies, or sleep apnea.

Chiari II malformations are more severe than Chiari I malformations. These individuals usually present at birth. Myelomeningocele is always present, and syringomyelia and hydrocephalus are extremely common.

Chiari III malformations include cerebellar herniation into a high cervical myelomeningocele. Chiari IV malformation refers to complete cerebellar agenesis. Both Chiari III and IV malformations are noted at birth and are rarely compatible with life.

Repeat brain and spine imaging in individuals with Chiari I malformations and known syringomyelia or hydromyelia is highly individualized.

Chiari II Malformations (Arnold Chiari Malformation) (HD-5.2)

HD.CM.0005.2.A

v2.0.2026

- See Chiari Malformations (HD-5.1)

Chiari III and IV Malformations (HD-5.3)

HD.CM.0005.3.A

v2.0.2026

- See **Chiari Malformations (HD-5.1)**

Basilar Impression/Basilar Invagination (HD-5.4)

HD.CM.0005.4.A

v2.0.2026

Medically necessary imaging for suspected or known Basilar Impression or Basilar Invagination:

- MRI Brain without contrast (CPT® 70551) **AND/OR** MRI Cervical Spine without contrast (CPT® 72141)
- If surgery is being considered, CT Head (CPT® 70450) **AND/OR** CT Cervical Spine (CPT® 72125) without contrast are also medically necessary **AND/OR** MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) **OR** CTA Head (CPT® 70496) **AND/OR** MRA Neck (CPT® 70547, CPT® 70548, or CPT® 70549) **OR** CTA Neck (CPT® 70498)
 - CTA Head and Neck (CPT® 70471) must be substituted for CTA Head (CPT® 70496) and CTA Neck (CPT® 70498) when performed during the same session.
- One-time screening of first-degree relatives with MRI Brain without contrast (CPT® 70551) is medically necessary.

Background and Supporting Information

Basilar impression involves malformation of the occipital bone in relation to C1-2 (cervical vertebrae 1 and 2). The top of the spinal cord is inside the posterior fossa and the foramen magnum is undersized. Over time, this can lead to brain stem and upper spinal cord compression. Basilar impression can also be associated with the Chiari malformation, producing very complex anatomical abnormalities.

Basilar invagination is an abnormality at the craniovertebral junction, either congenital or degenerative, resulting in the odontoid prolapsing into the already limited space of the foramen magnum. It is commonly associated with conditions such as Chiari malformation, syringomyelia, and Klippel-Feil syndrome.¹²

Platybasia (HD-5.5)

HD.CM.0005.5.A

v2.0.2026

Medically necessary imaging indications for suspected or known Platybasia:

- MRI Brain without contrast (CPT® 70551) or CT Head without contrast (CPT® 70450)
- If surgery is being considered,
 - CT Head (CPT® 70450) **AND/OR**
 - CT Cervical Spine (CPT® 72125) **AND/OR**
 - MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) **OR**
 - CTA Head (CPT® 70496) **AND/OR**
 - MRA Neck (CPT® 70547, CPT® 70548, or CPT® 70549) **OR**
 - CTA Neck (CPT® 70498)
 - CTA Head and Neck (CPT® 70471) must be substituted when CTA Head (CPT® 70496) and CTA Neck (CPT® 70498) are performed during the same session.

Background and Supporting Information

Platybasia is a flattening malformation of the skull base, in which the clivus has a horizontal orientation.

Evidence Discussion (HD-5)

v2.0.2026

- A CT scan of the head is less sensitive than an MRI of the brain for evaluation of intracranial structures, including major structural abnormalities of the posterior fossa.^{14,15}
- Neuroimaging in the initial evaluation of Chiari malformation should include the spinal cord due to the common occurrence or increased frequency of associated conditions such as cervical syrinx and tethered cord.^{1,2,3,4,9,10}
- For initial evaluation, treatment planning, and follow up, MRI is the preferred modality for malformations of the brain and cervicocranial junction.^{7,14,15,16} MRI is ideal for evaluating soft tissues, neural structures, and ligaments.^{7,13}
- As congenital brainstem and cerebellar anomalies are associated with spinal anomalies, MRI of the complete spine is helpful for diagnosis, follow up, and treatment planning.^{1,2,3,4,14}
- A phase-contrast CSF flow study at the craniocervical junction is a supportive study for evaluation of Chiari malformation.^{5,16}
- Evaluation of cervicojunction anomalies, including basilar invagination and platybasia, may require more than one modality for diagnosis and surgical planning.^{7,12,13} CT characterizes osseous anatomy and may be helpful for surgical planning.^{7,13} MRI is preferred for evaluation of the soft tissues, neural structures, and ligaments for these conditions.^{7,13} As craniocervical junction anomalies may lead to compression of adjacent vascular structures, CT- or MR-Angiography of the head and neck are useful for surgical planning.¹³

References (HD-5)

v2.0.2026

1. Strahle J, Muraszko KM, Kapurch J, et al. Chiari malformation Type I and syrinx in children undergoing magnetic resonance imaging. *J Neurosurg Pediatr.* 2011 Aug; 8 (2): 205-213
2. Strahle J, Muraszko KM, Kapurch J, et al. Natural history of Chiari malformation Type I following decision for conservative treatment. *J Neurosurg Pediatr.* 2011 Aug; 8 (2): 214-221
3. Strahle J, Muraszko KM, Garton HJL, et al. Syrinx location and size according to etiology: identification of Chiari-associated syrinx. *J Neurosurg Pediatr.* 2015 July; 16 (1): 21-9 Epub 2015 Apr 3
4. Strahle J, Smith BW, Martinez M, et al. The association between Chiari malformation Type I, spinal syrinx, and scoliosis. *J Neurosurg Pediatr.* 2015 Jun; 15 (6): 607-611
5. Victorio MC, Khoury CK. Headache and Chiari I Malformation in Children and Adolescents. *Seminars in Pediatric Neurology.* 2016;23(1):35-39
6. Radic JAE, Cochrane DD. Choosing Wisely Canada: Pediatric Neurosurgery Recommendations. *Paediatrics & Child Health.* 2018;23(6):383-387. doi:10.1093/pch/pxy012
7. Smoker WRK and Khanna G. Imaging the craniocervical junction. *Childs Nerv Syst.* 2008 Oct; 24 (10): 1123-1145
8. Kinsman SL and Johnston MV. Congenital anomalies of the central nervous system. Nelson Textbook of Pediatrics, Chapter 609. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 3063-3082
9. Dantas FLR, Dantas F, Caires AC, Botelho RV. Natural History and Conservative Treatment Options in Chiari Malformation Type I in Adults: A Literature Update. *Cureus.* 2020;12(12):e12050. Published 2020 Dec 13. doi:10.7759/cureus.12050
10. Holly LT, Batzdorf U. Chiari malformation and syringomyelia. *J Neurosurg Spine.* 2019;31(5):619-628. doi:10.3171/2019.7.SPINE181139
11. Rosenblum JS, Pomeranec IJ, Heiss JD. Chiari Malformation (Update on Diagnosis and Treatment). *Neurol Clin.* 2022;40(2):297-307. doi:10.1016/j.ncl.2021.11.007
12. Brito JNPO, Santos BAD, Nascimento IF, Martins LA, Tavares CB. Basilar invagination associated with chiari malformation type I: A literature review. *Clinics (Sao Paulo).* 2019;74:e653. doi:10.6061/clinics/2019/e653
13. Pinter NK, McVige J, Mechtler L. Basilar Invagination, Basilar Impression, and Platybasia: Clinical and Imaging Aspects. *Curr Pain Headache Rep.* 2016;20(8):49. doi:10.1007/s11916-016-0580-x
14. Expert Panel on Pediatric Imaging, Radhakrishnan R, Shea LAG, et al. ACR Appropriateness Criteria® Ataxia-Child. *J Am Coll Radiol.* 2022;19(11S):S240-S255. doi:10.1016/j.jacr.2022.09.010
15. Expert Panel on Neurologic Imaging, Pallavi S, Utukuri MD, et al. ACR Appropriateness Criteria® Headache. Available at <https://acsearch.acr.org/docs/69482/Narrative/> American College of Radiology. 2022.
16. Expert Panel on Pediatric Imaging, Hayes LL, Palasis S, et al. ACR Appropriateness Criteria® Headache-Child. *J Am Coll Radiol.* 2018;15(5S):S78-S90. doi:10.1016/j.jacr.2018.03.017
17. American Medical Association. CPT—Current Procedural Terminology. American Medical Association. . Published 2026. Copyright 1995 – 2026

Facial Palsy (Bell's Palsy)/Hemifacial Spasm (HD-6)

Guideline	Page
Facial Palsy (HD-6.1).....	50
Hemifacial Spasm (HD-6.2).....	52
Evidence Discussion (HD-6).....	53
References (HD-6).....	54

Facial Palsy (HD-6.1)

HD.FP.0006.1.A

v2.0.2026

- MRI Brain without contrast (CPT® 70551) (with attention to posterior fossa and IACs) or MRI Brain without and with contrast (CPT® 70553) (with attention to posterior fossa and IACs) **AND/OR** MRI Orbit/Face/Neck without contrast (CPT® 70540) or MRI Orbit/Face/Neck without and with contrast (CPT® 70543) is/are medically necessary when unexplained facial paresis/paralysis is associated with any of the following "red flag" clinical scenarios:
 - Trauma to the temporal bone
 - History of tumor, cancer, HIV, or Lyme disease
 - No improvement in 8 weeks
 - No full recovery in 3 months
 - Gradual onset over weeks to months
 - Vertigo or hearing loss
 - Bilateral involvement
 - Other atypical or inconsistent features including:
 - Second episode of paralysis on the same side
 - Paralysis of isolated branches of the facial nerve
 - Paralysis associated with other cranial nerves
- MRI Brain without and with contrast (CPT® 70553) is medically necessary for known sarcoidosis with suspected neurosarcoid or CNS involvement is supported, (see also **Autoimmune/ Paraneoplastic Encephalitis & NeuroInflammatory Disorders (HD-14.3)**)
- CT Orbit/Temporal Bone without contrast (CPT® 70480) is medically necessary, in the presence of "red flags", to assess osseous integrity of the temporal bone, to characterize fractures, pre-surgical anatomy, inflammatory middle ear disease, bone tumor, facial canal foraminal expansion and/or bone erosion.
- CT Orbit/Temporal Bone with contrast (CPT® 70481) is medically necessary, in the presence of red flags, for suspected tumors and/or infection.
- CT Maxillofacial without contrast (CPT® 70486) is medically necessary to assess bony facial nerve canal **OR** with contrast (CPT® 70487) when infection or tumor are suspected, if requested per institutional protocol.
- MRA Head without contrast (CPT® 70544), with contrast (CPT® 70545), or without and with contrast (CPT® 70546) **AND/OR** MRA Neck without contrast (CPT® 70547), with contrast (CPT® 70548), or without and with contrast (CPT® 70549) **OR** CTA Head (CPT® 70496) **AND/OR** CTA Neck (CPT® 70498) **OR** CTA Head and Neck (CPT® 70471) (combination code must be used when both CTA Head (CPT® 70496) and CTA Neck (CPT® 70498) are performed during the same session), is/are

medically necessary for clinically suspected stroke (see **General Guidelines- CT and MR Angiography (CTA/CTV and MRA/MRV) (HD-1.5)** and **Stroke/TIA (HD-21.1)**).

Background and Supporting Information

Typical features of Bell's palsy include variable initial ipsilateral temporal and auricular pain before facial weakness, onset over 72 hours, ipsilateral complete facial weakness, and an otherwise normal neurological and systemic examination. There is usually slow improvement over several months. Unless "red flags" are present, imaging is not medically necessary.

Hemifacial Spasm (HD-6.2)

HD.FP.0006.2.A

v2.0.2026

- For hemifacial spasm, facial synkinesis, or blepharospasm, the following are medically necessary:
 - MRI Brain without and with contrast (CPT[®] 70553)
 - Add CTA Head (CPT[®] 70496) or MRA Head (CPT[®] 70544, CPT[®] 70545, or CPT[®] 70546) for consideration of vascular decompression surgical procedure to clarify the vascular anatomy in individuals who have failed conservative medical management
- For tardive dyskinesia, see **Movement Disorders (HD-15.1)**

Evidence Discussion (HD-6)

v2.0.2026

- Facial nerve palsy/Bell's Palsy, commonly referred to as Bell's Palsy, does not routinely require imaging as recommended by the American Academy of Neurology and the American Academy of Otolaryngology Head and Neck Surgery Foundation.^{1,2,3,4,6} Complete recovery typically occurs within 3 to 6 months.¹²
- When imaging is medically necessary, MRI is the preferred modality for evaluating the facial nerve from its origin in the brainstem, through its intracranial and extracranial segments.² This would include imaging of the brain, face or both areas concurrently.² MRI is useful to exclude structural causes of facial nerve paralysis in the setting of red flags.²
- Imaging is reserved for cases with "red flags," which include atypical, recurrent, or persistent cases.^{2,4,10,12} Limiting imaging to those with "red flags" avoids unnecessary radiation exposure, identification of incidental findings, contrast reactions, and unnecessary costs.^{1,7} The risk of limiting imaging includes missing identifiable and treatable causes of facial paralysis. To mitigate this risk, clinical follow up is recommended at 3 months.¹
- MRI has sensitivity ranging from 73% to 100% in detecting peripheral spread of tumor.²
- As the facial nerve courses through the temporal bone, CT temporal bone is useful to identify temporal bone fractures, bony anatomy, bone erosion and for surgical planning.²
- Vascular imaging is helpful if stroke is clinically suspected.²
- For evaluation of hemifacial spasm, MRA allows characterization of vascular loops compressing the facial nerve, with sensitivity >95% and correlates well with surgical findings.^{2,3}

References (HD-6)

v2.0.2026

1. Baugh RF, Basura GJ, Ishii LE, et al. Clinical practice guideline. Bell's Palsy Executive Summary. *Otolaryngology–Head and Neck Surgery*. 2013;149(5):656-663. doi:10.1177/0194599813506835
2. Expert Panel on Neurological Imaging, Rath TJ, Policeni B, et al. ACR Appropriateness Criteria® Cranial Neuropathy: 2022 Update. *J Am Coll Radiol*. 2022;19(11S):S266-S303. doi:10.1016/j.jacr.2022.09.021
3. Yalitho TC, Jankovic J. The many faces of hemifacial spasm: Differential diagnosis of unilateral facial spasms. *Movement Disorders*. 2011;26(9):1582-1592. doi:10.1002/mds.23692
4. Reich SG. Bell's Palsy. *CONTINUUM: Lifelong Learning in Neurology*. 2017;23(2):447-466. doi:10.1212/con.0000000000000447
5. Stern BJ, Royal W, Gelfand JM, et al. Definition and Consensus Diagnostic Criteria for Neurosarcoidosis. *JAMA Neurology*. 2018;75(12):1546. doi:10.1001/jamaneurol.2018.2295
6. Gronseth GS, Paduga R; American Academy of Neurology. Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2012;79(22):2209-2213. doi:10.1212/WNL.0b013e318275978c
7. Induruwa I, Holland N, Gregory R, Khadjooi K. The impact of misdiagnosing Bell's palsy as acute stroke. *Clin Med (Lond)*. 2019;19(6):494-498. doi:10.7861/clinmed.2019-0123
8. Yücel V, Özbal Güneş S, Keseroğlu K, et al. Prognostic and Clinical Role of Contrast Enhancement on Magnetic Resonance Imaging in Patients with Bell's Palsy. *Turk Arch Otorhinolaryngol*. 2022;60(2):80-87. doi:10.4274/tao.2022.2022-2-14
9. Bacorn C, Fong NST, Lin LK. Misdiagnosis of Bell's palsy: Case series and literature review. *Clin Case Rep*. 2020;8(7):1185-1191. Published 2020 Apr 16. doi:10.1002/ccr3.2832
10. Hohman MH, Hadlock TA. Etiology, diagnosis, and management of facial palsy: 2000 patients at a facial nerve center. *Laryngoscope*. 2014;124:E283-93
11. Savary T, Fieux M, Douplat M, et al. Incidence of Underlying Abnormal Findings on Routine Magnetic Resonance Imaging for Bell Palsy. *JAMA Netw Open*. 2023;6(4):e239158. doi:10.1001/jamanetworkopen.2023.9158
12. Seok JI, Park JH, Park JA, Do Y. Contrast-enhanced MRI findings of patients with acute Bell palsy within 7 days of symptom onset: A retrospective study. *Medicine (Baltimore)*. 2023;102(48):e36337. doi:10.1097/MD.00000000000036337
13. American Medical Association. CPT—Current Procedural Terminology. American Medical Association. Published 2026. Copyright 1995 – 2026

Recurrent Laryngeal Palsy/Vocal Cord Palsy (HD-7)

Guideline	Page
Recurrent Laryngeal Palsy/Vocal Cord Palsy (HD-7.1).....	56

Recurrent Laryngeal Palsy/Vocal Cord Palsy (HD-7.1)

HD.RL.0007.1.A

v2.0.2026

- See Recurrent Laryngeal Nerve Palsy in Neck-7.1

Mild Cognitive Impairment (MCI) and Dementia (HD-8)

Guideline	Page
Mild Cognitive Impairment (MCI) and Dementia - MRI/CT (HD-8.1)	58
Mild Cognitive Impairment (MCI) and Dementia - PET (HD-8.2).....	65
Lewy Body Dementia (LBD) - SPECT and PET (HD-8.3).....	74
Normal Pressure Hydrocephalus (NPH) (HD-8.4).....	77
Imaging Related to Alzheimer's Treatment with Amyloid Reduction Medications (HD-8.5).....	79
References (HD-8).....	81

Mild Cognitive Impairment (MCI) and Dementia - MRI/CT (HD-8.1)

HD.DM.0008.1.A

v2.0.2026

Mild Cognitive Impairment (MCI) Evaluation

Dementia Evaluation

Imaging Related to Alzheimer's Treatment with Amyloid Reduction Medications

Background and Supporting Information

Evidence Discussion (HD-8.1)

- For subjective cognitive decline with normal cognitive testing, advanced imaging is not medically necessary.

Mild Cognitive Impairment (MCI) Evaluation

For the evaluation of memory loss and/or cognitive impairment due to suspected Mild Cognitive Impairment (MCI) when treatment with amyloid reducing medications is not documented.

- MRI Brain without contrast (CPT® 70551) or MRI Brain without and with contrast (CPT® 70553) or CT Head without contrast (CPT® 70450) is medically necessary when **ALL** the following criteria are met:
 - A detailed history of cognitive decline with impairments confirmed by family members or others with knowledge of the individual's status
- OR**
- Abnormal mental status test score or neuropsychological test results consistent with mild cognitive impairment/mild neurocognitive disorder
 - Examples of abnormal mental status test results consistent with MCI include neuropsychological testing demonstrating a decline in cognitive function and/or the following test scores:
 - Montreal Cognitive Assessment (MOCA) 19-25,
 - Saint Louis University Mental Status (SLUMS) score for high school education 21-26, for less than high school education 20-24, or
 - Mini Mental State Exam (MMSE) 22-27

- See *Background and Supporting Information* for additional information regarding the diagnosis of MCI

Dementia Evaluation

For the evaluation of memory loss and/or cognitive impairment due to suspected dementia when treatment with amyloid reducing medications is not documented.

- MRI Brain without contrast (CPT[®] 70551) or MRI Brain without and with contrast (CPT[®] 70553) or CT Head without contrast (CPT[®] 70450) is medically necessary when all the following criteria are met:
 - Initial clinical diagnosis of dementia has been established
 - A detailed history and neurologic exam including mental status testing should be performed prior to advanced imaging
 - Date of onset of symptoms with documentation of six (6) months of cognitive decline
 - Documentation of a decline in cognitive function obtained with **either**:
 - A detailed history of memory loss with impairment of day-to-day activities confirmed by family members or others with knowledge of the individual's status

OR

- Abnormal mental status test score consistent with dementia or neuropsychological test results consistent with dementia/major neurocognitive disorder
 - Examples of abnormal bedside mental status testing scores include:
 - Mini-Mental State Exam (MMSE) <26,
 - Montreal Cognitive Assessment (MoCA) <26,
 - Memory Impairment Screen (MIS) <5,
 - St. Louis University Mental Status (SLUMS) <21, or
 - Eight-item Informant Interview to Differentiate Aging and Dementia (AD8) Dementia Score >2
- Presumptive causes of dementia have been excluded
 - Cannot occur exclusively during bouts of delirium
 - Cannot be explained by another mental disorder

Imaging Related to Alzheimer's Treatment with Amyloid Reduction Medications

The following includes imaging to determine eligibility for treatment with FDA-approved amyloid reducing medications and imaging during treatment:

Donanemab (Kisunla®)

Indication	Medically Necessary Imaging
To determine eligibility for treatment	- Baseline (within the last 12 months) MRI Brain without contrast (CPT® 70551) OR - MRI Brain without and with contrast (CPT® 70553) - Repeat MRI Brain prior to drug initiation is medically necessary if requested
On donanemab therapy, prior to the 2nd, 3rd, 4th, and 7th infusions	- MRI Brain without contrast (CPT® 70551) OR - MRI Brain without and with contrast (CPT® 70553)
Follow-up while on donanemab therapy with radiographically observed amyloid-related imaging abnormality (ARIA) per the treating neurologist See Background and Supporting Information	- MRI Brain without contrast (CPT® 70551) OR - MRI Brain without and with contrast (CPT® 70553)

Indication	Medically Necessary Imaging
Neurologic signs and/or symptoms occurring while on treatment with donanemab	- CT Head without contrast (CPT® 70450) OR - MRI Brain without contrast (CPT® 70551) OR - MRI Brain without and with contrast (CPT® 70553) - Follow up MRI Brain is medically necessary after CT Head if requested
When transitioning to a different amyloid targeting monoclonal antibody, the individual should meet all initial treatment criteria.	

Lecanemab (Leqembi®)

Indication	Medically Necessary Imaging
To determine eligibility for treatment	- Baseline (within the last 12 months) MRI Brain without contrast (CPT® 70551) OR - MRI Brain without and with contrast (CPT® 70553) - Repeat MRI Brain prior to drug initiation is medically necessary if requested
On lecanemab therapy, prior to the 3rd, 5th, 7th, and 14th infusions	- MRI Brain without contrast (CPT® 70551) OR - MRI Brain without and with contrast (CPT® 70553)
Follow up while on lecanemab therapy with radiographically observe amyloid-related imaging abnormality (ARIA) per the treating neurologist See Background and Supporting Information	- MRI Brain without contrast (CPT® 70551) OR - MRI Brain without and with contrast (CPT® 70553)

Indication	Medically Necessary Imaging
Neurologic signs and/or symptoms occurring while on treatment with lecanemab	• CT Head without contrast (CPT® 70450) OR • MRI Brain without contrast (CPT® 70551) OR • MRI Brain without and with contrast (CPT® 70553) • Follow up MRI Brain is medically necessary after CT Head if requested
When transitioning to a different amyloid targeting monoclonal antibody, the individual should meet all initial treatment criteria.	

- Quantitative Magnetic Resonance Image (MRI) Analysis of the Brain
 - Volumetric or quantitative analysis of the brain or temporal lobes and hippocampus may be ordered as (CPT® 0865T or CPT® 0866T).
 - These studies lack sufficient specificity and sensitivity to be clinically useful. Their use is limited to research studies and are considered not medically necessary in the evaluation of dementia.
 - Volumetric or quantitative analysis of the brain or temporal lobes and hippocampus may be ordered as 3D rendering (CPT® 76376 and CPT® 76377).
 - These studies are considered not medically necessary in the evaluation of dementia.
- For amyloid PET requests in the treatment with amyloid reducing medications, see **Mild Cognitive Impairment (MCI) and Dementia – PET (HD-8.2)**
- For acute mental status change, see **Mental Status Change (HD-4.2)** and/or **Stroke/TIA (HD-21.1)**
- For evaluation of Lewy Body Dementia, see **Lewy Body Dementia (LBD) – SPECT and PET (HD-8.3)**
- For the evaluation of Normal Pressure Hydrocephalus, see **Normal Pressure Hydrocephalus (HD-8.4)**
- For evaluation of rapidly progressive memory loss see **Autoimmune/Paraneoplastic Encephalitis & Neuroinflammatory Disorders (HD-14.3)**
- For evaluation of suspected vascular dementia see **Cerebrovascular Disease (HD-21.1)**

Background and Supporting Information

Subjective cognitive decline (SCD) refers to individuals who are concerned about a cognitive decline but perform normally on cognitive testing.

Mild Cognitive Impairment (MCI), also referred to as mild neurocognitive disorder, is marked by focal or multifocal cognitive impairment with minimal impairment of instrumental activities of daily living that do not cross the threshold for dementia.

Cognitive domains affected by MCI may include memory, attention, language, visuospatial processing, executive function, and social behavior. Examples of memory loss include forgetfulness, repeating questions, forgetting recent events or conversations. Attention deficits may include periods of decreased alertness or distractibility. Language impairment may be displayed as word finding difficulties, difficulty communicating and/or understanding. Visuospatial processing impairment may present as getting lost. Executive dysfunction including difficulty completing multi-step commands, planning, or using appliances. Concerning social behaviors include impulsiveness and inappropriate behaviors.

The functional impact of cognitive symptoms should be evaluated. Individuals with mild cognitive impairment may have difficulties completing instrumental activities of daily living such as managing finances, cooking, medications, and using transportation.

On neuropsychological testing, individuals with mild neurocognitive disorder perform at least 1 standard deviation below appropriate norms. Of note, a highly educated individual who scores within the normal range on screening tests, for example, a score of 29/30 on the MMSE, may show objective deficits in cognitive function on formal neuropsychological testing, consistent with a diagnosis of MCI.

Dementia, or major neurocognitive disorder, as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), refers to significant cognitive decline, with impairment in cognitive performance in domains including complex attention, executive function, learning and memory, language, perceptual-motor skills, or social cognition.

On neuropsychological testing, individuals with a major neurocognitive disorder perform 2 or more standard deviations below appropriate norms.

Impairment in activities of daily living include bathing, dressing, grooming, feeding and toileting.

Presumptive causes of cognitive decline include metabolic abnormalities such as hypothyroidism, uncontrolled diabetes, vitamin deficiencies, and/or untreated disorders such as sleep apnea.

Evidence Discussion (HD-8.1)

- The primary role of neuroimaging in the work up of individuals diagnosed with mild cognitive impairment or dementia is to exclude other serious differential diagnosis such as tumors, subdural hematomas, and normal pressure hydrocephalus.^{2,3} The American Academy of Neurology (AAN) recommended the use of non-contrast CT or Brain MRI for aiding in the diagnosis of dementia.^{3,31} Cross-sectional imaging may also identify characteristic brain atrophy patterns found in common neurodegenerative diseases and vascular insults.² CT imaging may also be used when MRI scans are contraindicated.
- Volumetric MRI Brain for the diagnosis of dementia is not currently recommended for routine clinical use by the AAN.^{3,31} There remains a significant evidence gap in the literature regarding clinical validation of volumetric MRI in the diagnosis of dementia. Their use remains limited to research studies.^{31,32}

Mild Cognitive Impairment (MCI) and Dementia - PET (HD-8.2)

HD.DM.0008.2.A

v2.0.2026

Brain PET CPT® Codes	Definition
78608	Used to report FDG PET metabolic brain studies for dementia, seizure disorders, and brain tumors
78609	Used to report PET brain perfusion studies, primarily used for brain tumors
78811	Limited PET, used for amyloid or tau PET, static imaging to measure amyloid and tau
78814	Limited PET/CT, used for amyloid or tau PET, static images to measure amyloid or tau

Metabolic (FDG) PET Brain CPT® 78608

Amyloid PET Brain CPT® 78814 or 78811

Tau PET Brain CPT® 78814 or 78811

Perfusion PET Brain CPT® 78609

Background and Supporting Information

Evidence Discussion

Metabolic (FDG) PET Brain (CPT® 78608)

Mild Cognitive Impairment

- Metabolic (FDG) PET (CPT® 78608) is medically necessary in the evaluation of for Mild Cognitive Impairment (MCI) when Alzheimer's Disease is suspected and all the following criteria are met:
 - Established diagnosis of mild cognitive impairment based on clinical history, physical examination, and cognitive testing, which may include neuropsychological testing.

- Documentation of cognitive decline obtained by either:
 - A detailed history of cognitive decline with impairments confirmed by family members or others with knowledge of the individuals status
- OR**
- Abnormal mental status test score or neuropsychological test results consistent with mild cognitive impairment/mild neurocognitive disorder
 - Examples of abnormal mental status test results consistent with MCI include:
 - Montreal Cognitive Assessment (MOCA) score 19-25
 - Saint Louis University Mental Status (SLUMS) score for high school education 21-26, for less than high school education 20-24
 - Mini Mental State Exam (MMSE) score 22-27
- Results of any structural brain imaging (MRI Brain or CT Head) previously performed.

Dementia

- Metabolic (FDG) PET Brain (CPT[®] 78608) is medically necessary in the evaluation of dementia to distinguish between Alzheimer's disease (AD) and Frontotemporal Dementia (FTD) when all the following criteria are met:
 - Established diagnosis of dementia:
 - Date of onset of symptoms with documentation of 6 months of cognitive decline
 - Documentation of a decline in cognitive function obtained with either:
 - A detailed history of memory loss with impairment of day-to-day activities confirmed by family members or others with knowledge of the individual's status
 - OR**
 - Abnormal mental status testing score consistent with dementia
 - Examples of abnormal bedside mental status testing scores include:
 - Mini-Mental State Exam (MMSE) <26,
 - Montreal Cognitive Assessment Survey (MoCA) <26,
 - Memory Impairment Screen (MIS) <5,
 - St. Louis University Mental Status (SLUMS) <21, or
 - Eight-item Informant Interview to Differentiate Aging and Dementia (AD8) Dementia Score >2
 - Results of any structural imaging (MRI Brain or CT Head) previously performed
 - Meets diagnostic criteria for AD and FTD
 - The results are expected to clarify the diagnosis between FTD and AD and help guide future treatment
 - Cause of clinical symptoms is uncertain

- Evaluation has ruled out specific alternative neurodegenerative disease or causative factors
 - Cannot occur exclusively during bouts of delirium
 - Cannot be explained by another mental disorder
- FDG PET brain (CPT® 78608) is otherwise considered not medically necessary for the purpose of diagnosis and management of other forms of dementia including, but not limited to, Parkinson's disease, normal pressure hydrocephalus, and chronic traumatic encephalopathy.
 - For requests related to Lewy Body Dementia, see **Lewy Body Dementia (LBD) – SPECT and PET (HD-8.3)**
- FDG-PET(CPT® 78608)/MRI Brain without contrast (CPT® 70551) OR MRI Brain without and with contrast (CPT® 70553) imaging may be considered on a case-by-case basis for those imaging centers that will utilize FDG-PET/MRI during an initial evaluation (instead of MRI alone) and who also have a standardization of imaging protocol.

Amyloid PET Brain (CPT® 78814 or 78811)

- Amyloid Brain PET is medically necessary when a diagnosis of MCI or dementia due to Alzheimer's disease is suspected based on cognitive testing, and evaluation including structural brain imaging has been completed, in ANY of the following clinical scenarios:
 - Individuals with MCI or dementia who are <65 years of age and in whom AD is suspected
 - Individuals with MCI or dementia that could be consistent with amnesic AD pathology with onset at ≥65 years of age
 - Individuals with MCI or dementia that could be consistent with AD but has atypical clinical features
 - Individuals with MCI or dementia with equivocal or inconclusive results on CSF biomarkers
 - To inform the prognosis of individuals with MCI due to suspected AD pathology
 - To determine eligibility for treatment with amyloid targeting therapy and to monitor response (as listed in the criteria in the tables below)

Imaging Related to Alzheimer's Treatment with Amyloid Reduction Medications

The following tables include imaging to determine eligibility for treatment with FDA-approved amyloid reducing medications and imaging during treatment.

Donanemab (Kisunla®)

Indication	Medically Necessary Imaging
ALL the following criteria must be met to determine eligibility for treatment: • Individual ≥ 59 years of age and ≤ 86 years of age • MCI or mild dementia due to AD • MMSE score ≥ 20 and ≤ 28 (or equivalent comparison test score) • Progressive change in memory function for at least 6 months • Baseline MRI Brain results are available to the ordering provider • No history of prior intracerebral hemorrhage greater than 1 cm, severe white matter disease, or vasogenic edema • Not currently taking another amyloid reducing drug • Prescribed by a neurologist or in consultation with a neurologist	Amyloid PET Brain (CPT® 78811 or CPT® 78814)
To monitor treatment response: • Follow up imaging during treatment at 6, 12, and 18 months	Amyloid PET Brain (CPT® 78811 or CPT® 78814)
When transitioning to a different amyloid targeting monoclonal antibody, the individual should meet all initial treatment criteria	

Lecanemab (Leqembi®)

Indication	Medically Necessary Imaging
ALL the following criteria must be met to determine eligibility for treatment: • Individual is ≥50 years of age and ≤90 years of age • MCI or mild dementia due to AD • Qualifying test scores include Mini-Mental Status Exam (MMSE) with score ≥22, Clinical Dementia Rating global score of ≥0.5 or 1.0, Clinical Dementia Rating-Sum of Boxes (CDR-SB) ≥0.5, and/or Memory Box score of 0.5 or greater (or equivalent comparison test score) • Baseline MRI Brain results are available to the ordering provider • No history of brain hemorrhage, bleeding disorder, history of seizures, or recent history (within 12 months) of stroke or transient ischemic attacks • Not currently taking another amyloid reducing drug • Prescribed by a neurologist or in consultation with a neurologist	Amyloid PET Brain (CPT® 78811 or CPT® 78814)
To monitor treatment response: • Post-treatment imaging at 18 months • If treatment is continued after 18 months, a follow up study is medically necessary between 12-18 months	Amyloid PET Brain (CPT® 78811 or CPT® 78814)
When transitioning to a different amyloid targeting monoclonal antibody, the individual should meet all initial treatment criteria	

Tau PET Brain (CPT® 78814 or 78811)

- Tau PET is medically necessary for evaluation of cognitive impairment in individuals with suspected AD with atypical clinical presentation when all the following criteria are met:

- Established diagnosis of mild cognitive impairment or dementia
- Evaluation has excluded other causes
- Results of structural brain imaging are available to the ordering provider

See *Background and Supporting Information* regarding suspected AD with atypical presentation .

Perfusion PET Brain (CPT® 78609)

Perfusion PET Brain imaging (CPT® 78609) is not medically necessary in the evaluation of dementia.

- For cerebral amyloid angiopathy, see **Stroke/TIA (HD-21.1)**.

Background and Supporting Information

An atypical clinical presentation of Alzheimer's Disease (AD) is one that meets core clinical criteria of cognitive impairment in multiple domains, which interfere with instrumental activities of daily living and functioning, but has sudden or rapid onset or the onset occurs at a younger age (<65).

Atypical AD variants include:

- Early-onset
- Amnesic variant early-onset AD
- Visuospatial variant AD (posterior cortical atrophy (PCA))
- Language variant AD (logopenic variant primary progressive aphasia [PPA])
- Behavioral variant/dysexecutive variant AD
- Motor variant AD corticobasal syndrome due to AD

The frontotemporal dementias (FTDs) are a group of neurodegenerative disorders that differ from Alzheimer's disease. The basic pathology involves accumulation of tau proteins in the brain rather than amyloid. Onset tends to be younger (less than 65) and progression usually more rapid than in senile dementia-Alzheimer type (SDAT). There is no treatment, and the medications used to help memory in Alzheimer's disease are not effective.

There are several subtypes of FTD; most common are the behavioral variant with early loss of executive functions, impaired judgment disinhibition and impulsivity, and the semantic variant with primary and progressive loss of language ability (primary progressive aphasia type FTD). Other less common subtypes include progressive supranuclear palsy, corticobasal syndrome, and FTD associated with motor neuron disease.

Diagnosis of FTD is based on clinical features, neuropsychological testing, and brain imaging (preferably MRI) to rule out other structural disease. Metabolic (FDG) PET Brain is helpful by demonstrating patterns of abnormality more consistent with FTD than Alzheimer's disease.

Recent research has examined the utility of PET/MRI for evaluation of individuals with dementia. Due to the prolonged acquisition time, motion during a PET may lead to artifacts such as blurring of the images. Use of co-registration of PET with MRI can lead to better PET assessment especially with quantitative measurements. Utilization of PET/MRI provides greater confidence in imaging reading by permitting greater structural correlation. A recent study compared FDG-PET/CT and FDG-PET/MRI in a memory disorders clinic. This study identified more individuals with cerebrovascular disease (stroke) and better cortical atrophy characterization. The authors found that PET/MRI provided significant improvement in diagnosis and management of individuals in which dementia is a consideration.

Evidence Discussion (HD-8.2)

The Alzheimer's Association workgroup has revised the criteria for diagnosis and staging of Alzheimer's Disease (AD).³⁵ The workgroup defined Alzheimer's disease as a biological process, rather than a clinical syndrome, which allows diagnosis in the asymptomatic phase, based on positive biomarkers (Core 1 biomarkers).³⁵ These Core 1 biomarkers include Amyloid PET and cerebrospinal fluid biomarkers.³⁵ An abnormal Core 1 biomarker is sufficient to establish a diagnosis of AD.^{2,35}

Structural, functional, and molecular brain imaging in individuals with MCI helps to identify potentially treatable structural abnormalities and identify imaging features that may confer an increased risk of transformation to a dementia.² In addition, molecular imaging helps inform prognosis, for patients and their families, and allows early treatment initiation.^{2,4}

Amyloid PET is positive in 60% of individuals with MCI.² Greater cognitive decline is noted in those with MCI and a positive amyloid PET scan, and they are more likely to progress to AD than those with a negative amyloid PET.^{2,4} Amyloid PET also results in a change in diagnosis in up to 44% of individuals, therefore increasing diagnostic confidence.²

Amyloid PET has a pooled sensitivity of 0.90 and specificity of 0.80 for diagnosis of AD, and a pooled sensitivity of 0.84 and specificity of 0.62 for predicting conversion of MCI to dementia.³⁶

Molecular brain imaging is particularly helpful in confirming a diagnosis of AD with atypical clinical presentation.² A positive amyloid PET in early-onset or atypical AD can lead to a change in diagnosis of 66.8%, improve confidence in diagnosis in 81.5% and

change management in 80% of cases.^{2,37} The use of amyloid PET led to changes in management in 63.5% of Medicare members with dementia.^{4,5}

The Society of Nuclear Medicine Imaging and Molecular Imaging released Appropriate Use Criteria (AUC) for amyloid PET which included the following clinical scenarios^{2,4}:

- Individuals with MCI or dementia who are <65 years of age and for whom AD is suspected
- Individuals with MCI or dementia consistent with amnesic AD pathology with onset ≥65 years of age
- Individuals with MCI or dementia that could be consistent with AD but has atypical features
- Individuals with MCI or dementia with equivocal or inconclusive results on CSF biomarkers
- To inform the prognosis of patients due to suspected AD pathology
- To determine eligibility for treatment with amyloid-targeting therapy and to monitor treatment response

Tau PET is considered appropriate for the evaluation of individuals presenting with MCI or a dementia syndrome that could be consistent with AD pathology but has atypical features.^{2,4} In these clinical scenarios, tau uptake correlates with cognitive function and is helpful to diagnose atypical clinical phenotypes of AD.²

The work groups supports tau PET in atypical cases as a tau binding pattern can help establish AD as the cause of impairment and the spatial pattern of tau uptake matches brain regions clinically affected.⁴ Furthermore, a high tau burden is associated with more rapid clinical progression.⁴

FDG PET Brain in the evaluation of MCI shows a pattern of hypometabolism consistent with AD in up to 79% of cases.² In addition, an abnormal pattern predicts conversion from MCI to AD with an accuracy over 80%.² Conversely, a negative FDG PET reduces the likelihood of progression to dementia.²

FDG-PET brain accurately discriminates Alzheimer's disease individuals from normal subjects with a sensitivity of 96% and specificity of 100%.²

Metabolic (FDG) PET brain is helpful by demonstrating patterns of abnormality more consistent with FTD than Alzheimer's disease. FDG PET brain has a sensitivity of 86% and specificity of 97.6% in evaluating individuals with FTD.² The use of FDG PET increases diagnostic accuracy and confidence for both AD and FTD.² It is particularly helpful in cases of diagnostic uncertainty.²

Recent research has examined the utility of PET/MRI for evaluation of individuals with dementia. Due to the prolonged acquisition time, motion during a PET may lead to artifacts such as blurring of the images. Use of co-registration of PET with MRI can lead to better PET assessment especially with quantitative measurements.^{23,25}

Utilization of PET/MRI provides greater confidence in reading images by permitting greater structural correlation. A recent study compared FDG-PET/CT and FDG-PET/MRI in a memory disorders clinic.²⁴ The main findings were that FDG PET/MRI revealed more vascular pathology in 35% of individuals, induced a change of the interpretation of FDG PET in 17% of individuals and was considered to influence management in 22% of individuals.²⁴

Lewy Body Dementia (LBD) - SPECT and PET (HD-8.3)

HD.DM.0008.3.A

v2.0.2026

SPECT Brain Scan

Metabolic (FDG) PET Brain

Background and Supporting Information

Evidence Discussion (HD-8.3)

SPECT Brain Scan

- SPECT Brain Scan (CPT[®] 78803 or CPT[®] 78830) is medically necessary for evaluation of suspected Lewy Body Dementia when all the following are met:
 - Established diagnosis of dementia:
 - date of onset of symptoms with documentation of 6 months of cognitive decline
 - documentation of decline in cognitive function obtained with either:
 - a detailed history of memory loss with impairment of day-to-day activities confirmed by family members or others with knowledge of the individual's status
 - OR**
 - abnormal mental status test score consistent with dementia or neuropsychological test results consistent with dementia/major neurocognitive disorder
 - examples of abnormal bedside mental status testing scores include:
 - Mini-Mental State Exam (MMSE) <26,
 - Montreal Cognitive Assessment Survey (MoCA) <26,
 - Memory Impairment Screen (MIS) <5,
 - St. Louis University Mental Status (SLUMS) <21, or
 - Eight-item Informant Interview to Differentiate Aging and Dementia (AD8) Dementia >2
 - Presumptive causes of dementia have been excluded
 - cannot occur exclusively during bouts of delirium
 - cannot be explained by another mental disorder

- Results of any structural imaging (MRI or CT Head) performed

Metabolic (FDG) PET Brain

- Metabolic (FDG) PET brain (CPT[®] 78608) is medically necessary to differentiate Lewy Body Dementia (LBD) from Alzheimer's Disease (AD) when all the following criteria are met:
 - Established diagnosis of dementia:
 - Date of onset of symptoms with documentation of 6 months of cognitive decline
 - Documentation of decline in cognitive function obtained with either:
 - a detailed history of memory loss with impairment of day-to-day activities confirmed by family members or others with knowledge of the individual's status
 - OR**
 - abnormal mental status test score consistent with dementia or neuropsychological test results consistent with dementia/major neurocognitive disorder
 - Examples of abnormal bedside mental status testing scores include:
 - Mini-Mental State Exam (MMSE) <26,
 - Montreal Cognitive Assessment Survey (MoCA) <26,
 - Memory Impairment Screen (MIS) <5,
 - St. Louis University Mental Status (SLUMS) <21, or
 - Eight- item Informant Interview to Differentiate Aging and Dementia (AD8) Dementia Score >2
 - Presumptive causes of dementia have been excluded
 - Cannot occur exclusively during bouts of delirium
 - Cannot be explained by another mental disorder
 - Results of any structural imaging (MRI or CT Head) performed

Background and Supporting Information

- Dementia with Lewy bodies is often hard to diagnose because its early symptoms may resemble those of Alzheimer's or a psychiatric illness. Over time people with LBD often develop similar symptoms due to the presence of Lewy bodies in the brain.
 - Clinicians and researchers may use the "1-year rule" to help make a diagnosis. If cognitive, psychiatric, emotional, and/or personality symptoms appear at the same time as or at least a year before movement problems/Parkinsonism, the diagnosis is dementia with Lewy bodies. If cognitive problems develop more than a

year after the onset of movement problems, Parkinson's disease, the diagnosis is Parkinson's disease dementia (PDD).

- Core Clinical Symptoms
 - Dementia
 - Movement problems/Parkinsonism
 - Cognitive fluctuations
 - Visual hallucinations
 - REM sleep behavior disorder
- Supportive Clinical Symptoms
 - Extreme sensitivity to antipsychotic medications
 - Falls, fainting
 - Severe problems with involuntary functions (maintaining blood pressure, incontinence, constipation, loss of smell)
 - Changes in personality and mood (depression, apathy, anxiety)

Test Results Supporting Diagnosis

- Abnormal ¹²³Iodine-MIBG myocardial scintigraphy showing reduced communication of cardiac nerves
- Sleep study confirming REM sleep behavior disorder without loss of muscle tone

Evidence Discussion (HD-8.3)

- For suspected Lewy Body Dementia (LBD), a CT or MRI head is appropriate as the initial imaging study.^{14,31}
- To increase diagnostic accuracy of LBD, SPECT modalities are helpful for differentiating LBD from Alzheimer's dementia.^{2,6,14,15}
- Functional imaging of the dopamine transporter (DAT) (Iodine-123 Ioflupane) using SPECT shows a deficiency in the nigrostriatal pathway in LBD. This is considered a second line imaging test after cross-sectional imaging has excluded other pathology, such as vascular lesions along the nigrostriatal pathway, which can lead to abnormal DAT images with false positive results.¹⁴
- An abnormal DAT-SPECT scan has a sensitivity of 78.7% and a specificity of 90.4% for probable LBD.^{2,14}
- Metabolic (FDG) PET imaging demonstrates features which would support a diagnosis of LBD. Hypometabolism in the occipital lobe differentiates LBD² from AD.^{2,38} In addition, the "cingulate island sign", which refers to the preservation of FDG metabolism in the posterior cingulate gyrus, is considered a biomarker for LBD.^{2,39}

Normal Pressure Hydrocephalus (NPH) (HD-8.4)

HD.DM.0008.4.A

v2.0.2026

- CT Head without contrast (CPT[®] 70450) **OR** MRI Brain without contrast (CPT[®] 70551) is medically necessary if the individual has at least two symptoms involving gait abnormality (see *Background and Supporting Information*), urinary incontinence, or dementia **AND**
 - The clinical symptoms cannot be completely explained by other neurological or non-neurological disease, **AND**
 - There is no apparent preceding disorder that would cause hydrocephalus
- The components of Dementia are delineated in **Mild Cognitive Impairment (MCI) and Dementia – MRI/CT (HD-8.1)**, but include:
 - Results of testing and/or neuropsychological testing can be performed when history and mental status examination cannot provide a confident diagnosis.
 - Examples of abnormal mental status testing such as Mini-Mental State Exam (MMSE) with score <26, Montreal Cognitive Assessment Survey (MoCA) with score <26, Memory Impairment Screen (MIS) with score <5, the St. Louis University Mental Status (SLUMS) with score <21, or the Eight-item Informant Interview to Differentiate Aging and Dementia (AD8) Dementia Score >2.
 - Presumptive causes or etiology/ies of dementia
 - Cannot occur exclusively during bouts of delirium
 - Cannot be explained by another mental disorder
- MRI Brain (CPT[®] 70551, CPT[®] 70552, or CPT[®] 70553) is not medically necessary for the diagnosis of NPH if a CT has been performed. However, MRI Brain is medically necessary if needed for pre-surgical planning.
 - After neuro imaging, the next steps are CSF sampling, drainage, and dynamics.
- Follow-up imaging for individuals diagnosed with NPH with a shunt should follow **Hydrocephalus Shunts (HD-11.14)**, **Low-Pressure Headache and CSF Leak (HD-11.15)**, or **Nuclear Medicine (HD-36.1)**

Background and Supporting Information

Normal Pressure Hydrocephalus (NPH) seen typically in the elderly. It comprises a triad of symptoms: cognitive dysfunction, incontinence of urine, and gait disturbance (typically a “magnetic”, small-step, shuffling, or broad-based gait). The reported neuroradiologic marker for this is ventriculomegaly (enlarged ventricles) in the brain. Unfortunately, these symptoms and this neuroradiologic finding is common in the elderly, making the

diagnosis of NPH in any given individual problematic. It is radiographically common and clinically rare.

Evidence Discussion (HD-8.4)

- Initial neuroimaging for the evaluation of suspected Normal Pressure Hydrocephalus (NPH) includes CT Head or MRI Brain in individuals with clinical symptoms and no explanation for hydrocephalus.^{2,21}
- Only a single modality study is medically necessary. The initial best modality is MRI Brain because of its higher intrinsic soft tissue resolution and because it can often be used as a pre-surgical exam.^{2,21}
- By using the appropriate single best test, we avoid duplicate imaging and unnecessary radiation to the lens of the eye and other head and neck structures.²
- Cine MRI showing hyperdynamic aqueductal CSF flow can also help in identifying shunt-responsive NPH individuals. The benefit of this exam is that it offers us functional information about CSF flow and can help improve individual outcomes.^{2,21,34}

Imaging Related to Alzheimer's Treatment with Amyloid Reduction Medications (HD-8.5)

HD.DM.0008.5.A

v2.0.2026

For structural brain imaging related to Alzheimer's treatment with amyloid reducing medications, see **Mild Cognitive Impairment (MCI) and Dementia – MRI/CT (HD-8.1)**.

For Amyloid PET brain imaging related to Alzheimer's treatment with amyloid reducing medications, see **Mild Cognitive Impairment (MCI) and Dementia- PET (HD-8.2)**.

Background and Supporting Information

Amyloid reduction medications are medically necessary for the treatment of Mild Cognitive Impairment (MCI) due to Alzheimer's disease and mild, early- stage Alzheimer's disease.²⁵

These medications are monoclonal antibodies that selectively bind to aggregated forms of beta amyloid. The accumulation of amyloid plaques in the brain is a defining pathophysiologic feature of Alzheimer's disease. In clinical trials, these medications reduce amyloid beta plaque compared with placebo.²⁵

Amyloid related imaging abnormalities (ARIA) have been caused by these medications. ARIA usually occurs early in treatment and may be asymptomatic although serious and life-threatening events may occur. Screening MRI Brain prior to treatment initiation and periodic monitoring during treatment is recommended. For moderate to severe ARIA, treatment may be suspended. Once ARIA is identified on a brain MRI, follow up MRIs are medically necessary to assess for radiographic resolution and/or symptom resolution with the imaging time frame determined by the treating physician. Resumption of dosing is guided by clinical judgment.²⁵

ARIA may be further characterized as ARIA with edema (ARIA-E) or ARIA with hemosiderin (ARIA-H). ARIA-E presents on MRI as brain edema or sulcal effusions. ARIA-H includes microhemorrhage and superficial siderosis. ARIA-E and ARIA-H may occur simultaneously.²⁵

Although ARIA is usually asymptomatic, symptoms associated with ARIA include headache, confusion, visual changes, dizziness, nausea, aphasia, weakness, gait difficulty and seizures, including status epilepticus. Focal neurologic deficits may also occur.²⁵ The risk of ARIA is increased in apolipoprotein E ϵ 4 (ApoE ϵ 4) homozygotes.²⁵

Leqembi® dosing after 18 months may be administered every 2 weeks or transitioned to a maintenance regimen every 4 weeks.

Transitioning from one amyloid targeting monoclonal antibody to another should be done when the individual has been off of the prior drug for 5 half-lives prior to initiation of the alternative drug. The half-life of aducanumab is 24.3 days; the half-life of lecanemab is 9.5 days, and the half-life of donanemab is 11.8 days. Individuals should be off of aducanumab for approximately 4 months or off lecanemab or donanemab for approximately 6 weeks prior to initiation of a different amyloid targeting monoclonal antibody.

Evidence Discussion (HD-8.5)

- Structural brain imaging in the work up of individuals diagnosed with dementia is primarily to exclude other significant intracranial abnormalities. A brain MRI will assist with the diagnosis of dementia by excluding structural pathology such as tumors or subdural hematomas.²
- Amyloid related imaging abnormalities (ARIA) have been associated with treatment by amyloid reduction medications. ARIA usually occurs early in treatment and may be asymptomatic although serious and life-threatening events may occur. Screening brain MRI prior to treatment initiation and periodic monitoring during treatment is recommended.^{17,27} For moderate to severe ARIA, treatment may be suspended. Once ARIA is identified on a brain MRI, follow-up MRIs are medically necessary to assess for radiographic resolution and/or symptom resolution with the imaging time-frame determined by the treating physician.^{17,27} Resumption of dosing is guided by clinical judgment.^{17,27}
- Amyloid PET brain is a form of molecular imaging, which uses a tracer that binds to amyloid plaques in the brain. At the present time, the use of Amyloid PET brain is limited to confirming the presence of amyloid in the brain, in those with mild cognitive impairment due to Alzheimer's disease or mild dementia due to Alzheimer's disease, prior to treatment with amyloid reducing medications.

References (HD-8)

v2.0.2026

1. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia*. 2011;7(3):263-269. doi:10.1016/j.jalz.2011.03.005
2. Soderlund KA, Austin MJ, Ben-Haim S, et al. ACR Appropriateness Criteria® Dementia. Available at <https://acsearch.acr.org/docs/3111292/Narrative/>. American College of Radiology. 2024.
3. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2001;56(9):1143-1153. doi:10.1212/wnl.56.9.1143
4. Rabinovici GD, Knopman DS, Arbizu J, et al. Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. *J Nucl Med*. Published online January 8, 2025. doi:10.2967/jnumed.124.268756
5. Rabinovici GD, Gatsonis C, Apgar C, et al. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. *Jama*. 2019;321(13):1286-1294. doi:10.1001/jama.2019.2000
6. Subramaniam RM, Frey KA, Hunt CH, et al. ACR-ACNM Practice Parameter for the Performance of Dopamine Transporter (DaT) Single Photon Emission Computed Tomography (SPECT) Imaging for Movement Disorders. *Clinical Nuclear Medicine*. 2017;42(11):847-852. doi:10.1097/rlu.0000000000001815
7. Graff-Radford NR, Jones DT. Normal Pressure Hydrocephalus. *CONTINUUM: Lifelong Learning in Neurology*. 2019;25(1):165-186. doi:10.1212/con.0000000000000689
8. Tartaglia MC, Rosen HJ, Miller BL. *Neuroimaging in Dementia*. *Neurotherapeutics*. 2011;8(1):82-92. doi:10.1007/s13311-010-0012-2
9. American College of Radiology. ACR-ACNM-ASNR-SNMMI Practice Parameter for brain PET/CT imaging in dementia. 2020; Available at: <https://gravitas.acr.org/PPTS/>
10. Consensus Recommendations for the Postmortem Diagnosis of Alzheimer's Disease. *Neurobiology of Aging*. 1997;18(4):S1-S2. doi:10.1016/s0197-4580(97)00057-2
11. Lombardi G, Crescioli G, Cavado E, et al. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment. *Cochrane Database of Systematic Reviews*. Published online March 2, 2020. doi:10.1002/14651858.cd009628.pub2
12. Yousaf T, Dervenoulas G, Valkimadi P-E, Politis M. Neuroimaging in Lewy body dementia. *Journal of Neurology*. 2019;266(1):1-26. doi:10.1007/s00415-018-8892-x
13. Goto H, Ishii K, Uemura T, et al. Differential Diagnosis of Dementia with Lewy Bodies and Alzheimer Disease Using Combined MR Imaging and Brain Perfusion Single-Photon Emission Tomography. *American Journal of Neuroradiology*. 2010;31(4):720-725. doi:10.3174/ajnr.a1926
14. McCleery J, Morgan S, Bradley KM, Noel-Storr AH, Ansorge O, Hyde C. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies. *Cochrane Database of Systematic Reviews*. Published online January 30, 2015. doi:10.1002/14651858.cd010633.pub2
15. Armstrong MJ. Lewy Body Dementias. *CONTINUUM: Lifelong Learning in Neurology*. 2019;25(1):128-146. doi:10.1212/con.0000000000000685
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Association; 2013. Pages 591-643.
17. Kisunla® intravenous infusion [prescribing information]. Indianapolis, IN: Eli Lilly and Company; July 2024
18. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. *JAMA*. 2023;330(6):512-527. doi:10.1001/jama.2023.13239
19. Zukotynski K, Kuo PH, Mikulis D, et al. PET/CT of Dementia. *American Journal of Roentgenology*. 2018;211(2):246-259. doi:10.2214/ajr.18.19822
20. Nakajima M, Yamada S, Miyajima M, et al. Guidelines for Management of Idiopathic Normal Pressure Hydrocephalus (Third Edition): Endorsed by the Japanese Society of Normal Pressure Hydrocephalus. *Neurologia medico-chirurgica*. 2021;61(2):63-97. doi:10.2176/nmc.st.2020-0292

21. Capone PM, Bertelson JA, Ajtai B. Neuroimaging of Normal Pressure Hydrocephalus and Hydrocephalus. *Neurologic Clinics*. 2020;38(1):171-183. doi:10.1016/j.ncl.2019.09.003
22. Park HY, Park CR, Suh CH, Kim MJ, Shim WH, Kim SJ. Prognostic Utility of Disproportionately Enlarged Subarachnoid Space Hydrocephalus in Idiopathic Normal Pressure Hydrocephalus Treated with Ventriculoperitoneal Shunt Surgery: A Systematic Review and Meta-analysis. *American Journal of Neuroradiology*. 2021;42(8):1429-1436. doi:10.3174/ajnr.a7168
23. Chen KT, Salcedo S, Chonde DB, et al. MR-assisted PET motion correction in simultaneous PET/MRI studies of dementia subjects. *J Magn Reson Imaging*. 2018;48(5):1288-1296. doi:10.1002/jmri.26000
24. Kaltoft NS, Marner L, Larsen VA, Hasselbalch SG, Law I, Henriksen OM. Hybrid FDG PET/MRI vs. FDG PET and CT in patients with suspected dementia - A comparison of diagnostic yield and propagated influence on clinical diagnosis and patient management. *PLoS One*. 2019;14(5):e0216409. Published 2019 May 2. doi:10.1371/journal.pone.0216409
25. Patel KP, Wymer DT, Bhatia VK, Duara R, Rajadhyaksha CD. Multimodality Imaging of Dementia: Clinical Importance and Role of Integrated Anatomic and Molecular Imaging. *Radiographics*. 2020;40(1):200-222. doi:10.1148/rg.2020190070
26. Svensson A, Granvik E, Sjögren Forss K. Performance of the Eight-item Informant Interview to Differentiate Aging and Dementia within a context similar to the Swedish primary healthcare sector: a systematic review of diagnostic test accuracy studies. *Scand J Prim Health Care*. 2020;38(4):454-463. doi:10.1080/02813432.2020.1844370
27. Leqembi[®] intravenous infusion [prescribing information]. Nutley, NJ: Eisai; July 2023. Updated August 2025.
28. Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: Appropriate Use Recommendations. *J Prev Alzheimers Dis*. 2023;10(3):362-377. doi:10.14283/jpad.2023.30
29. Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A β protofibril antibody [published correction appears in *Alzheimers Res Ther*. 2022 May 21;14(1):70]. *Alzheimers Res Ther*. 2021;13(1):80. Published 2021 Apr 17. doi:10.1186/s13195-021-00813-8
30. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. *N Engl J Med*. 2023;388(1):9-21. doi:10.1056/NEJMoa2212948
31. McCollum L, Karlawish J. Cognitive Impairment Evaluation and Management. *Med Clin North Am*. 2020;104(5):807-825. doi:10.1016/j.mcna.2020.06.007
32. Pemberton HG, Zaki LAM, Goodkin O, et al. Technical and clinical validation of commercial automated volumetric MRI tools for dementia diagnosis-a systematic review [published correction appears in *Neuroradiology*. 2021 Nov;63(11):1955. doi: 10.1007/s00234-021-02818-4.]. *Neuroradiology*. 2021;63(11):1773-1789. doi:10.1007/s00234-021-02746-3
33. Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. *Brain*. 2007;130(Pt 10):2616-2635. doi:10.1093/brain/awm177
34. Bradley WG Jr. CSF Flow in the Brain in the Context of Normal Pressure Hydrocephalus. *AJNR Am J Neuroradiol*. 2015;36(5):831-838. doi:10.3174/ajnr.A4124
35. Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. *Alzheimers Dement*. 2024;20(8):5143-5169. doi:10.1002/alz.13859
36. Ruan D, Sun L. Amyloid- β PET in Alzheimer's disease: A systematic review and Bayesian meta-analysis. *Brain Behav*. 2023;13(1):e2850. doi:10.1002/brb3.2850
37. Ceccaldi M, Jonveaux T, Verger A, et al. Added value of (18)F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study. *Alzheimers Dement*. 2018;14:293-305
38. Oldan JD, Jewells VL, Pieper B, Wong TZ. Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist. *AJNR Am J Neuroradiol*. 2021;42(6):998-1007. doi:10.3174/ajnr.A7079
39. Feng LR, Vogel A, Møllergaard C, et al. Clinical validation of the cingulate island sign visual rating scale in dementia with Lewy bodies. *J Neurol Sci*. 2023;451:120719. doi:10.1016/j.jns.2023.120719
40. Saint Louis University. SLU Mental Status Exam (SLUM). <https://www.slu.edu/medicine/internal-medicine/geriatric-medicine/aging-successfully/assessment-tools/mental-status-exam.php>. 2006.
41. MoCA Cognition. MoCA Clinic Data. <https://mocacognition.com/moca-clinic-data/>. 2005.
42. Nasreddine ZS, Phillips NA, Bédirian V, et al. . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *Journal of the American Geriatrics Society*. 2005;53(4):695-699.

43. Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. *JAMA*. 2014;312(23):2551-2561 doi:10.1001/jama.2014.13806
44. Rabinovici GD, Selkoe DJ, Schindler SE, et al. Donanemab: Appropriate use recommendations. *J Prev Alzheimers Dis*. 2025;12(5):100150. doi:10.1016/j.tjpad.2025.100150
45. NeuroQuant - Cortechs.ai. Cortechs.ai. Published January 9, 2025

Epilepsy/Seizures (HD-9)

Guideline	Page
Epilepsy/Seizures (HD-9.1).....	85
Perioperative Evaluations for Drug-Resistant Epilepsy (HD-9.2).....	87
References (HD-9).....	90

Epilepsy/Seizures (HD-9.1)

HD.EP.0009.1.A

v2.0.2026

- MRI Brain without contrast (CPT® 70551) **OR** MRI Brain without and with contrast (CPT® 70553) is medically necessary for:
 - evaluation of new onset seizures
 - refractory or drug-resistant seizures
 - new neurologic deficit or no return to previous neurologic baseline
 - change in the type of seizure
 - additional evaluation, if CT Head was performed for an initial evaluation for new onset seizure, MRI (as described above) is medically necessary for additional evaluation
 - follow-up, MRI Brain with “Epilepsy Protocol” is medically necessary
- MRI Brain without contrast (CPT® 70551) **OR** MRI Brain without and with contrast (CPT® 70553) **OR** CT Head without contrast (CPT® 70450) is medically necessary for:
 - repeat imaging at the discretion of the neurologist or neurosurgeon, or any provider in consultation with a neurologist or neurosurgeon.
- CT Head without contrast (CPT® 70450) is medically necessary for:
 - evaluation of structural findings in seizure etiologies that contain dystrophic calcifications, such as with oligodendrogliomas and tuberous sclerosis
 - acute setting of seizure evaluation
- CT Head (contrast as requested) (CPT® 70450, CPT® 70460, **OR** CPT® 70470) is medically necessary when:
 - MRI is contraindicated
 - request is urgent
- For seizure and/or altered mental status associated with head trauma, see **Head Trauma (HD-13.1)**
- 3D T1 and/or FLAIR sequences are useful in improving lesion detection for the diagnosis and monitoring of epilepsy. 3D T1 and FLAIR sequences do not require an additional CPT® for 3D rendering (CPT® 76376 and CPT® 76377).¹²
- Quantitative Magnetic Resonance Image (MRI) Analysis of the Brain
 - Volumetric or quantitative analysis of the brain or temporal lobes and hippocampus may be requested as (CPT® 0865T or CPT® 0866T)
 - These studies lack sufficient specificity and sensitivity to be clinically useful. Their use is limited to research studies and are not medically necessary in the evaluation of epilepsy.

Evidence Discussion (HD-9.1)

- The use of advanced imaging is medically necessary for the initial evaluation of adults with seizure. Unenhanced CT is more readily available so is usually the initial imaging examination performed for adults presenting with first seizure. In the acute setting this primary exam is utilized to exclude conditions requiring urgent or emergent intervention, such as a bleed.⁵ CT is also appropriate if MRI is contraindicated and to evaluate seizure foci that contain dystrophic calcifications, such as oligodendrogliomas and tuberous sclerosis, yet the overall success of CT in detecting focal lesions in epilepsy is low, at approximately 30%.^{1,5} In studies where individuals were evaluated with both MRI and CT, CT failed to detect potentially epileptogenic lesions identified on MRI 16-42% of the time.⁵ Therefore, MRI of the brain is the study of choice to evaluate new-onset seizures (when available), refractory or drug-resistant seizures, prior to discontinuation of anti-epileptic therapy, and known seizure with change in semiology.
- If CT is initially performed, it can be followed by an MRI. If an MRI not using the "Epilepsy Protocol" is initially performed, it can be followed by an MRI with the "Epilepsy Protocol" for greater sensitivity of detection of epileptogenic lesions. The failure rate for detection of lesions improving from 39% to 91% with epilepsy-trained radiologist reading MRI images obtained using a specialized, epilepsy protocol.^{1,12,23}

Perioperative Evaluations for Drug-Resistant Epilepsy (HD-9.2)

HD.EP.0009.2.A

v2.0.2026

- **ANY** or **ALL** the following requests are medically necessary, obtained concurrently or sequentially, for consideration of potential surgery:
 - MRI Brain without contrast (CPT[®] 70551) **OR** MRI Brain without and with contrast (CPT[®] 70553)
 - Follow-up MRI Brain after a previous routine study if performed with special "Epilepsy Protocol" (typically 3T or 7T magnet, thin sections with angled slices through hippocampus and temporal lobes)
 - Metabolic FDG PET (CPT[®] 78608)
 - Metabolic PET/MRI is MRI Brain without contrast (CPT[®] 70551) **OR** MRI Brain with and without (CPT[®] 70553) co-registered **WITH** FDG-PET Brain (CPT[®] 78608) and is medically necessary for pre-surgical evaluation of refractory seizure when requested by neurosurgeon or neurologist or any provider in consultation with a neurosurgeon or neurologist.
 - Metabolic PET/MRI is MRI Brain without contrast (CPT[®] 70551) **OR** MRI Brain without and with (CPT[®] 70553) co-registered **WITH** FDG-PET Brain (CPT[®] 78608) and is medically necessary for pre-surgical evaluation of refractory seizure when requested by neurosurgeon or neurologist or any provider in consultation with a neurosurgeon or neurologist.
 - Ictal SPECT (CPT[®] 78803 or 78830)
 - Functional MRI (fMRI) (CPT[®] 70555 or CPT[®] 70554)
 - If MRA Head (CPT[®] 70544) is medically necessary but Functional MRI (CPT[®] 70554 or CPT[®] 70555) was erroneously ordered, then CPT[®] 70544 may be substituted when appropriate (see **Functional MRI (fMRI) (HD-24.2)**)
 - MRI Brain without contrast (CPT[®] 70551) **OR** MRI Brain with and without and with (CPT[®] 70553)
 - Medically necessary if co-registered with Magnetoencephalography (MEG)
 - Quantitative Magnetic Resonance Image (MRI) Analysis of the Brain
 - Volumetric or quantitative analysis of the brain or temporal lobes and hippocampus may be requested as (CPT[®] 0865T or CPT[®] 0866T)
 - These studies lack sufficient specificity and sensitivity to be clinically useful. Their use is limited to research studies and are considered not medically necessary in the evaluation of epilepsy.
 - 3D rendering CPT[®] 76377 (3D rendering requiring image post-processing on an independent workstation) or CPT[®] 76376 (3D rendering not requiring image post-

processing on an independent workstation) is not medically necessary for epilepsy surgery alone, since 3D rendering can be obtained as part of the MRI Brain "Epilepsy Protocol", unless complicated surgical repair considerations involving craniotomy are required.

- When non-invasive EEG monitoring is insufficient, intracranial monitoring with stereo-EEG or grids/strips and depth electrodes is medically necessary with additional imaging for neuronavigation. See **Neurosurgical Imaging (HD-28.1)** and **Neuronavigation (HD-28.2)**
 - Post-operative imaging including after intracranial (EEG) monitoring per neurosurgeon or neurologist or any provider in consultation with neurosurgeon or neurologist.
- See **Primary Central Nervous System Tumors-General Considerations (ONC-2.1)** in the Oncology Imaging Guidelines and/or **Neurosurgical Imaging (HD-28.1)** for additional imaging requests for surgery

Background and Supporting Information

- Magnetoencephalography (MEG) plays an important role in clarifying the significance of abnormalities seen on both structural and functional imaging, for the purpose of epileptogenic zone localization for surgical planning. When used in conjunction with other techniques, MEG plays a major role in the non-invasive epilepsy surgery evaluation. Currently, the guidelines only require review for the MRI co-registered with MEG.
- MEG followed by co-registration with Brain MRI is referred to as Magnetic Source Imaging (MSI)

Below are examples of surgical treatment or an interventional modality that may be under active consideration for individuals with intractable epilepsy (not all inclusive):

- Focal Resection
 - Temporal Lobe Resection
 - Extratemporal Resection
- Lesionectomy
- Multiple Subpial Transections
- Laser Interstitial Thermal Therapy (LITT)
- Anatomical or Functional Hemispherectomy and Hemispherotomy
- Corpus Callosotomy
- Stereotactic Radiosurgery
- Neurostimulation Device Implantations (Neuromodulation) including
 - Vagus Nerve Stimulation (VNS)
 - Responsive Neurostimulation (RNS) system also known as NeuroPace
 - Deep Brain Stimulation (DBS)

Evidence Discussion (HD-9.2)

- MRI Head for the initial imaging of individuals with known seizure disorder requiring surgical planning to identify the seizure focus including tumor, hippocampal sclerosis, and vascular lesions. Follow-up MRI after a previous standard protocol study if performed with special "Epilepsy Protocol" can provide additional information.¹
- FDG-PET/CT Brain may be complementary as a functional tool to structural imaging using MRI to localize the focus of refractory seizure activity, with reported sensitivities of PET in the assessment of temporal lobe epilepsy ranging from 87% to 90% and extra-temporal lobe epilepsy ranging from 38% to 55%.¹
- PET/MRI, performed as MRI Brain without contrast, or without and with contrast, co-registered with FDG-PET brain, increased the sensitivity of brain MRI in 60% of non-lesional individuals and is therefore supported for pre-surgical evaluation of refractory seizures.²⁷
- Ictal SPECT, Functional MRI (fMRI) and MRI Brain co-registered with Magnetoencephalography (MEG) are also useful to further identify the seizure focus as well as eloquent areas of the cortex that are essential for language, motor function and memory in surgical candidates when done as a replacement for the higher risk Wada test or direct electrical stimulation mapping.^{14,15,16}

References (HD-9)

v2.0.2026

1. Expert Panel on Neurological Imaging, Lee RK, Burns J, et al. ACR Appropriateness Criteria® Seizures and Epilepsy. *J Am Coll Radiol*. 2020;17(5S):S293-S304. doi:10.1016/j.jacr.2020.01.037
2. Krumholz A, Wiebe S, Gronseth GS, et al. Evidence-based guideline: Management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Neurology*. 2015;84(16):1705-1713. doi:10.1212/wnl.0000000000001487
3. Hirtz D, Berg A, Bettis D, et al. Practice parameter: treatment of the child with a first unprovoked seizure: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology*. 2003;60(2):166-175. doi:10.1212/01.wnl.0000033622.27961.b6
4. Lapalme-Remis S, Nguyen DK. Neuroimaging of Epilepsy. *Continuum (Minneap Minn)*. 2022;28(2):306-338. doi:10.1212/CON.0000000000001080
5. Tranvinh E, Lanzman B, Provenzale J, Wintermark M. Imaging Evaluation of the Adult Presenting With New-Onset Seizure. *AJR Am J Roentgenol*. 2019;212(1):15-25. doi:10.2214/ajr.18.20202
6. Ho K, Lawn N, Bynevelt M, Lee J, Dunne J. Neuroimaging of first-ever: Contribution of MRI if CT is normal. *Neurol Clin Pract*. 2013;3(5):398-403. doi:10.1212/CPJ.0b013e3182a78f25
7. Knowlton RC, Elgavish RA, Bartolucci A, et al. Functional imaging: II. Prediction of epilepsy surgery outcome. *Ann Neurol*. 2008;64(1):35-41. doi:10.1002/ana.21419
8. Weil S, Noachtar S, Arnold S, Yousry TA, Winkler PA, Tatsch K. Ictal ECD-SPECT differentiates between temporal and extratemporal epilepsy: confirmation by excellent postoperative seizure control. *Nucl Med Commun*. 2001;22(2):233-237. doi:10.1097/00006231-200102000-00016.
9. Qiu J, Cui Y, Qi B, Sun L, Zhu Z. The application of preoperative computed tomography angiogram for hemispherectomy. *Clin Pract*. 2017;7(4). doi:10.4081/cp.2017.992.
10. Guedj E, Varrone A, Boellaard R, et al. EANM procedure guidelines for brain PET imaging using [¹⁸F]FDG, version 3 [published correction appears in Eur J Nucl Med Mol Imaging. 2022 Mar 7;:]. *Eur J Nucl Med Mol Imaging*. 2022;49(2):632-651. doi:10.1007/s00259-021-05603-w
11. Correction to: EANM procedure guidelines for brain PET imaging using [¹⁸F]FDG, version 3. Guedj E, Varrone A, Boellaard R, Albert NL, Barthel H, van Berckel B, Brendel M, Cecchin D, Ekmekcioglu O, Garibotto V, Lammertsma AA, Law I, Peñuelas I, Semah F, Traub-Weidinger T, van de Giessen E, Van Weehaeghe D, Morbelli S. *Eur J Nucl Med Mol Imaging*. 2022 May;49(6):2100-2101. doi: 10.1007/s00259-022-05755-3.
12. Bernasconi A, Cendes F, Theodore WH, et al. Recommendations for the use of structural magnetic resonance imaging in the care of patients with epilepsy: A consensus report from the International League Against Epilepsy Neuroimaging Task Force. *Epilepsia*. 2019;60(6):1054-1068. doi:10.1111/epi.15612
13. Passaro EA. Neuroimaging in Adults and Children With Epilepsy. *Continuum (Minneap Minn)*. 2023;29(1):104-155. doi:10.1212/CON.0000000000001242
14. Szaflarski JP, Gloss D, Binder JR, et al. Practice guideline summary: Use of fMRI in the presurgical evaluation of patients with epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*. 2017;88(4):395-402. doi:10.1212/WNL.0000000000003532
15. Ponisio MR, Zempel JM, Day BK, et al. The Role of SPECT and PET in Epilepsy. *AJR Am J Roentgenol*. 2021;216(3):759-768. doi:10.2214/AJR.20.23336
16. Rampp S, Stefan H, Wu X, et al. Magnetoencephalography for epileptic focus localization in a series of 1000 cases. *Brain*. 2019;142(10):3059-3071. doi:10.1093/brain/awz223
17. Culler GW 4th, Jobst BC. Surgical Treatments for Epilepsy. *Continuum (Minneap Minn)*. 2022;28(2):536-558. doi:10.1212/CON.0000000000001106
18. Delev D, Quesada CM, Grote A, et al. A multimodal concept for invasive diagnostics and surgery based on neuronavigated voxel-based morphometric MRI postprocessing data in previously nonlesional epilepsy. *J Neurosurg*. 2018;128(4):1178-1186. doi:10.3171/2016.12.jns.161676.
19. Englot DJ, Nagarajan SS, Imber BS, et al. Epileptogenic zone localization using magnetoencephalography predicts seizure freedom in epilepsy surgery. *Epilepsia*. 2015;56(6):949-958. doi:10.1111/epi.13002

20. Laohathai C, Ebersole JS, Mosher JC, et al. Practical Fundamentals of Clinical MEG Interpretation in Epilepsy. *Front Neurol*. 2021;12:722986. Published 2021 Oct 14. doi:10.3389/fneur.2021.722986
21. Carrette E, Stefan H. Evidence for the role of magnetic source imaging in the presurgical evaluation of refractory epilepsy patients. *Front Neurol*. 2019;10:933. Published 2019 Sep 10. doi:10.3389/fneur.2019.00933
22. Spencer D. MRI (minimum recommended imaging) in epilepsy. *Epilepsy Curr*. 2014;14(5):261-263. doi:10.5698/1535-7597-14.5.261
23. Wellmer J, Quesada CM, Rothe L, Elger CE, Bien CG, Urbach H. Proposal for a magnetic resonance imaging protocol for the detection of epileptogenic lesions at early outpatient stages. *Epilepsia*. 2013;54(11):1977-1987. doi:10.1111/epi.12375
24. Oldan JD, Shin HW, Khandani AH, Zamora C, Benefield T, Jewells V. Subsequent experience in hybrid PET-MRI for evaluation of refractory focal onset epilepsy. *Seizure*. 2018;61:128-134. doi:10.1016/j.seizure.2018.07.022
25. Salamon N, Kung J, Shaw SJ, et al. FDG-PET/MRI coregistration improves detection of cortical dysplasia in patients with epilepsy. *Neurology*. 2008;71(20):1594-1601. doi:10.1212/01.wnl.0000334752.41807.2f
26. Johnson R, Rizk G, Kaur H, Ibekwe H, Atta M, Gayed I. Refractory seizures: Prediction of outcome of surgical intervention based on results from PET-CT, PET-MRI and electroencephalography. *Neuroradiol J*. 2020;33(1):57-65. doi:10.1177/1971400919881464
27. Tóth M, Barsi P, Tóth Z, et al. The role of hybrid FDG-PET/MRI on decision-making in presurgical evaluation of drug-resistant epilepsy. *BMC Neurol*. 2021;21(1):363. Published 2021 Sep 18. doi:10.1186/s12883-021-02352-z
28. NeuroQuant - Cortechs.ai. Cortechs.ai. Published January 9, 2025

Trigeminal Neuralgia and other Centrally Mediated Facial Pain Syndromes (HD-10)

Guideline	Page
Trigeminal Neuralgia/Trigeminal Neuropathy (HD-10.1)	93
Glossopharyngeal Neuralgia/Glossopharyngeal Neuropathy (HD-10.2)	95
Evidence Discussion (HD-10).....	96
References (HD-10).....	97

Trigeminal Neuralgia/Trigeminal Neuropathy (HD-10.1)

HD.TM.0010.1.A

v2.0.2026

- MRI Brain without and with contrast (CPT[®] 70553) (with special attention to the skull base) or MRI Brain without contrast (CPT[®] 70551) **AND/OR** facial imaging, MRI Orbit/Face/Neck without contrast (CPT[®] 70540) or MRI Orbit/Face/Neck without and with contrast (CPT[®] 70543) is medically necessary for:
 - symptoms of trigeminal neuropathy
 - trigeminal neuralgia
 - trigeminal neuralgia which involves the ophthalmic nerve, (periorbital or forehead pain), once post-herpetic neuralgia (a complication of shingles) has been excluded by history
- CT Maxillofacial without contrast (CPT[®] 70486) **OR** CT Maxillofacial with contrast (CPT[®] 70487) is medically necessary for evaluating the skull base and neural foramina
- Contrast-enhanced navigation protocol CT (CPT[®] 76497) is medically necessary for gamma knife stereotactic radiosurgery for trigeminal neuralgia, (see also, **Neuronavigation (HD-28.2)** and **Post-Operative Imaging (HD-28.3)**) for post-treatment imaging studies
- MRI Cervical spine without contrast (CPT[®] 72141) **OR** MRI Cervical spine without and with contrast (CPT[®] 72156) is medically necessary for suspected lesion of the spinal trigeminal tract and nucleus.
- MRA Head (CPT[®] 70544, CPT[®] 70545 or CPT[®] 70546) **OR** CTA Head (CPT[®] 70496) is medically necessary for:
 - trigeminal neuralgia (vascular imaging may be obtained concurrently with structural brain imaging)
 - failed medical treatment
 - surgical planning

Background and Supporting Information

The differential diagnosis of facial pain is extensive, complex, and difficult, and there is considerable case-to-case variation in optimal imaging pathway.

Symptoms of trigeminal neuropathy include facial pain, facial numbness, and/or weakness of the muscles of mastication.

Trigeminal neuralgia, also known as tic douloureux (the involuntary wincing associated with the occurrence of pain), refers to sudden, severe, shooting "electrical" pains along

one or more sensory divisions of the trigeminal nerve, provoked by movements such as chewing, or by external stimuli, such as wind blowing or touching the face.

The spinal trigeminal tract and nucleus extend from the midpons caudally into the upper cervical cord at the C2-4 levels. For suspected lesions of the spinal trigeminal tract and nucleus, imaging the brain stem and the cervical spinal cord is supported.

Glossopharyngeal Neuralgia/ Glossopharyngeal Neuropathy (HD-10.2)

HD.TM.0010.2.A

v2.0.2026

- MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without contrast (CPT[®] 70551) **AND/OR** MRI Orbit/Face/Neck without and with contrast (CPT[®] 70543) or MRI Orbit/Face/Neck without contrast (CPT[®] 70540) is medically necessary for suspected glossopharyngeal neuralgia or neuropathy
- CT Neck with contrast (CPT[®] 70491) is medically necessary to delineate skull-base erosion, deep space neck masses, calcifications, the skull base bony anatomy, and/or the stylohyoid ligament (see also **Eagle Syndrome (Neck-10.3)**)
- MRA Head with contrast (CPT[®] 70545), or MRA Head without and with contrast (CPT[®] 70546), **AND/OR** MRA Neck with contrast (CPT[®] 70548), or MRA Neck without and with contrast (CPT[®] 70549) is medically necessary to assess for neurovascular compression for the evaluation of glossopharyngeal neuralgia

Background and Supporting Information

- Glossopharyngeal neuralgia presents as severe pain in the throat and neck, classically triggered by swallowing.
- Glossopharyngeal neuropathy may present with pain, dysphagia, loss of gag reflex, impaired taste, and impaired sensation along posterior one-third of the tongue and/or inability to elevate the palate.

Evidence Discussion (HD-10)

v2.0.2026

- The American Academy of Neurology recommends routine use of MRI in the evaluation of individuals with trigeminal neuralgia.⁴ Neuroimaging identifies structural causes in up to 15% of individuals. The most commonly identified abnormalities include cerebellopontine angle tumors and multiple sclerosis plaques.⁴
- MRI brain and/or MRI orbits, face and neck are necessary for direct visualization of the entire course of the trigeminal nerve.⁵
- MRA head, when combined with MRI brain for evaluation of vascular compression of the trigeminal nerve, has sensitivity of 97%-100% and specificity of 100%.⁵ CTA is less commonly performed concurrently with MRI of the trigeminal nerve.⁵
- CT maxillofacial may be complementary to MRI in characterizing skull-base erosions, calcifications, and skull-base foramina.
- In the evaluation of glossopharyngeal neuralgia, MRI of the brain and/or MRI orbits, face and neck, allows direct visualization of the entire course of the glossopharyngeal nerve. Imaging should include the pharynx and larynx to exclude a neck mass. To further evaluate bony anatomy, calcifications, and the stylohyoid ligament, CT neck is also appropriate. MRA head and neck is helpful to exclude neurovascular compression in individuals with glossopharyngeal neuralgia.⁵

References (HD-10)

v2.0.2026

1. Goh BT, Poon CY, Peck RHL. The importance of routine magnetic resonance imaging in trigeminal neuralgia diagnosis. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology*. 2001;92(4):424-429. doi:10.1067/moe.2001.115130.
2. Yalthro TC, Jankovic J. The many faces of hemifacial spasm: Differential diagnosis of unilateral facial spasms. *Movement Disorders*. 2011;26(9):1582-1592. doi:10.1002/mds.23692.
3. Cruccu G. Trigeminal Neuralgia. *CONTINUUM: Lifelong Learning in Neurology*. 2017;23(2):396-420. doi:10.1212/con.0000000000000451.
4. AAN Practice Parameter: The Diagnostic Evaluation and Treatment of Trigeminal Neuralgia. October 2008. Reaffirmed 5/22/2021.
5. Expert Panel on Neurological Imaging, Rath TJ, Policeni B, et al. ACR Appropriateness Criteria® Cranial Neuropathy: 2022 Update. *J Am Coll Radiol*. 2022;19(11S):S266-S303. doi:10.1016/j.jacr.2022.09.021

Headache (HD-11)

Guideline	Page
Headache General Guidelines (HD-11.0).....	99
Headache and Suspected Vascular Dissection (HD-11.1).....	101
Headaches with Red Flags (HD-11.2).....	102
Sudden Onset of Headache (HD-11.3).....	103
Trigeminal Autonomic Cephalgias (HD-11.4).....	105
Skull Base, Orbit, Periorbital or Oromaxillary (HD-11.5).....	106
Suspected Intracranial Extension of Sinusitis or Mastoiditis (HD-11.6).....	107
New Headache Onset Older than Age 50 (HD-11.7).....	108
Cancer or Immunosuppression (HD-11.8).....	109
Abnormal Blood Clotting (HD-11.9).....	110
Pregnancy (HD-11.10).....	111
Physical Exertion (HD-11.11).....	112
Headaches Associated With Head Trauma (HD-11.12).....	113
Systemic Infections (HD-11.13).....	114
Hydrocephalus Shunts (HD-11.14).....	115
Low-Pressure Headache and CSF Leak (HD-11.15).....	117
Cervicogenic Headaches Including Occipital Neuritis/Neuralgia (HD-11.16).....	119
Advanced Imaging Indications Related To Migraines (HD-11.17).....	121
Evidence Discussion (HD-11).....	123
References (HD-11).....	125

Headache General Guidelines (HD-11.0)

HD.HA.0011.0.A

v2.0.2026

- MRI Brain without contrast (CPT® 70551) or MRI Brain without and with contrast (CPT® 70553) or CT Head without contrast (CPT® 70450) are medically necessary for **any** of the following:
 - Headache accompanied by seizures, vomiting, focal neurological complaints including dizziness, visual change, altered mental status, or acute hypertension
 - Abnormal examination findings (including, but not limited to, altered mental status, papilledema, focal signs or symptoms including unilateral weakness or sensory loss, hyperreflexia, clonus, increased tone, Hoffman or Babinski sign, loss of coordination, seizures, gait disturbance, cranial nerve abnormality, vision loss, nystagmus, dysarthria, dysphagia, fever, meningismus)
 - For papilledema, see **Papilledema/Pseudotumor Cerebri (HD-17.1)**
- Chronic headache with significant change in character, severity, or frequency of headache (for example: progressively worsening headache over a period of days or weeks, transformation of established migraine to chronic daily headaches), the following are medically necessary:
 - MRI Brain without contrast (CPT® 70551) **OR**
 - MRI Brain without and with contrast (CPT® 70553) **OR**
 - CT Head without contrast (CPT® 70450)
 - MRA/MRV Head (CPT® 70544, CPT® 70545, or CPT® 70546) or CTA/CTV Head (CPT® 70496) is medically necessary as an addition to evaluate the recent onset of a progressive, severe, daily headache, with or without papilledema and concern for cerebral venous sinus thrombosis.
 - CT and MR Venography (CTV and MRV) are reported with the same codes as the CTA/MRA counterpart. If arterial and venous CT or MR studies are both performed in the same session, only **ONE** CPT® code should be used to report both procedures.
- Advanced imaging of the head is **NOT** medically necessary for any of the following:
 - Primary headache disorder in the absence of focal neurological deficits or "red flags" (see **Headaches with Red Flags (HD-11.2)** and **Advanced Imaging Indications Related to Migraines (HD-11.17)**)
 - Newly diagnosed migraine or tension-type headache with a normal neurologic exam or for chronic stable headache including migraine with no neurologic deficit.
 - Duplex Ultrasound Carotid Arteries (CPT® 93880) does not have a role in the evaluation of headaches (including migraines), except for suspected carotid dissection (see **Initial Imaging (PVD-3.1)** in the Peripheral Vascular Disease

Imaging Guidelines, **Headache and Suspected Vascular Dissection (HD-11.1)**,
and **Stroke/TIA (HD-21.1)**)

Background and Supporting Information

- The yield of detecting abnormal, treatable lesions by CT or MRI in individuals with headache but normal neurological exam has been found to be low.

Health Equity Considerations

Headache disorders, including migraines, are among the most prevalent and disabling neurological conditions, yet their diagnosis and management are marked by significant disparities across racial, socioeconomic, and geographic lines. Despite comparable prevalence rates, historically marginalized populations are less likely to receive accurate diagnoses, evidence-based treatments, and specialist care, resulting in disproportionate burden and reduced quality of life.⁴⁵

Headaches can affect well-being and cause disability, yet the majority of countries face issues with limited access to health care, awareness, and insufficient health policies.⁴⁶ Globally, the prevalence of migraines is estimated around 14%, and accounting for 52% of active headache disorders.⁴⁵ It is estimated that a headache disorder will affect 90% of individuals during their lifetime.⁴⁷ In the U.S., acute headache is the fourth most common reason for a visit to the emergency room.⁴⁸

Racial and ethnic minorities in the U.S. may not receive equitable care when compared to White individuals. For example, Black individuals are 40% less likely to be treated by a neurologist and are more likely to end up in emergency departments for an untreated migraine.⁴⁵

Headache disorders can present within a wide range of severity, which calls for levels of care for headache services.⁴⁶ However, a dearth in headache education in medical studies results in inadequate diagnoses and treatment, limiting access to proper care.⁴⁶ Telemedicine, which is the remote delivery of healthcare, can allow individuals access to services that may otherwise be inaccessible due to factors such as long waiting times or long-distance travel.⁴⁶ However, this requires access to technology and infrastructure, as well as technological literacy, for individuals who may not possess the necessary tools.⁴⁶

Headache and Suspected Vascular Dissection (HD-11.1)

HD.HA.0011.1.A

v2.0.2026

- CTA Neck (CPT® 70498) and MRA Neck (CPT® 70547, CPT® 70548, or CPT® 70549) are medically necessary in the evaluation for headache with suspected carotid or vertebral artery dissection and in certain high-risk scenarios including, but not exclusive to: Fibromuscular dysplasia (FMD), Marfan disease, acute MVA with whiplash, and acute headache and/or neck pain due to chiropractic manipulation.
 - CTA Head (CPT® 70496) or MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) is medically necessary if there is concern for extension of a carotid dissection to the skull base or above. CTA Head and Neck (CPT® 70471) must be substituted when both CTA Head (CPT® 70496) and CTA Neck (CPT® 70498) are performed during the same session.
 - Evaluation of posterior circulation disease requires both neck and head MRA/CTA to visualize the entire vertebro-basilar system.
- MRA Neck (CPT® 70547, CPT® 70548, or CPT® 70549) or CTA Neck (CPT® 70498) is medically necessary if arterial dissection is suspected, or known and re-evaluation is needed (as directed by neurologist or neurosurgeon or any provider in consultation with a neurologist or neurosurgeon).
- MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) or CTA Head (CPT® 70496, or CPT® 70498) is medically necessary if arterial dissection is suspected, or known and re-evaluation is needed (as directed by neurologist or neurosurgeon or any provider in consultation with a neurologist or neurosurgeon)
- Other vascular imaging indications for headaches require additional information.
 - See **Stroke/TIA (HD-21.1)**, **Sudden Onset of Headache (HD-11.3)**, **New Headache Onset Older than Age 50 (HD-11.7)**, **Abnormal Blood Clotting (HD-11.9)**, **Pregnancy (HD-11.10)**, **Physical Exertion (HD-11.11)**, and **Systemic Infections (HD-11.13)**

Headaches with Red Flags (HD-11.2)

HD.HA.0011.2.A

v2.0.2026

- Headaches with any of the following Red Flags:
 - If any of the below unusual symptoms or history are present, advanced imaging studies are medically necessary (see relevant section):
 - Cancer history or immunosuppression (see **Cancer or Immunosuppression (HD-11.8)**)
 - Sudden onset (see **Sudden Onset of Headache (HD-11.3)**)
 - New onset age >50 (see **New Headache Onset Older than Age 50 (HD-11.7)** and **Migraine Exceptions (HD-11.17)**)
 - History of head trauma (see **Headaches Associated with Head Trauma (HD-11.12)**, and **Head and Facial Trauma (HD-13)**)
 - Headache precipitated by cough or Valsalva, physical exertion, or sexual activity (see **Physical Exertion (HD-11.11)**)
 - Currently pregnant (including pregnancy and the immediate postpartum period) (see **Pregnancy (HD-11.10)**)
 - Hypercoagulable state or bleeding disorder (see **Abnormal Blood Clotting (HD-11.9)**)
 - New persistent headache (see **Migraine Exceptions (HD-11.17)**)
 - Headache awakens individual from sleep (see **Sudden Onset of Headache (HD-11.3)**)

Background and Supporting Information

Aura symptoms may accompany or precede a headache within 60 minutes and may include, but are not exclusive to, the following symptoms:

- Visual (flashing lights, loss of vision)
- Sensory (paresthesia)
- Speech and/or language (difficulty speaking)
- Motor (any weakness)
- Brainstem (dizziness, double vision) and retinal (visual complaints)

Sudden Onset of Headache (HD-11.3)

HD.HA.0011.3.A

v2.0.2026

- For sudden onset of headache including:
 - worst, most severe headache ever experienced or thunderclap-type (example: awakening from sleep)
 - sudden onset unilateral headache, suspected carotid or vertebral dissection or ipsilateral Horner's syndrome
 - consideration of reversible cerebral vasoconstriction syndrome (RCVS) (typically bilateral headache)
 - high-risk scenarios including Fibromuscular Dysplasia (FMD), Marfan Disease, MVA with whiplash, and chiropractic manipulation
- If any of these onset of headache features are present, the following are medically necessary:
 - CT Head without contrast (CPT® 70450) **OR** MRI Brain without contrast (CPT® 70551) **OR** MRI Brain without and with contrast (CPT® 70553) **AND/OR**
 - CTA Head (CPT® 70496) **or** MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546)
 - MRA Neck (CPT® 70547, CPT® 70548, or CPT® 70549) **OR** CTA Neck (CPT® 70498) if carotid or vertebral artery dissection is suspected
 - CTA Head and Neck (CPT® 70471) combination code must be substituted when both CTA Head (CPT® 70496) and CTA Neck (CPT® 70498) are performed in the same session.
 - CT and MR Venography (CTV and MRV) are reported with the same codes as the CTA/MRA counterpart. If arterial and venous CT or MR studies are both performed in the same session, only **ONE** CPT® code should be used to report both procedures
- Repeat MRI Brain and/or MRA/CTA Head and Neck imaging is medically necessary in 2-4 weeks if suspicion of Reversible Cerebral Vasoconstriction Syndrome (RCVS) is high and to follow up until resolution of vasospasm, edema and/or hemorrhage, at the discretion of the neurologist, neurosurgeon, hematologist, or physiatrist, or any provider in consultation with a neurologist, neurosurgeon, hematologist, or physiatrist
- MRA Neck (CPT® 70547, CPT® 70548, or CPT® 70549) or CTA Neck (CPT® 70498) is medically necessary if arterial dissection is suspected, or known and re-evaluation is needed (as directed by neurologist or neurosurgeon or any provider in consultation with a neurologist or neurosurgeon)
- MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) or CTA Head (CPT® 70496, CPT® 70498) is medically necessary if arterial dissection is suspected, or known and

re-evaluation is needed (as directed by neurologist or neurosurgeon or any provider in consultation with a neurologist or neurosurgeon)

- CTA Head and Neck (CPT ® 70471) combination code must be substituted when both CTA Head (CPT® 70496) and CTA Neck (CPT® 70498) are performed in the same session
- Other vascular imaging indications for headaches require additional information.
 - See **Stroke/TIA (HD-21.1)**, **New Headache Onset Older than Age 50 (HD-11.7)**, **Abnormal Blood Clotting (HD-11.9)**, **Pregnancy (HD-11.10)**, **Physical Exertion (HD-11.11)**, **Cerebral Aneurysms (HD-12.1)** and **Systemic Infections (HD-11.13)**

Trigeminal Autonomic Cephalgias (HD-11.4)

HD.HA.0011.4.A

v2.0.2026

- For trigeminal autonomic cephalgias and cluster headache, the following are medically necessary:
 - MRI Brain without and with contrast (CPT[®] 70553) **OR**
 - MRI Brain without contrast (CPT[®] 70551)
 - May also include pituitary screening (see **Pituitary, Sella, Hypothalamus (HD-19)**)
- For facial pain (see **Trigeminal Neuralgia and other Centrally Mediated Facial Pain Syndromes (HD-10)**)

Background and Supporting Information

Trigeminal autonomic cephalgias includes cluster headache, short-lasting, unilateral, neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) syndromes; short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) and hemicrania paroxysmal and continua.

Skull Base, Orbit, Periorbital or Oromaxillary (HD-11.5)

HD.HA.0011.5.A

v2.0.2026

- Skull base, orbital, periorbital or oromaxillary imaging is medically necessary for concern of skull base tumors in individuals with head and neck cancers, other skull base abnormalities seen on previous imaging, any invasive sinus infections as well as sinus tumors or orbital tumors with intracranial extension.
- In these clinical scenarios, the following studies are medically necessary:
 - MRI Brain and/or Orbits/Face/Neck without and with contrast (CPT[®] 70553 and/or CPT[®] 70543) **OR**
 - MRI Brain and/or Orbits/Face/Neck without contrast (CPT[®] 70551 and/or CPT[®] 70540) **OR**
 - CT Head and/or Orbits/Temporal bone without and with contrast (CPT[®] 70470 and/or CPT[®] 70482) **OR**
 - CT Head and/or Orbits/Temporal bone with contrast (CPT[®] 70460 and/or CPT[®] 70481)

Suspected Intracranial Extension of Sinusitis or Mastoiditis (HD-11.6)

HD.HA.0011.6.A

v2.0.2026

- For suspected intracranial extension of sinusitis or mastoiditis, the following is medically necessary:
 - MRI Brain without and with contrast (CPT[®] 70553)
 - See **Mastoid Disease or Ear Pain (HD-26.1)** and **Skull Base, Orbit, Periorbital or Oromaxillary (HD-11.5)**

New Headache Onset Older than Age 50 (HD-11.7)

HD.HA.0011.7.A

v2.0.2026

- For new onset headache in individuals older than 50 years of age, the following are medically necessary:
 - MRI Brain without contrast (CPT[®] 70551) **OR**
 - MRI Brain without and with contrast (CPT[®] 70553) **OR**
 - CT Head without contrast (CPT[®] 70450)
 - If Giant Cell Arteritis, also known as Temporal Arteritis, is suspected, MRA Head (CPT[®] 70544, CPT[®] 70545, or CPT[®] 70546), see **Cerebral Vasculitis (HD-22)**

Cancer or Immunosuppression (HD-11.8)

HD.HA.0011.8.A

v2.0.2026

- For new headache in individuals with cancer, history of cancer, or those who are immunocompromised, the following are medically necessary:
 - MRI Brain without contrast (CPT[®] 70551) **OR**
 - MRI Brain without and with contrast (CPT[®] 70553)
- For CT imaging in the setting of individuals with cancer, with history of cancer or who are immunocompromised, see **General Guidelines – CT Head (HD-1.4)**
- See also **Primary Central Nervous System Tumors – General Considerations (ONC-2.1)** and **Brain Metastases (ONC-31.3)**

Abnormal Blood Clotting (HD-11.9)

HD.HA.0011.9.A

v2.0.2026

- MRI Brain without contrast (CPT[®] 70551) **OR** MRI Brain without and with contrast (CPT[®] 70553) **OR** CT Head without contrast (CPT[®] 70450) is medically necessary for:
 - new onset headaches in individual with hypercoagulable states or bleeding disorder
 - MRA/MRV Head (CPT[®] 70544, CPT[®] 70545, or CPT[®] 70546) or CTA/CTV Head (CPT[®] 70496) is medically necessary, in addition, for venogram when requested.
 - CT and MR Venography (CTV and MRV) are reported with the same codes as the CTA/MRA counterpart. If arterial and venous CT or MR studies are both performed in the same session, only **ONE** CPT[®] code should be used to report both procedures
 - individuals with potential for bleeding diathesis
 - Taking anticoagulants or two or more anti-aggregants or having a medical condition that predisposes to bleeding (for example, but not limited to: thrombocytopenia, liver failure, idiopathic thrombocytopenic purpura (ITP), etc.).

Pregnancy (HD-11.10)

HD.HA.0011.10.A

v2.0.2026

- For new onset headache during pregnancy or immediate post-partum period (within 3 months after delivery), ANY or ALL of the following are medically necessary:
 - MRI Brain without contrast (gadolinium relatively contraindicated in pregnancy) (CPT® 70551)
 - CT Head without contrast (CPT® 70450) if urgent
 - MRA/MRV Head (CPT® 70544, CPT® 70545, or CPT® 70546) or CTA/CTV Head (CPT® 70496) when venogram is requested
 - CT and MR Venography (CTV and MRV) are reported with the same codes as the CTA/MRA counterpart. If arterial and venous CT or MR studies are both performed in the same session, only one CPT® code should be used to report both procedures. (gadolinium relatively contraindicated in pregnancy)
 - Vascular imaging is medically necessary concurrently with brain imaging
- Important causes of secondary headache include vascular disorders, such as pre-eclampsia, reversible cerebral vasoconstriction syndrome, and cerebral venous thrombosis, as well as idiopathic intracranial hypertension
- For post-LP/epidural anesthesia, see **Low-Pressure Headache and CSF Leak (HD-11.15)**

Physical Exertion (HD-11.11)

HD.HA.0011.11.A

v2.0.2026

- For onset of headache with Valsalva maneuver, cough, physical exertion, change in position, **or** sexual activity, but not merely a worsening of a pre-existing headache with these activities, the following procedures are medically necessary:
 - MRI Brain without contrast (CPT® 70551) **OR**
 - MRI Brain without and with contrast (CPT® 70553) **OR**
 - CT Head without contrast (CPT® 70450) **AND/OR**
 - MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) **OR**
 - CTA Head without and with contrast (CPT® 70496)
 - MRA Neck (CPT® 70547, CPT® 70548, or CPT® 70549) or CTA Neck (CPT® 70498) if carotid or vertebral artery dissection or aneurysm is suspected
 - CTA Head and Neck (CPT® 70471) combination code must be substituted when both CTA Head (CPT® 70496) and CTA Neck (CPT® 70498) are performed in the same session.

Headaches Associated With Head Trauma (HD-11.12)

HD.HA.0011.12.A

v2.0.2026

- For new or progressively worsening headache with subacute head trauma, defined as within 7 days to three months post-trauma, with or without unexplained cognitive or neurologic deficits, the following are medically necessary:
 - CT Head without contrast (CPT[®] 70450) **OR**
 - MRI Brain without contrast (CPT[®] 70551)
- For persistent headaches attributed to traumatic injury to the head persisting for longer than 3 months following the injury, with or without unexplained cognitive or neurologic deficits, the following are medically necessary:
 - MRI Brain without contrast (CPT[®] 70551) **OR**
 - MRI Brain without and with contrast (CPT[®] 70553)
- Acute head trauma with headache, (see **Head Trauma (HD-13.1)**)
- Acute headache attributed to traumatic injury to the head that developed within 7 days of injury that does not meet criteria under **Head and Facial Trauma (HD-13)**, other subsections may apply including, but not exclusive to: **Headaches with Red Flags (HD-11.2)** and **Sudden Onset of Headache (HD-11.3)**

Systemic Infections (HD-11.13)

HD.HA.0011.13.A

v2.0.2026

- For headaches in the setting of acute, subacute, or chronic systemic infections, the following are medically necessary:
 - MRI Brain without contrast (CPT[®] 70551); or MRI Brain without and with contrast (CPT[®] 70553)
 - MRA/MRV Head (CPT[®] 70544, CPT[®] 70545, or CPT[®] 70546)
 - CT and MR Venography (CTV and MRV) are reported with the same codes as the CTA/MRA counterpart. If arterial and venous CT or MR studies are both performed in the same session, only one CPT[®] code should be used to report both procedures
 - CT Head without contrast (CPT[®] 70450) or CT Head without and with contrast (CPT[®] 70470), when MRI Brain is contraindicated (see **General Guidelines – CT Head (HD-1.4)** for additional CT Head indications)
 - CT Head without (CPT[®] 70450) prior to performance of lumbar puncture (aka spinal tap)
- See **CNS and Head Infection (HD-14.1)**
- See **Neuro-COVID-19 and Sars-CoV-2 Vaccines (HD-14.2)** for headache related to neuro-COVID-19 or SARS-CoV-2 vaccines

Hydrocephalus Shunts (HD-11.14)

HD.HA.0011.14.A

v2.0.2026

Initial Imaging Indications

- MRI Brain without and with contrast (CPT[®] 70553) is medically necessary

Repeat Imaging Indications including CSF flow shunting and Ventriculostomy

- MRI Brain without contrast (CPT[®] 70551) or CT Head without contrast (CPT[®] 70450) is medically necessary for any of the following:
 - New signs or symptoms suggesting shunt malfunction or endoscopic third ventriculostomy (ETV) malfunction
 - Symptoms may include but are not limited to: sepsis after shunt setting adjustments, decreased level of consciousness, protracted vomiting, visual or neurologic deterioration, decline of mentation after initial improvement, or new or changing pattern of seizures
 - Requests ordered by a neurologist, neurosurgeon, or any provider in consultation with a neurologist or neurosurgeon
- MRI Brain without contrast (CPT[®] 70551) or CT Head without contrast (CPT[®] 70450) is medically necessary in the post-operative period following shunt placement or ETV, with further follow-up imaging 6-12 months after the procedure and then every 12 months for individuals with stable clinical findings
- Shunting into the peritoneum (VP shunts) can give rise to abdominal complications, but these are generally symptomatic, so surveillance imaging of the abdomen is not medically necessary unless ordered by or in consultation with neurology, neurosurgery, or interventional radiology.
 - Abdominal ultrasound (CPT[®] 76700) **AND/OR** CT Abdomen or CT Abdomen/Pelvis (contrast as requested), is medically necessary depending on the clinical suspicion
 - Examples include, but are not limited to, suspicion of CSF pseudocyst formation, distal shunt outlet obstruction, or infection.
- See **General Guidelines – Other Imaging Situations (HD-1.7)**

Additional Rarely Used Studies

- Cisternogram (CPT[®] 78630) is medically necessary for the following:
 - Known hydrocephalus with worsening symptoms.
 - Suspected obstructive hydrocephalus.
 - Suspected normal pressure hydrocephalus with gait disturbance and either dementia or urinary incontinence.

- For indications related to CSF Leak, (see **Low-Pressure Headache and CSF Leak (HD-11.15)** and **Nuclear Medicine (HD-36.1)**)
- Cerebrospinal Ventriculography (CPT[®] 78635) is medically necessary for the following:
 - Evaluation of internal shunt, porencephalic cyst, or posterior fossa cyst.
- Nuclear Medicine Shunt Evaluation (CPT[®] 78645) and CSF Flow SPECT (CPT[®] 78803) is medically necessary for the following:
 - Suspected malfunction of ventriculoperitoneal, ventriculopleural, or ventriculovenous shunts.
- For CSF flow imaging, see **CSF Flow Imaging (HD-24.4)**
- See also **General Guidelines - CT Head (HD-1.4)**

Background and Supporting Information

- Ventriculomegaly is the condition where ventricles are enlarged, and this may be due to 1) hydrocephalus, a condition of increased intracranial pressure (ICP) (imaging shows ventricles are disproportionately enlarged compared to sulci), or 2) brain atrophy, most commonly related to age or trauma, which is not associated with increased ICP (imaging shows ventricles and sulci are proportionately enlarged).
- Hydrocephalus is divided into obstructive/non-communicating vs. communicating types, and these usually have different etiologies and radiographic features.
- Obstructive or non-communicating hydrocephalus classically involves an intraventricular obstruction in which CSF flow over the convexities and between the ventricles is reduced, and the proximal ventricle(s) is/are dilated. This is a medical emergency.
- Communicating hydrocephalus involves extraventricular obstruction, poor absorption, or overproduction of CSF. There is normal intracranial CSF flow and absence of disproportionate ventricular dilation, yet there is still a mildly increased CSF pressure. Normal pressure hydrocephalus is an example of this type.
- Distinguishing between ventriculomegaly due to brain atrophy and non-communicating hydrocephalus can be difficult with MRI Brain or CT Head alone, and modalities which visualize CSF flow may be useful such as cisternography or CT cisternography.

Low-Pressure Headache and CSF Leak (HD-11.15)

HD.HA.0011.15.A

v2.0.2026

- Evaluation of suspected CSF leak (rhinorrhea/otorrhea) or refractory post-lumbar puncture headache, post-spinal surgery headache, orthostatic headache, or low-pressure headache:

Indication	Medically Necessary Imaging
Intracranial imaging	• MRI Brain without contrast (CPT[®] 70551) or • MRI Brain without and with contrast (CPT[®] 70553)
Spinal imaging (MRI)	• MRI Cervical Spine without contrast (CPT[®] 72141) or without and with contrast (CPT[®] 72156) AND/OR • MRI Thoracic Spine without contrast (CPT[®] 72146) or without and with contrast (CPT[®] 72157) AND/OR • MRI Lumbar Spine without contrast (CPT[®] 72148) or without and with contrast (CPT[®] 72158)
Spinal imaging, post-myelogram	• CT Cervical Spine with contrast (CPT[®] 72126) AND/OR • CT Thoracic Spine with contrast (CPT[®] 72129) AND/OR • CT Lumbar Spine with contrast (CPT[®] 72132)
Spinal imaging, MR myelogram	• MRI Spine, contrast as requested • Requests following initial negative/non-diagnostic MRI Spine and MRI Brain are also medically necessary
Cisternogram, radionuclide (111 In-DTPA)	• Radionuclide cisternogram (CPT[®] 78630)

Indication	Medically Necessary Imaging
Cisternogram, post-myelogram (iodinated contrast)	- CT Head with contrast (CPT[®] 70460) OR - CT Maxillofacial with contrast (CPT[®] 70487) OR - CT Temporal Bone with contrast (CPT[®] 70481)
Symptoms of CSF rhinorrhea or otorrhea	- CT Head without contrast (CPT[®] 70450) AND/OR - CT Maxillofacial without contrast (CPT[®] 70486) OR - CT Temporal Bone without contrast (CPT[®] 70480)

- Additional Cisternogram (CPT[®] 78630) indications:
 - Known hydrocephalus with worsening symptoms (for example headache)
 - Suspected obstructive hydrocephalus
- Individuals with a Shunt (see **Hydrocephalus Shunts (HD-11.14)**)

Background and Supporting Information

- Common radiological findings of CSF leaks include abnormalities of the cribriform plate or ethmoid sinus, dural dehiscence at the anterior skull base, pneumatization of the sphenoid sinus, and fluid within the middle ear.
- CSF leaks may occur in:
 - CSF shunt over-drainage
 - traumatic CSF leaks
 - Thecal holes and rents from lumbar punctures and epidural catheterizations
 - Spinal and cranial surgeries including skull base and some sinus surgeries
 - Proximal brachial plexus and nerve root avulsion injuries
 - Spontaneous leaks may occur in, but are not exclusive to:
 - Pre-existing weakness of the dural sac including:
 - disorders of connective tissue matrix including Marfan syndrome, Marfanoid features
 - joint hypermobility
 - Trivial trauma in the setting of preexisting dural weakness
 - Spondylotic spurs, herniated discs

Cervicogenic Headaches Including Occipital Neuritis/Neuralgia (HD-11.16)

HD.HA.0011.16.A

v2.0.2026

- Brain imaging should follow applicable sections in **Headache (HD-11)**
- MRI Cervical Spine without contrast (CPT[®] 72141) is medically necessary for:
 - failure of 6-week trial of provider-directed treatment after the current set of symptoms or physical exam findings started or changed and clinical re-evaluation after treatment period (unless presence of a red flag) as defined in **Red Flag Indications (SP-1.2)**
 - See **Neck (Cervical Spine) Pain Without/With Neurological Features (Including Stenosis) (SP-3.1)** and **Neck (Cervical Spine) Trauma (SP-3.2)** in the Spine Imaging Guidelines
 - Exemptions to the 6 weeks of conservative care include:
 - high-risk mechanism of cervical spine injury within the last 3 months (see **Neck (Cervical Spine) Trauma (SP-3.2)** in the Spine Imaging Guidelines)
 - **Red Flag Indications (SP-1.2)** in the Spine Imaging Guidelines
 - **ANY** of the following:
 - Bony abnormalities: Atlanto-axial dislocations/instability (including but not limited to: Down's syndrome, Ehlers-Danlos and Marfan syndromes and rheumatoid arthritis), platybasia, osteomas, callous formation of the posterior C1/2 arches
 - Posterior fossa lesions, Chiari malformations, demyelinating disease
 - Myelopathy/myelitis (see **Myelopathy (SP-7.1)** in the Spine Imaging Guidelines)

Background and Supporting Information

- Cervicogenic Headache
 - Headache caused by a disorder of the cervical spine, usually accompanied by neck pain or other signs and symptoms of cervical disease. Typical findings include reduced cervical range of motion, side-locked pain, and symptoms exacerbated by provocative maneuvers such as head movement or digital pressure.
- Occipital Neuralgia/Neuritis - Occipital neuralgia is classified unilateral or bilateral paroxysmal, shooting or stabbing pain in the posterior part of the scalp, in the distribution(s) of the greater, lesser and/or third occipital nerves, sometimes accompanied by diminished sensation or dysaesthesia in the affected area and commonly associated with tenderness over the involved nerve(s).

- Pain has at least two of the following three characteristics:
 - Recurring in paroxysmal attacks lasting from a few seconds to minutes
 - Severe in intensity
 - Shooting, stabbing or sharp in quality
- Pain is associated with both of the following:
 - Dysaesthesia and/or allodynia apparent during innocuous stimulation of the scalp and/or hair
 - Either or both of the following:
 - Tenderness over the affected nerve branches
 - Trigger points at the emergence of the greater occipital nerve or in the distribution of C2
- Pain is eased temporarily by local anesthetic block of the affected nerve(s)

Advanced Imaging Indications Related To Migraines (HD-11.17)

HD.HA.0011.17.A

v2.0.2026

- Advanced imaging of the head is **NOT** medically necessary for newly diagnosed migraine with a normal neurological exam or chronic stable migraine with no neurological deficit and/or no red flags (see **Headaches with Red Flags (HD-11.2)**).
 - See below for advanced imaging indications related to migraines.
- New migraine with age ≥ 50 (see **New Headache Onset Older than Age 50 (HD-11.7)**)
- Change in frequency or severity of migraine (see **Headaches with Red Flags (HD-11.2)**)
- MRI Brain without (CPT[®] 70551) or MRI Brain without and with (CPT[®] 70553) or CT Head without (CPT[®] 70450) for the following:
 - Unusual, prolonged, or persistent aura (greater than 60 minutes) (See *Background and Supporting Information*)
 - Worst migraine
 - Hemiplegic migraine
 - Migraine with any motor weakness.
 - Migrainous accompaniments
 - Passing neurological symptoms that can affect vision, speech, movement, and behavior—"mimic stroke"
 - Migraine aura without headache
 - Migraine with an aura in which the aura is neither accompanied nor followed by a headache within 60 minutes.
 - Side-locked migraine (unilateral)
 - Unilateral hemicranial pain – includes primary and secondary causes.
 - New daily persistent headache (new daily headache present greater than three months)
 - Trigeminal autonomic cephalgias includes cluster headache short-lasting, unilateral, neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) syndromes; short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) and hemicrania paroxysmal and continua are covered in **Trigeminal Autonomic Cephalgias (HD-11.4)**
 - Post-traumatic migraine
 - See **Head Trauma (HD-13.1)** and **Headaches Associated with Head Trauma (HD-11.12)**

Background and Supporting Information

- Aura symptoms may accompany or precede a headache within 60 minutes and may include, but are not exclusive to, the following symptoms:
 - Visual (flashing lights, loss of vision)
 - Sensory (paresthesia)
 - Speech and/or language (difficulty speaking)
 - Motor (any weakness)
 - Brainstem (double vision) and retinal (visual complaints)

Evidence Discussion (HD-11)

v2.0.2026

- The majority of headaches are due to benign causes and are self-limited. The yield of positive findings on a CT Head for evaluation of headache in the emergency department setting ranged from 7% to 13%.¹
- The American College of Radiology in the Choosing Wisely campaign recommended against imaging for primary headache syndromes in the absence of red flags and with a normal neurologic exam.^{1,32} The American Headache Society and Choosing Wisely Task Force stated that the overuse or misuse of imaging studies for headache was the most commonly mentioned problem.³² Overuse of CT Head was identified as the main concern.³² The authors note that a single CT scan of the head exposes individuals to an average of 2 millisievert (mSV) of radiation, the equivalent of 8 months of background radiation.³²
- Incidental findings are common and can result in anxiety for the individual, additional referrals and specialist consults, and more imaging studies.^{30,31} Incidental findings on MRI occur in 2% of the general population.³¹
- The American Headache Society and the American Academy of Neurology recommended neuroimaging in individuals with headaches with atypical features, "red flags", and/or abnormal neurologic exam findings.^{1,13,29}
- The presence of neurologic or systemic signs, new headaches over age 50, or headaches in the setting of malignancy or immunosuppression, always require further evaluation with advanced imaging, and are considered "red flags," due to the higher likelihood of intracranial pathology.^{1,30,36,37} CT Head in the presence of "red flags" is helpful to exclude intracranial hemorrhage.¹ However, MRI Brain has higher contrast resolution than CT Head and is preferred for evaluation of structural pathologies, particularly in non-urgent settings.¹
- Subarachnoid hemorrhage due to ruptured cerebral aneurysm accounts for 4%-12% of acute severe headaches.¹ CT Head is medically necessary as initial imaging for thunderclap headache. CT Head had a negative predictive value between 99.9%-100% in detecting aneurysmal subarachnoid hemorrhage within 6 hours of headache onset. The sensitivity is over 90% when CT Head is performed within the first 24 hours. CT Angiography (CTA) Head obtained concurrently or in follow up may identify cerebral aneurysm, dissection, and reversible cerebral vasoconstriction syndrome.¹
- In selected cases, CT Head is supported for evaluation and follow up of headache caused by subdural or epidural hemorrhage, skull fracture, sinus infection or subarachnoid hemorrhage.³⁰
- New headaches in the setting of pregnancy and the postpartum period require special consideration.^{1,30,35}

- Over a third of pregnant women presenting to the hospital with headache have a secondary cause.^{1,34,35} Of individuals with headache in the immediate postpartum period, 41% had an abnormal MRI Brain.³⁵
- Imaging in this scenario includes MRI Brain, MR Venogram (MRV) Head, and/or MR Angiography (MRA) Head. Gadolinium contrast is relatively contraindicated during pregnancy and should be avoided.¹
- Trigeminal autonomic cephalgias, including cluster headaches, are required to have MRI brain to exclude pathology in the pituitary region.^{1,30} MRI should include the brain and the pituitary region.^{1,13}
- Headaches concerning for raised intracranial pressure or intracranial hypotension, required additional evaluation with neuroimaging.^{1,30} To exclude hydrocephalus, a mass, or cerebral venous sinus thrombosis, MRI Brain, Orbits, and Venogram are medically necessary in the setting of papilledema and/or intracranial hypertension.^{1,30} In urgent cases, a CT Head can rapidly diagnose causes such as mass, edema, or hydrocephalus.¹
- MRI is also useful to evaluate for structural causes of headache due to intracranial hypotension and cerebrospinal (CSF) leaks.^{1,30} Depending on the suspected source of the leak, imaging the brain and spinal cord may be required. Spinal imaging may include MRI of the spinal cord, or CT myelogram.¹
- In the evaluation of headaches from suspected intracranial hypotension with negative initial brain and spine imaging, and high clinical suspicion of a CSF leak, MR myelography is indicated to detect subtle spinal leak sources, such as CSF-venous fistulas and slow meningeal diverticular leaks.⁴¹
- CTA Head or MRA Head in the evaluation of headache are medically necessary for suspicion of carotid or vertebral arterial dissections, AVMs and cerebral aneurysm, as secondary causes of headache.¹
- CT Venogram (CTV) head or MRV head in the evaluation of headache are supported for suspicion of cerebral venous sinus thrombosis or stenosis in select cases, included suspected headache associated with pregnancy and the post-partum period, headache with papilledema, intracranial hypertension, and the trigeminal autonomic cephalgias.¹
- Computerized tomography (CT) is the gold standard for the evaluation of abdominal complications related to ventriculoperitoneal shunts (VPS).³⁸

References (HD-11)

v2.0.2026

1. Utukuri PS, Shih RY, Ajam AA, et al. ACR Appropriateness Criteria® Headache. Available at <https://acsearch.acr.org/docs/69482/Narrative/>. American College of Radiology. Revised 2022
2. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. *Cephalalgia*. 2018;38(1):1-211
3. Thurtell MJ. Idiopathic Intracranial Hypertension. *CONTINUUM: Lifelong Learning in Neurology*. 2019;25(5):1289-1309. doi:10.1212/con.0000000000000770
4. Burch R. Headache in Pregnancy and the Puerperium. *Neurologic Clinics*. 2019;37(1):31-51. doi:10.1016/j.ncl.2018.09.004
5. Jamieson DG, Mcvige JW. Imaging of Neurologic Disorders in Pregnancy. *Neurologic Clinics*. 2020;38(1):37-64. doi:10.1016/j.ncl.2019.09.001
6. Rayhill M. Headache in Pregnancy and Lactation. *Continuum (Minneapolis)*. 2022; 28(1): 72-92. doi: 10.1212/CON.0000000000001070
7. Kamel H, Navi BB, Sriram N, Hovsepian DA, Devereux RB, Elkind MS. Risk of a Thrombotic Event after the 6-Week Postpartum Period. *New England Journal of Medicine*. 2014;370(14):1307-1315. doi:10.1056/nejmoa1311485
8. Perillo T, Paoletta C, Perrotta G, Serino A, Caranci F, Manto A. Reversible cerebral vasoconstriction syndrome: review of neuroimaging findings. *Radiol Med*. 2022; 127(9): 981-990. doi: 10.1007/s11547-022-01532-2
9. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance of Computed Tomography (CT) of the extracranial head and neck. 2021; Available at: <https://gravitas.acr.org/PPTS/>
10. Dobrocky T, Nicholson P, Häni L, et al. Spontaneous intracranial hypotension: searching for the CSF leak. *Lancet Neurol*. 2022; 21(4): 369-380. doi: 10.1016/S1474-4422(21)00423-3.
11. Expert Panel on Neurologic Imaging; Salmela MB, Mortazavi S, et al. ACR Appropriateness Criteria® Cerebrovascular Disease. *J Am Coll Radiol*. 2017;14(5S):S34-S61. doi:10.1016/j.jacr.2017.01.051
12. Pruitt AA. Central Nervous System Infections Complicating Immunosuppression and Transplantation. *CONTINUUM: Lifelong Learning in Neurology*. 2018;24(5):1370-1396. doi:10.1212/con.0000000000000653
13. Evans, RW, Burch RC, Frishberg BM, et al. Neuroimaging for Migraine: The American Headache Society Systematic Review and Evidence-Based Guideline. *Headache*. 2020;60(2):318-336. doi:10.1111/head.13720
14. Expert Panel on Neurological Imaging, Shih RY, Burns J, et al. ACR Appropriateness Criteria® Head Trauma: 2021 Update. *J Am Coll Radiol*. 2021;18(5S):S13-S36. doi:10.1016/j.jacr.2021.01.006
15. American College of Radiology. ACR-ASNR - SPR Practice Parameter for the performance of myelography and cisternography. 2024; Available at: <https://gravitas.acr.org/PPTS/>
16. Jordan JE, Flanders AE. Headache and neuroimaging: Why we continue to do it. *AJNR Am J Neuroradiol*. 2020; 41(7): 1149-1155. doi:10.3174/ajnr.A6591
17. Sweet JA, Mitchell LS, Narouze S, et al. Occipital nerve stimulation for the treatment of patients with medically refractory occipital neuralgia. *Neurosurgery*. 2015;77(3):332-341. doi:10.1227/neu.0000000000000872
18. International Headache Society Classification of Headache Disorders-3 Part III: Neuropathies and Facial Pains and other headaches. Section 13.4 Occipital Neuralgia-ICHD-3. <https://ichd-3.org>.
19. International Headache Society Classification of Headache Disorders-3 Part II: The secondary headaches 11.2.1 Cervicogenic headache-ICHD-3. <https://ichd-3.org>.
20. Doddamani RS, Meena RK, Sawarkar D, Aggarwal D, Chandra PS. Management options in occipital neuralgia: A review. *Journal of Peripheral Nerve Surgery*. Vol. 2020;4(1)
21. O'Neill F, Nurmikko T, Sommer C. Other facial neuralgias. *Cephalalgia*. 2017;37(7):658-669. doi:10.1177/0333102417689995
22. Barmherzig R, Kingston W. Occipital neuralgia and cervicogenic headache: Diagnosis and management. *Current Neurology and Neuroscience Reports*. 2019;19(5). doi:10.1007/s11910-019-0937-8
23. Labastida-Ramírez A, Benemei S, Albanese M, et al. Persistent post-traumatic headache: a migrainous loop or not? The clinical evidence. *The Journal of Headache and Pain*. 2020;21(1). doi:10.1186/s10194-020-01122-5

24. Henderson FC Sr, Austin C, Benzel E, et al. Neurological and spinal manifestations of the Ehlers-Danlos syndromes. *Am J Med Genet C Semin Med Genet*. 2017;175(1):195-211. doi:10.1002/ajmg.c.31549
25. Chou DE. Secondary headache syndromes. *CONTINUUM: Lifelong Learning in Neurology*. 2018;24(4):1179-1191. doi:10.1212/con.0000000000000640
26. Smith JH. Other primary headache disorder. *Continuum (Minneap Minn)*. 2021; 27(3): 652-664. doi: 10.1212/CON.0000000000000960
27. Nahas SJ. Cluster headache and other trigeminal autonomic cephalalgias. *Continuum (Minneap Minn)*. 2021; 27(3): 633-651. doi: 10.1212/CON.0000000000000965
28. Recober A. Pathophysiology of migraine. *Continuum (Minneap Minn)*. 2021; 27(3): 586-596. doi: 10.1212/CON.0000000000000983
29. Frishberg B, Rosenberg J, Matchar D, et al. Evidence-based guidelines in the primary care setting: Neuroimaging in patients with nonacute headache. *American Academy of Neurology: US Headache Consortium*
30. Ray JC, Hutton EJ. Imaging in headache disorders. *Aust Prescr*. 2022;45:88-92. <https://doi.org/10.18773/austprescr.2022.023>
31. Morris Z, Whiteley WN, Longstreth WT Jr, Weber F, Lee YC, Tsushima Y, et al. Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. *BMJ*. 2009;339:b3016. <https://doi.org/10.1136/bmj.b3016>
32. Loder E, Weizenbaum E, Frishberg B, Silberstein S; American Headache Society Choosing Wisely Task Force. Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question. *Headache*. 2013;53(10):1651-1659. doi:10.1111/head.12233
33. Robbins MS, Farmakidis C, Dayal AK, Lipton RB. Acute headache diagnosis in pregnant women: a hospital-based study. *Neurology*. 2015;85(12):1024-1030. doi:10.1212/WNL.0000000000001954
34. Raffaelli B, Neeb L, Israel-Willner H, et al. Brain imaging in pregnant women with acute headache. *J Neurol*. 2018;265(8):1836-1843. doi:10.1007/s00415-018-8924-6
35. Shobeiri E, Torabinejad B. Brain magnetic resonance imaging findings in postpartum headache. *Neuroradiol J*. 2019;32(1):4-9. doi:10.1177/1971400918804193
36. Do TP, Remmers A, Schytz HW, et al. Red and orange flags for secondary headaches in clinical practice: SNNOOP10 list. *Neurology*. 2019;92(3):134-144. doi:10.1212/WNL.0000000000006697
37. Holle D, Obermann M. The role of neuroimaging in the diagnosis of headache disorders. *Ther Adv Neurol Disord*. 2013;6(6):369-374. doi:10.1177/1756285613489765
38. Ferreira Furtado LM, Da Costa Val Filho JA, Moreira Faleiro R, Lima Vieira JA, Dantas Dos Santos AK. Abdominal Complications Related to Ventriculoperitoneal Shunt Placement: A Comprehensive Review of Literature. *Cureus*. 2021;13(2):e13230. Published 2021 Feb 8. doi:10.7759/cureus.13230
39. Ghritlaharey RK. Management of ventriculoperitoneal shunt complications in children: A review of 34 cases. *Afr J Paediatr Surg*. 2023 Apr-Jun;20(2):109-115. doi: 10.4103/ajps.ajps_68_21. PMID: 36960505; PMCID: PMC10209765
40. Pannell JS, Corey AS, Shih RY, et al. ACR Appropriateness Criteria® Cerebrovascular Diseases-Stroke and Stroke-Related Conditions. Available at <https://acsearch.acr.org/docs/3149012/Narrative/>. American College of Radiology. New 2023
41. Timpone VM, Parsons MS, Boulter DJ, et al. ACR Appropriateness Criteria® Imaging of Suspected Intracranial Hypotension. Available at <https://acsearch.acr.org/docs/3195159/Narrative/>. American College of Radiology. New 2024
42. Zamora C, Castillo M. Role of MRI and CT in the Evaluation of Headache in Pregnancy and the Postpartum Period. *Neurol Clin*. 2022;40(3):661-677. doi:10.1016/j.ncl.2022.02.010
43. Eldalya RW, Parsons MS, Hutchins TA, et al. ACR Appropriateness Criteria® Cervical Pain or Cervical Radiculopathy. Available at <https://acsearch.acr.org/docs/69426/Narrative/>. American College of Radiology. New 2024
44. Kuan EC, Wang EW, Adappa ND, et al. International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors. *Int Forum Allergy Rhinol*. 2024;14(2):149-608. doi:10.1002/alr.23262
45. Tana C, Raffaelli B, Souza MNP, et al. Health equity, care access and quality in headache - part 1. *J Headache Pain*. 2024;25(1):12. Published 2024 Jan 29. doi:10.1186/s10194-024-01712-7
46. Raffaelli B, Rubio-Beltrán E, Cho SJ, et al. Health equity, care access and quality in headache - part 2. *J Headache Pain*. 2023;24(1):167. Published 2023 Dec 13. doi:10.1186/s10194-023-01699-7

47. Florczyk S, Elliott T, Lawrence K, Penwell-Waines L, Robes C. Headache Treatment Options. *J Am Board Fam Med*. 2024;37(4):737-744. doi:10.3122/jabfm.2023.230450R1
48. Viera AJ, Antono B. Acute Headache in Adults: A Diagnostic Approach. *Am Fam Physician*. 2022;106(3):260-268.
49. American Medical Association. CPT—Current Procedural Terminology. American Medical Association. Published 2026. Copyright 1995 – 2026

Cerebral Aneurysm and AVM (HD-12)

Guideline	Page
Cerebral Aneurysms (HD-12.1).....	129
Arteriovenous Malformations (AVMs) and Related Lesions (HD-12.2).....	133
Evidence Discussion (HD-12).....	139
References (HD-12).....	141

Cerebral Aneurysms (HD-12.1)

HD.AN.0012.1.A

v2.0.2026

Disorders and Indications (Any of the following)	Medically Necessary Imaging
Coarctation of the aorta	See <u>Aortic Coarctation and IAA (interrupted aortic arch) (PEDCD-2.4.11)</u>
Screening for high-risk populations as defined by the following criteria (screening usually begins at age 20 unless unusual circumstances as aneurysms are uncommon in children and adolescents): • Positive Family History: Two or more first degree relatives (parent, sibling, or child) with history of cerebral aneurysm or subarachnoid hemorrhage (SAH): screening every 5 years beginning at age 20. One first degree relative (parent, sibling, or child) with history of cerebral aneurysm or SAH can have one screening study • Autosomal dominant polycystic kidney disease (screening begins at age 20 to 65 and is repeated at five-year intervals) • Alpha-1-antitrypsin deficiency • Alpha-glucosidase deficiency • Azygos anterior cerebral artery (presence of) • Bicuspid aortic valve • Fibromuscular dysplasia (one screening study after confirmed diagnosis) • Ehlers-Danlos Syndrome Type 4 (Vascular) • Glucocorticoid-remediable aldosteronism (GRA) • Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu Syndrome) See <u>Screening for Vascular related genetic connective tissue Disorders (PVD-2.2)</u>	• CTA Head (CPT® 70496) OR • MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546)

Disorders and Indications (Any of the following)	Medically Necessary Imaging
Screening for high-risk populations as defined by the following criteria (screening usually begins at age 20 unless unusual circumstances as aneurysms are uncommon in children and adolescents) - CONTINUED: • Kawasaki disease • Klinefelter syndrome • Klippel-Trenaunay-Weber Syndrome • Loeys-Dietz Syndrome • Marfan Syndrome • Microcephalic osteodysplastic primordial dwarfism • Neurofibromatosis Type 1 • Noonan Syndrome • Pheochromocytoma • Pseudoxanthoma elasticum • Tuberous sclerosis See Screening for Vascular related genetic connective tissue Disorders (PVD-2.2)	• CTA Head (CPT® 70496) OR • MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546)
New or worsening clinical symptoms or signs of cerebral aneurysm, including: • Thunderclap headache (see Sudden Onset of Headache (HD-11.3)) • Third nerve palsy with pupillary involvement (pupil-sparing third nerve palsies are not caused by external compression) • Suspicion of aneurysm bleed [CT head or MRI brain or CSF exam showing evidence of SAH or intracerebral hemorrhage] • Abnormal CT Head or MRI Brain suggesting possible aneurysm	• CTA Head (CPT® 70496) OR • MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) AND/OR • MRI Brain without contrast (CPT® 70551) or MRI Brain without and with contrast (CPT® 70553)
Questionable or equivocal findings on an initial MRA Head	CTA Head (CPT® 70496)

Disorders and Indications (Any of the following)	Medically Necessary Imaging
For suspected or confirmed cerebral aneurysm, ruptured or unruptured, for initial evaluation, treatment, intervention, or follow-up OR If initial catheter angiography is negative, repeat imaging is medically necessary.	3D Rendering (CPT® 76377 or CPT® 76376) with cervicocerebral angiography/arteriography and/or cerebral angiography (See General Guidelines - Other Imaging Situations (HD-1.7))
Follow-up of known cerebral aneurysm: The optimal interval and duration for radiologic follow-up has not been determined. Radiographic follow-up for unruptured or treated intracranial aneurysms upon request by the neurosurgeon or team managing the intracranial aneurysm.	• CTA Head (CPT® 70496) OR • MRA Head (CPT® 70544, CPT® 70545 or CPT® 70546) AND/OR • MRI Brain without contrast (CPT® 70551) or MRI Brain without and with contrast (CPT® 70553)
Additional physical characteristics of a known aneurysm: • To evaluate and treat a giant aneurysm (>2.5 cm) • Posterior fossa aneurysms • Thrombosed or partially thrombosed aneurysms • To evaluate the relationship of the aneurysm to the dura • To evaluate for the presence of calcification • Other surveillance criteria as per the neurosurgeon or team managing the aneurysm repair	• MRI Brain without contrast (CPT® 70551) or MRI Brain without and with contrast (CPT® 70553)
Follow up of cerebral aneurysm located in the vertebro-basilar circulation OR If intracranial etiology of SAH has not been found	• MRA Neck (CPT® 70547, CPT® 70548, or CPT® 70549) OR • CTA Neck (CPT® 70498) ◦ CTA Head and Neck (CPT® 70471) must be substituted if performed during the same session

Disorders and Indications (Any of the following)	Medically Necessary Imaging
Subacute complications (i.e., vasospasm, delayed cerebral ischemia, and hydrocephalus), beginning days to weeks, arising from a subarachnoid hemorrhage and/or aneurysm treatment, upon request from the neurosurgeon and/or team managing the episode	CT Head OR MRI Brain contrast as requested
To evaluate individuals with SAH and negative studies for brain aneurysm in whom spinal abnormalities (i.e., AVM) may be suspected as the cause of hemorrhage	MRI Spine (Cervical without and with contrast CPT® 72156, AND/OR Thoracic without and with contrast CPT® 72157, AND/OR Lumbar without and with contrast CPT® 72158)
Catheter angiogram negative in SAH individual with remaining suspicion for cerebral aneurysm and these studies have not yet been performed:	• CTA Head (CPT® 70496) AND/OR • MRA Head (CPT® 70544, CPT® 70545 or CPT® 70546)

- High-risk scenarios for vascular dissection include, but are not limited to: Fibromuscular dysplasia (FMD), Marfan Disease, MVA with whiplash, and chiropractic manipulation
 - MRA Neck (CPT® 70547, CPT® 70548, or CPT® 70549) or CTA Neck (CPT® 70498) if arterial dissection is suspected, or known and re-evaluation is needed (as directed by neurologist or neurosurgeon or any provider in consultation with a neurologist or neurosurgeon)
 - MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) or CTA Head (CPT® 70496, CPT® 70498) if arterial dissection is suspected, or known and re-evaluation is needed (as directed by neurologist or neurosurgeon or any provider in consultation with a neurologist or neurosurgeon)
 - CTA Head and Neck (CPT® 70471) combination code must be substituted when both CTA Head (CPT® 70496) and CTA Neck (CPT® 70498) are performed in the same session.
- Other vascular imaging indications for headaches require additional information. See **Stroke/TIA (HD-21.1)**, **Sudden Onset of Headache (HD-11.3)**, **New Headache Onset Older than Age 50 (HD-11.7)**, **Abnormal Blood Clotting (HD-11.9)**, **Pregnancy (HD-11.10)**, **Physical Exertion (HD-11.11)**, and **Systematic Infections (HD-11.13)**

Arteriovenous Malformations (AVMs) and Related Lesions (HD-12.2)

HD.AN.0012.2.A

v2.0.2026

Disorders and Indications (Any of the following)	Medically Necessary Imaging
Any aneurysmal and/or AVM disorders listed in this guideline - When MRI contraindicated - Any urgent setting	- CT Head without contrast (CPT[®] 70450) AND/OR - CTA Head (CPT[®] 70496) AND/OR - CTA Neck (CPT[®] 70498) - CTA Head and Neck (CPT[®] 70471) must be substituted if performed during the same session
Known AVM When requested by a neurologist, neurosurgeon, or any provider in consultation with a neurologist or neurosurgeon	- MRI Brain without contrast (CPT[®] 70551) OR - MRI Brain without and with contrast (CPT[®] 70553) AND/OR - MRA Head (CPT[®] 70544, CPT[®] 70545, CPT[®] 70546) OR - CTA Head (CPT[®] 70496)

Disorders and Indications (Any of the following)	Medically Necessary Imaging
Known AVM in the vertebral-basilar system When requested by a neurologist, neurosurgeon, or any provider in consultation with a neurologist or neurosurgeon	- Imaging as listed above in “known AVM” AND/OR - MRA Neck (CPT[®] 70547, CPT[®] 70548, OR CPT[®] 70549) OR - CTA Neck (CPT[®] 70498) OR - CTA Head and Neck (CPT[®] 70471) must be substituted if performed during the same session
Subarachnoid Hemorrhage (SAH) AVM is suspected based on a history of SAH	- MRI Brain without and with contrast (CPT[®] 70553) OR - MRI Brain without contrast (CPT[®] 70551)
Hereditary Hemorrhagic Telangiectasia (HHT; Osler-Weber-Rendu Syndrome) - Suspected based on family history with at least one affected first-degree relative (biological parent or sibling) - At diagnosis, especially if confirmed by genetic testing - Screening for confirmed HHT - Clinical signs or symptoms concerning for disease progression - When requested by a neurologist, neurosurgeon, geneticist, or any provider in consultation with a neurologist, neurosurgeon, or geneticist	- MRI Brain without and with contrast (CPT[®] 70553) OR - MRI Brain without contrast (CPT[®] 70551) AND/OR - MRA Head (CPT[®] 70544, CPT[®] 70545, CPT[®] 70546) OR - CTA Head (CPT[®] 70496)

Disorders and Indications (Any of the following)	Medically Necessary Imaging
Capillary Malformation-Arteriovenous Malformation (CM-AVM) • Suspected based on family history with at least one affected first-degree relative (biological parent or sibling) • At diagnosis, especially if confirmed by genetic testing • Screening for confirmed CM-AVM • Clinical signs or symptoms concerning for disease progression • When requested by a neurologist, neurosurgeon, geneticist, or any provider in consultation with a neurologist, neurosurgeon, or geneticist	• MRI Brain without and with contrast (CPT[®] 70553) OR • MRI Brain without contrast (CPT[®] 70551) AND/OR • MRA Head (CPT[®] 70544, CPT[®] 70545, CPT[®] 70546) OR • CTA Head (CPT[®] 70496) AND/OR • MRI Cervical Spine without and with contrast (CPT[®] 72156) OR • MRI Cervical Spine without contrast (CPT[®] 72141) AND/OR • MRI Thoracic Spine without and with contrast (CPT[®] 72157) OR • MRI Thoracic Spine without contrast (CPT[®] 72146)

Disorders and Indications (Any of the following)	Medically Necessary Imaging
Cerebral Cavernous Malformations (CCM) • At diagnosis, especially if confirmed by genetic testing • Screening for confirmed CCM • Clinical signs or symptoms concerning for disease progression • When requested by a neurologist, neurosurgeon, geneticist, or any provider in consultation with a neurologist, neurosurgeon, or geneticist	• MRI Brain without and with contrast (CPT[®] 70553) OR • MRI Brain without contrast (CPT[®] 70551) AND/OR • MRA Head (CPT[®] 70544, CPT[®] 70545, CPT[®] 70546) OR • CTA Head (CPT[®] 70496) AND/OR • MRI Cervical Spine without and with contrast (CPT[®] 72156) OR • MRI Cervical Spine without contrast (CPT[®] 72141) AND/OR MRI Thoracic Spine without and with contrast (CPT[®] 72157) OR • MRI Thoracic Spine without contrast (CPT[®] 72146)

Disorders and Indications (Any of the following)	Medically Necessary Imaging
Microcephalic Osteodysplastic Primordial Dwarfism, Type II (MOPD II) - At diagnosis, especially if confirmed by genetic testing - Screening for confirmed MOPD II, repeated annually - Clinical signs or symptoms concerning for disease progression - When requested by a neurologist, neurosurgeon, geneticist, or any provider in consultation with a neurologist, neurosurgeon, or geneticist	- MRI Brain without contrast (CPT[®] 70551) OR - MRI Brain without and with contrast (CPT[®] 70553) AND/OR - MRA Head (CPT[®] 70544, CPT[®] 70545, CPT[®] 70546) OR - CTA Head (CPT[®] 70496) AND/OR - MRA Neck (CPT[®] 70547, CPT[®] 70548, OR CPT[®] 70549) OR - CTA Neck (CPT[®] 70498) - CTA Head and Neck (CPT[®] 70471) must be substituted if performed during the same session.
Sturge-Weber Syndrome - At diagnosis - Clinical signs or symptoms concerning for disease progression - When requested by a neurologist or neurosurgeon or any provider in consultation with a neurologist or neurosurgeon	- MRI Brain without contrast (CPT[®] 70551) OR - MRI Brain without and with contrast (CPT[®] 70553) AND/OR - MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543) OR - MRI Orbits/Face/Neck without contrast (CPT[®] 70540)

- MRI Brain without and with contrast (CPT[®] 70553) **OR** MRI Brain without contrast (CPT[®] 70551), **OR** CT Head without contrast (CPT[®] 70450) **AND/OR** MRA Head (CPT[®] 70544, CPT[®] 70545, or CPT[®] 70546) or CTA Head (CPT[®] 70496) is medically necessary for symptoms including headache, seizure, and/or focal neurologic deficits
- For concerns related to stroke, see **Stroke/TIA HD-21.1**
- 3D imaging (CPT[®] 76376 or CPT[®] 76377) with MRI Brain without and with contrast (CPT[®] 70553) **OR** MRI Brain without contrast (CPT[®] 70551) is medically necessary.
- 3D Rendering (CPT[®] 76377 or CPT[®] 76376) with cervicocerebral catheter angiography is medically necessary to define the presence, location, and anatomy of intracranial and cervical vascular malformations at diagnosis and for follow up, including post-treatment, (see **General Guidelines - Other Imaging Situations (HD-1.7)** and **Background and Supporting Information**).
- See **General Guidelines – CT and MR Angiography (CTA/CTV and MRA/MRV) (HD-1.5)**
- Functional MRI (CPT[®] 70554 **OR** CPT[®] 70555) for surgical planning, see **Functional MRI (fMRI) (HD-24.2)**

Background and Supporting Information

- Trauma is the most common reason for subarachnoid hemorrhage. Ruptured berry aneurysm is the most common reason for non-traumatic subarachnoid hemorrhage in adults.
- Small aneurysms are present in about 1% to 2% of adults, but very few ever reach a size for which bleeding is a risk (>5 mm). Small (<3 mm to 4 mm) unruptured aneurysms in those with no personal history of SAH have a 0.1% to 0.5% a year rate of bleeding. The risk of cerebral aneurysm with family history ranges from 2% with one first-degree relative to 30% to 35% for identical twin or two parents. The risks and benefits of screening these populations need to be considered before advanced imaging.
- AVMs most often come to clinical notice either by bleeding or by acting as a seizure focus. They are usually congenital, recognized later in life and have an initial risk of bleeding of 2% per year.
- Cerebral angiography is a form of angiography which provides images of blood vessels in and around the brain and/or neck. This is a catheter-based procedure, using x-ray imaging guidance and iodine-based contrast to visualize blood vessels.
- Most intracranial AVMs are congenital, vary widely in their location and type, and are discovered at birth due to associated clinical findings or incidentally later in life. Certain hereditary conditions are associated with an increased risk for AVM development.
- Vascular malformations include arteriovenous, venous, cavernous, and capillary malformations.
- Hereditary AVMs usually have an autosomal dominant pattern of inheritance.

Evidence Discussion (HD-12)

v2.0.2026

- After the initial identification of a subarachnoid hemorrhage, the search for a ruptured cerebral aneurysm begins with imaging of the cerebral vessels with CT Angiography (CTA), MR Angiography (MRA) or diagnostic cervicocerebral catheter angiography.²²
- CTA Head has over 90% sensitivity and specificity for the diagnosis of cerebral aneurysm in the setting of subarachnoid hemorrhage.²²
- MRA Head has a sensitivity of 95% and a specificity of 89% for diagnosis of cerebral aneurysm.²²
- Diagnostic cervicocerebral catheter angiography has the highest spatial and temporal resolution of any vascular imaging study, however, is invasive and requires use of contrast. It has a sensitivity and specificity over 98% for identification of aneurysm and can also diagnose vascular abnormalities in up to 13% with subarachnoid hemorrhage and a negative CTA. In addition, this modality can identify an aneurysm in 25% of previously negative studies and repeat studies are supported for this reason.²²
- In select cases of subarachnoid hemorrhage when an intracranial aneurysm is not identified, imaging the neck vessels and spinal vessels is appropriate.¹²
- Aneurysm growth ranges from 4% to 14% on follow up imaging. For surveillance of incidentally identified cerebral aneurysms or ruptured and/or treated aneurysms, the less invasive modalities, CTA and/or MRA are supported, over the more invasive diagnostic cervicocerebral angiography.²²
- Screening for cerebral aneurysms in high-risk individual populations is also recommended with the less invasive modalities, CTA head or MRA head. This includes individuals with autosomal dominant polycystic kidney disease (ADPKD), who had a prevalence of cerebral aneurysm ranging from 10%-11.5%. The American Heart Association recommended screening those with at least 2 family members with cerebral aneurysm or subarachnoid hemorrhage.²²
- Screening is also recommended for conditions with known increased risk of cerebral aneurysm.^{4,22}
- Although vascular imaging is the primary focus of neuroimaging in the diagnosis and follow up of cerebral aneurysms, parenchymal imaging with MRI Brain may be helpful in select clinical scenarios including giant aneurysms, posterior fossa aneurysms, in the setting of cranial neuropathies or focal neurologic findings and suspected stroke.¹²
- Cervicocerebral angiography is the gold standard for imaging arteriovenous malformations (AVM) and arteriovenous fistulas (AVF). CT Angiography head (CTA) has a 90% sensitivity for the overall detection of AVMs and 100% for AVMs >3 cm in size. In the evaluation of pulsatile tinnitus, CTA has a sensitivity of 86% with a

specificity of 100% in identifying high flow AVFs. MR Angiography (MRA) is an alternative modality in these scenarios.²²

- MRI Brain for diagnosis and follow up of AVM has an overall sensitivity of 89% and 100% for lesions >3 cm in size.²²

References (HD-12)

HD.AN.0012.3.A

v2.0.2026

1. Rozenfeld MN, Ansari SA, Shaibani A, Russell EJ, Mohan P, Hurley MC. Should Patients with Autosomal Dominant Polycystic Kidney Disease Be Screened for Cerebral Aneurysms? *American Journal of Neuroradiology*. 2013;35(1):3-9. doi:10.3174/ajnr.a3437
2. Vlak MHM, Rinkel GJE, Greebe P, Greving JP, Algra A. Lifetime risks for aneurysmal subarachnoid haemorrhage: multivariable risk stratification. *Journal of Neurology, Neurosurgery & Psychiatry*. 2013;84(6):619-623. doi:10.1136/jnnp-2012-303783
3. Nguyen TN. Management of Unruptured Intracranial Aneurysms and Brain Arteriovenous Malformations. *Continuum (Minneapolis)*. 2023;29(2):584-604. doi:10.1212/CON.0000000000001247
4. Thompson BG, Brown RD, Amin-Hanjani S, et al. Guidelines for the Management of Patients With Unruptured Intracranial Aneurysms. *Stroke*. 2015;46(8):2368-2400. doi:10.1161/str.0000000000000070
5. Chu LC, Johnson PT, Dietz HC, Fishman EK. CT Angiographic Evaluation of Genetic Vascular Disease: Role in Detection, Staging, and Management of Complex Vascular Pathologic Conditions. *American Journal of Roentgenology*. 2014;202(5):1120-1129. doi:10.2214/ajr.13.11485
6. Hishikawa T, Date I, Tokunaga K, et al. Risk of rupture of unruptured cerebral aneurysms in elderly patients. *Neurology*. 2015;85(21):1879-1885. doi:10.1212/wnl.0000000000002149
7. Backes D, Rinkel GJE, Greving JP, et al. ELAPSS score for prediction of risk of growth of unruptured intracranial aneurysms. *Neurology*. 2017;88(17):1600-1606. doi:10.1212/wnl.0000000000003865
8. Ding D, Etminan N. A model for predicting the growth of unruptured intracranial aneurysms. *Neurology*. 2017;88(17):1594-1595. doi:10.1212/wl.0000000000003874
9. Kadian-Dodov D, Gornik HL, Gu X, et al. Dissection and Aneurysm in Patients With Fibromuscular Dysplasia. *Journal of the American College of Cardiology*. 2016;68(2):176-185. doi:10.1016/j.jacc.2016.04.044
10. McDonald J, Stevenson DA. Hereditary Hemorrhagic Telangiectasia. In: Adam MP, Mirzaa GM, Pagon RA, et al., eds. *GeneReviews®*. Seattle (WA): University of Washington, Seattle; June 26, 2000. [Updated 2021 Nov 24]
11. Derdeyn CP, Zipfel GJ, Albuquerque FC, et al. Management of Brain Arteriovenous Malformations: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*. 2017;48(8). doi:10.1161/str.0000000000000134.
12. Expert Panel on Neurologic Imaging: Salmela MB, Mortazavi S, et al. ACR Appropriateness Criteria® Cerebrovascular Disease. *J Am Coll Radiol*. 2017;14(5S):S34-S61. doi:10.1016/j.jacr.2017.01.051
13. Rosser T. Neurocutaneous Disorders. *CONTINUUM: Lifelong Learning in Neurology*. 2018;24(1):96-129. doi:10.1212/con.0000000000000562
14. Horne MA, Flemming KD, Su I-C, et al. Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data. *The Lancet Neurology*. 2016;15(2):166-173. doi:10.1016/s1474-4422(15)00303-8
15. Vella M, Alexander M, Mabray M, et al. Comparison of MRI, MRA, and DSA for Detection of Cerebral Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia. *American Journal of Neuroradiology*. 2020;41(6):969-975. doi:10.3174/ajnr.a6549
16. Lawton MT and Vates GE. Subarachnoid Hemorrhage. *N Engl J Med*. 2017;377:257-66. doi: 10.1056/NEJMcp1605827
17. Connolly ES, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage. *Stroke*. 2012;43(6):1711-1737. doi:10.1161/str.0b013e3182587839
18. Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the Primary Prevention of Stroke. *Stroke*. 2014;45(12):3754-3832. doi:10.1161/str.0000000000000046
19. Bober MB, Jackson AP. Microcephalic Osteodysplastic Primordial Dwarfism, Type II: a Clinical Review. *Curr Osteoporos Rep*. 2017 Apr;15(2):61-69. doi: 10.1007/s11914-017-0348-1.
20. Chen, C-J et al. Brain arteriovenous malformations: A review of natural history, pathobiology, and interventions. *Neurology*. 2020 95(20):917-927. doi: 10.1212/WNL.0000000000010968

21. American College of Radiology. ACR-ASNR-SIR-SNIS Practice Parameter for the Performance of diagnostic cervicocerebral catheter angiography in adults. 2021; Available at: <https://gravitas.acr.org/PPTS/>
22. Expert Panel on Neurological Imaging, Ledbetter LN, Burns J, et al. ACR Appropriateness Criteria® Cerebrovascular Diseases-Aneurysm, Vascular Malformation, and Subarachnoid Hemorrhage. *J Am Coll Radiol*. 2021;18(11S):S283-S304. doi:10.1016/j.jacr.2021.08.012
23. Nesvick CL, Oushy S, Ravindran K, et al. Repeat Catheter Angiography in Patients with Aneurysmal-Pattern Angiographically Negative Subarachnoid Hemorrhage. *Neurocritical Care*. Published online June 28, 2021. doi:10.1007/s12028-021-01247-8
24. Rosenberg TL, Suen JY, Richter GT. Arteriovenous Malformations of the Head and Neck. *Otolaryngologic Clinics of North America*. 2018;51(1):185-195. doi:10.1016/j.otc.2017.09.005
25. Litchfield WR, Anderson BF, Weiss RJ, Lifton RP, Dluhy RG. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. *Hypertension*. 1998;31(1 Pt 2):445-450. doi:10.1161/01.hyp.31.1.445
26. Johnson MD, Staarmann B, Zuccarello M. A Rational Approach to the Management of Cerebral Arteriovenous Malformations. *World Neurosurg*. 2022;159:338-347. doi:10.1016/j.wneu.2021.08.045
27. Hoh BL, Ko NU, Amin-Hanjani S, et al. 2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart Association/American Stroke Association [published online ahead of print, 2023 May 22]. *Stroke*. 2023;10.1161/STR.0000000000000436. doi:10.1161/STR.0000000000000436
28. Faughnan ME, Mager JJ, Hetts SW, et al. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. *Ann Intern Med*. 2020;173(12):989-1001. doi:10.7326/M20-1443
29. Expert Panel on MR Safety, Kanal E, Barkovich AJ, et al. ACR guidance document on MR safe practices: 2013. *J Magn Reson Imaging*. 2013;37(3):501-530. doi:10.1002/jmri.24011
30. Sabeti S, Ball KL, Bhattacharya SK, et al. Consensus Statement for the Management and Treatment of Sturge-Weber Syndrome: Neurology, Neuroimaging, and Ophthalmology Recommendations. *Pediatr Neurol*. 2021;121:59-66. doi:10.1016/j.pediatrneurol.2021.04.013
31. Bayrak-Toydemir P, Stevenson DA. Capillary Malformation-Arteriovenous Malformation Syndrome. In: Adam MP, Mirzaa GM, Pagon RA, et al., eds. *GeneReviews®*. Seattle (WA): University of Washington, Seattle; February 22, 2011. Updated: September 12, 2019.
32. Hammill AM, Wusik K, Kasthuri RS. Hereditary hemorrhagic telangiectasia (HHT): a practical guide to management. *Hematology Am Soc Hematol Educ Program*. 2021;2021(1):469-477. doi:10.1182/hematology.2021000281
33. Morrison L, Akers A. Cerebral Cavernous Malformation, Familial. In: Adam MP, Mirzaa GM, Pagon RA, et al., eds. *GeneReviews®*. Seattle (WA): University of Washington, Seattle; February 24, 2003.
34. Malhotra A, Wu X, Matouk CC, Forman HP, Gandhi D, Sanelli P. MR Angiography Screening and Surveillance for Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Cost-effectiveness Analysis. *Radiology*. 2019;291(2):400-408. doi:10.1148/radiol.2019181399.
35. American Medical Association. CPT—Current Procedural Terminology. American Medical Association. Published 2026. Copyright 1995 – 2026

Head and Facial Trauma (HD-13)

Guideline	Page
Head Trauma (HD-13.1).....	144
Facial Trauma (HD-13.2).....	147
Evidence Discussion (HD-13).....	148
References (HD-13).....	150

Head Trauma (HD-13.1)

HD.TR.0013.1.A

v2.0.2026

For acute head trauma (0 to 7 days post-trauma)

- CT Head without contrast (CPT[®] 70450) is medically necessary in individuals with **ANY** of the following modified Canadian CT Head Rule/New Orleans Criteria.
 - Regardless of documented or stated head impact, ANY "dangerous mechanism of injury", either direct or indirect, including, but not exclusive to:
 - Fall from height greater than 3 feet
 - Fall greater than 5 steps down stairs
 - Any pedestrian motor vehicle accident
 - High impact motor vehicle accident
 - Individual >60 years old
 - Loss of consciousness, amnesia, or disorientation accompanying blunt head trauma within 24 hours
 - Taking one anticoagulant or two antiaggregants, (e.g., aspirin and Plavix)
 - Known platelet or clotting disorder
 - Glasgow coma scale (GCS) score of less than 15 at 2 hours following injury
 - >30 minutes of amnesia before impact
 - Suspected open skull fracture
 - Signs of basilar skull fracture (Battle's sign, Raccoon eyes, CSF rhinorrhea, cranial nerve palsy, hemotympanum, acute hearing loss)
 - Vomiting
 - Alcohol or drug intoxication
 - Visible trauma above clavicles
 - Deficits in short term memory, altered level of alertness, abnormal behavior, or focal neurological deficit
 - Seizure
 - Headache, see **Headache Associated with Head Trauma (HD-11.12))**

For subacute head trauma (7 days to 3 months post-trauma) and chronic head trauma (greater than 3 months post-trauma) symptoms

- MRI Brain without contrast (CPT[®] 70551) or CT Head without contrast (CPT[®] 70450) is medically necessary for the initial imaging of individuals with subacute or chronic head trauma and unexplained cognitive or neurologic deficits.
- MRI Brain without and with contrast (CPT[®] 70553) is medically necessary if post-traumatic infection is suspected.

Repeat and follow-up imaging

- Follow-up imaging is medically necessary for known subdural hematomas, intracerebral hemorrhage, or contusions can be done at the discretion of the ordering provider with one of the following:
 - MRI Brain without and with contrast (CPT[®] 70553) **OR**
 - MRI Brain without contrast (CPT[®] 70551) **OR**
 - CT Head without and with contrast (CPT[®] 70470) **OR**
 - CT Head without contrast (CPT[®] 70450)
- For short term follow-up imaging of acute traumatic brain injury (TBI) without neurologic deterioration, CT Head without contrast (CPT[®] 70450) is medically necessary in individuals with ANY of the following risk factors:
 - subfrontal/temporal intraparenchymal contusions
 - anticoagulation
 - age >65 years
 - intracranial hemorrhage
- MRI Brain without contrast (CPT[®] 70551) or MRI Brain without and with contrast (CPT[®] 70553) is medically necessary as a complementary study when neurological findings or symptoms are not sufficiently explained by CT or in subacute and chronic TBI for new, persistent, or slowly progressive symptoms.

For suspected intracranial venous or arterial injury, the following is medically necessary:

- CTA/CTV Head (CPT[®] 70496) or MRA/MRV Head (CPT[®] 70544, CPT[®] 70545, or CPT[®] 70546)
 - CT and MR Venography (CTV and MRV) are reported with the same codes as the CTA/MRA counterpart. If arterial and venous CT or MR studies are both performed in the same session, only one CPT[®] code should be used to report both procedures (see **General Guidelines - CT and MR Angiography (CTA/CTV and MRA/MRV) (HD-1.5)**)

SPECT, PET, CT/MRI perfusion, DTI (diffusion tensor imaging), functional MRI, and MR spectroscopy are considered not medically necessary for the evaluation of traumatic brain injury.

Quantitative Magnetic Resonance Image (MRI) Analysis of the Brain

- Volumetric or quantitative analysis of the brain or temporal lobes and hippocampus may be requested as (CPT[®] 0865T or CPT[®] 0866T)
 - These studies lack sufficient specificity and sensitivity to be clinically useful. Their use is limited to research studies and are considered not medically necessary in the evaluation of traumatic brain injury.

See **Neck (Cervical Spine) Pain Without/With Neurological Features (Including Stenosis) and Trauma (SP-3.2)** in the Spine Imaging Guidelines

See **General Guidelines – CT and MR Angiography (CTA/CTV and MRA/MRV) (HD-1.5)** for traumatic vascular injuries

Background and Supporting Information

Individuals with head trauma are at risk for facial and cervical trauma.

Recent studies have shown that diffusion tensor MRI tractography may be more sensitive in demonstrating abnormalities such as axonal injury in closed head injury than conventional MRI, but these techniques are best described presently as research tools and their use in clinical practice is not determined.

Decisions regarding return to normal activities, including sports, are made based on the clinical status of the individual and repeat imaging is medically unnecessary.

In cases of post-traumatic infection, contrast-enhanced MRI or CT may be helpful.

Facial Trauma (HD-13.2)

HD.TR.0013.2.A

v2.0.2026

- CT Maxillofacial without contrast (CPT® 70486) and/or CT Head without contrast (CPT® 70450) is/are medically necessary for any concern regarding significant injury to facial structures including, but not limited to:
 - Concern for orbital, maxillary, or mandibular fractures
 - Trauma with associated symptoms of anosmia, hearing, vision or speech changes, vertigo, facial numbness
 - Physical exam findings of CSF rhinorrhea (suspected post-traumatic CSF leak), malocclusion, severe focal facial tenderness, focal loss of facial sensation
- CT Orbits/Temporal Bone without contrast (CPT® 70480) and/or CT Head without contrast (CPT® 70450) is/are medically necessary for:
 - concern for orbital injury or orbital wall fracture
 - symptoms of diplopia, blurred vision, vision loss
 - physical exam findings of enophthalmos, entrapment of extraocular muscle(s)
 - suspicion for temporal bone fracture
 - physical exam findings of CSF otorrhea (suspected post-traumatic CSF leak)
- MRI Maxillofacial without contrast (CPT® 70540) **OR** MRI Maxillofacial without and with contrast (CPT® 70543) is medically necessary for evaluation of cranial nerve deficits not explained or incompletely characterized on CT.
- If concern for CSF leak and CT Maxillofacial or Temporal bone is inconclusive, (see **Low-Pressure Headache and CSF Leak (HD-11.15)**)

Background and Supporting Information

Imaging is not necessary in the evaluation of simple nasal fractures if tenderness and swelling is limited to the nasal bridge, the individual can breathe through each naris, and there is no septal hematoma.

Evidence Discussion (HD-13)

v2.0.2026

- For evaluation of acute mild head trauma, less than 10% will have positive findings on CT head, and of this group, less than 1% will require neurosurgical intervention.^{7,18}
- The American College of Emergency Physicians and the Choosing Wisely Initiative recommend avoiding CT scans of the head in emergency department individuals with minor head injury who are at low risk based on validated decision rules. This recommendation was based on the concern for individual exposure to ionizing radiation and the increased lifetime risk of cancer with such exposure.¹⁷
- Selective CT scanning is recommended by validated clinical practice guidelines, including the New Orleans Criteria and the Canadian CT Head Rule.^{1,7,18} Both guidelines are 100% sensitive for mild head trauma requiring neurosurgical intervention.^{7,18} The New Orleans Criteria has a sensitivity >97% for any traumatic finding on CT, with a specificity less than 6%.^{7,18} The Canadian CT Head Rule has a sensitivity between 83.4% - 87.2% with a specificity between 37.2% – 39.7%.^{1,7,18} The Canadian CT Head Rule has a 100% sensitivity and 29% specificity in cases of intracranial hemorrhage.^{1,7,18}
- When imaging is indicated by a validated clinical decision rule, CT head is the preferred imaging modality for evaluation of acute head trauma.^{7,15,17,18}
- If the initial CT head confirms subdural hematoma, follow-up CT head is supported to monitor progression.^{7,8}
- For follow-up in individuals with persistent neurologic deficits without etiology identified on initial CT head, MRI brain is more sensitive, and can visualize cortical contusions, subdural hematomas, and white matter lesions in diffuse axonal injury.⁷ Up to 27% of individuals with mild traumatic brain injury (TBI) with normal initial CT head show abnormalities on MRI Brain.^{7,8}
- When vascular injury is suspected in the setting of head trauma, CT Angiography (CTA) head and neck is a non-invasive, rapid, and useful modality to evaluate for arterial injury.^{7,1} MR Angiography is an alternative option. For suspected intracranial venous injury, CT Venography (CTV) is medically necessary, with MR Venography (MRV) an alternative option.^{7,16}
- There is insufficient evidence to support the use of single-photon emission computed tomography (SPECT), FDG-PET/CT brain, CT/MRI-Perfusion, MR spectroscopy (MRS), functional MRI (fMRI), or diffusion tensor imaging (DTI) in the evaluation of head trauma.⁷
- Individuals with head trauma are also at risk for orbital, facial and temporal bone injuries.¹¹ CT of the orbit can diagnose fractures, displaced fracture fragments, foreign bodies, traumatic hematoma, and extraocular muscle injury.¹¹ CT head is also recommended in the evaluation of suspected orbital fractures due to concomitant intracranial injury incidence of 9%.¹⁶

- CT maxillofacial is useful in diagnosing maxillofacial injuries including non-displaced fractures. CT provides multiplanar and 3-D image reconstructions, allowing for better characterization of complex fractures, which is useful for surgical planning.¹⁶
- Over one-third of individuals with frontal sinus fractures are likely to have a concomitant intracranial injury, thus concurrent CT head imaging is recommended in individuals with suspected frontal sinus fractures. In addition, between 8% to 10% of individuals with frontal sinus fractures have subdural or epidural hematomas requiring surgical treatment.¹⁶
- High resolution CT (HRCT) facial and temporal bone are sensitive modalities for subtle or non-displaced skull base defects, with sensitivity of 92% for identifying cerebrospinal fluid leak.^{7,15}

References (HD-13)

HD.TR.0013.3.A

v2.0.2026

1. Stiell IG, Wells GA, Vandemheen K, et al. The Canadian CT Head Rule for patients with minor head injury. *Lancet*. 2001;357(9266):1391-1396. doi:10.1016/s0140-6736(00)04561-x
2. Giza CC, Kutcher JS, Ashwal S, et al. Summary of evidence-based guideline update: Evaluation and management of concussion in sports: Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2013;80(24):2250-2257. doi:10.1212/wnl.0b013e31828d57dd
3. Silverberg ND, Iaccarino MA, Panenka WJ, et al. Management of Concussion and Mild Traumatic Brain Injury: A Synthesis of Practice Guidelines. *Arch Phys Med Rehabil*. 2020;101(2): 382-393. doi: 10.1016/j.apmr.2019.10.179.
4. Hoffmann JF. An Algorithm for the Initial Management of Nasal Trauma. *Facial Plast Surg*. 2015;31(3): 183-193. doi: 10.1055/s-0035-1555618.
5. Sun JK, Lemay DR. Imaging of facial trauma. *Neuroimaging Clin N Am*. 2002;12(2):295-309. doi:10.1016/s1052-5149(02)00002-3
6. Harmon KG, Clugston JR, Dec K, et al. American Medical Society for Sports Medicine position statement on concussion in sport. *Br J Sports Med*. 2019;53(4):213-225. doi:10.1136/bjsports-2018-100338
7. Expert Panel on Neurological Imaging, Shih RY, Burns J, et al. ACR Appropriateness Criteria® Head Trauma: 2021 Update. *J Am Coll Radiol*. 2021;18(5S):S13-S36. doi:10.1016/j.jacr.2021.01.006
8. Wintermark M, Sanelli PC, Anzai Y, et al. Imaging Evidence and Recommendations for Traumatic Brain Injury: Conventional Neuroimaging Techniques. *J A Coll Radiol*. 2015;12(2):e1-e14. doi:10.1016/j.jacr.2014.10.014
9. Papa L, Stiell IG, Clement CM, et al. Performance of the Canadian CT Head Rule and the New Orleans Criteria for predicting any traumatic intracranial injury on computed tomography in a United States Level I trauma center. *Acad Emerg Med*. 2012;19(1): 2-10. doi: 10.1111/j.1553-2712.2011.01247.x.
10. Reljic T, Mahony H, Djulbegovic B, et al. Value of Repeat Head Computed Tomography after Traumatic Brain Injury: Systematic Review and Meta-Analysis. *J Neurotrauma*. 2014;31(1):78-98. doi:10.1089/neu.2013.2873
11. Expert Panel on Neurologic Imaging; Kennedy TA, Corey AS, et al. ACR Appropriateness Criteria® Orbits Vision and Visual Loss. *J Am Coll Radiol*. 2018;15(5S):S116-S131. doi:10.1016/j.jacr.2018.03.023
12. Mower WR, Hoffman JR, Herbert M, et al. Developing a Decision Instrument to Guide Computed Tomographic Imaging of Blunt Head Injury Patients. *J Trauma*. 2005;59(4):954-959. doi:10.1097/01.ta.0000187813.79047.42
13. Haydel MJ, Preston CA, Mills TJ, Luber S, Blaudeau E, Deblieux PM. Indications for Computed Tomography in Patients with Minor Head Injury. *N Engl J Med*. 2000;343(2):100-105. doi:10.1056/nejm200007133430204
14. CDC. Traumatic Brain Injury & Concussion. Traumatic Brain Injury & Concussion. Published August 13, 2024. <https://www.cdc.gov>
15. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance of Computed Tomography (CT) of the extracranial head and neck. 2021; Available at: <https://gravitas.acr.org/PPTS/>
16. Expert Panel on Neurological Imaging, Parsons MS, Policeni B, et al. ACR Appropriateness Criteria® Imaging of Facial Trauma Following Primary Survey. *J Am Coll Radiol*. 2022;19(5S):S67-S86. doi:10.1016/j.jacr.2022.02.013.
17. American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Mild Traumatic Brain Injury, Valente JH, Anderson JD, et al. Clinical Policy: Critical Issues in the Management of Adult Patients Presenting to the Emergency Department With Mild Traumatic Brain Injury: Approved by ACEP Board of Directors, February 1, 2023 Clinical Policy Endorsed by the Emergency Nurses Association (April 5, 2023). *Ann Emerg Med*. 2023;81(5):e63-e105. doi:10.1016/j.annemergmed.2023.01.014
18. Smits M, Dippel DW, de Haan GG, et al. External validation of the Canadian CT Head Rule and the New Orleans Criteria for CT scanning in patients with minor head injury. *JAMA*. 2005;294(12):1519-1525. doi:10.1001/jama.294.12.1519
19. NeuroQuant - Cortechs.ai. Cortechs.ai. Published January 9, 2025

CNS and Head Infection/ Neuro-COVID-19 (HD-14)

Guideline	Page
CNS and Head Infection (HD-14.1)	152
Neuro-COVID-19 and Sars-CoV-2 Vaccines (HD-14.2)	154
Autoimmune/Paraneoplastic Encephalitis & Neuroinflammatory Disorders (HD-14.3)	158
References (HD-14)	162

CNS and Head Infection (HD-14.1)

HD.HI.0014.1.A

v2.0.2026

INITIAL IMAGING

- Signs of intracranial infection include, but are not limited to:
 - headaches, seizures, meningeal signs (neck stiffness)
 - new focal neurological deficits in a setting of fever or elevated white blood cell count (WBC)
 - known infection elsewhere **or**
 - immunosuppression
- **ONE** of the following studies is medically necessary for suspected intracranial infection if any of these signs of infection are present:
 - MRI Brain without and with contrast (CPT[®] 70553) **OR** MRI Brain without contrast (CPT[®] 70551) **OR**
 - CT Head (CPT[®] 70450, CPT[®] 70460, or CPT[®] 70470) in cases where MRI is contraindicated, in urgent scenarios, or prior to lumbar puncture, see **General Guidelines-CT Head (HD-1.4)**
 - If vascular involvement is suspected, in addition to MRI Brain, the following are medically necessary:
 - MRA Head (CPT[®] 70544, CPT[®] 70545, or CPT[®] 70546) **OR**
 - CTA Head (CPT[®] 70496) **AND/OR**
 - MRA Neck (CPT[®] 70547, CPT[®] 70548, or CPT[®] 70549) **OR**
 - CTA Neck (CPT[®] 70498) **OR**
 - CTA Head and Neck (CPT[®] 70471) must be substituted if performed during the same session
 - (CT and MR Venography (CTV and MRV) are reported with the same codes as the CTA/MRA counterpart (there is no specific code for CT/MR venography)
 - Concern for vasculitis, see **Cerebral Vasculitis (HD-22)**

REPEAT IMAGING

- As requested by an infectious disease specialist, neurologist, neurosurgeon, radiologist, or any provider coordinating care with an infectious disease specialist, neurologist, neurosurgeon, or radiologist
- Repeat imaging would refer to any of the CPT codes listed above as initial imaging.
 - See **General Guidelines – CT Head (HD-1.4)** regarding additional indications for CT Head.

- See **Skull Base Osteomyelitis (SBO) (HD-20.1)**, **Sinus and Facial Imaging (HD-29.1)**, **Dental/Periodontal/Maxillofacial Imaging (HD-30.2)**, **Mental Status Change (HD-4.2)**, and **Eye Disorders and Visual Loss (HD-32.1)**

Evidence Discussion (HD-14.1)

- A head CT is recommended for quickly assessing intracranial infections in urgent cases. However, MRI is more effective for examining conditions that affect the cranial nerves, brain tissue, and meninges.¹⁵ Although MRI is superior in detecting minor changes in the brain associated with infections, CT scans can promptly identify pathophysiological changes that may influence the individual's prognosis.¹
- Acute bacterial meningitis often presents with a normal CT scan. However, due to the high mortality rate of up to 50% when left untreated, a CT scan is necessary to rule out other causes of encephalopathy or neurologic deficits. In certain clinical situations, CT is also required to exclude increased intracranial pressure before performing a lumbar puncture. Venous thromboses increase the risk of hemorrhage and are linked to high mortality. Consequently, both CT and MRI scans, including T1-weighted sequences, are recommended. These scans help detect high signal changes in several venous sinuses and can be complemented with CT or MRvenography.
- Similar considerations apply when diagnosing non-bacterial central nervous system (CNS) infections. CT scans are advantageous due to quick access to care, faster diagnosis, and earlier treatment initiation, which can reduce morbidity. However, MRI is superior in detecting patterns of vasogenic versus cytotoxic edema, contrast enhancement, and the distribution of involvement, whether multifocal or unifocal/uni-hemispheric. These distinctions are crucial in differentiating between differential diagnoses, such as systemic infections with hematogenous spread versus head/neck infections with a direct spread pattern.³⁹
- Many individuals present with neurologic signs and symptoms that are indicative of either a cortical or subcortical syndrome. Often, these cannot be fully characterized by clinical presentation alone. As a result, radiologic evaluation becomes essential in diagnosing the etiology of the underlying process. The potential causes are varied and include meningoencephalitis, acute cerebrovascular disease, hemorrhagic necrotizing encephalopathy, immune-mediated (Bickerstaff) encephalitis, and demyelinating diseases such as acute disseminated encephalomyelitis (ADEM) and multiple sclerosis (MS).⁴⁰ Therefore, prompt and accurate diagnosis is critical to select the most appropriate imaging method (MRI vs. CT) for each clinical scenario.

Neuro-COVID-19 and Sars-CoV-2 Vaccines (HD-14.2)

HD.HI.0014.2.A

v2.0.2026

- The following studies are medically necessary for evaluation of:
 - Acute or chronic Neuro-COVID-19 syndrome
 - MRI Brain without contrast (CPT[®] 70551) **OR**
 - MRI Brain without and with contrast (CPT[®] 70553) **OR**
 - CT Head without contrast (CPT[®] 70450) **OR**
 - CT Head without and with contrast (CPT[®] 70470) is medically necessary if there is a contraindication to MRI **AND/OR**
 - MRA Head (CPT[®] 70544, CPT[®] 70545, or CPT[®] 70546) OR CTA Head (CPT[®] 70496) **AND/OR**
 - MRA Neck (CPT[®] 70547, CPT[®] 70548, or CPT[®] 70549) or CTA Neck (CPT[®] 70498)
 - CTA Head and Neck (CPT[®] 70471) must be substituted if performed during the same session
 - CT and MR Venography (CTV and MRV) are reported with the same codes as the CTA/MRA counterpart (there is no specific code for CT/MR venography):
 - If arterial and venous CT or MR studies are both performed in the same session, only one CPT[®] code is used to report both procedures
 - If an arterial CTA or MRA study has been performed and subsequently a repeat study is needed to evaluate the venous anatomy, then this study is medically necessary
 - If a venous CTV or MRV has been performed and subsequently a repeat study is needed to evaluate the arterial anatomy, then this study is medically necessary
 - MRA without and with contrast with venous sinus thrombosis to differentiate total from subtotal occlusion is medically necessary
 - For suspected neurologic adverse reactions after SARS- CoV-2 vaccination, the following is medically necessary:
 - MRI Brain without contrast (CPT[®] 70551) **OR**
 - MRI Brain without and with contrast (CPT[®] 70553) **OR**
 - CT Head without contrast (CPT[®] 70450) **OR**
 - CT Head without and with contrast (CPT[®] 70470) is medically necessary if there is a contraindication to MRI **AND/OR**

- MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) OR CTA Head (CPT® 70496) **AND/OR**
- MRA Neck (CPT® 70547, CPT® 70548, or CPT® 70549) or CTA Neck (CPT® 70498)
 - CTA Head and Neck (CPT® 70471) must be substituted if performed during the same session
- CT and MR Venography (CTV and MRV) are reported with the same codes as the CTA/MRA counterpart (there is no specific code for CT/MR venography):
 - If arterial and venous CT or MR studies are both performed in the same session, only one CPT® code is used to report both procedures
 - If an arterial CTA or MRA study has been performed and subsequently a repeat study is needed to evaluate the venous anatomy, then this study is medically necessary
 - If a venous CTV or MRV has been performed and subsequently a repeat study is needed to evaluate the arterial anatomy, then this study is medically necessary
 - MRA without and with contrast with venous sinus thrombosis to differentiate total from subtotal occlusion is medically necessary
- If suspected transverse myelitis, acute necrotizing myelitis, and/or COVID-19 infection, then **ANY** the following are medically necessary:
 - MRI Cervical without and with contrast (CPT® 72156)
 - MRI Thoracic without and with contrast (CPT® 72157)
 - MRI Lumbar Spine without and with contrast (CPT® 72158)
 - See **Stroke/TIA (HD-21.1)** for vascular imaging
 - See **Transverse Myelitis (HD-16.4)** regarding spine imaging to evaluate for post-vaccination neurological syndrome
- Repeat imaging considered on a case-by-case basis for a change in neurological symptoms or signs on the neurological exam and/or change in the treatment.

Background and Supporting Information

- The findings observed in the central nervous system in the acute-phase of COVID-19 may extend into a prolonged symptomatic phase of Neuro-COVID in long haulers with chronic COVID syndrome. Symptoms may include, but are not inclusive to: "brain fog", dizziness, inability to concentrate, psychiatric symptoms, and confusion.
- Acute-phase neurologic manifestations of COVID-19 include: headache, dizziness, taste and smell dysfunction, impaired consciousness (described as confusion or agitation), cerebrovascular events (ischemic stroke, cerebral venous sinus thrombosis, cerebral hemorrhage), seizures, meningoencephalitis, and immune-mediated neurologic diseases (Guillan-Barre syndrome, Miller-Fisher syndrome, polyneuritis cranialis, transverse myelitis).

- Neurologic adverse reactions in those receiving SARS-CoV-2 vaccines, including mRNA vaccines (Pfizer, Moderna), have been reported, and include, although not limited to: headache, Guillan-Barre syndrome, transverse myelitis, facial nerve palsy, small fiber neuropathy, autoimmune encephalitis, reversible cerebral vasoconstriction syndrome, multiple sclerosis, neuromyelitis optica, intracerebral bleeding, cerebral venous sinus thrombosis, hypophysitis, epilepsy, encephalopathy, and acute disseminated encephalomyelitis.
- Cases of Thrombosis with Thrombocytopenia Syndrome (TTS) following administration of the Johnson & Johnson/Janssen COVID-19 Vaccine have been reported in males and females, in a wide age range of individuals 18 years and older, with the highest reporting rate (approximately 8 cases per 1,000,000 doses administered) in females ages 30-49 years; overall, approximately 15% of TTS cases have been fatal. Currently available evidence supports a causal relationship between TTS and the Johnson & Johnson/Janssen COVID-19 Vaccine. The clinical course of these events shares features with autoimmune heparin-induced thrombocytopenia. In individuals with suspected TTS following administration of the Johnson & Johnson/Janssen COVID-19 Vaccine, the use of heparin may be harmful and alternative treatments may be needed. Consultation with hematology specialists is strongly recommended. The American Society of Hematology has published considerations relevant to the diagnosis and treatment of TTS following administration of the Janssen COVID-19 Vaccine.

Evidence Discussion (HD-14.2)

- A head CT is recommended for quickly assessing intracranial infections in urgent cases. However, MRI is more effective for examining conditions that affect the cranial nerves, brain tissue, and meninges.¹⁵ Although MRI is superior in detecting minor changes in the brain associated with infections, CT scans can promptly identify pathophysiological changes that may influence the individual's prognosis.¹
- Acute bacterial meningitis often presents with a normal CT scan. However, due to the high mortality rate of up to 50% when left untreated, a CT scan is necessary to rule out other causes of encephalopathy or neurologic deficits. In certain clinical situations, CT is also required to exclude increased intracranial pressure before performing a lumbar puncture. Venous thromboses increase the risk of hemorrhage and are linked to high mortality. Consequently, both CT and MRI scans, including T1-weighted sequences, are recommended. These scans help detect high signal changes in several venous sinuses and can be complemented with CT- or MR-venography.
- Similar considerations apply when diagnosing non-bacterial central nervous system (CNS) infections. CT scans are advantageous due to quick access to care, faster diagnosis, and earlier treatment initiation, which can reduce morbidity. However, MRI is superior in detecting patterns of vasogenic versus cytotoxic edema, contrast enhancement, and the distribution of involvement, whether multifocal or unifocal/

unihemispheric. These distinctions are crucial in differentiating between differential diagnoses, such as systemic infections with hematogenous spread versus head/neck infections with a direct spread pattern.³⁹

- Many individuals present with neurologic signs and symptoms that are indicative of either a cortical or subcortical syndrome. Often, these cannot be fully characterized by clinical presentation alone. As a result, radiologic evaluation becomes essential in diagnosing the etiology of the underlying process. The potential causes are varied and include meningoencephalitis, acute cerebrovascular disease, hemorrhagic necrotizing encephalopathy, immune-mediated (Bickerstaff) encephalitis, and demyelinating diseases such as acute disseminated encephalomyelitis (ADEM) and multiple sclerosis (MS).⁴⁰ Therefore, prompt and accurate diagnosis is critical to select the most appropriate imaging method (MRI vs. CT) for each clinical scenario.

Autoimmune/Paraneoplastic Encephalitis & Neuroinflammatory Disorders (HD-14.3)

HD.HI.0014.3.A

v2.0.2026

Indications:

When acute/subacute or rapid progression (<3 months) of altered mental status, focal findings including cranial nerve, motor or sensory symptoms or memory loss or psychiatric symptoms, seizure, and/or focal CNS findings are present.

OR

There is a stated concern for neuro-inflammatory encephalitis from or in consultation with a neurologist, neurosurgeon, psychiatrist, oncologist, rheumatologist, or infectious disease specialist.

Medically Necessary Initial Imaging:

- MRI Brain without and with contrast (CPT[®] 70553) **OR** MRI Brain without contrast (CPT[®] 70551) **OR**
- CT Head without contrast (CPT[®] 70450) **OR** CT Head without and with contrast (CPT[®] 70470) when MRI is unavailable or contraindicated or for bony pathology concerns
- MRA Head (CPT[®] 70544, CPT[®] 70545, or CPT[®] 70546) **OR** CTA Head (CPT[®] 70496) **AND/OR** MRA Neck (CPT[®] 70547, CPT[®] 70548, or CPT[®] 70549) **OR** CTA Neck (CPT[®] 70498)
 - CTA Head and Neck (CPT[®] 70471) must be submitted if performed during the same session

The above imaging studies are for evaluating large vessel obstructions, aneurysms and vascular malformations, dissection, vasospasm, and vasculopathies such as CNS vasculitis (see **Cerebral Vasculitis (HD-22.1)**, **Cerebral Aneurysms (HD-12.1)**, **Arteriovenous Malformations (AVMs) and Related Lesions (HD-12.2)**, **Stroke/TIA (HD-21.1)**)

Medically Necessary Repeat Imaging:

MRI Brain without and with contrast (CPT[®] 70553) **OR** MRI Brain without contrast (CPT[®] 70551) when specialized sequences are needed such as, but not limited to:

- high T2 contrast sequences (CISS, FIESTA) sequences to identify blood (SWI) or

- identifying acute cytotoxic edema (DWI) or
- when requested by or in consultation with a neurologist, oncologist, rheumatologist, infectious disease specialist, neurosurgeon, or psychiatrist

Metabolic (FDG) Brain PET (CPT[®] 78608) is medically necessary to evaluate individuals suspected of having encephalitis, including autoimmune encephalitis, if diagnosis remains unclear after evaluation with MRI Brain, CSF analysis, and/or lab testing including serology.

Neurosarcoidosis:

- The following are medically necessary for known or suspected neurosarcoidosis.
 - MRI Brain without and with contrast (CPT[®] 70553)

AND/OR

- If spinal cord involvement suspected, then
 - MRI Cervical Spine without and with contrast (CPT[®] 72156) **AND/OR**
 - MRI Thoracic Spine without and with contrast (CPT[®] 72157) **AND/OR**
 - MRI Lumbar Spine without and with contrast (CPT[®] 72158)

AND/OR

- If peri-orbital involvement suspected, then
 - MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543)
- Repeat imaging supported if requested by neurologist, rheumatologist, ophthalmologist, oncologist, or radiologist or provider in consultation with a neurologist, rheumatologist, ophthalmologist, oncologist or radiologist.
- For non-neurologic imaging related to sarcoidosis (see **Sarcoid (CH-15.1)**)

Background and Supporting Information

Supportive studies in the evaluation of Autoimmune/Paraneoplastic Encephalopathy include:

- CSF pleocytosis (>5 WBC/ μ L) or
- EEG changes or
- Supporting labs (including positive CSF antibody positivity and/or serologies)

Potential etiologies:

- Paraneoplastic
 - NMDA Receptor encephalitis
 - LGI1 antibody encephalitis
- Autoimmune
 - Neurosarcoidosis can involve any of the following:

- Brain, Cranial Nerves, Spinal Cord, and/or Peripheral Nerves
- Acute Disseminated Encephalomyelitis (ADEM), Anti-MOG Syndrome, Multiple Sclerosis (MS), Neuromyelitis Optica (NMO)
- IgG4 related disease
- CNS histiocytosis
- Neuro-rheumatologic
 - ANCA related disease
 - Behcet's disease
 - Sjogren Syndrome +/- Rheumatoid Arthritis (RA)

FDG-PET imaging of the brain for paraneoplastic and autoimmune encephalitis may be more sensitive than brain MRI (87% vs. 56%) but is nonspecific. Areas of hypometabolism are seen in neurodegenerative disorders such as dementias. However, topographic patterns of hypometabolism may help characterize the disorder as autoimmune/ paraneoplastic encephalitis, in a way that may help clarify diagnosis and alter management strategies. For example, anterior to posterior gradient of hypometabolism is seen in NMDA Receptor encephalitis. Hemispheric hypometabolism out of proportion to atrophy characterizes Rasmussen encephalitis.

Non-Head Imaging

- MRI is helpful in determining the length of spine lesion (short versus longitudinally extensive transverse myelitis), width (partial versus transverse), and location (eccentric, central, hemicord, anterior versus posterior, conus, tracts, or meningeal).
 - See **Myelopathy (SP-7.1)** and **Anti-MOG Syndromes (HD-16.3)**
- The Trident Sign on axial MRI, which has been described in relation to neurosarcoidosis, demonstrates leptomeningeal or dorsal subpial enhancement that may or may not involve the central canal.
 - See **Myelopathy (SP-7.1)**
- Involvement of the conus medullaris is a clue to Anti-MOG (Myelin Oligodendrocyte Glycoprotein-associated disorder) as the cause of longitudinally extensive transverse myelitis.
 - See **Transverse Myelitis (HD-16.4)**
- CT of the chest, abdomen, and pelvis with contrast is a generally accepted first method of screening for occult malignancy or systemic inflammation (e.g., sarcoidosis).
 - See **Paraneoplastic Syndromes (ONC-30.3)** and **Sarcoid (CH-15.1)**

Evidence Discussion (HD-14.3)

- The American College of Radiology (ACR) Appropriateness Criteria® provided guidance on the appropriateness of CT versus MRI Brain in certain clinical scenarios

relating to altered mental status. For acute, undifferentiated presentations and with focal symptoms, CT Head is an appropriate modality, but with known intracranial process, suspected medical illness or toxic-metabolic etiology, and/or psychosis, MRI Brain, is appropriate and in some cases may be preferable.⁴⁵

- In the appropriate clinical scenarios, recognition of structural and functional imaging patterns of brain involvement using CT head, MRI brain, and brain PET, in autoimmune encephalitis (including paraneoplastic and non-rheumatologic inflammatory disorders) can facilitate rapid access to appropriate treatment, as well as avoid invasive diagnostic procedures such as brain biopsy.²⁶
- FDG-PET/CT brain performed at a median 4 weeks of symptom onset was more often abnormal than initial MRI, EEG, or laboratory cerebrospinal fluid testing, in individuals with suspected autoimmune encephalitis (AE), with focal hypometabolism, the most common PET/CT finding.²
- Spine MRI shows abnormalities in up to 45% of cases of paraneoplastic myeloneuropathy.⁴⁷
- The three-dimensional (3D) constructive interference in steady state (CISS) is a gradient-echo MRI or Fast Imaging Employing Steady-state Acquisition Cycled Phases (FIESTA-C) on GE MRI systems are widely employed for over a decade and have been shown to have utility in demonstration of contrast between cerebrospinal fluid and brain parenchymal structure. Therefore, these have particular utility in the examination of cranial nerves, the ventricular system, cavernous sinus, and other structures which are commonly involved in neuro-inflammatory conditions.⁴⁸
- Neuropsychiatric lupus and other neuro-inflammatory conditions have been described to mimic vascular disease, such as vasculitis and small vessel cerebrovascular disease, and in these cases vessel imaging with CT Angiography (CTA) and MR Angiography (MRA) Brain can contribute to meaningful diagnosis.⁴⁹
- In the evaluation of a first episode of psychosis when an autoimmune cause is suspected, up to 4% of cases have abnormalities on MRI brain.⁵⁰
- Sarcoidosis can manifest with neurologic complications in every part of the neural axis, with diagnostic challenges represented by multiple pathophysiologic pathways and frequently lack of specific histopathologic diagnosis. In clinically suspected neurosarcoidosis on the basis of synthesized clinical history and physical examination findings, the demonstration of neuro-inflammation using cerebrospinal fluid testing and contrast-enhanced MRI is useful. In difficult or complicated cases, FDG-PET and Gallium-67 imaging have been useful for identification of targets for biopsy.^{h1}

References (HD-14)

v2.0.2026

1. Abdalkader M, Xie J, Cervantes-Arslanian A, Takahashi C, Mian AZ. Imaging of Intracranial Infections. *Seminars in Neurology*. 2019;39(03):322-333. doi:10.1055/s-0039-1693161
2. Probasco JC, Solnes L, Nalluri A, et al. Abnormal brain metabolism on FDG-PET/CT is a common early finding in autoimmune encephalitis. *Neurology - Neuroimmunology Neuroinflammation*. 2017;4(4). doi:10.1212/ nxi.0000000000000352
3. Rubin R. As their numbers grow, COVID-19 "long haulers" stump experts. *JAMA*. 2020;324(14):1381–1383. doi:10.1001/jama.2020.17709
4. E. M. Liotta et al. Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. *Annals of Clinical and Translational Neurology* 2020;7(11): 2221–2230 doi: 10.1002/acn3.51210.
5. Chen X, Laurent S, Onur OA, Kleineberg NN, Fink GR, Schweitzer F, Warnke C. A systematic review of neurological symptoms and complications of COVID-19. *Journal of Neurology*. 2021 Feb;268(2):392-402. doi: 10.1007/s00415-020-10067-3
6. Finsterer J Neurological side effects of SARS-CoV-2 vaccinations. *Acta Neurol Scand*. 2022 145(1): 5–9. doi: 10.1111/ane.13550
7. Kaulen LD, Doubrovinskaia S, Mooshage C, et al. Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series. *Eur J Neurol*. 2022 Feb;29(2):555-563. doi: 10.1111/ene.15147
8. Maury A, Lyoubi A, Peiffer-Smadja N, de Broucker T, Meppiel E. Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: A narrative review for clinicians. *Rev Neurol (Paris)*. 2021 Jan-Feb;177(1-2):51-64. doi: 10.1016/j.neurol.2020.10.001
9. Moreno-Escobar MC, Kataria S, Khan E, et al. Acute transverse myelitis with Dysautonomia following SARS-CoV-2 infection: A case report and review of literature. *J Neuroimmunol*. 2021 Apr 15;353:577523. doi: 10.1016/j.jneuroim.2021.577523
10. Patone M, Handunnetthi L, Saatci D, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. *Nat Med*. 2021 Dec;27(12):2144-2153. doi: 10.1038/s41591-021-01556-7
11. Rosenblum HG, Hadler SC, Moulia D, et al. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021. *MMWR Morb Mortal Wkly Rep*. 2021 Aug 13;70(32):1094-1099. doi: 10.15585/mmwr.mm7032e4
12. Rosenblum HG, Gee J, Liu R, et al. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe. *Lancet Infect Dis*. 2022 Mar 7:S1473-3099(22)00054-8. doi: 10.1016/S1473-3099(22)00054-8
13. Vasconcelos TMF, Oliveira DN, Ferreira GM, et al. Covid-19 post-infectious acute transverse myelitis responsive to corticosteroid therapy: report of two clinical cases. *J Neurovirol*. 2021 Oct;27(5):791-796. doi: 10.1007/s13365-021-01010-x 12
14. Frontera JA, Tamborska AA, Doheim MF, et al; contributors from the Global COVID-19 Neuro Research Coalition. Neurological Events Reported after COVID-19 Vaccines: An Analysis of VAERS. *Ann Neurol*. 2022 Mar 2. doi: 10.1002/ana.26339
15. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance of computed tomography (CT) of the Head. 2020; Available at: <https://gravitas.acr.org/PPTS/>
16. Expert Panel on Neurological Imaging, Rath TJ, Policeni B, et al. ACR Appropriateness Criteria® Cranial Neuropathy: 2022 Update. *J Am Coll Radiol*. 2022;19(11S):S266-S303. doi:10.1016/j.jacr.2022.09.021
17. Anand P. Neurologic Infections in Patients on Immunomodulatory and Immunosuppressive Therapies. *Continuum (Minneap Minn)*. 2021;27(4):1066-1104. doi:10.1212/CON.0000000000000985
18. Chow F. Neurosyphilis. *Continuum (Minneap Minn)*. 2021;27(4):1018-1039. doi:10.1212/CON.0000000000000982
19. Roos KL. Neurologic Complications of Lyme Disease. *Continuum (Minneap Minn)*. 2021;27(4):1040-1050. doi:10.1212/CON.0000000000001015

20. Singh SK, Hasbun R. Neuroradiology of infectious diseases. *Curr Opin Infect Dis.* 2021;34(3):228-237. doi:10.1097/QCO.0000000000000725
21. Weidauer S, Wagner M, Enkirch SJ, Hattingen E. CNS Infections in Immunoincompetent Patients : Neuroradiological and Clinical Features. *Clin Neuroradiol.* 2020;30(1):9-25. doi:10.1007/s00062-019-00837-6
22. Sakai M, Higashi M, Fujiwara T, et al. MRI imaging features of HIV-related central nervous system diseases: diagnosis by pattern recognition in daily practice. *Jpn J Radiol.* 2021;39(11):1023-1038. doi:10.1007/s11604-021-01150-4
23. Corrêa DG, de Souza SR, Freddi TAL, Fonseca APA, Dos Santos RQ, Hygino da Cruz LC Jr. Imaging features of neurosyphilis. *J Neuroradiol.* 2023;50(2):241-252. doi:10.1016/j.neurad.2023.01.003
24. Beghi E, Helbok R, Ozturk S, et al. Short- and long-term outcome and predictors in an international cohort of patients with neuro-COVID-19. *Eur J Neurol.* 2022;29(6):1663-1684. doi:10.1111/ene.15293
25. Premraj L, Kannapadi NV, Briggs J, Seal SM, Battaglini D, Fanning J, Suen J, Robba C, Fraser J, Cho SM. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. *J Neurol Sci.* 2022 Mar 15;434:120162. doi: 10.1016/j.jns.2022.120162. Epub 2022 Jan 29. PMID: 35121209; PMCID: PMC8798975.
26. Wahed LA, Cho TA. Imaging of Central Nervous System Autoimmune, Paraneoplastic, and Neuro-rheumatologic Disorders. *Continuum (Minneap Minn).* 2023 Feb 1;29(1):255-291. doi: 10.1212/CON.0000000000001244. PMID: 36795880.
27. Bordonne, M., Chawki, M.B., Doyen, M. *et al.* Brain 18F-FDG PET for the diagnosis of autoimmune encephalitis: a systematic review and a meta-analysis. *Eur J Nucl Med Mol Imaging* 48, 3847–3858 (2021). <https://doi.org/10.1007/s00259-021-05299-y>
28. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. *Lancet Neurol.* 2016;15(4):391-404. doi:10.1016/S1474-4422(15)00401-9
29. Budhram A, Leung A, Nicolle MW, Burneo JG. Diagnosing autoimmune limbic encephalitis. *CMAJ.* 2019;191(19):E529-E534. doi:10.1503/cmaj.181548
30. Solnes LB, Jones KM, Rowe SP, et al. Diagnostic Value of ¹⁸F-FDG PET/CT Versus MRI in the Setting of Antibody-Specific Autoimmune Encephalitis. *J Nucl Med.* 2017;58(8):1307-1313. doi:10.2967/jnumed.116.184333
31. Stern BJ, Royal W, Gelfand JM, et al. Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group. *JAMA Neurology.* 2018;75(12):1546. doi:10.1001/jamaneurol.2018.2295.
32. Bradshaw MJ, Pawate S, Koth LL, Cho TA, Gelfand JM. Neurosarcoidosis: Pathophysiology, Diagnosis, and Treatment. *Neurol Neuroimmunol Neuroinflamm.* 2021 Oct 4;8(6):e1084. doi: 10.1212/NXI.0000000000001084
33. Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. *BMC Neurol.* 2016 Nov 15;16(1):220. doi: 10.1186/s12883-016-0741-x
34. Pawate S. Sarcoidosis and the Nervous System. *Continuum (Minneap Minn).* 2020 Jun;26(3):695-715. doi: 10.1212/CON.0000000000000855
35. Khan E, Shrestha AK, Colantonio MA, Liberio RN, Sriwastava S. Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of the literature. *J Neurol.* 2022;269(3):1121-1132. doi:10.1007/s00415-021-10785-2
36. Ismail II, Salama S. Association of CNS demyelination and COVID-19 infection: an updated systematic review. *J Neurol.* 2022;269(2):541-576. doi:10.1007/s00415-021-10752-x
37. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. *Clin Infect Dis.* 2004;39(9):1267-1284. doi:10.1086/425368
38. Proulx N, Fréchette D, Toye B, Chan J, Kravcik S. Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. *QJM.* 2005;98(4):291-298. doi:10.1093/qjmed/hci047
39. Nguyen I, Urbanczyk K, Mtui E, Li S. Intracranial CNS infections: A literature review and radiology case studies. *Semin Ultrasound CT MR.* 2020 Feb;41(1):106-120. doi: 10.1053/j.sult.2019.09.003. Epub 2019 Oct 2. PMID: 31964490.
40. Sklinda K, Dorobek M, Wasilewski PG, et al. Radiological Manifestation of Neurological Complications in the Course of SARS-CoV-2 Infection. *Front Neurol.* 2021 Oct 20;12:711026. doi: 10.3389/fneur.2021.711026. PMID: 34744963; PMCID: PMC8563625.

41. Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. *Brain*. 2020;143:3104–20. 10.1093/brain/awaa240
42. Kremer S, Lersy F, de Sèze J, et al. Brain MRI findings in severe COVID-19: a retrospective observational study. *Radiology*. (2020) 297:E242–51. 10.1148/radiol.2020202222
43. Radmanesh A, Raz E, Zan E, Derman A, Kaminetzky M. Brain imaging use and findings in COVID-19: a single academic center experience in the epicenter of disease in the United States. *Am J Neuroradiol*. (2020) 41:1179–83. 10.3174/ajnr.A6610
44. Tu TM, Yi SJ, Koh JS, et al. Incidence of cerebral venous thrombosis following SARS-CoV-2 infection vs mRNA SARS-CoV-2 vaccination in Singapore. *JAMA Netw Open*. 2022;5(3):e222940. doi:10.1001/jamanetworkopen.2022.2940
45. Soares BP, Shih RY, Utukuri PS, et al. ACR Appropriateness Criteria® Altered Mental Status, Coma, Delirium, and Psychosis. Available at <https://acsearch.acr.org/docs/3102409/Narrative/>. American College of Radiology. Revised 2024.
46. Gomez CK, Schiffman SR, Bhatt AA. Radiological review of skull lesions. *Insights Imaging*. 2018;9(5):857-882. doi:10.1007/s13244-018-0643-0
47. Shah S, Vazquez Do Campo R, Kumar N, McKeon A, Flanagan EP, Klein C, Pittock SJ, Dubey D. Paraneoplastic Myeloneuropathies: Clinical, Oncologic, and Serologic Accompaniments. *Neurology*. 2021 Jan 26;96(4):e632-e639. doi: 10.1212/WNL.0000000000011218. Epub 2020 Nov 18. PMID: 33208548; PMCID: PMC7905784.
48. Hingwala D, Chatterjee S, Kesavadas C, Thomas B, Kapilamoorthy TR. Applications of 3D CISS sequence for problem solving in neuroimaging. *Indian J Radiol Imaging*. 2011 Apr;21(2):90-7. doi: 10.4103/0971-3026.82283. PMID: 21799590; PMCID: PMC3137865.
49. Lancaster E. The Diagnosis and Treatment of Autoimmune Encephalitis. *J Clin Neurol*. 2016 Jan;12(1):1-13. doi: 10.3988/jcn.2016.12.1.1. PMID: 26754777; PMCID: PMC4712273.
50. Guasp M, Giné-Servén E, Maudes E, et al. Clinical, neuroimmunologic, and CSF investigations in first episode psychosis. *Neurology*. 2021;97(1):e61-e75. doi:10.1212/WNL.00000000000012191
51. Ibitoye RT, Wilkins A, Scolding NJ. Neurosarcoidosis: a clinical approach to diagnosis and management. *J Neurol*. 2017 May;264(5):1023-1028. doi: 10.1007/s00415-016-8336-4. Epub 2016 Nov 22. PMID: 27878437; PMCID: PMC5413520.
52. Guada L, Cabrero FR, Baldwin NL, Levi AD, Gultekin SH, Verma A. Acute ascending necrotizing myelitis after COVID-19 infection: A clinicopathologic report. *Neurol Clin Pract*. 2022;12(3):e28-e32. doi:10.1212/CPJ.0000000000001175
53. American Medical Association. CPT—Current Procedural Terminology. American Medical Association. Published 2026. Copyright 1995 – 2026

Movement Disorders (HD-15)

Guideline	Page
Movement Disorders (HD-15.1).....	166
References (HD-15).....	169

Movement Disorders (HD-15.1)

HD.MD.0015.1.A

v2.0.2026

- The majority of movement disorders are diagnosed based on a clinical diagnosis and imaging is not medically necessary. These include:
 - typical Parkinson's Disease
 - essential tremor or tremors of anxiety or weakness
 - restless leg syndrome
 - tics or spasms which can be duplicated at will
 - Tourette syndrome
 - tardive dyskinesia
- MRI Brain without contrast (CPT[®] 70551) or MRI Brain without and with contrast (CPT[®] 70553) is medically necessary in the following clinical scenarios:
 - Clinical diagnostic uncertainty
 - Incomplete or uncertain response to medication
 - Anti-psychotic drug-induced Parkinsonism or atypical tardive dyskinesia
 - Atypical Parkinsonism suspected because of unusual clinical features. These may include, but are not limited to:
 - Persistent unilateral signs or symptoms
 - Onset under age 50
 - Rapid progression
 - See *Background and Supporting Information* for further information on atypical parkinsonism and Parkinson's Plus Syndromes
 - Suspected Huntington Disease
- Evaluation for surgical treatment of essential tremor, Parkinson's disease, and/or spasmodic torticollis/dystonia, see **Torticollis and Dystonia (Neck-10.2)** in the Neck Imaging Guidelines
 - Deep Brain Stimulation (DBS) therapy
 - MRI Brain without contrast (CPT[®] 70551) **OR** MRI Brain without and with contrast (CPT[®] 70553) **AND/OR** unlisted CT procedure code (CPT[®] 76497) are medically necessary
 - MR guided Focused Ultrasound:
 - CT Head without contrast (CPT[®] 70450) to evaluate bone density **AND/OR** MRI Brain without contrast (CPT[®] 70551) **OR** MRI Brain without and with contrast (CPT[®] 70553) are medically necessary
 - Repeat imaging studies for pre-surgical evaluation, MRI Brain without contrast (CPT[®] 70551) **OR** MRI Brain without and with contrast (CPT[®] 70553) **AND/OR** CT Head without contrast (CPT[®] 70450), are medically necessary when ordered by a

- Neurosurgeon or Neurologist or any provider in consultation with a Neurosurgeon or Neurologist if greater than 6 months old **and/or** for new symptoms/signs
- Post-op imaging is medically necessary when ordered by a Neurosurgeon or Neurologist or any provider in consultation with a Neurosurgeon or Neurologist for either procedure, see also **Post-Operative Imaging (HD-28.3)** indications
 - Dopamine Transporter Scan [DAT-SPECT Radiopharmaceutical Localization SPECT (Ioflupane I-123 SPECT)] (CPT[®] 78803 or CPT[®] 78830) **OR** Fluorodopa F¹⁸ (F-DOPA) PET Brain (CPT[®] 78608) is medically necessary to:^{2,3,16,17,18}
 - evaluate motor symptoms (tremor, rigidity, bradykinesia, and/or postural instability) in suspected Parkinsonian Syndromes (Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, Corticobasal Degeneration) when the diagnosis is unclear, to differentiate from non-neurodegenerative disorders, such as Essential Tremor, drug-induced tremor, vascular parkinsonism, and/or psychogenic tremor
 - Imaging with either modality, **not both**, is medically necessary when the diagnosis remains unclear after evaluation by a neurologist, medication trials and brain imaging.
 - See *Background and Supporting Information* for additional information regarding Parkinson's Plus Syndromes.
 - Neither DAT Scans nor F-DOPA PET scans are medically necessary for differentiation of subtypes of Parkinson's syndromes, to monitor progression of disease, or predict risk of development of disease mainly to exclude other conditions with similar clinical presentations.
 - MRI Brain without and with contrast (CPT[®] 70553) is medically necessary for initial imaging for suspected motor neuron disease (see **Motor Neuron Disease/ Amyotrophic Lateral Sclerosis (ALS) (PND-8.1)** in the Peripheral Nerve and Neuromuscular Disorders Imaging Guideline)
 - Dementia associated with movement disorder (see **Lewy Body Dementia (LBD) – SPECT Brain Scan and PET (HD-8.3)**)

Background and Supporting Information

- Parkinson's Plus Syndromes are a group of disorders characterized by atypical parkinsonism. They are NOT Parkinson's disease. They represent different neurodegenerative diseases with features of PD, and may be confused with PD. These syndromes include, but are not limited to:
 - Multiple system atrophy: orthostatic hypotension (dysautonomia), dysphonia, dysarthria
 - Progressive Supranuclear Palsy: balance difficulties, vertical gaze paresis
 - Corticobasal Syndrome: dysphasia, apraxia, myoclonus, alien-limb phenomenon
- These are distinct entities. Care must be taken to determine if there are unusual features present that will suggest atypical parkinsonian syndrome.

- Dementia with Lewy bodies (DLB): dementia prior to movement disorder (see **Lewy Body Dementia (LBD) - SPECT Brain Scan and PET (HD-8.3)**)

Evidence Discussion (HD-15)

- The majority of movements disorders are diagnosed based on history and clinical examination findings and do not require imaging.^{1,2,3,24} For cases of diagnostic uncertainty, incomplete response to medication, for atypical Parkinsonism or drug-induced parkinsonism, and for suspected Huntington disease, MRI brain is the preferred imaging modality.^{1,3,24}
- Structural imaging with MRI Brain is usually normal in individuals with Parkinson's disease but is useful to diagnose causes of secondary parkinsonism, such as stroke, iron deposition, normal pressure hydrocephalus, and neoplasm.^{1,2,3}
- CT Head is not preferred due to its limited soft-tissue characterization when compared to MRI.¹
- Functional imaging studies assessing dopaminergic function in Parkinson's disease include single-photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging.^{1,2,3} These studies are used as an adjunct diagnostic test.^{1,2,3}
- Both Dopamine Transporter single-photon emission computed tomography (DAT-SPECT) and [18F]-fluorodopa (F-DOPA) PET brain are useful to differentiate suspected parkinsonian syndromes from non-neurodegenerative disorders such as Essential Tremor, drug-induced tremors, vascular parkinsonism, and/or psychogenic tremors.^{1,2,3,17,18}
- DAT-SPECT has a sensitivity of 91% with a specificity of 100% for essential tremor, a sensitivity of 86.2% with a specificity of 93.8% for drug-induced parkinsonism, and a sensitivity of 86.2% with a specificity of 82.9% for vascular parkinsonism.^{18,25,26}
- F-DOPA PET brain has a sensitivity of 73% with a specificity of 91% for evaluation of parkinsonian syndrome vs non-neurodegenerative parkinsonian syndrome.¹⁷
- Neither DAT-SPECT scans nor F-DOPA PET brain scans are useful for the differentiation between subtypes of Parkinsonian syndromes, to monitor progression of disease nor to predict the risk of development of disease.^{1,2,3}
- There is insufficient evidence for the routine use of FDG-PET brain in the diagnosis of parkinsonian syndromes.¹

References (HD-15)

v2.0.2026

1. Expert Panel on Neurological Imaging, Harvey HB, Watson LC, et al. ACR Appropriateness Criteria® Movement Disorders and Neurodegenerative Diseases. *J Am Coll Radiol*. 2020;17(5S):S175-S187. doi:10.1016/j.jacr.2020.01.042
2. Thaler A, Alcalay RN. Diagnosis and Medical Management of Parkinson Disease. *Continuum (Minneap Minn)*. 2022;28(5):1281-1300. doi:10.1212/CON.0000000000001152
3. Maiti B, Perlmuter JS. Imaging in Movement Disorders. *Continuum (Minneap Minn)*. 2023;29(1):194-218. doi:10.1212/CON.0000000000001210
4. Subramaniam RM, Frey KA, Hunt CH, et al. ACR-ACNM Practice Parameter for the Performance of Dopamine Transporter (DaT) Single Photon Emission Computed Tomography (SPECT) Imaging for Movement Disorders. *Clinical Nuclear Medicine*. 2017;42(11):847-852. doi:10.1097/rlu.0000000000001815
5. Bega D, Gonzalez-Latapi P, Zadikoff C, Spies W, Simuni T. Is There a Role for DAT-SPECT Imaging in a Specialty Movement Disorders Practice? *Neurodegenerative Diseases*. 2015;15(2):81-86. doi:10.1159/000370116
6. Mohammed N, Patra D, Nanda A. A meta-analysis of outcomes and complications of magnetic resonance-guided focused ultrasound in the treatment of essential tremor. *Neurosurgical Focus*. 2018;44(2). doi:10.3171/2017.11.focus17628
7. Schreglmann SR, Krauss JK, Chang JW, Bhatia KP, Kägi G. Functional lesional neurosurgery for tremor: a systematic review and meta-analysis. *Journal of Neurology, Neurosurgery & Psychiatry*. 2018;89(7):717-726. doi:10.1136/jnnp-2017-316302
8. Halpern CH, Santini V, Lipsman N, et al. Three-year follow-up of prospective trial of focused ultrasound thalamotomy for essential tremor. *Neurology*. 2019;93(24). doi:10.1212/wnl.00000000000008561
9. Pouratian N, Baltuch G, Elias WJ, Gross R. American Society for Stereotactic and Functional Neurosurgery Position Statement on Magnetic Resonance-Guided Focused Ultrasound for the Management of Essential Tremor. *Neurosurgery*. 2019. doi:10.1093/neuros/nyz510
10. Shah BR, et al. Advanced MRI techniques for transcranial high intensity focused ultrasound targeting. *Brain*. 2020;1-9. doi:10.1093/brain/awaa107
11. Elias JW. A randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor. *N Engl J Med*. 2016;375:730-9. doi: 10.1056/NEJMoa1600159
12. Rughani A, Schwalb JM, Sidiropoulos C, et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Subthalamic Nucleus and Globus Pallidus Internus Deep Brain Stimulation for the Treatment of Patients With Parkinson's Disease: Executive Summary. *Neurosurgery*. 2018;82(6):753-756. doi:10.1093/neuros/nyy037.
13. Xiao Y, Lau JC, Hemachandra D, Gilmore G, Khan AR, Peters TM. Image Guidance in Deep Brain Stimulation Surgery to Treat Parkinson's Disease: A Comprehensive Review [published correction appears in IEEE Trans Biomed Eng. 2021 May;68(5):1748. doi: 10.1109/TBME.2021.3070666.]. *IEEE Trans Biomed Eng*. 2021;68(3):1024-1033. doi:10.1109/TBME.2020.3006765
14. Sakamoto F, Shiraishi S, Ogasawara K, et al. A diagnostic strategy for Lewy body disease using DAT-SPECT, MIBG and Combined index. *Annals of Nuclear Medicine*. 2020;34(6):415-423. doi:10.1007/s12149-020-01464-9.
15. Humanitarian Device Exemption. U.S. Food and Drug Administration (FDA). Updated: 07/12/2021. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfhde/hde.cfm?id=H020007>
16. Fluorodopa F18 Injection Package Insert. Highlights of prescribing information. U.S. Food and Drug Administration Website. <https://www.accessdata.fda.gov/>. Revised 10/2019.
17. Dhawan V, Niethammer MH, Lesser ML, et al. Prospective F-18 FDOPA PET Imaging Study in Human PD. *Nucl Med Mol Imaging*. 2022;56(3):147-157. doi:10.1007/s13139-022-00748-4
18. Morbelli S, Esposito G, Arbizu J, et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. *Eur J Nucl Med Mol Imaging*. 2020;47(8):1885-1912. doi:10.1007/s00259-020-04817-8

19. Jain R, Correll CU. Tardive Dyskinesia: Recognition, Patient Assessment and Differential Diagnosis. *J Clin Psychiatry*. 2018;79(2):nu17034ah1c. doi:10.4088/JCP.nu17034ah1c
20. Perju-Dumbrava L, Kempster P. Movement disorders in psychiatric patients. *BMJ Neurol Open*. 2020;2(2):e000057. Published 2020 Dec 1. doi:10.1136/bmjno-2020-000057
21. Ward KM, Citrome L. Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management. *Neurol Ther*. 2018;7(2):233-248. doi:10.1007/s40120-018-0105-0
22. Serajee FJ, Mahbubul Huq AH. Advances in Tourette syndrome: diagnoses and treatment. *Pediatr Clin North Am*. 2015;62(3):687-701. doi:10.1016/j.pcl.2015.03.007
23. Wagle Shukla A. Diagnosis and Treatment of Essential Tremor. *Continuum (Minneap Minn)*. 2022;28(5):1333-1349. doi:10.1212/CON.0000000000001181
24. Politis M. Neuroimaging in Parkinson disease: from research setting to clinical practice. *Nat Rev Neurol*. 2014;10(12):708-722. doi:10.1038/nrneurol.2014.205
25. Ba F, Martin WR. Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice. *Parkinsonism Relat Disord*. 2015;21(2):87-94. doi:10.1016/j.parkreldis.2014.11.007
26. Brigo F, Martinella A, Erro R, Tinazzi M. [¹²³I]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson's disease and vascular or drug-induced parkinsonisms: a meta-analysis. *Eur J Neurol*. 2014;21(11):1369-e90. doi:10.1111/ene.12444

Multiple Sclerosis (MS) and Related Conditions (HD-16)

Guideline	Page
Multiple Sclerosis (MS) (HD-16.1)	172
Neuromyelitis Optica Spectrum Disorders (HD-16.2)	182
MOG Antibody-Associated Disease (MOGAD) (HD-16.3)	188
Transverse Myelitis (HD-16.4)	193
Evidence Discussion (HD-16)	197
References (HD-16)	198

Multiple Sclerosis (MS) (HD-16.1)

HD.MS.0016.1.A

v2.0.2026

Establishing a New Diagnosis of Multiple Sclerosis

Repeat Imaging for Unclear Diagnosis

New Neurologic Symptoms in an Individual with Multiple Sclerosis

Baseline Imaging with Disease Modifying Therapy (DMT)

Current Treatment with High-Risk Disease Modifying Therapy (DMT)

Annual Imaging on Low-Risk DMT or No Treatment

History of Clinically Isolated Syndrome (CIS) or Radiologically Isolated Syndrome (RIS)

Prolonged Treatment with Tysabri® (natalizumab)

Progressive Multifocal Leukoencephalopathy (PML) Evaluation

Background and Supporting Information

Multiple Sclerosis General Information Page

- MRI Lumbar Spine is not medically necessary since Cervical and Thoracic studies will usually visualize the entire spinal cord. If the clinical concern is for lumbosacral radiculopathy, see **Lower Extremity Pain with Neurological Features (Radiculopathy, Radiculitis, or Plexopathy and Neuropathy) with or without Low Back (Lumbar Spine) Pain (SP-6.1)** in the Spine Imaging Guidelines.
- Family members need not be screened, unless they exhibit suspicious signs or symptoms suggestive of MS.
- Computed Tomography (CT) scans of the head and/or spine are **NOT** medically necessary for the evaluation of multiple sclerosis due to inferior soft tissue resolution when compared to MRI.
- Quantitative Magnetic Resonance Image (MRI) Analysis of the Brain
 - Volumetric or quantitative analysis of the brain or temporal lobes and hippocampus may be ordered as (CPT® 0865T or CPT® 0866T).
 - These studies lack sufficient specificity and sensitivity to be clinically useful. Their use is limited to research studies and are not medically necessary in the evaluation of Multiple Sclerosis.

- Volumetric or quantitative analysis of the brain or temporal lobes and hippocampus may be ordered as 3D rendering (CPT[®] 76376 and CPT[®] 76377).
- These studies are considered not medically necessary in the evaluation of multiple sclerosis.

Establishing a New Diagnosis of Multiple Sclerosis

Indication	Medically Necessary Imaging
Establishing a new diagnosis of Multiple Sclerosis is based on the following: - Clinical suspicion based on recurrent episodes of variable neurological signs and/or symptoms AND - Baseline exclusion of appropriate alternative conditions that can mimic MS OR Clinically Isolated Syndrome (CIS)* based on ALL the following: - First episode of neurologic symptoms and neurologic deficits concerning for possible demyelinating disease - Symptoms last ≥ 24 hours - Baseline exclusion of appropriate alternative conditions that can mimic MS OR Radiologically Isolated Syndrome (RIS)* based on ALL the following: - Individual with brain MRI obtained for unrelated reason with findings conspicuous for demyelinating disease	- MRI Brain without and with contrast (CPT[®] 70553) OR - MRI Brain without contrast (CPT[®] 70551) if there is a contraindication to gadolinium If optic neuritis** is suspected the following imaging is ALSO medically necessary: - MRI Orbit without and with contrast (CPT[®] 70543) OR - MRI Orbit without contrast (CPT[®] 70540) **For additional information related to optic neuritis see <u>Eye Disorders and Visual Loss (HD-32.1)</u> AND/OR - MRI Cervical Spine without and with contrast (CPT[®] 72156) OR - MRI Cervical Spine without contrast (CPT[®] 72141) AND/OR - MRI Thoracic Spine without and with contrast (CPT[®] 72157) OR - MRI Thoracic Spine without contrast (CPT[®] 72146)

Indication	Medically Necessary Imaging
Baseline exclusion of appropriate alternative conditions that can mimic MS *For more information about CIS and RIS, see <i>Background and Supporting Information</i>	

Repeat Imaging for Unclear Diagnosis

Indication	Medically Necessary Imaging
Diagnosis of Multiple Sclerosis remains unclear or equivocal after initial MRI Repeat imaging 3-6 months after initial MRI Brain	- MRI Brain without contrast (CPT[®] 70551) OR - MRI Brain without and with contrast (CPT[®] 70553)

New Neurologic Symptoms in an Individual with Multiple Sclerosis

Indication	Medically Necessary Imaging
New neurologic signs or symptoms in an individual with multiple sclerosis	• MRI Brain without contrast (CPT[®] 70551) OR • MRI Brain without and with contrast (CPT[®] 70553) If optic neuritis is suspected**, the following imaging is ALSO medically necessary: • MRI Orbit without and with contrast (CPT[®] 70543) OR • MRI Orbit without contrast (CPT[®] 70540) **For additional information related to optic neuritis, see <u>Eye Disorders and Visual Loss (HD-32.1)</u> If there are new or worsening symptoms concerning for spinal cord involvement, the following imaging is ALSO medically necessary: • MRI Cervical Spine without contrast (CPT[®] 72141) OR • MRI Cervical Spine without and with contrast (CPT[®] 72156) AND/OR • MRI Thoracic Spine without contrast (CPT[®] 72146) OR • MRI Thoracic Spine without and with contrast (CPT[®] 72157)

Baseline Imaging with Disease Modifying Therapy (DMT)

Indication	Medically Necessary Imaging
- Before starting OR changing disease modifying therapy (DMT) AND/OR 3-6 months after starting or changing DMT to establish a new MRI treatment baseline AND/OR - If there are new abnormal MRI Brain findings without clinical symptoms, an additional follow-up MRI Brain is supported after 6 months	- MRI Brain without contrast (CPT[®] 70551) OR - MRI Brain without and with contrast (CPT[®] 70553)

Current Treatment with High-Risk Disease Modifying Therapy (DMT)

Indication	Medically Necessary Imaging <i>Every 6 Months</i>	Medically Necessary Imaging <i>Annually</i>
Individuals treated with DMT* associated with either the risk of progressive multifocal leukoencephalopathy (PML) AND/OR other CNS opportunistic infections * For list of medications, see Background and Supporting Information	- MRI Brain without contrast (CPT[®] 70551) OR - MRI Brain without and with contrast (CPT[®] 70553)	- MRI Cervical Spine without contrast (CPT[®] 72141) OR - MRI Cervical Spine without and with contrast (CPT[®] 72156) AND/OR - MRI Thoracic Spine without contrast (CPT[®] 72146) OR - MRI Thoracic Spine without and with contrast (CPT[®] 72157)

Annual Imaging on Low-Risk DMT or No Treatment

Indication	Medically Necessary Imaging Annually
Individuals with diagnosed Multiple Sclerosis with EITHER of the following: • Not treated with disease modifying therapy (DMT)* OR • Treated with low-risk DMT (beta interferon or glatiramer acetate medications) * For list of DMT medications, see Background and Supporting Information	• MRI Brain without contrast (CPT[®] 70551) OR • MRI Brain without and with contrast (CPT[®] 70553) AND/OR • MRI Cervical Spine without contrast (CPT[®] 72141) OR • MRI Cervical Spine without and with contrast (CPT[®] 72156) AND/OR • MRI Thoracic Spine without contrast (CPT[®] 72146) OR • MRI Thoracic Spine without and with contrast (CPT[®] 72157)

History of Clinically Isolated Syndrome (CIS) or Radiologically Isolated Syndrome (RIS)

Indication	Medically Necessary Imaging <i>Annually</i>
Individual with history of Clinically Isolated Syndrome* (CIS) OR Individual with history of Radiologically Isolated Syndrome* (RIS) *For more information about CIS or RIS, see Background and Supporting Information	• MRI Brain without contrast (CPT® 70551) OR • MRI Brain without and with contrast (CPT® 70553) If there are new or worsening symptoms concerning for spinal cord involvement, the following imaging is ALSO medically necessary: • MRI Cervical Spine without contrast (CPT® 72141) OR • MRI Cervical Spine without and with contrast (CPT® 72156) AND/OR • MRI Thoracic Spine without contrast (CPT® 72146) OR • MRI Thoracic Spine without and with contrast (CPT® 72157)

Prolonged Treatment with Tysabri® (natalizumab)

Indication	Medically Necessary Imaging <i>Every 3-6 Months</i>	Medically Necessary Imaging <i>Annually</i>
Individuals treated with Tysabri® (natalizumab) with the following medical history: ≥18 months of treatment - During Tysabri® (natalizumab) treatment and up to 9-12 months after transitioning off Tysabri® (natalizumab) AND - JC virus antibody positive	- MRI Brain without contrast (CPT® 70551) OR - MRI Brain without and with contrast (CPT® 70553)	- MRI Cervical Spine without contrast (CPT® 72141) OR - MRI Cervical Spine without and with contrast (CPT® 72156) AND/OR - MRI Thoracic Spine without contrast (CPT® 72146) OR - MRI Thoracic Spine without and with contrast (CPT® 72157)

Progressive Multifocal Leukoencephalopathy (PML) Evaluation

Indication	Medically Necessary Imaging
Symptoms suggestive of PML* during treatment with Tysabri® (natalizumab) or other medication with similar risk * For more information about PML, see Background and Supporting Information	- MRI Brain without contrast (CPT® 70551) OR - MRI Brain without and with contrast (CPT® 70553)

Background and Supporting Information

- Multiple sclerosis is an autoimmune disease that is associated with inflammation, demyelination, and neurodegenerative changes within the optic nerves, brain, and spinal cord (i.e., central nervous system (CNS)).

- Multiple sclerosis commonly begins with a relapsing-remitting course with partial or complete neurologic recovery following acute events.
 - An acute demyelinating event lasts at least 24 hours or longer
 - Common types of MS relapses include:
 - Unilateral optic neuritis
 - Brainstem or cerebellar syndrome (i.e. trigeminal neuralgia, diplopia or intranuclear ophthalmoplegia (INO), and/or ataxia)
 - Partial transverse myelitis
- The first event concerning for demyelinating disease without meeting criteria for separation of time is known as a clinically isolated syndrome (CIS).
- Individuals who undergo a brain MRI for other indications (i.e., headaches, trauma, seizure) which incidentally reveals abnormalities that are characteristic for demyelination in the absence of clinical symptoms is known as radiologically isolated syndrome (RIS).
- Progressive Multifocal Leukoencephalopathy (PML) is a progressive multi-focal disease of the central nervous system that can occur in individuals treated with immunosuppressive or immunomodulatory medications.
 - In individuals treated with natalizumab, there is an increased risk of developing PML in individuals who:
 - Received prior immunosuppressive medication, and/or
 - Have a high JC virus antibody index, and/or
 - Received natalizumab for ≥ 18 months
- Interferon beta medications include (but are not limited to): Avonex[®], Betaseron[®], Extavia[®], Plegridy[®], Rebif[®]
- Glatiramer acetate medications include (but are not limited to): Copaxone, Glatopa[®]
- High-risk medications are associated with a risk of PML and/or other CNS opportunistic infections (i.e. herpes encephalitis, cryptococcal meningitis). These include (but are not limited to): Tysabri[®] (natalizumab), Tecfidera[®] (dimethyl fumarate), Gilenya[®] (fingolimod), Tascenso[®] ODT (fingolimod), Aubagio[®] (teriflunomide), Ocrevus[®] (ocrelizumab), Kesimpta[®] (ofatumumab), Mavenclad[®] (cladribine), Mayzent[®] (siponimod), Ponvory[®] (ponesimod), Vumerity[®] (diroximel fumarate), Zeposia[®] (ozanimod), Lemtrada[®] (alemtuzumab), Bafiertam[®] (monomethyl fumarate), Briumvi[®] (ublituximab), Rituxan[®] (rituximab)

Neuromyelitis Optica Spectrum Disorders (HD-16.2)

HD.MS.0016.2.A

v2.0.2026

Initial evaluation of Neuromyelitis Optica (NMO) or Neuromyelitis Optica Spectrum Disorders (NMOSD) with any of the following:

Indication	Medically Necessary Imaging
Clinical concern for optic neuritis	• MRI Orbit without and with contrast (CPT[®] 70543) OR • MRI Orbit without contrast (CPT[®] 70540)
Recurrent hiccups or intractable nausea and/or vomiting (clinical concern for area postrema syndrome)	• MRI Brain without and with contrast (CPT[®] 70553) OR • MRI Brain without contrast (CPT[®] 70551)
Other neurologic signs or symptoms concerning for brain involvement	• MRI Brain without and with contrast (CPT[®] 70553) OR • MRI Brain without contrast (CPT[®] 70551)

Indication	Medically Necessary Imaging
Clinical concern for transverse myelitis	• MRI Cervical Spine without and with contrast (CPT® 72156) OR • MRI Cervical Spine without contrast (CPT® 72141) AND/OR • MRI Thoracic Spine without and with contrast (CPT® 72157) OR • MRI Thoracic Spine without contrast (CPT® 72146) AND/OR Due to potential for conus involvement: • MRI Lumbar Spine without and with contrast (CPT® 72158) OR • MRI Lumbar Spine without contrast (CPT® 72148)

Indication	Medically Necessary Imaging
Positive NMO antibody test when ordered by a neurologist or any provider in consultation with a neurologist	• MRI Brain without and with contrast (CPT[®] 70553) OR • MRI Brain without contrast (CPT[®] 70551) AND/OR • MRI Orbit without and with contrast (CPT[®] 70543) OR • MRI Orbit without contrast (CPT[®] 70540) AND/OR • MRI Cervical Spine without and with contrast (CPT[®] 72156) OR • MRI Cervical Spine without contrast (CPT[®] 72141) AND/OR • MRI Thoracic Spine without and with contrast (CPT[®] 72157) OR • MRI Thoracic Spine without contrast (CPT[®] 72146)

Individual with established diagnosis of (NMOSD) with any of the following:

Indication	Medically Necessary Imaging
Clinical concern for optic neuritis	• MRI Orbit without and with contrast (CPT[®] 70543) OR • MRI Orbit without contrast (CPT[®] 70540)
New neurologic signs or symptoms concerning for brain involvement	• MRI Brain without and with contrast (CPT[®] 70553) OR • MRI Brain without contrast (CPT[®] 70551)

Indication	Medically Necessary Imaging
Clinical concern for transverse myelitis	• MRI Cervical Spine without and with contrast (CPT[®] 72156) OR • MRI Cervical Spine without contrast (CPT[®] 72141) AND/OR • MRI Thoracic Spine without and with contrast (CPT[®] 72157) OR • MRI Thoracic Spine without contrast (CPT[®] 72146) AND/OR Due to potential for conus involvement: • MRI Lumbar Spine without and with contrast (CPT[®] 72158) OR • MRI Lumbar Spine without contrast (CPT[®] 72148)

Indication	Medically Necessary Imaging
Repeat imaging for ANY of the following: - Re-establish baseline after starting treatment (typically 3-6 months after last MRI) - Changing disease modifying therapy (DMT) - As requested when ordered by a neurologist, neuro-ophthalmologist, ophthalmologist, or any provider in consultation with a neurologist, neuro-ophthalmologist, or ophthalmologist	- MRI Brain without and with contrast (CPT[®] 70553) OR - MRI Brain without contrast (CPT[®] 70551) AND/OR - MRI Orbit without and with contrast (CPT[®] 70543) OR - MRI Orbit without contrast (CPT[®] 70540) AND/OR - MRI Cervical Spine without and with contrast (CPT[®] 72156) OR - MRI Cervical Spine without contrast (CPT[®] 72141) AND/OR - MRI Thoracic Spine without and with contrast (CPT[®] 72157) OR - MRI Thoracic Spine without contrast (CPT[®] 72146)

- For Neuromyelitis Optica Spectrum Disorder with concern for occult neoplasm, see **Paraneoplastic Syndromes (ONC-30.3)** in the Oncology Imaging Guidelines.
- Computed Tomography (CT) scans of the head and/or spine are not recommended for the evaluation of NMOSD due to inferior soft tissue resolution when compared to MRI.
- Quantitative Magnetic Resonance Image (MRI) Analysis of the Brain
 - Volumetric or quantitative analysis of the brain or temporal lobes and hippocampus may be ordered as (CPT[®] 0865T or CPT[®] 0866T).
 - These are not medically necessary in the evaluation of NMOSD.
 - Volumetric or quantitative analysis of the brain or temporal lobes and hippocampus may be ordered as 3D rendering (CPT[®] 76376 and CPT[®] 76377).
 - These studies are considered not medical necessary in the evaluation of NMOSD.

Background and Supporting Information

- Neuromyelitis optica spectrum disorder (NMOSD, Devic's disease) is a chronic inflammatory autoimmune disease that involves the optic nerves, spinal cord, and brain.
- Core clinical characteristics of NMOSD include
 - Optic neuritis
 - Frequently bilateral optic nerve involvement with severe vision loss
 - Longitudinally extensive transverse myelitis
 - Extends ≥ 3 complete vertebral segments of the spinal cord
 - Area postrema syndrome
 - Otherwise, unexplained episode of recurrent hiccups or intractable nausea and vomiting
 - Brainstem or cerebral syndrome with NMOSD typical brain lesions
 - Rarely paraneoplastic syndromes occur with NMO spectrum disorder
 - Medications used for the treatment of NMO spectrum disorders include (but are not limited to) azathioprine, Enspryng[®] (satralizumab), mycophenolate, Soliris[®] (eculizumab), rituximab, Uplizna[®] (inebilizumab) and Ultomiris[®] (ravulizumab)⁵⁴
 - Possible adverse reactions associated with treatment include risk of PML and meningococcal infections.

MOG Antibody-Associated Disease (MOGAD) (HD-16.3)

HD.MS.0016.3.A
v2.0.2026

Initial evaluation of MOG (myelin oligodendrocyte glycoprotein) antibody-associated diseases (MOGAD) with any of the following:

Indication	Medically Necessary Imaging
Clinical concern for optic neuritis	• MRI Orbit without and with contrast (CPT[®] 70543) OR • MRI Orbit without contrast (CPT[®] 70540)
Neurologic signs or symptoms concerning for brain involvement	• MRI Brain without and with contrast (CPT[®] 70553) OR • MRI Brain without contrast (CPT[®] 70551)
Clinical concern for transverse myelitis	• MRI Cervical Spine without and with contrast (CPT[®] 72156) OR • MRI Cervical Spine without contrast (CPT[®] 72141) AND/OR • MRI Thoracic Spine without and with contrast (CPT[®] 72157) OR • MRI Thoracic Spine without contrast (CPT[®] 72146) AND/OR Due to potential for conus involvement: • MRI Lumbar Spine without and with contrast (CPT[®] 72158) OR • MRI Lumbar Spine without contrast (CPT[®] 72148)

Indication	Medically Necessary Imaging
Positive MOG antibody test when ordered by a neurologist or any provider in consultation with a neurologist	• MRI Brain without and with contrast (CPT[®] 70553) OR • MRI Brain without contrast (CPT[®] 70551) AND/OR • MRI Orbit without and with contrast (CPT[®] 70543) OR • MRI Orbit without contrast (CPT[®] 70540) AND/OR • MRI Cervical Spine without and with contrast (CPT[®] 72156) AND/OR MRI Thoracic Spine without and with contrast (CPT[®] 72157) OR • MRI Cervical Spine without contrast (CPT[®] 72141) AND/OR MRI Thoracic Spine without contrast (CPT[®] 72146) AND/OR Due to potential for conus involvement: • MRI Lumbar Spine without and with contrast (CPT[®] 72158) OR • MRI Lumbar Spine without contrast (CPT[®] 72148)

Individuals with established diagnosis of (MOGAD) with any of the following:

Indication	Medically Necessary Imaging
Clinical concern for optic neuritis	• MRI Orbit without and with contrast (CPT[®] 70543) OR • MRI Orbit without contrast (CPT[®] 70540)
Neurologic signs or symptoms concerning for brain involvement	• MRI Brain without and with contrast (CPT[®] 70553) OR • MRI Brain without contrast (CPT[®] 70551)

Indication	Medically Necessary Imaging
Clinical concern for transverse myelitis	• MRI Cervical Spine without and with contrast (CPT[®] 72156) OR • MRI Cervical Spine without contrast (CPT[®] 72141) AND/OR • MRI Thoracic Spine without and with contrast (CPT[®] 72157) OR • MRI Thoracic Spine without contrast (CPT[®] 72146) AND/OR Due to potential for conus involvement: • MRI Lumbar Spine without and with contrast (CPT[®] 72158) OR • MRI Lumbar Spine without contrast (CPT[®] 72148)
Repeat imaging for ANY of the following: • Re-establish baseline after starting treatment (typically 3-6 months after last MRI) • Changing disease modifying therapy (DMT) • As requested when ordered by a neurologist, neuro-ophthalmologist, ophthalmologist, or any provider in consultation with a neurologist, neuro-ophthalmologist, or ophthalmologist	• MRI Brain without and with contrast (CPT[®] 70553) OR • MRI Brain without contrast (CPT[®] 70551) AND/OR • MRI Orbit without and with contrast (CPT[®] 70543) OR • MRI Orbit without contrast (CPT[®] 70540) AND/OR • MRI Cervical Spine without and with contrast (CPT[®] 72156) AND/OR MRI Thoracic Spine without and with contrast (CPT[®] 72157) OR • MRI Cervical Spine without contrast (CPT[®] 72141) AND/OR MRI Thoracic Spine without contrast (CPT[®] 72146)

- For MOG (myelin oligodendrocyte glycoprotein) Antibody-Associated Disease with concern for occult neoplasm, see **Paraneoplastic Syndromes (ONC-30.3)** in the Oncology Imaging Guidelines.
- Computed Tomography (CT) scans of the head and/or spine are not recommended for the evaluation of MOG (myelin oligodendrocyte glycoprotein) Antibody-Associated Disease due to inferior soft tissue resolution when compared to MRI.

Background and Supporting Information

- MOG (myelin oligodendrocyte glycoprotein)-IgG disorders are CNS inflammatory diseases, distinct from multiple sclerosis and NMO-spectrum disorders.
- Unlike multiple sclerosis and neuromyelitis optica spectrum disorder (NMOSD), individuals with MOG antibody-associated disease (MOGAD) can have a monophasic or relapsing course.
 - Relapses are more common in the first six months after the first episode.
 - An acute relapse is considered when an individual with MOGAD develops new neurologic signs or symptoms at least 30 days following the previous event.
- Diagnosis is based on the clinical presentation, MRI findings, and the presence of auto-antibodies.
- Clinical features of individuals with MOGAD include
 - Optic neuritis
 - Bilateral optic neuritis is common at onset, and seems to be more frequent in individuals with MOGAD than with those with multiple sclerosis or neuromyelitis optica spectrum disorder (NMOSD).
 - Vision improves quickly with return to normal or near normal visual acuity following treatment with intravenous corticosteroids.
 - Transverse myelitis
 - Cauda equina and peripheral nerve root involvement can occur (lumbar spine imaging is medically necessary)
 - Can occur as an isolated episode of transverse myelitis, as a component of ADEM or in conjunction with optic neuritis.
 - T2 spinal cord lesions often are centrally located and can be restricted to the grey matter producing the “H sign” on MRI
 - Most T2 lesions resolve or reduce in size substantially on follow-up MRI
 - Brainstem encephalitis
 - Encephalitis with seizures
 - Acute disseminated encephalomyelitis (ADEM)
 - Occurs mainly in children but can occur in adults.
 - Tumefactive brain lesions
 - Cranial neuropathies

- Unlike multiple sclerosis, it is rare for individuals with MOGAD to develop asymptomatic lesions within the brain, optic nerves, and/or spinal cord.

Transverse Myelitis (HD-16.4)

HD.MS.0016.4.A

v2.0.2026

An initial assessment, to include a pertinent history and neurologic exam, should be performed prior to imaging requests.

Clinical Concern for Transverse Myelitis

Indication	Medically Necessary Imaging
Clinical concern for transverse myelitis	• MRI Cervical Spine without and with contrast (CPT® 72156) OR • MRI Cervical Spine without contrast (CPT® 72141) AND/OR • MRI Thoracic Spine without and with contrast (CPT® 72157) OR • MRI Thoracic Spine without contrast (CPT® 72146) AND/OR Due to potential for conus involvement: • MRI Lumbar Spine without and with contrast (CPT® 72158) OR • MRI Lumbar Spine without contrast (CPT® 72148) AND/OR • MRI Brain without and with contrast (CPT® 70553) OR • MRI Brain without contrast (CPT® 70551) If optic neuritis is suspected*, the following imaging is ALSO medically necessary: • MRI Orbit without and with contrast (CPT® 70543) OR • MRI Orbit without contrast (CPT® 70540) *For additional information related to optic neuritis see <u>Eye Disorders and Visual Loss (HD-32.1)</u>

New Neurologic Signs or Symptoms in an individual with a history of transverse myelitis (TM)

Indication	Medically Necessary Imaging
New neurologic signs or symptoms	• MRI Cervical Spine without and with contrast (CPT® 72156) OR • MRI Cervical Spine without contrast (CPT® 72141) AND/OR • MRI Thoracic Spine without and with contrast (CPT® 72157) OR • MRI Thoracic Spine without contrast (CPT® 72146) AND/OR • MRI Brain without and with contrast (CPT® 70553) OR • MRI Brain without contrast (CPT® 70551) If optic neuritis is suspected*, the following imaging is ALSO medically necessary: • MRI Orbit without and with contrast (CPT® 70543) OR • MRI Orbit without contrast (CPT® 70540) *For additional information related to optic neuritis, see <u>Eye Disorders and Visual Loss (HD-32.1)</u>

Surveillance of Transverse Myelitis

Indication	Medically Necessary Imaging Annually for 5 years
Individual with a history of transverse myelitis Ordered by a neurologist or any provider in consultation with a neurologist	- MRI Cervical Spine without and with contrast (CPT® 72156) OR - MRI Cervical Spine without contrast (CPT® 72141) AND/OR - MRI Thoracic Spine without and with contrast (CPT® 72157) OR - MRI Thoracic Spine without contrast (CPT® 72146) AND/OR - MRI Brain without and with contrast (CPT® 70553) OR - MRI Brain without contrast (CPT® 70551)

- For transverse myelitis with concern for occult neoplasm, see **Paraneoplastic Syndromes (ONC-30.3)** in the Oncology Imaging Guidelines.
- Individuals with transverse myelitis present with various symptoms of sensory, motor and/or autonomic dysfunction.
 - Bilateral signs and/or symptoms (although not necessarily symmetrical)
 - Examination findings may include but are not limited to any of the following:
 - Bilateral limb weakness
 - Loss of manual dexterity
 - New or worsening foot drop
 - Sensory abnormalities
 - Sensory level
 - Hyperreflexia (including upgoing toes, positive Babinski, Hoffman's sign, clonus)
 - Gait abnormality (spastic or ataxic gait)
 - See also: **Background and Supporting Information**
 - If inflammation is identified within the spinal cord suggestive of transverse myelitis, a brain MRI is recommended to evaluate for a multifocal inflammatory process
- See **Multiple Sclerosis (MS) (HD-16.1)**, **Neuromyelitis Optica Spectrum Disorders (HD-16.2)**, **MOG Antibody-Associated Diseases (MOGAD) (HD-16.3)**

Background and Supporting Information

- Symptoms may include but are not limited to the following:
 - Motor weakness of a limb or limbs, including paraparesis and/or complete paralysis

- Change in sensation in a limb or limbs that may be associated with paresthesias and/or dyesthesias.
- Urinary urgency, incontinence, and/or urinary retention
- Worsening constipation and/or bowel urgency/incontinence
- Sexual dysfunction
- Lhermitte's sign
- New or worsening spasticity
- Acute transverse myelitis is defined as an acute inflammatory syndrome leading to motor and/or sensory impairment, with or without sphincter dysfunction, secondary to a variety of autoimmune or inflammatory diseases.
- Diagnosed by spinal MRI and/or cerebrospinal fluid.
- Individuals typically progress to maximal neurological deficits within 4 weeks.
- Longitudinally extensive transverse myelitis (≥ 3 vertebral segments) is more commonly associated with neuromyelitis optica spectrum disorders (NMOSD) and/or MOG antibody-associated diseases (MOGAD)
- Transverse myelitis:
 - May be idiopathic
 - Initial event of multiple sclerosis (see **Multiple Sclerosis (MS) (HD-16.1)**)
 - Initial event of neuromyelitis optica spectrum disorder (NMOSD) (see **Neuromyelitis Optica Spectrum Disorders (HD-16.2)**)
 - Initial event of MOG antibody-associated disease (MOGAD) (see **MOG Antibody-Associated Diseases (MOGAD) (HD-16.3)**)
 - May be associated with connective tissue disease
 - Systemic lupus erythematosus (SLE)
 - Rheumatoid Arthritis (RA)
 - Sjögren's syndrome
 - Systemic sclerosis
 - Manifestation of neurosarcoidosis (see **Autoimmune/Paraneoplastic Encephalitis & Neuroinflammatory Disorders (HD-14.3)**)
 - Post-infectious and/or post-vaccination related
 - COVID-19 and COVID-19 post-vaccination myelitis cases have been reported (see **Neuro-COVID-19 and Sars-COV-2 Vaccines (HD-14.2)**)
 - May have a prodromal syndrome with fever, respiratory and/or gastrointestinal symptoms
 - May be associated with headache, neck stiffness or recurrence of fever

Evidence Discussion (HD-16)

v2.0.2026

- Magnetic resonance imaging (MRI) is the recommended imaging modality for the diagnosis and monitoring of multiple sclerosis (MS) and other inflammatory diseases of the central nervous system (CNS). Its high sensitivity for the evaluation of inflammatory and neurodegenerative processes in the brain and spinal cord has made it the gold standard for the evaluation of individuals with MS.^{8,31}
- Computed Tomography Scan (CT) is not recommended for the evaluation of MS due to inferior soft tissue resolution when compared to MRI.^{28,41,42}
- MRI plays an important role in the following clinical scenarios:
 - establishing the diagnosis of multiple sclerosis (MS) by establishing evidence for dissemination in space and time.^{8,31}
 - diagnostic workup. Approximately 50%-90% of individuals with MS have spinal cord lesions.⁸
 - detecting optic nerve abnormalities in individuals with symptoms concerning for optic neuritis.^{7,42}
 - assessment of treatment response and in monitoring for potential treatment related safety concerns. Management and surveillance intervals are primarily consensus based and have been addressed in several evidence and practice-based guidelines.^{7,8}
 - evaluation of other central nervous system (CNS) inflammatory diseases, including autoimmune disseminated encephalomyelitis (ADEM), neuromyelitis optica (NMO), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and transverse myelitis (TM).^{28,31,36,44}
 - detecting conus medullaris involvement in individuals with myelin oligodendrocyte glycoprotein-associated disease (MOGAD) and transverse myelitis.^{28,36,44}

References (HD-16)

v2.0.2026

1. Wattjes MP, Ciccarelli O, Reich DS, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. *The Lancet Neurology*. 2021;20(8):653-670. doi:10.1016/S1474-4422(21)00095-8
2. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *The Lancet Neurology*. 2018;17(2):162-173. doi:10.1016/s1474-4422(17)30470-2
3. Kaunzner UW, Gauthier SA. MRI in the assessment and monitoring of multiple sclerosis: an update on best practice. *Therapeutic Advances in Neurological Disorders*. 2017;10(6):247-261. doi:10.1177/1756285617708911
4. Rae-Grant A, Day GS, Marrie RA, et al. Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis. *Neurology*. 2018;90(17):789-800. doi:10.1212/wnl.0000000000005345
5. Shosha E, Dubey D, Palace J, et al. Area postrema syndrome. *Neurology*. 2018;91(17). doi:10.1212/wnl.0000000000006392
6. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology*. 2015;85(2):177-189. doi:10.1212/wnl.0000000000001729
7. Kaunzner UW, Gauthier SA. MRI in the assessment and monitoring of multiple sclerosis: an update on best practice. *Therapeutic Advances in Neurological Disorders*. 2017;10(6):247-261. doi:10.1177/1756285617708911
8. Expert Panel on Neurologic Imaging; Kennedy TA, Corey AS, et al. ACR Appropriateness Criteria® Orbits Vision and Visual Loss. *J Am Coll Radiol*. 2018;15(5S):S116-S131. doi:10.1016/j.jacr.2018.03.023
9. Hornby PJ. Central neurocircuitry associated with emesis. *The American Journal of Medicine*. 2001;111(8):106-112. doi:10.1016/s0002-9343(01)00849-x
10. Ciccarelli O, Cohen JA, Reingold SC, et al. Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. *The Lancet Neurology*. 2019;18(2):185-197. doi:10.1016/s1474-4422(18)30460-5
11. Major EO. Progressive Multifocal Leukoencephalopathy Lesions and JC Virus. *JAMA Neurology*. 2018;75(7):789. doi:10.1001/jamaneurol.2018.0004
12. Vukusic S, Rollet F, Casey R, et al. Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France. *JAMA Neurology*. 2020;77(1):94. doi:10.1001/jamaneurol.2019.2670
13. Wattjes MP, Barkhof F. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. *Current Opinion in Neurology*. 2014;27(3):260-270. doi:10.1097/wco.000000000000099
14. Hegen H, Reindl M. Recent developments in MOG-IgG associated neurological disorders. *Ther Adv Neurol Disord*. 2020 Jul 31;13:1756286420945135. doi: 10.1177/1756286420945135
15. De Stefano N, Battaglini M, Pareto D, et al. MAGNIMS recommendations for harmonization of MRI data in MS multicenter studies. *Neuroimage Clin*. 2022;34:102972. doi:10.1016/j.nicl.2022.102972
16. Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. *N Engl J Med*. 2018;378(2):169-180. doi:10.1056/NEJMr1401483
17. Lopez Chiriboga S, Flanagan EP. Myelitis and Other Autoimmune Myelopathies. *CONTINUUM: Lifelong Learning in Neurology*. 2021;27(1):62-92. doi:10.1212/con.0000000000000900
18. Genovese AV, Hagemeyer J, Bergsland N, et al. Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. *Radiology*. 2019;293(2):424-433. doi:10.1148/radiol.2019190306
19. Jakimovski D, Zivadinov R, Bergsland N, Ramasamy DP, Hagemeyer J, Genovese AV, Hojnacki D, Weinstock-Guttman B, Dwyer MG. Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes. *Neuroimage Clin*. 2021;29:102554. doi: 10.1016/j.nicl.2020.102554
20. Saslow L, Li DKB, Halper J, et al. An International Standardized Magnetic Resonance Imaging Protocol for Diagnosis and Follow-up of Patients with Multiple Sclerosis. *International Journal of MS Care*. 2020;22(5):226-232. doi:10.7224/1537-2073.2020-094

21. Berger B, Hottenrott T, Rauer S, Stich O. Screening for onconeural antibodies in neuromyelitis optica spectrum disorders. *BMC Neurology*. 2017;17(1). doi:10.1186/s12883-016-0779-9
22. Carnero Contentti E, Correale J. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. *Journal of Neuroinflammation*. 2021;18(1). doi:10.1186/s12974-021-02249-1
23. Winkelmann A, Loebermann M, Reisinger EC, Hartung H-P, Zettl UK. Disease-modifying therapies and infectious risks in multiple sclerosis. *Nature Reviews Neurology*. 2016;12(4):217-233. doi:10.1038/nrneuro.2016.21
24. Gastaldi M, Marchioni E, Banfi P, et al. Predictors of outcome in a large retrospective cohort of patients with transverse myelitis. *Mult Scler*. 2018;24(13):1743-1752. doi:10.1177/1352458517731911
25. Lavi ES, Pal A, Bleicher D, Kang K, Sidani C. MR imaging of the spine: Urgent and emergent indications. *Semin Ultrasound CT MR*. 2018;39(6):551-569. doi:10.1053/j.sult.2018.10.006
26. Sarbu N, Lolli V, Smirniotopoulos JG. Magnetic resonance imaging in myelopathy: a pictorial review. *Clin Imaging*. 2019;57:56-68. doi:10.1016/j.clinimag.2019.05.002
27. Stern BJ, Royal W 3rd, Gelfand JM, et al. Definition and consensus diagnostic criteria for neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group. *JAMA Neurol*. 2018;75(12):1546-1553. doi:10.1001/jamaneurol.2018.2295
28. Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. *Lancet Neurol*. 2023;22(3):268-282. doi:10.1016/S1474-4422(22)00431-8
29. Holmoy T, Høglund RA, Illes Z, Myhr KM, Torkildsen Ø. Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. *J Neurol*. 2021;268(12):4522-4536. doi:10.1007/s00415-020-10235-5
30. Ismail II, Salama S. Association of CNS demyelination and COVID-19 infection: an updated systematic review. *J Neurol*. 2022;269(2):541-576. doi:10.1007/s00415-021-10752-x
31. Jarius S, Aktas O, Ayzenberg I, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. (published online ahead of print, 2023 Apr 6). *J Neurol*. 2023;10.1007/s00415-023-11634-0. doi:10.1007/s00415-023-11634-0
32. Khan E, Shrestha AK, Colantonio MA, Liberio RN, Sriwastava S. Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of the literature. *J Neurol*. 2022;269(3):1121-1132. doi:10.1007/s00415-021-10785-2
33. Marrodan M, Hernandez MA, Kohler AA, Correale J. Differential diagnosis in acute inflammatory myelitis. *Multi Scler Relat Disord* 2020;46:102481. doi:10.1016/j.msard.2020.102481
34. Murphy OC, Messacar K, Benson L, et al. Acute flaccid myelitis: cause, diagnosis, and management. *Lancet*. 2021;397(10271):334-346. doi:10.1016/S0140-6736(20)32723-9
35. Okuda DT, Kantarci O, Lebrun-Fréney C, et al. Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome. *Ann Neurol*. 2023;93(3):604-614. doi:10.1002/ana.26555
36. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. *Neurology*. 2002;59(4):499-505. doi:10.1212/wnl.59.4.499
37. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology*. 2014;83(3):278-286. doi:10.1212/WNL.0000000000000560
38. Bulut E, Shoemaker T, Karakaya J, et al. MRI Predictors of Recurrence and Outcome after Acute Transverse Myelitis of Unidentified Etiology. *AJNR Am J Neuroradiol*. 2019;40(8):1427-1432. doi:10.3174/ajnr.A6121
39. Tillema JM. Imaging of Central Nervous System Demyelinating Disorders. *Continuum (Minneapolis)*. 2023;29(1):292-323. doi:10.1212/CON.0000000000001246
40. Kartau M, Sipilä JO, Auvinen E, Palomäki M, Verkkoniemi-Ahola A. Progressive Multifocal Leukoencephalopathy: Current Insights. *Degener Neurol Neuromuscul Dis*. 2019;9:109-121. Published 2019 Dec 2. doi:10.2147/DNND.S203405
41. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance and interpretation of Magnetic Resonance Imaging (MRI) of the brain. 2024; Available at: <https://gravitas.acr.org/PPTS/>
42. Expert Panel on Neurological Imaging, Agarwal V, Shah LM, et al. ACR Appropriateness Criteria® Myelopathy: 2021 Update. *J Am Coll Radiol*. 2021;18(5S):S73-S82. doi:10.1016/j.jacr.2021.01.020
43. Sastre-Garriga J, Pareto D, Battaglini M, et al. MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. *Nat Rev Neurol*. 2020;16(3):171-182. doi:10.1038/s41582-020-0314-x

44. Shahriari M, Sotirchos ES, Newsome SD, Yousem DM. MOGAD: How It Differs From and Resembles Other Neuroinflammatory Disorders. *AJR Am J Roentgenol*. 2021;216(4):1031-1039. doi:10.2214/AJR.20.24061
45. Trentinaglia M, Dinoto A, Carta S, et al. Investigating the association between neoplasms and MOG antibody-associated disease. *Front Neurol*. 2023;14:1193211. Published 2023 Jun 9. doi:10.3389/fneur.2023.1193211
46. Molazadeh N, Bose G, Lotan I, Levy M. Autoimmune diseases and cancers overlapping with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A systematic review. *Mult Scler J Exp Transl Clin*. 2022;8(4):20552173221128170. Published 2022 Oct 20. doi:10.1177/20552173221128170
47. Ding M, Lang Y, Cui L. AQP4-IgG positive paraneoplastic NMOSD: A case report and review. *Brain Behav*. 2021;11(10):e2282. doi:10.1002/brb3.2282
48. Kümpfel T, Giglhuber K, Aktas O, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management [published correction appears in J Neurol. 2024 Jun;271(6):3702-3707]. *J Neurol*. 2024;271(1):141-176. doi:10.1007/s00415-023-11910-z

Papilledema/Pseudotumor Cerebri (HD-17)

Guideline	Page
Papilledema/Pseudotumor Cerebri (HD-17.1).....	202
References (HD-17)	204

Papilledema/Pseudotumor Cerebri (HD-17.1)

HD.PP.0017.1.A

v2.0.2026

- See **Eye Disorders and Visual Loss (HD-32.1)**
- Papilledema and Pseudotumor Cerebri (Idiopathic Intracranial Hypertension, Benign Intracranial Hypertension):
 - MRI Orbits/Face/Neck without contrast (CPT[®] 70540) **OR** MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543) **OR** CT Orbits/Temporal bone with contrast (CPT[®] 70481) **OR** CT Orbit/Temporal bone without contrast (CPT[®] 70480) **AND/OR** MRI Brain without contrast (CPT[®] 70551) **OR** MRI Brain without and with contrast (CPT[®] 70553) is/are medically necessary for:
 - Suspected elevated intracranial pressure **AND/OR** papilledema
 - CT Head without contrast (CPT[®] 70450) is medically necessary when MRI is contraindicated or for urgent evaluation
 - See **General Guidelines – CT Head (HD-1.4)** regarding required use of CT Head prior to lumbar puncture and/or spinal tap.
 - See **Eye Disorders and Visual Loss (HD-32.1)** regarding concern for orbital pseudotumor or primary orbital disorder.
 - MRA Head (CPT[®] 70544, CPT[®] 70545, or CPT[®] 70546) or CTA Head (CPT[®] 70496) is medically necessary, in addition, for venogram when requested.
 - CT and MR Venography (CTV and MRV) are reported with the same codes as the CTA/MRA counterpart. If arterial and venous CT or MR studies are both performed in the same session, only one CPT[®] code should be used to report both procedures
 - See **Stroke/TIA (HD-21.1)**
 - See **Cerebral Venous Thrombosis (HD-21.8)**
 - Repeat structural and/or vascular imaging, with any of the above listed studies, for follow-up, including to confirm stent patency, and for evaluation of worsening symptoms, or suspected complications, as requested by a neurologist or a neurosurgeon or any provider in consultation with a neurologist or a neurosurgeon.
 - See also **Hydrocephalus Shunts (HD-11.14)**

Background and Supporting Information

Treatment for idiopathic intracranial hypertension (IIH) includes weight loss and acetazolamide. Surgical interventions include optic nerve sheath fenestration,

cerebrospinal fluid shunting, and bariatric surgeries. These surgical procedures are invasive and associated with complications.

Venous sinus stenting is a treatment option for those with idiopathic intracranial hypertension who have failed first line therapy. Prior to stenting, individuals should undergo venography. CTV and/or MRV can be performed to confirm stent patency.

Stenting improves tinnitus, papilledema, diplopia/visual disturbances, and headaches.

Post- stent complications include subdural hematoma, subarachnoid hemorrhage, worsening headaches, visual impairment, worsening papilledema, blindness, arterial dissection, and death. Venous sinus stenting has lower complications relative to surgical interventions.

Evidence Discussion (HD-17)

- In the evaluation of suspected or known intracranial hypertension and/or exam findings of papilledema, neuroimaging is helpful for diagnosis, excluding other structural causes, and for the identification of venous outflow obstruction.^{2,4,5}
- MRI Brain allows detection of findings supportive of intracranial hypertension and detection of structural abnormalities such as mass, edema, or hydrocephalus.^{1,2,3,5,7} MR Venogram allows identification of venous sinus stenosis and thrombosis for treatment planning in these scenarios.^{2,3,5}
- Alternatively, CT Head allows exclusion of secondary causes such as hydrocephalus, mass, or edema, particularly in urgent scenarios.^{1,2,5,7} CT Venogram allows direct vessel visualization to exclude venous outflow obstruction in these cases.^{1,2,5}
- In addition, orbital symptoms may be evaluated with either CT Orbits or MRI Orbits, with CT providing superior bony anatomy evaluation and calcification detection and MRI providing superior soft tissue resolution and evaluation of the optic nerve.^{1,5,7}

References (HD-17)

v2.0.2026

1. Friedman DI. Papilledema and Idiopathic Intracranial Hypertension. *CONTINUUM: Lifelong Learning in Neurology*. 2014;20:857-876. doi:10.1212/01.con.0000453314.75261.66
2. Expert Panel on Neurologic Imaging, Pallavi S, Utukuri MD, et al. ACR Appropriateness Criteria® Headache. Available at <https://acsearch.acr.org/docs/69482/Narrative/> American College of Radiology.2022.
3. Thurtell MJ. Idiopathic Intracranial Hypertension. *CONTINUUM: Lifelong Learning in Neurology*. 2019;25(5):1289-1309. doi:10.1212/con.0000000000000770
4. Wall M. Update on Idiopathic Intracranial Hypertension. *Neurologic Clinics*. 2017;35(1):45-57. doi:10.1016/j.ncl.2016.08.004
5. Costello F, Scott JN. Imaging in Neuro-ophthalmology. *CONTINUUM: Lifelong Learning in Neurology*. 2019;25(5):1438-1490. doi:10.1212/con.0000000000000783
6. Aylward SC, Reem RE. Pediatric Intracranial Hypertension. *Pediatr Neurol*. 2017 Jan;66:32-43. doi: 10.1016/j.pediatrneurol.2016.08.010
7. Expert Panel on Neurologic Imaging; Kennedy TA, Corey AS, et al. ACR Appropriateness Criteria® Orbits Vision and Visual Loss. *J Am Coll Radiol*. 2018;15(5S):S116-S131. doi:10.1016/j.jacr.2018.03.023
8. Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. *Neurology*. 2002;59(10):1492-1495. doi:10.1212/01.wnl.0000029570.69134.1b
9. Barkatullah AF, Leishangthem L, Moss HE. MRI findings as markers of idiopathic intracranial hypertension. *Curr Opin Neurol*. 2021;34(1):75-83. doi:10.1097/WCO.0000000000000885
10. Azzam AY, Mortezaei A, Morsy MM, et al. Venous sinus stenting for idiopathic intracranial hypertension: An updated Meta-analysis. *J Neurol Sci*. 2024;459:122948. doi:10.1016/j.jns.2024.122948
11. Ong F, Phillips T, Selkirk G, McAuliffe W. Intracranial venous stenting for idiopathic intracranial hypertension. *J Med Imaging Radiat Oncol*. 2023;67(5):526-530. doi:10.1111/1754-9485.13505

Paresthesias and/ or Weakness (HD-18)

Guideline	Page
Sensory/Weakness Complaints (HD-18.1).....	206
References (HD-18).....	210

Sensory/Weakness Complaints (HD-18.1)

HD.PS.0018.1.A

v2.0.2026

Advanced imaging for complaints of sensory loss and/or paresthesias (see **Background and Supporting Information**) and/or weakness that are unaccompanied by other symptoms and not preceded by trauma must have the following: a thorough clinical history and a detailed neurological exam (including the symptomatic area).

Imaging for sensory and weakness complaints is medically necessary with the following findings:

Indications	Medically Necessary Imaging
ANY of the following: • Hyperreflexia • Babinski/Hoffman sign* • Increased tone in affected limb • Bladder and/or bowel dysfunction • Motor symptoms in ANY of the following patterns: ◦ Two limbs on same side of body ◦ Face and limb involvement • Sensory symptoms in ANY of the following patterns: ◦ Two limbs on same side of body ◦ Face and limb involvement *See Background and Supporting Information	• MRI Brain without contrast (CPT[®] 70551) OR • MRI Brain without and with contrast (CPT[®] 70553) AND/OR • MRI Cervical Spine without contrast (CPT[®] 72141) OR • MRI Cervical Spine without and with contrast (CPT[®] 72156) AND/OR • MRI Thoracic Spine without contrast (CPT[®] 72146) OR • MRI Thoracic Spine without and with contrast (CPT[®] 72157)

Findings Specific to the Spinal Cord	Medically Necessary Imaging
ANY of the following: - Decreased pinprick sensation on one side of the body with weakness and decreased proprioception on the other side - Sensory level (also called spinal cord level) on the trunk with sensory loss in both legs - Tight band around the trunk or torso - Pure sensory symptoms with proximal and distal involvement and a symmetric pattern - Decreased or absent reflexes AND noted concern for spinal cord shock or acute spinal cord injury* *See Background and Supporting Information	- MRI Cervical Spine without contrast (CPT[®] 72141) OR - MRI Cervical Spine without and with contrast (CPT[®] 72156) AND/OR - MRI Thoracic Spine without contrast (CPT[®] 72146) OR - MRI Thoracic Spine without and with contrast (CPT[®] 72157)

Findings Specific to the Terminal End of the Spinal Cord	Medically Necessary Imaging
Concern for conus medullaris syndrome.* - Symptoms may include, but are not limited to: - Saddle anesthesia - Urinary retention - Bowel incontinence - Lower limb paresthesias - Lower limb weakness *See Background and Supporting Information	- MRI Lumbar Spine without contrast (CPT[®] 72148) OR - MRI Lumbar Spine without and with contrast (CPT[®] 72158)

- MRI Lumbar Spine is not typically medically necessary to visualize the spinal cord except in the clinical scenarios noted above. MRI Cervical Spine and MRI Thoracic Spine will image the entire spinal cord.
- Findings NOT consistent with central nervous system localization and NOT supporting brain or spinal cord imaging include:
 - Sensory loss that involves the hands and feet and not the trunk
 - Limb pain
- For symptoms after trauma, refer to **Head Trauma (HD-13.1)** and/or the appropriate level in the Spine Imaging Guidelines
- For generalized weakness, polyneuropathy, and/or other patterns of sensory and/or motor symptoms not referenced above, refer to the following guidelines:
 - Myopathy or myositis, see **Muscle Diseases (PN-8.5)** and **Gaucher Disease (Storage Disorders) (PN-8.6)**
 - Motor Neuron Disease or Amyotrophic Lateral Sclerosis (ALS), see **Motor Neuron Disease/Amyotrophic Lateral Sclerosis (ALS) (PN-8.1)**
 - Neuromuscular Junction Disorders, see **Neuromuscular Junction Disorders (PN-8.4)**
 - Multifocal Motor Neuropathy (MMN) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), see **Polyneuropathy (PN-3.1)**
 - Polyneuropathy, see **Polyneuropathy (PN-3.1)**
 - Neuropathy with concern for malignancy, see **Paraneoplastic Syndromes (ONC-30.3)** in the Oncology Imaging Guidelines
 - Proximal asymmetric and concern for plexopathy, see **Brachial Plexus (PN-4.1)** and/or **Lumbar and Lumbosacral Plexus (PN-5.1)**
 - Sensory and/or motor symptoms localized to a single nerve, see **Focal Neuropathy (PN-2.1)**
 - Thoracic Outlet Syndrome, see **Thoracic Outlet Syndrome (CH-31.1)** in the Chest Imaging Guidelines
 - Radiculopathy, see appropriate level in the Spine Imaging Guidelines
 - Cauda Equina Syndrome, see **Red Flag Indications (SP-1.2)** in the Spine Imaging Guidelines

Background and Supporting Information

- Paresthesia refers to an abnormal sensation that is associated with nervous system dysfunction and may be described as a tingling, pricking, pins and needles, or a burning sensation. The priority is to determine whether the etiology is due to pathology of the peripheral nervous system (PNS) or central nervous system (CNS).
- A thorough clinical history, including symptom location and time course, can be helpful to differentiate PNS pathologies from CNS. For example, paresthesia affecting one side of the face and/or body (i.e., hemisensory deficit) points strongly towards

central nervous system dysfunction. Therefore, brain and/or spinal cord imaging may be supported based on the location of symptoms. Typically, lumbar spine imaging is not supported unless there is sphincter involvement, saddle anesthesia, and/or cauda equina syndrome is suspected. In contrast, an insidious course of distal, symmetric limb paresthesia is more commonly associated with peripheral nerve abnormalities. In such cases, NCS/EMG testing results should be completed prior to advanced imaging. (See *Peripheral Nerve and Neuromuscular Disorders Imaging Guidelines*).

- Upper motor neuron signs (e.g., increased tone, hyperreflexia, presence of Babinski or Hoffman signs) may support a need for central nervous system imaging.
- Lower motor neuron signs (e.g., decreased tone, hypo- or areflexia, muscle atrophy) may support evaluation for peripheral nervous system diseases. Nerve conduction and needle EMG testing should be completed prior to advanced imaging.
- It is important to note that both peripheral and central nervous system disease can co-exist. As a result, if both upper and lower motor neuron signs are observed simultaneously, advanced imaging may be supported regardless of NCS/EMG testing results, (see **Polyneuropathy (PN-3.1)** in the *Peripheral Nerve and Neuromuscular Disorders (PNND) Imaging Guidelines*).
- Babinski sign - presence of an upgoing big toe with stimulation of the lateral plantar region of the foot.
- Hoffman sign - involuntary flexion of the fingers, particularly the thumb and index fingers, triggered by flicking the distal segment of the middle finger.
- Spinal cord shock/acute spinal cord injury - occurs after hyperacute or acute injury to the cord and presents with flaccid areflexia below the level of injury. May be associated with hypotension and/or bradycardia if loss of sympathetic tone occurs. Signs may last from days to weeks before upper motor neuron findings develop.
- Conus Medullaris Syndrome - compressive damage to the spinal cord from T12-L2. Symptoms suggestive of conus medullaris syndrome include saddle anesthesia, urinary retention, bowel incontinence, and/or lower extremity motor or sensory changes.

Evidence Discussion (HD-18)

- The imaging modality of choice for the evaluation of signs or symptoms localizing to the spinal cord is with MRI.^{3,4,5,10,11} MRI allows visualization of the soft tissues and structures that comprise the neural axis.^{3,10,11} Imaging of the cervical and thoracic segments are sufficient to view the entire spinal cord.^{4,10}
- MRI of the lumbar spine is reserved for the evaluation of conus and the cauda equina.⁴
- For evaluation of isolated distal symmetric polyneuropathy, MRI of the brain and/or spine rarely change management in these individuals despite being frequently performed. MRI has little role in these scenarios as it evaluates the central nervous system.⁷

References (HD-18)

v2.0.2026

1. Paresthesia Information Page. National Institute of Neurological Disorders and Stroke. <https://www.ninds.nih.gov/>
2. Freedman M, Levin MC. Numbness. In: Merck Manual Professional Version. Merck & Co., Inc.; Updated August 2025. <https://www.merckmanuals.com/>
3. London ZN. A Structured Approach to the Diagnosis of Peripheral Nervous System Disorders. *CONTINUUM: Lifelong Learning in Neurology*. 2020;26(5):1130-1160. doi:10.1212/con.0000000000000922
4. Hardy TA. Spinal Cord Anatomy and Localization. *CONTINUUM: Lifelong Learning in Neurology*. 2021;27(1):12-29. doi:10.1212/con.0000000000000899
5. Larson ST and Wilbur J. Muscle Weakness in Adults: Evaluation and Differential Diagnosis. *Am Fam Physician*. 2020;101(2):95-108
6. Filippakis A, Jara J, Ventura N, Scala S, Scopa C, Ruthazer R, Karakis I, Srinivasan J, Russell JA, Ho DT. A prospective study of benign fasciculation syndrome and anxiety. *Muscle & nerve*. 2018 Dec;58(6):852-4
7. Callaghan BC, Price RS, Feldman EL. Distal Symmetric Polyneuropathy. *JAMA*. 2015;314(20):2172. doi:10.1001/jama.2015.13611
8. Hughes R. Investigation of peripheral neuropathy. *BMJ*. 2010;341(nov05 1):c6100-c6100. doi:10.1136/bmj.c6100.6
9. Campbell WW. DeJong's The Neurologic Examination, 7th ed, Lippincott Williams & Wilkins, Philadelphia 2013
10. Wattjes MP, Ciccarelli O, Reich DS, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. *The Lancet Neurology*. 2021;20(8):653-670. doi:10.1016/S1474-4422(21)00095-8
11. Expert Panel on Neurological Imaging, Agarwal V, Shah LM, et al. ACR Appropriateness Criteria® Myelopathy: 2021 Update. *J Am Coll Radiol*. 2021;18(5S):S73-S82. doi:10.1016/j.jacr.2021.01.020
12. Expert Panel on Neurologic Imaging: Bykowski J, Aulino JM, et al. ACR Appropriateness Criteria® Plexopathy. *J Am Coll Radiol*. 2017;14(5S):S225-S233. doi:10.1016/j.jacr.2017.02.002

Pituitary, Sella, Hypothalamus (HD-19)

Guideline	Page
Pituitary (HD-19.1).....	212
Post-Operative and Repeat Imaging Indications (HD-19.2).....	220
Empty Sella Turcica (HD-19.3).....	221
Craniopharyngioma and Other Hypothalamic/Pituitary Region Tumors (HD-19.4).....	222
Evidence Discussion (HD-19).....	223
References (HD-19).....	224

Pituitary (HD-19.1)

HD.PT.0019.1.A

v2.0.2026

- Endocrine laboratory studies should be performed prior to considering advanced imaging, except in the cases of stable, non-functioning microadenomas or macroadenomas, cysts, and/or for incidentally found lesions.
- MRI Brain without and with contrast (CPT® 70553) or MRI Brain without contrast (CPT® 70551) with a specific pituitary protocol that includes fine cuts through the sella is medically necessary as the primarily performed pituitary imaging:
 - MRI Orbit/Face/Neck without and with contrast (CPT® 70543) or CT Head without and with contrast (CPT® 70470) are medically necessary alternatives
 - CT Head without contrast (CPT® 70450) or without and with contrast (CPT® 70470) **AND/OR** CT Maxillofacial without contrast (CPT® 70486) is medically necessary in addition to MRI to visualize perisellar bony structures in the pre-operative evaluation of certain sellar tumors and for pre-operative planning for transphenoidal approaches
 - See **General Guidelines – Anatomic Issues (HD-1.1)** as CT Temporal bone (CPT® 70480) is medically necessary instead of CT Maxillofacial per surgeon's preference and contrast level
 - CTA Head (CPT® 70496) or MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) is medically necessary for surgical planning
 - MRI Brain without and with contrast (CPT® 70553) covers both brain and dedicated pituitary if performed at the same time; no additional CPT® codes are medically necessary
- Medically necessary repeat imaging for incidentally found lesions on other studies:
 - MRI Brain without and with contrast (CPT® 70553) or MRI Orbit/Face/Neck without and with contrast (CPT® 70543) follow-up dedicated pituitary study obtained if a pituitary abnormality is reported incidentally on a MRI Brain or CT Head performed for other reasons (MRI Brain without and with contrast [CPT® 70553] covers both brain and dedicated pituitary if performed at the same time; no additional CPT® codes are needed); further evaluation and subsequent imaging dependent on specific imaging and biochemical laboratory evaluation findings.
- Repeat imaging in the setting of worsening clinical status or new neurologic symptoms
- See in the Pelvic Imaging Guidelines for initial lab and imaging work up to exclude other causes. See Female Hypogonadism or Prolactinoma or other relevant sections in the grid if suspicion for pituitary tumor/disease or **Craniopharyngioma and Other Hypothalamic/Pituitary Region Tumors (HD-19.4)** for suspicion of hypothalamic causes.

Pituitary Imaging

Indication	Medically Necessary Initial Imaging	Medically Necessary Repeat Imaging
Microadenoma: Nonfunctioning, unexplained pituitary asymmetries, or incidentally found small tumors (<10 mm)	MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without contrast (CPT[®] 70551)	MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without contrast (CPT[®] 70551) at 12 months and then (if stable in size), every 1-2 years for 3 years, and less frequently thereafter based on clinical status
Macroadenoma (≥10 mm): Nonfunctioning and/or not surgically removed including those with a post-operative remnant	MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without contrast (CPT[®] 70551)	MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without contrast (CPT[®] 70551) every 6 months for the first year and then (if stable in size), every year for 3 years, and less frequently thereafter based on clinical status (longer if craniopharyngioma)
Acromegaly* (Elevated IGF-1 confirmed by lack of suppression of growth hormone on glucose suppression testing)	MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without contrast (CPT[®] 70551)	- MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without contrast (CPT[®] 70551) - At least 12 weeks after surgery to evaluate for residual tumor - If treated with Pegvisomant, 6 to 12 months after treatment initiated, then annually if stable - Long-term follow-up imaging based on clinical and biochemical status at the request of a specialist or any provider in consultation with a specialist

Indication	Medically Necessary Initial Imaging	Medically Necessary Repeat Imaging
Cushing's Disease** (Pituitary ACTH excess leading to hypercortisolism)	MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without contrast (CPT[®] 70551)	- MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without contrast (CPT[®] 70551) - At least 12 weeks after surgery as new baseline - Annually after bilateral adrenalectomy for Cushing's disease or ectopic ACTH production - Long-term follow-up imaging based on clinical and biochemical status at the request of a specialist or any provider in consultation with a specialist
Rathke's cleft cyst/ Simple cyst	MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without contrast (CPT[®] 70551)	MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without contrast (CPT[®] 70551) in one year; if stable and without mass effect or invasion into surrounding structures, no further imaging is required.

Indication	Medically Necessary Imaging
Prolactinomas***	• MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without contrast (CPT[®] 70551) with: ◦ Diagnosis: ▪ Unexplained prolactin level above the normal range ◦ On Dopamine Agonist (DA) therapy with good response: ▪ Macroadenomas 3 months after start of DA therapy ▪ Microadenomas 1 year after start of DA therapy ▪ To decide on stoppage of therapy after ~2 years if in “remission” (normal PRL and no visible tumor on MRI) ◦ On Dopamine Agonist therapy with suboptimal response: ▪ PRL levels rise ▪ New symptoms develop (galactorrhea, vision changes, headaches, pituitary deficiency) ▪ If on high dose maximal DA and no plans for surgery/radiation therapy use guideline for microadenoma or macroadenoma ◦ After Dopamine Agonist therapy: ▪ Rise in PRL level ▪ For DA stoppage at menopause, use guideline for microadenoma or macroadenoma ◦ Not on therapy – refer to recommendations for repeat imaging for microadenoma or macroadenoma ◦ Galactorrhea/nipple discharge with normal prolactin and thyroid function levels: See <u>Nipple Discharge/ Galactorrhea (BR-6.1)</u> in the Breast Imaging Guidelines
Medication-induced Prolactinemia****	• To differentiate between medication-induced hyperprolactinemia and hyperprolactinemia due to a pituitary or hypothalamic mass if the medication cannot be discontinued or hyperprolactinemia persists after medication discontinuation

Indication	Medically Necessary Imaging
TSH, FSH, or LH producing adenomas (inappropriate pituitary hypersecretion of TSH, FSH or LH)*****	• MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without contrast (CPT[®] 70551) when hormone levels are inappropriately elevated and there is a concern for a pituitary lesion. • Refer to appropriate post-operative, or Microadenoma/Macroadenoma guidelines based on the size of the lesion and initial management. ◦ Long-term follow-up imaging based on clinical and biochemical status at the request of a specialist or any provider in consultation with a specialist
Male Hypogonadism*****	• MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without contrast (CPT[®] 70551) if ONE of the following: ◦ Severe secondary hypogonadism (as indicated by morning serum testosterone level <150 ng/dl and low or normal LH and FSH levels) (See <i>Background and Supporting Information</i>) ◦ Below normal testosterone level (serum total testosterone, free testosterone, and/or bioavailable morning testosterone) AND low or normal LH and FSH levels, in an individual with either: ▪ Panhypopituitarism ▪ Hyperprolactinemia ▪ Signs of tumor mass effect (headache, visual impairment, or visual field deficit) ▪ Elevated sex hormone binding globulin (SHBG)
Female Hypogonadism (Secondary Amenorrhea may be a feature)	• MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without contrast (CPT[®] 70551) for normal or low FSH with low estradiol (LH may be normal or low also)

Indication	Medically Necessary Imaging
Growth Hormone Deficiency (Adult onset)	MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without contrast (CPT[®] 70551) for the following: • Low Growth Hormone (GH) OR • Low IGF-1 AND • One abnormal provocative test (likely will be Glucagon Stimulation test as GNRH is unavailable and Insulin Tolerance test poses risks) • If 3 or more pituitary hormones are deficient (including GH), then provocative test is not needed.
Secondary (Central) Adrenal Insufficiency	MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without contrast (CPT[®] 70551) for the following: • ACTH is low or normal at 10 or lower AND • Low baseline cortisol level <3 µg/dL OR • abnormal ACTH stimulation test with suboptimal cortisol stimulation where cortisol does not reach above 18 µg/dL
Central Hypothyroidism	• MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without contrast (CPT[®] 70551) for the following: ◦ Low free T4 with normal, low, or mildly elevated TSH
Hypopituitarism (deficiency of one or more pituitary hormones)	• MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without contrast (CPT[®] 70551)

Indication	Medically Necessary Initial Imaging	Medically Necessary Repeat Imaging for Non-Operative Care
Diabetes Insipidus (DI) - ADH deficiency	- MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without contrast (CPT[®] 70551) if: - Laboratory testing consistent with DI (serum osmolality should be high and urine osmolality should be low) and etiology uncertain	NA
Syndrome of Inappropriate ADH (SIADH)	- MRI Brain without and with contrast (CPT[®] 70553) or MRI Brain without contrast (CPT[®] 70551) if: - Etiology remains uncertain or is thought to be in the nervous system - Urine osmolality should be high and serum osmolality low	NA
Other Pituitary Region Tumors	Evaluation may require CT in addition to MRI to evaluate for hyperostosis.	

Background and Supporting Information

- ***Acromegaly:** A serum level of growth hormone greater than 1ng/mL when measured two hours following an oral glucose load confirms acromegaly.
- ****Cushing's Disease:** It is important to differentiate Cushing's syndrome (hypercortisolism from any source) from Cushing's disease which is ACTH hypersecretion from the pituitary gland. Hypercortisolism is quantified by 24hour urine cortisol collection, low dose dexamethasone suppression test and/or late-night salivary cortisol measurement. ACTH is elevated or inappropriately normal in Cushing's disease and ectopic sources of ACTH production but suppressed in other causes of hypercortisolism. A high dose dexamethasone suppression test can help determine if the elevated ACTH is from a pituitary or ectopic source. Petrosal sinus sampling may be required for tumor localization pre-operatively in the setting of a normal pituitary MRI or a small adenoma. These tumors may be managed with surgery, medical therapy, radiation, and/or bilateral adrenalectomy.
- *****Prolactinoma:** To establish the diagnosis of hyperprolactinemia, a single measurement of serum prolactin is recommended; a level above the upper limit of normal confirms the diagnosis as long as the serum sample was obtained without excessive venipuncture stress. Pregnancy and primary hypothyroidism should be

excluded as physiologic causes of prolactin elevation and medications that may be contributing to prolactin elevation should be considered. Dopamine agonist therapy is typically stopped during pregnancy, monitoring of prolactin levels ceases. Routine imaging surveillance during pregnancy is not recommended due to risk to fetus. Repeat imaging with MRI without gadolinium can be performed however for new or worsening symptoms, such as headaches or visual symptoms.

- **** **Medication-induced prolactin elevation:** Medication induced hyperprolactinemia is seen most commonly with antipsychotics/neuroleptics and antidepressants but may also be seen with some anti-emetics and antihypertensive agents. In individuals on prolactin elevating drugs, a prolactin level should be repeated after withdrawal of medications for 72 h, however, this approach may not be safe if this treatment is offered for psychiatric indications. If stopping the drug is not feasible, pituitary MRI is advised to rule out a sellar/parasellar tumor.
- *******TSH, FSH, or LH producing adenomas:** These are the least common of all hormonally active pituitary tumors. Individuals with TSH secreting adenomas have inappropriate TSH elevation in the setting of hyperthyroidism (elevated thyroid hormone levels). Almost all gonadotroph adenomas are clinically non-functioning. The infrequent presentation of a functioning gonadotroph adenoma should be differentiated clinically from appropriate FSH and LH elevation seen in low estrogen states (including menopause) as well as primary hypogonadism (testicular failure). Functioning TSH, FSH or LH pituitary adenomas may be managed with surgical, radiation and/or medical therapies.
- *******Male Hypogonadism:** Alterations in sex hormone-binding globulin (SHBG) can impact testosterone levels. Free or bioavailable testosterone concentrations should be measured when total testosterone concentrations are close to the lower limit of the normal range and when altered SHBG levels are suspected (e.g. moderate obesity, nephrotic syndrome, hypo- and hyperthyroidism, use of glucocorticoids, progestins, estrogens, and androgenic steroids, anticonvulsants, acromegaly, diabetes mellitus, aging, HIV disease, liver cirrhosis, hepatitis). LH and FSH should be obtained to evaluate for secondary (central) hypogonadism once low testosterone level is confirmed. Morning testosterone level is drawn anytime before 10 am for a typical sleep-wake cycle.
- Central hypothyroidism is an anatomic or functional disorder of the pituitary gland or the hypothalamus, resulting in altered TSH secretion. Diagnosis is usually made biochemically with low circulating free T4 (FT4) concentrations associated with low/normal serum TSH levels.

Post-Operative and Repeat Imaging Indications (HD-19.2)

HD.PT.0019.2.A

v2.0.2026

- For imaging in the immediate post-operative period or for acute surgical complications
 - See **Primary Central Nervous System Tumors (ONC-2.1)** in the Oncology Imaging Guidelines.
- A routine post-operative MRI is generally done at 3 months and/or at the discretion of, or in consultation with an Endocrinologist, Neurologist, Neurosurgeon, ENT, Ophthalmologist, Neuro-Ophthalmologist or Radiation Oncologist.
- Frequency of follow-up imaging depends on the post-operative size and/or functional status of the pituitary adenoma. Refer to the grid sections for Microadenoma/Macroadenoma as well as those for disorders of pituitary hormone excess.
- Individuals with hyper-functioning tumors such as acromegaly, Cushing's disease, and excess TSH secretion may be treated with a combination of surgery, medical therapy, and radiation. Long-term monitoring of clinical status and repeat imaging at the discretion of, or in consultation with an Endocrinologist, Neurologist, Neurosurgeon, ENT, Ophthalmologist, Neuro-Ophthalmologist or Radiation Oncologist.

Empty Sella Turcica (HD-19.3)

HD.DPT.0019.3.A

v2.0.2026

- Enlarged/Empty Sella Turcica: An enlarged sella turcica without evident tumor is an incidental finding on MRI Brain or CT Head from a defect in the dural diaphragm of the sella (especially if there is elevated intracranial pressure from another cause), pituitary surgery, or as a result of a pituitary tumor which has expanded the sella and then infarcted (pituitary apoplexy).
- MRI Brain without and with contrast (pituitary protocol) (CPT[®] 70553) with thin sections of pituitary or MRI Brain without contrast (CPT[®] 70551) is medically necessary. CT Head without and with contrast (CPT[®] 70470) – If MRI is contraindicated.
 - Primary Empty Sella:
 - Incidentally found on other studies, asymptomatic and no related abnormalities: follow-up at 2 years. No further imaging unless clinical symptoms develop (neuro-/ophthalmological symptoms, intracranial hypertension, or endocrine/hormonal abnormalities).
 - Following medical or surgical treatment of related endocrine, neurological, or ophthalmological problems: follow-up imaging every 6 months in the year after treatment and/or at the request of a specialist or any provider in consultation with a specialist (see **Papilledema/Pseudotumor Cerebri (HD-17.1)** for additional imaging recommendations)
 - Secondary Empty Sella
 - Imaging according to the cause or if clinical disease progression (such as adenomas, infiltrative or malignant disorders, hormonal abnormalities, neuro-/ophthalmological symptoms)

Craniopharyngioma and Other Hypothalamic/Pituitary Region Tumors (HD-19.4)

HD.DPT.0019.4.A

v2.0.2026

- See Craniopharyngioma and Other Hypothalamic/Pituitary Region Tumors (PEDONC-4.10)

Evidence Discussion (HD-19)

v2.0.2026

- MRI imaging of the Sella region using high-resolution pituitary protocols is the preferred diagnostic imaging modality for evaluation of the pituitary and sellar regions and is considered the gold standard for imaging the pituitary gland when there is suspicion of hypothalamic pituitary disease.⁸
- Both the anatomy and pathology of the pituitary gland and surrounding areas including optic chiasm, infundibulum, and vascular structures, as well as an empty sella, are reliably depicted on MRI.⁸
- MRI is the most sensitive imaging study for evaluating pituitary disease.⁸
- CT of the Sella can be used to detect bone destructive lesions of the skull base, such as craniopharyngiomas, meningiomas, or larger pituitary macroadenomas, but CT is insensitive when compared to MRI for pituitary pathology.⁸
- MRI utilizes a magnetic field and radio waves with computer processing to produce detailed images whereas CT uses ionizing radiation. Radiation dosages vary based on many factors and can be harmful to tissues. Thus, from radiation safety perspective MRI should be utilized when appropriate and supported by existing literature.²⁷

References (HD-19)

v2.0.2026

1. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients—2002 Update. *Endocrine Practice*. 2002;8(6):439-456. doi:10.4158/ep.8.6.439
2. Katznelson L, Laws ER, Melmed S, et al. Acromegaly: An Endocrine Society Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism*. 2014;99(11):3933-3951. doi:10.1210/jc.2014-2700
3. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism*. 2011;96(2):273-288. doi:10.1210/jc.2010-1692
4. Hoang JK, Hoffman AR, González RG, et al. Management of Incidental Pituitary Findings on CT, MRI, and 18 F-Fluorodeoxyglucose PET: A White Paper of the ACR Incidental Findings Committee. *Journal of the American College of Radiology*. 2018;15(7):966-972. doi:10.1016/j.jacr.2018.03.037
5. Marinis LD, Bonadonna S, Bianchi A, Maira G, Giustina A. Primary Empty Sella. *The Journal of Clinical Endocrinology & Metabolism*. 2005;90(9):5471-5477. doi:10.1210/jc.2005-0288
6. Chiloiri S, Giampietro A, Bianchi A, et al. DIAGNOSIS OF ENDOCRINE DISEASE: Primary empty sella: a comprehensive review. *European Journal of Endocrinology*. 2017;177(6). doi:10.1530/eje-17-0505
7. Freda PU, Beckers AM, Katznelson L, et al. Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism*. 2011;96(4):894-904. doi:10.1210/jc.2010-1048
8. Expert Panel on Neurologic Imaging; Burns J, Policeni B, et al. ACR Appropriateness Criteria® Neuroendocrine Imaging. *J Am Coll Radiol*. 2019;16(5S):S161-S173. doi:10.1016/j.jacr.2019.02.017
9. Thompson CJ et al.eds. Melmed S et al. Chapter 10: Posterior Pituitary. In: *Williams Textbook of Endocrinology*, 14th ed., 2019: 303-330
10. Cooke DW et al.eds. Melmed S et al. Chapter 25: Normal and Aberrant Growth in Children. In: *Williams Textbook of Endocrinology*, 14th ed. 2019: 937-1022
11. Styne DM. eds. Melmed S et al. Chapter 26: Physiology and Disorders of Puberty. In: *Williams Textbook of Endocrinology*, 14th ed. 2019: 1023-1164
12. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism*. 2018;103(5):1715-1744. doi:10.1210/jc.2018-00229
13. Chen CC, Carter BS, Wang R, et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Preoperative Imaging Assessment of Patients With Suspected Nonfunctioning Pituitary Adenomas. *Neurosurgery*. 2016;79(4). Pp E524-526. doi:10.1227/neu.0000000000001391
14. Nieman LK, Biller BMK, Findling JW, et al. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism*. 2015;100(8):2807-2831. doi:10.1210/jc.2015-1818
15. Woodmansee WW, Carmichael J, Kelly D, Katznelson L. American Association Of Clinical Endocrinologists And American College Of Endocrinology Disease State Clinical Review: Postoperative Management Following Pituitary Surgery. *Endocrine Practice*. 2015;21(7):832-838. doi:10.4158/ep14541.dscr
16. Ziu M, Dunn IF, Hess C, et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Posttreatment Follow-up Evaluation of Patients With Nonfunctioning Pituitary Adenomas. *Neurosurgery*. 2016;79(4):E541-E543. doi:10.1227/neu.0000000000001392
17. Jane JA, Jr. Surgical Treatment of Pituitary Adenomas. (Updated 10/4/2019). In: Feingold KR, Anawalt B, Boyce A, et al. eds. Endotext [Internet]. South Dartmouth (MA): MD Text com, Inc; 2000
18. Cardinale F, Pero G, Quilici L, et al. Cerebral Angiography for Multimodal Surgical Planning in Epilepsy Surgery: Description of a New Three-Dimensional Technique and Literature Review. *World Neurosurgery*. 2015;84(2):358-367. doi:10.1016/j.wneu.2015.03.028
19. Prevedello D, Otto B, Carrau R, de Lara D, Ditzel Filho LeoFS. Application of Image Guidance in Pituitary Surgery. *Surgical Neurology International*. 2012;3(3):73. doi:10.4103/2152-7806.95418

20. Guo Z, Liu C, Hou H, et al. Preoperative Computed Tomography (CT) Evaluation of Anatomical Abnormalities in Endonasal Transsphenoidal Approach in Pituitary Adenoma. *Medical Science Monitor*. 2018;24:1268-1275. doi:10.12659/msm.904402
21. Aghi MK, Chen CC, Fleseriu M, et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Management of Patients With Nonfunctioning Pituitary Adenomas. *Neurosurgery*. 2016;79(4):521-523. doi:10.1227/neu.0000000000001386
22. Samperi I, Lithgow K, Karavitaki N. Hyperprolactinaemia. *Journal of Clinical Medicine*. 2019;8(12):2203. doi:10.3390/jcm8122203
23. Esposito D, Olsson DS, Ragnarsson O, Buchfelder M, Skoglund T, Johannsson G. Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management. *Pituitary*. 2019;22(4):422-434. doi:10.1007/s11102-019-00960
24. Persani L. Central Hypothyroidism: Pathogenic, Diagnostic, and Therapeutic Challenges. *The Journal of Clinical Endocrinology & Metabolism*. 2012;97(9):3068-3078. doi:10.1210/jc.2012-1616
25. Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2016;101(11):3888-3921. doi:10.1210/jc.2016-2118
26. Sharma ST; AACE Adrenal Scientific Committee. AN INDIVIDUALIZED APPROACH TO THE EVALUATION OF CUSHING SYNDROME. *Endocr Pract*. 2017;23(6):726-737. doi:10.4158/EP161721.RA
27. American College of Radiology. ACR Practice Parameter for performing and interpreting magnetic resonance imaging (MRI). 2022; Available at: <https://gravitas.acr.org/PPTS/>

Scalp and Skull (HD-20)

Guideline	Page
Scalp and Skull Lesions (HD-20.1)	227
Skull Base Osteomyelitis (SBO) (HD-20.2)	229
References (HD-20)	231

Scalp and Skull Lesions (HD-20.1)

HD.SK.0020.1.A

v2.0.2026

The majority of these are benign soft tissue or bony lesions easily defined by physical examination or with skull x-rays or ultrasound.

- Ultrasound is the initial imaging of scalp lesions
- X-ray is the initial imaging of skull (bony) lesions
- CT Head without or without and with contrast (CPT[®] 70450 or CPT[®] 70470) is medically necessary for the following scenarios:
 - Any lesion on physician examination and skull x-ray or ultrasound which is not clearly benign.
 - In cases where surgical planning is in progress, x-rays and/or ultrasound are not required.
 - When bony lesions are detected on physical examination with any of the following:
 - Signs or symptoms of Langerhan's cell histiocytosis
 - Signs or symptoms of multiple myeloma
 - History of a cancer condition with a suspicion of metastasis
 - History of Paget's disease
 - History of radiation therapy to the head region
- MRI Brain without contrast (CPT[®] 70551) or MRI Brain without and with contrast (CPT[®] 70553) is medically necessary if there is concern for intracranial extension.
- See **Dental/Periodontal/Maxillofacial Imaging (HD-30.2)** for mandibular masses
- The following imaging is medically necessary for children and adults with Pott Puffy Tumor:
 - MRI Brain without and with contrast (CPT[®] 70553) or CT Head without and with contrast (CPT[®] 70470)
 - Repeat imaging is medically necessary if requested by a neurologist, neurosurgeon, otolaryngologist (ENT) and/or oromaxillofacial surgeon (OMS) or any provider coordinating care with a neurologist, neurosurgeon, otolaryngologist (ENT) and/or oromaxillofacial surgeon (OMS)

Background and Supporting Information

Pott Puffy Tumor is an abscess involving the frontal bone with adjacent osteomyelitis as the result of a frontal sinus infection that spreads contiguously through the wall of the sinus or through hematogenous spread via the veins that drain sinus mucosa.

Evidence Discussion (HD-20.1)

- The ACR Practice Parameter or the Performance of Computed Tomography (CT) of the head and of the extracranial head and neck gives a broad description of some of the pathologies that would be beneficially imaged using this modality, and points out that the reason for imaging must be for a valid medical reason and should be done with the aim for using only the minimum necessary radiation. This in some cases requires the use of additional modalities.^{1,7}
- The majority of skull lesions is benign, but advanced imaging characteristics may aid in defining the lesion as having a relatively high pretest probability of malignancy (prior to histological confirmation). However, clinical contextual information is necessary to help decide which individuals would benefit from advanced imaging including the individual's age and features of the individual's presenting history.⁶
- Ultrasound offers many radiographic advantages for the characterization of scalp masses, which are not visualized by CT or MRI, the primary goal being to differentiate benign vs. malignant scalp masses. Cancers of the scalp represent 2% of all skin cancers. In both squamous and basal cell carcinomas, the US shows hypoechoic solid tumors with increased vascularity, and basal cell pathology can also consist of hyperechoic spots internally.⁸
- In folliculotropic mycosis fungoides (FMF), the most common manifestation of cutaneous T-cell lymphoma, the sonographic features include skin thickening, and hypoechoic upper dermis and hair follicles, with large surrounding hyperechoic deposits.⁸
- Skull (bony) lesions are most often discovered incidentally either clinically or as a result of CT or MRI of the brain performed for another indication, and these skull masses can be either malignant or benign. The individual's history is essential to understand along with the imaging characteristics in order to obtain accurate diagnosis. Radiographic features, both CT- and MRI- specific can be used to differentiate between benign and malignant lesions, identifying whether lesions have well-defined borders, sclerotic margins, and a narrow transition zone.
- The presence of bony destruction is a useful observation, periosteal reaction, soft tissue component, and intracranial or extracranial extension can be identified as malignant features in addition, and patterns such as lytic vs. sclerotic, dingle vs multiple, homogeneous vs varied composition also can give helpful information for diagnosis, and various patterns are recognizable that may support the tissue type of origin such as fibrogenic, chondrogenic, osteogenic, vascular, etc.⁶
- Plain radiograph can identify some of these features as a first diagnostic study, but advanced imaging may be necessary, in conjunction with x-ray, and at times CT and MRI are useful as complementary studies.⁹
- Pott puffy tumor is a rare complication of sinusitis or trauma, and early diagnosis is important since it is treatable with broad spectrum antibiotics, therefore advanced imaging is medically necessary with a clinical suspicion.¹⁰

Skull Base Osteomyelitis (SBO)

(HD-20.2)

HD.SK.0020.2.A

v2.0.2026

- Note: SBO may occur from the temporal bones or paranasal sinuses and imaging should be of the region of origin
- Any of the following imaging studies are medically necessary in the diagnosis and treatment of skull base osteomyelitis and/or necrotizing external otitis:
 - MRI Brain without and with contrast (with IAC views) (CPT® 70553)
 - CT Temporal bone without contrast (CPT® 70480)
 - CT Temporal bone with contrast (CPT® 70481)
 - CT Maxillofacial without contrast (CPT® 70486)
 - CT Maxillofacial with contrast (CPT® 70487)
 - CT Neck with contrast (CPT® 70491)
 - CTA/CTV Head (CPT® 70496)
 - MRA/MRV Head, contrast as requested (CPT® 70544, 70545, 70546)
 - Gallium-67 Scan (CPT® 78800 or 78801, and 78803, 78831, 78830 or 78832)
 - Bone Scan (CPT® 78830 or 78832)
 - Skull base osteomyelitis: + Gallium and + Bone scan
 - Necrotizing otitis externa: + Gallium and - Bone scan
 - Indium WBC (CPT® 78800 or 78801, and 78803, 78831, 78830 or 78832) is medically necessary as a substitute for or used in addition to Gallium scanning to evaluate response to therapy and especially in cases that have undergone surgical debridement.
- Treatment response: Gallium-67 Scan every 4-6 weeks till scan is negative
- Surveillance Scanning: Gallium-67 Scan at 4 weeks and 3 months post-treatment
- For CT Head imaging, see General Guidelines - CT Head (HD-1.4) and/or Headache (HD-11)
- Internal Auditory Canal: (IAC) MRI can be reported as a limited study with one code from the set (CPT® 70540, CPT® 70542, or CPT® 70543), but should not be used in conjunction with MRI Brain codes (CPT® 70551, CPT® 70552, or CPT® 70553) if IAC views are performed as part of the brain.

Background and Supporting Information

Skull base osteomyelitis is a rare complication of otitis externa. It occurs most commonly among the immunocompromised, older members (greater than 65 years of age) and members with diabetes.

MRI Brain will be positive earliest in the disease process. CT scans will best define bony destruction and are positive later in the disease process.

Evidence Discussion (HD-20.2)

- CT, although involves radiation, is more readily available and provides superior information regarding bony erosion and/or demineralization in the individual with suspected osteomyelitis.⁵
- MRI can assist with early detection of bone changes in as early as 3-5 days from onset of osteomyelitis.⁵ In cases of diabetic osteomyelitis MRI provides a sensitivity of 90% and a specificity of 79%. MRI provides superior soft tissue detail and intracranial involvement secondary to its superior resolution when compared to CT for evaluation of skull-base osteomyelitis.^{5,11,12}
- Both nuclear imaging by means of Technetium 99m (^{99m}Tc) and Gallium 67 (⁶⁷Ga) scan can assist in localizing infection. The Gallium scan is often used to determine the resolution of the infection and thus the end of antibiotic therapy.^{11,12} The Technetium 99m scan can be useful for detecting the infection however often times remains positive prolonged period of time, and thus should not be used to determine resolution of infection.¹²

References (HD-20)

v2.0.2026

1. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance of Computed Tomography (CT) of the extracranial head and neck. 2021; Available at: <https://gravitas.acr.org/PPTS/>
2. Khan M, Quadri SQ, Kazmi A, et al. A comprehensive review of skull base osteomyelitis: Diagnostic and therapeutic challenges among various presentations. *Asian Journal of Neurosurgery*. 2018;13(4):959. doi:10.4103/ajns.ajns_90_17
3. Expert Panel on Neurologic Imaging; Kirsch CFE, Bykowski J, et al. ACR Appropriateness Criteria® Sinonasal Disease. *J Am Coll Radiol*. 2017;14(11S):S550-S559. doi:10.1016/j.jacr.2017.08.041
4. Barnett RR, Piazza MG, Elton SW. Pediatric Neurosurgery in Primary Care: Masses of the Scalp and Skull in Children. *Pediatr Clin North Am*. 2021;68(4):743-757. doi:10.1016/j.pcl.2021.04.003
5. Treviño González JL, Reyes Suárez LL, Hernández de León JE. Malignant otitis externa: An updated review. *Am J Otolaryngol*. 2021 Mar-Apr;42(2):102894. doi: 10.1016/j.amjoto.2020.102894. Epub 2021 Jan 5. PMID: 33429178
6. Gomez CK, Schiffman SR, Bhatt AA. Radiological review of skull lesions. *Insights Imaging*. 2018 Oct;9(5):857-882. doi: 10.1007/s13244-018-0643-0. Epub 2018 Sep 19. PMID: 30232767; PMCID: PMC6206383
7. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance of computed tomography (CT) of the Head. 2020; Available at: <https://gravitas.acr.org/PPTS/>
8. Wortsman X, Wortsman J, Matsuoka L, Saavedra T, Mardones F, Saavedra D, Guerrero R, Corredoira Y. Sonography in pathologies of scalp and hair. *Br J Radiol*. 2012 May;85(1013):647-55. doi: 10.1259/bjr/22636640. Epub 2012 Jan 17. PMID: 22253348; PMCID: PMC3479884.
9. Uggla L, Cuocolo R, Cocozza S, et al. Spectrum of lytic lesions of the skull: a pictorial essay. *Insights Imaging*. 2018;9(5):845-856. doi:10.1007/s13244-018-0653-y
10. Sharma P, Sharma S, Gupta N, Kochar P, Kumar Y. Pott puffy tumor. *Proc (Bayl Univ Med Cent)*. 2017 Apr;30(2):179-181. doi: 10.1080/08998280.2017.11929575. PMID: 28405074; PMCID: PMC5349820.
11. Álvarez Jáñez F, Barriga LQ, Iñigo TR, Roldán Lora F. Diagnosis of Skull Base Osteomyelitis. *Radiographics*. 2021 Jan-Feb;41(1):156-174. doi: 10.1148/rg.2021200046. PMID: 33411616.
12. Khan H. Necrotising Otitis Externa: An Overview Of Imaging Modalities. *J Ayub Med Coll Abbottabad*. 2022;34(4):858-861. doi:10.55519/JAMC-04-8899
13. Argarwal M, Juliano, AF, Hagiwara M, et al. ACR Appropriateness Criteria® Inflammatory Ear Disease. Available at <https://acsearch.acr.org/docs/3195157/Narrative/>. American College of Radiology. Revised 2024

Cerebrovascular Disease (HD-21)

Guideline	Page
Stroke/TIA (HD-21.1).....	233
Risk Assessment for Extracranial Carotid Disease (HD-21.2).....	237
Cryptogenic Stroke (HD-21.3).....	238
Transient Global Amnesia (HD-21.4).....	239
Moyamoya Syndrome/Disease (HD-21.5).....	240
Sickle Cell Disease (HD-21.6).....	243
Multisystemic Smooth Muscle Syndrome (MSMS)/Smooth Muscle Dysfunction Syndrome (SMDS)/ACTA2 Mutations (HD-21.7).....	244
Cerebral Venous Sinus Thrombosis (HD-21.8).....	246
Evidence Discussion (HD-21).....	248
References (HD-21).....	250

Stroke/TIA (HD-21.1)

HD.HL.0021.1.A

v2.0.2026

Indications	Medically Necessary Imaging
- Acute ischemic stroke - Transient ischemic attacks (TIA) - Suspected hemorrhagic stroke - Suspected subdural hemorrhage	ANY or ALL of the following: - CT Head without contrast (CPT® 70450) - CTA Head (CPT® 70496) AND/OR CTA Neck (CPT® 70498) - CTA Head and Neck (CPT® 70471) must be substituted if performed during the same session - CT Perfusion (CPT® 70472 or 70473) - MRI Brain without contrast (CPT® 70551) or MRI Brain without and with contrast (CPT® 70553) - MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) - MRA Neck (CPT® 70547, CPT® 70548, or CPT® 70549)
Repeat imaging for follow-up and resolution of stroke or hemorrhage	As requested by a neurologist, neurosurgeon, hematologist, or physiatrist (PM&R), or any provider in consultation with a neurologist, neurosurgeon, hematologist, or physiatrist
Contraindication to MRI	- CT Head without contrast (CPT® 70450) OR - CT Head without and with contrast (CPT® 70470)

Indications	Medically Necessary Imaging
Arterial Vascular Imaging supported for TIA/Stroke evaluation including dissection: Supported concurrently with brain imaging	- MRA Head (CPT[®] 70544, CPT[®] 70545, or CPT[®] 70546) OR - CTA Head (CPT[®] 70496) AND/OR - MRA Neck (CPT[®] 70547, CPT[®] 70548, or CPT[®] 70549) OR - CTA Neck (CPT[®] 70498) OR - CTA Head and Neck (CPT[®] 70471) if performed during the same session
Venous vascular imaging for evaluation of venous infarcts	- MRA/MRV ([CPT[®] 70544, CPT[®] 70545, or CPT[®] 70546]) OR - CTA/CTV Head (CPT[®] 70496) AND/OR - MRI Brain without contrast (CPT[®] 70551) - MRI Brain without and with contrast (CPT[®] 70553) OR - CT Head without contrast (CPT[®] 70450) Also see Cerebral Venous Sinus Thrombosis (HD-21.8)
Cervicocerebral Catheter Angiography for stroke evaluation	3D Rendering (CPT[®] 76377 or CPT[®] 76376)
Stroke in Pregnancy and other hypercoagulable states - See arterial and venous vascular imaging studies above for vascular imaging requests - See Background and Supporting Information	- MRI Brain without contrast (CPT[®] 70551) OR - CT Head without contrast (CPT[®] 70450)

Indications	Medically Necessary Imaging
Amaurosis Fugax or Ocular Microembolism May include optic nerve/retinal arterial or Hollenhorst plaques on exam	See above for TIA or New Stroke brain imaging options and vascular imaging
Reversible Cerebral Vasoconstriction Syndrome	See also <u>Sudden Onset of Headache (HD-11.3)</u>
Neurologic signs and/or symptoms, including headaches, associated with COVID-19 infection and/or COVID-19 vaccination (Ischemia may be arterial or venous)	- MRI Brain without contrast (CPT[®] 70551) OR - MRI Brain without and with contrast (CPT[®] 70553) See also <u>General Guidelines-CT head (HD-1.4)</u>, <u>Abnormal Blood Clotting (HD-11.9)</u>, and <u>Neuro-Covid-19 (HD-14.2)</u>, and <u>Cerebral Venous Sinus Thrombosis (HD-21.8)</u>
Adults with HbSS (Sickle cell disease) or HbSb Thalassemia	One time MRI Brain without contrast (CPT[®] 70551) or MRI Brain without and with contrast (CPT[®] 70553) for screening to detect silent cerebral infarcts Follow-up or repeat testing per neurologist or hematologist or in consultation with a neurologist or hematologist See also <u>Sickle Cell Disease (HD-21.6)</u>
Secondary work-up of stroke/TIA	Transcranial Doppler Studies See <u>Transcranial Doppler CPT[®] 93886 (HD-24.8)</u>
Moyamoya Disease when surgery or other vascular intervention is being considered	See <u>Moyamoya Syndrome/Disease (HD-21.5)</u>
Evaluation of paradoxical venous thromboembolism in cryptogenic stroke with PFO	See <u>Acute deep venous thrombosis (DVT) (PVD-12.2)</u> and <u>Cryptogenic Stroke (HD-21.3)</u>

Indications	Medically Necessary Imaging
Cerebral Amyloid Angiopathy (CAA)	- MRI Brain without contrast (CPT[®] 70551) OR - MRI Brain without and with contrast (CPT[®] 70553) OR - CT Head without contrast (CPT[®] 70450) Amyloid-PET Brain (CPT[®] 78811 or CPT[®] 78814) is considered not medically necessary for stroke evaluation. See Mild Cognitive Impairment (MCI) and Dementia - PET (HD-8.2)
Multisystem Smooth Muscle Syndrome/ Smooth Muscle Dysfunction Syndrome	See Multisystem Smooth Muscle Syndrome/Smooth Muscle Dysfunction Syndrome (HD-21.7)

Background and Supporting Information

- Pregnancy is an independent risk factor for stroke. Additional risk factors are not required for assessment of a stroke/TIA with acute focal neurological deficits.
- Additional arterial and venous hypercoagulable states that impose a stroke risk include:
 - Antiphospholipid syndrome
 - Hyperhomocysteinemia
 - Factor V Leiden mutation
 - Prothrombin gene mutation
 - Protein S deficiency
 - Protein C deficiency
 - Anti-thrombin deficiency

Risk Assessment for Extracranial Carotid Disease (HD-21.2)

HD.HL.0021.2.A

v2.0.2026

- Duplex Ultrasound Carotid Arteries (CPT[®] 93880 or CPT[®] 93882) is medically necessary for the following:
 - Asymptomatic or symptomatic cervical bruits;
 - Clinical suspicion of extracranial carotid occlusion and the rationale is included
 - Pulsatile neck mass
 - Evaluation of blunt or penetrating neck trauma
 - Amaurosis fugax or ocular microembolism (optic nerve/retinal arterial or Hollenhorst plaques seen on exam)
 - Recent history of focal cerebral or ocular transient ischemic attacks
- Follow-up with CTA or contrast enhanced MRA
 - CTA and contrast enhanced MRA are comparable non-invasive imaging alternatives each with their own advantages and disadvantages
- For additional indications for Duplex Ultrasound Carotid Arteries
 - See **Initial Imaging (PVD-3.1)** in the Peripheral Vascular Disease (PVD) Imaging Guidelines
- For repeat (Surveillance) Duplex Ultrasound Carotid Arteries (CPT[®] 93880 or CPT[®] 93882)
 - See **Surveillance Imaging with NO History of Carotid Surgery or Intervention (PVD-3.2)** and **Surveillance Imaging WITH History of Carotid Surgery or Intervention (PVD-3.3)** in the Peripheral Vascular Disease (PVD) Imaging Guidelines.

Cryptogenic Stroke (HD-21.3)

HD.ST.0021.3.A

v2.0.2026

- 25% of individuals with ischemic stroke have no probable cause and is considered cryptogenic after a standard workup including an echocardiogram, inpatient cardiac telemetry or 24-Holter monitoring, CT or MRI Brain and vessel imaging of the brain or neck arteries and hematologic tests.
- A stroke may also be considered cryptogenic after a standard evaluation fails to yield an etiology in an individual <50 years of age without risk factors with more extensive testing.
- Most cryptogenic sources are embolic in etiology from venous or arterial sources with investigations from disturbances in coagulation and sources of embolism including patent foramen ovale (PFO) and paroxysmal atrial fibrillation.
- Specialized evaluation with the following documentation:
 - MRI/CT Brain with results of stroke
 - Results of MRA/CTA Head and Neck
 - TTE or TEE
 - 24-Hr Holter monitor or Inpatient cardiac telemetry and 12-Lead ECG
- Hematologic testing to include: CBC, Platelet count, INR, PT, PTT, D-Dimer and Arterial and Venous Hypercoagulability tests
 - MRA or CTA Pelvis for the evaluation of paradoxical venous thromboembolism with PFO
 - See **Acute Limb Swelling (PVD-12)** in the Peripheral Vascular Disease (PVD) Imaging Guidelines.
 - Work-up for occult cancer, CT Chest, Abdomen, and/or Pelvis with contrast after the previously indicated tests with results are provided.
 - See **Paraneoplastic Syndromes (ONC-30.3)** in the Oncology Imaging Guidelines.

Transient Global Amnesia (HD-21.4)

HD.ST.0021.4.A

v2.0.2026

- Transient Global Amnesia (TGA) is a clinical diagnosis with the differential diagnosis including, but not exclusive to: ischemic events, migraine headaches, and transient epileptic amnesia.
- Characteristics of TGA may include the following:
 - Inability to retain new information, lasting for several hours with preservation of alertness and all other cognitive functions with repetitive queries and amnesia
 - Witnessed episode
 - There must be anterograde amnesia during the attack
 - Cognitive impairment is limited to amnesia
 - No clouding of consciousness or loss of personal identity
 - No focal neurological signs/symptoms
 - No epileptic features
 - Attack must resolve within 24 hours
 - No recent head injury or active epilepsy
- Head and vessel imaging for ischemic etiology work-up should follow **Stroke/TIA (HD-21.1)**
- For suspected seizure, see **Epilepsy/Seizures (HD-9.1)**

Moyamoya Syndrome/Disease (HD-21.5)

HD.ST.0021.5.A

v2.0.2026

Initial imaging for Moyamoya Syndrome/Disease

- The imaging listed below is medically necessary for initial evaluation of Moyamoya Syndrome/Disease:
 - MRI Brain without contrast (CPT® 70551) **OR**
 - MRI Brain without and with contrast (CPT® 70553) **AND/OR**
 - MRA Head (CPT® 70544, CPT® 70545, **OR** CPT® 70546) **AND/OR**
 - MRA Neck (CPT® 70547, CPT® 70548 **OR** CPT® 70549)
 - If MRA is contraindicated or not readily available, then CTA Head (CPT® 70496) **AND/OR** CTA Neck (CPT® 70498) **OR** CTA Head and Neck (CPT® 70471) must be substituted if performed during the same session is/are medically necessary

Repeat imaging for Moyamoya Syndrome/Disease

- MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) **AND/OR** MRA Neck (CPT® 70547, CPT® 70548 or CPT® 70549)
 - Follow-up or repeat testing per neurologist, neurosurgeon, hematologist or in consultation with a neurologist, neurosurgeon, or hematologist.
 - If MRA is contraindicated or not readily available, then CTA Head (CPT® 70496) **AND/OR** CTA Neck (CPT® 70498) **OR** CTA Head and Neck (CPT® 70471) must be substituted if performed during the same session is/are medically necessary.
- MRI Brain without contrast (CPT® 70551) **OR** MRI Brain without and with contrast (CPT® 70553)
 - Follow-up or repeat testing per neurologist, neurosurgeon, hematologist or in consultation with a neurologist, neurosurgeon, or hematologist.
- Radiopharmaceutical Localization Imaging SPECT (CPT® 78803, CPT® 78830 or CPT® 78832) with vasodilating agent acetazolamide (Diamox) challenge is supported when surgery or other vascular intervention is considered. Follow-up or repeat testing per neurologist, neurosurgeon, hematologist or in consultation with a neurologist, neurosurgeon, or hematologist.
- 3D Rendering (CPT® 76377 or CPT® 76376) with cerebral angiography is medically necessary to define the presence, location, and anatomy of intracranial and cervical vascular malformations.
 - See **General Guidelines – Other Imaging Situations (HD-1.7)** and in the Preface Imaging Guidelines

- CT Perfusion (CPT[®] 70472 or 70473) **OR** MRI Perfusion (CPT[®] 70551 OR CPT[®] 70552 OR CPT[®] 70553) is medically necessary for any of the following:
 - When requested by neurologist and/or neurosurgeon
 - Prior to change in treatment
 - Post-surgical

Screening imaging for Moyamoya Disease

- Screening is not medically necessary for Moyamoya Syndrome.
 - See *Background and Supporting Information*
- Screening for Moyamoya Disease is medically necessary for:
 - First-degree relatives (biological parent, full sibling, or biological child) of individuals with Moyamoya Disease when requested by, or any provider in consultation with, a neurologist, geneticist, or neurosurgeon
- The imaging listed below is medically necessary for screening evaluation of Moyamoya Disease:
 - MRA Head (CPT[®] 70544, CPT[®] 70545, **OR** CPT[®] 70546) **OR** Transcranial Doppler (TCD) Ultrasound (CPT[®] 93886 or CPT[®] 93888) (see **Transcranial Doppler (CPT[®] 93886) (HD-24.8)** in the Head Imaging Guidelines)
 - If MRA is contraindicated or not readily available, then CTA Head (CPT[®] 70496) is medically necessary

CT Perfusion (CPT[®] 70472 or 70473)

- Is medically necessary if requested by a neurologist, neurosurgeon or any provider coordinating care with a neurologist or neurosurgeon

MRI Perfusion

- MRI Perfusion may be obtained with MRI Brain (CPT[®] 70551 OR CPT[®] 70552 OR CPT[®] 70553)
 - No additional CPT[®] codes are medically necessary or appropriate to perform MRI perfusion.

Background and Supporting Information

Moyamoya disease (MMD) is a rare cerebrovascular disease characterized by progressive spontaneous bilateral occlusion of the intracranial internal carotid arteries (ICA) and their major branches (middle cerebral artery, MCA, and anterior cerebral artery, ACA) with compensatory capillary collaterals as an expression of pathologically increased angiogenic activity resembling a "puff of smoke" (Japanese: Moyamoya) on cerebral angiography. Moyamoya Disease is most prevalent individuals with East Asian

ancestry. Up to 15% of individuals with Moyamoya Disease may have a family history of Moyamoya Disease.

Moyamoya Disease is distinguished from Moyamoya Syndrome (MMS). MMD is a primary disease process. MMS is a secondary process that occurs in response to another underlying pathological process that causes stenosis of intracranial blood vessels. There are two peaks of incidence with different clinical presentations, at around 10 years and 30-40 years. The peak appears to occur later in women than men. In children, ischemic symptoms, especially transient ischemic attacks, are predominant. Intellectual decline, seizures, and involuntary movements are also more common in this age group. In contrast, adult individuals present with intracranial hemorrhage more often than pediatric individuals.

Sickle Cell Disease (HD-21.6)

HD.ST.0021.6.A

v2.0.2026

- MRI Brain without contrast (CPT[®] 70551) **OR** MRI Brain without and with contrast (CPT[®] 70553) is medically necessary for the following:
 - Screening to detect silent cerebral infarcts
 - New symptoms or cognitive impairment occurs or a change in academic performance
 - Prior to any change in therapy
- MRA Head (CPT[®] 70544, CPT[®] 70545 **OR** CPT[®] 70546) **OR** CTA Head (CPT[®] 70496) is medically necessary for the following:
 - Any new, indeterminate, or equivocal findings on MRI Brain
 - Prior to any change in therapy

Background and Supporting Information

Individuals with sickle cell disease are at significantly increased risk for stroke and silent infarction, beginning at a very young age. Recent advances allow physicians to identify individuals at high risk for stroke and begin a primary stroke prevention program.

Identification of silent cerebral infarction is important because treatment with prophylactic red cell transfusions to maintain hemoglobin S levels at <30% of total hemoglobin may reduce recurrent stroke and extent of neurologic damage.

- TCD for children aged 17 years old may be medically necessary on a case-by-case basis.
- See **Transcranial Doppler (CPT[®] 93886)(HD-24.8)** in the Head Imaging Guidelines for other indications for this modality and **Stroke/TIA (HD-21.1)** in the Head Imaging Guidelines.
- After 17 years old, for individuals with a history of abnormal TCDs, TCDs may be repeated every 3 months.
- TCD is not medically necessary for individuals with other phenotypes (Hgb SC, Hgb Sβ⁺).

Multisystemic Smooth Muscle Syndrome (MSMS)/Smooth Muscle Dysfunction Syndrome (SMDS)/ACTA2 Mutations (HD-21.7)

HD.ST.0021.7.A

v2.0.2026

Indications	Medically Necessary Imaging
Initial evaluation for confirmed ACTA2 mutation	- MRI Brain without and with contrast (CPT[®] 70553) with OR without MRI perfusion AND/OR - MRA Head (CPT[®] 70544, CPT[®] 70545, or CPT[®] 70546) AND/OR - MRA Neck (CPT[®] 70547, CPT[®] 70548, or CPT[®] 70549)
Repeat imaging if requested by neurologist and/or neurosurgeon and/or geneticist and/or provider coordinating care with a neurologist and/or neurosurgeon and/or geneticist	- MRI Brain without and with contrast (CPT[®] 70553) with OR without MRI perfusion AND/OR - MRA Head (CPT[®] 70544, CPT[®] 70545, or CPT[®] 70546) AND/OR - MRA Neck (CPT[®] 70547, CPT[®] 70548, or CPT[®] 70549)

- MRI Perfusion may be obtained with MRI Brain (CPT[®] 70551 OR CPT[®] 70552 OR CPT[®] 70553)
 - No additional CPT[®] codes are medically necessary to perform MRI perfusion.
- Because radiation is a known risk factor for development of moyamoya, MRI/MRA Head is recommended instead of Computed Tomography (CT)/CTA.

- See *Background and Supporting Information*
- Conventional catheter angiogram 3D rendering (CPT[®] 76376 or CPT[®] 76377) should be reserved for individuals with focal neurologic symptoms or evidence on MRA or transcranial Doppler (TCD) of critical or progressive narrowing of the cerebral arteries.
- See **Screening for Suspected Peripheral Artery Disease/Aneurysmal Disease (PVD-2)**

Background and Supporting Information

Smooth muscle dysfunction syndrome (SMDS)/Multisystemic Smooth Muscle Syndrome (MSMS) presents with a recognizable pattern of complications, including congenital mydriasis, patent ductus arteriosus (PDA), pulmonary arterial hypertension, aortic and other arterial aneurysms, moyamoya-like cerebrovascular disease, intestinal hypoperistalsis and malrotation, and hypotonic bladder.

SMDS/MSMS is caused by heterozygous mutations of the ACTA2 altering arginine 179, most commonly p.Arg179His. With a single exception, all cases are due to de novo mutations.

Cerebral Venous Sinus Thrombosis

(HD-21.8)

HD.ST.0021.8.A

v2.0.2026

CT and MR Venography (CTV and MRV) are reported with the same codes as the CTA/MRA counterpart (there is no specific code for CT/MR venography):

- If arterial and venous CT or MR studies are both performed in the same session, only one CPT® code is used to report both procedures.
- If an arterial CTA or MRA study has been performed and subsequently a repeat study is needed to evaluate the venous anatomy, then this study is medically necessary.
- If a venous CTV or MRV study has been performed and subsequently a repeat study is needed to evaluate the arterial anatomy, then this study is medically necessary.

Indications	Medically Necessary Imaging
Venous vascular imaging for evaluation of venous infarcts	MR or CT Venography: • MRV Head (CPT® 70544, CPT® 70545, or CPT® 70546) OR • CTV Head (CPT® 70496)
Suspected cerebral venous thrombosis	• MRI Brain without contrast (CPT® 70551) OR • MRI Brain without and with contrast (CPT® 70553) OR • CT Head without contrast CPT® 70450 AND/OR • MRV Head (CPT® 70544, CPT® 70545, or CPT® 70546) OR • CTV Head (CPT® 70496)
Follow up of known cerebral venous sinus thrombosis	• MRI Brain without contrast (CPT® 70551) OR • MRI Brain without and with contrast (CPT® 70553) OR • CT Head without contrast (CPT® 70450) AND/OR • MRV Head (CPT® 70544, CPT® 70545, or CPT® 70546) OR • CTV Head (CPT® 70496)

Indications	Medically Necessary Imaging
To differentiate total from subtotal occlusion	MRA without and with contrast (CPT® 70546)

Evidence Discussion (HD-21)

v2.0.2026

- Guidelines from the American Heart Association (AHA) and American Stroke Association supported the role of neuroimaging in stroke triage and individual selection for endovascular therapy in the management of acute stroke.^{1,6,55} Current AHA guidelines also recommended non-invasive imaging of the carotid arteries for individuals with TIA or stroke who may be candidates for carotid endarterectomy or stenting.^{1,6} This includes CT Angiography (CTA) of the head and neck or MR Angiography (MRA) of the head and neck.
- For clinically suspected stroke, initial imaging includes CT head to exclude intracranial hemorrhage, exclude other structural causes and assess for early ischemic changes.¹ CT Angiography (CTA) head is medically necessary during the initial evaluation to assess for large vessel occlusion and has high sensitivity of 93% and specificity of 100%.^{1,54} CTA neck is also a rapid modality for imaging the extracranial vasculature to identify carotid stenosis, occlusion, and vertebral-basilar disease.¹
- CT Perfusion (CTP) can identify individuals with large vessel occlusion who may be candidates for endovascular therapy in the acute stroke setting.
- A CT stroke protocol that includes unenhanced CT, CTA head, and CTP has effective radiation doses between 10-15 mSv, with newer generation scanners and optimized sequences with lower radiation doses closer to 2 mSv.⁵
- MRI Brain with Diffusion Weighted Imaging (DWI) is the most sensitive test to detect an acute ischemic infarct, with a sensitivity of 94% and a specificity of 97%.^{1,6,56,57}
- MR Angiography (MRA) Head and Neck is an alternative to CTA for identification of vascular lesions in the setting of a stroke evaluation.¹ Diagnostic cervicocerebral catheter angiography has the highest spatial and temporal resolution of any vascular imaging study, however, is invasive and requires use of contrast.¹
- Compared with CT, a full stroke protocol with MRI is longer to acquire and susceptible to motion artifacts, in addition to contraindication with metallic devices, and certain implants.⁵⁵ MRI, however, does have the advantage of increased sensitivity for acute ischemia, including in transient ischemic attack, and does not require radiation.
- In the delayed stroke evaluation, CT Head may identify complications such as hemorrhagic conversion, mass effect and herniation.⁵⁵ MRI Brain in this scenario can confirm the extent of an ischemic stroke, evaluate for underlying pathology, and identify any complications.⁵⁵
- For clinically suspected transient ischemic attack (TIA), CT Head is useful to exclude hemorrhage and other intracranial abnormalities.¹ CT perfusion can identify abnormalities in the setting of TIA in up to one-third of cases.¹ CT Angiography (CTA) Head and Neck is a rapid modality for evaluating intracranial and extracranial vascular lesions.¹ MRA Head and neck is an alternative modality, preferred in those

with renal impairment and iodine contrast allergy.¹ MRI Brain is the most sensitive modality for acute ischemic infarct.¹ MRI Brain with Diffusion Weighted Imaging (DWI) sequences can identify ischemic changes in approximately 40% of individuals with TIA.⁵⁸

- For clinically suspected venous sinus thrombosis, imaging is medically necessary to identify the clot and assess for complications, such as venous infarction or hemorrhagic transformation. In addition to imaging previously reviewed for the stroke protocol, CT Venogram (CTV) or MR Venogram (MRV) are appropriate to localize the clot within the venous system.¹
- For stroke or hemorrhage related to Cerebral amyloid angiopathy (CAA), Amyloid PET Brain has a sensitivity that ranges from 82% to 91%, however, its specificity is poor, ranging from 44% to 55%; therefore, this modality is not recommended.³³

References (HD-21)

v2.0.2026

1. Expert Panel on Neurological Imaging, Pannell JS, Corey AS, et al. ACR Appropriateness Criteria® Cerebrovascular Diseases- Stroke and Stroke-Related Conditions. Available at <https://acsearch.acr.org/docs/3149012/Narrative/>. American College of Radiology. Revised 2023.
2. Kovacs MJ. Letter by Kovacs Regarding Article, "Diagnosis and Management of Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association." *Stroke*. 2011;42(7). doi:10.1161/strokeaha.111.619437
3. Stam J. Thrombosis of the Cerebral Veins and Sinuses. *New England Journal of Medicine*. 2005;352(17):1791-1798. doi:10.1056/nejmra042354
4. Schievink WI. Spontaneous dissection of the carotid and vertebral arteries. *The New England Journal of Medicine*. 2001;344(12):898-906. doi:10.1056/NEJM200103223441206
5. Arnold M, Boussier M-G. Carotid and vertebral artery dissection. *Practical Neurology*. 2005;5(2):100-109. doi:10.1111/j.1474-7766.2005.00292.x
6. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*. 2019;50(12). doi:10.1161/str.0000000000000211
7. Burton TM, Bushnell CD. Reversible Cerebral Vasoconstriction Syndrome. *Stroke*. 2019;50(8):2253-2258. doi:10.1161/strokeaha.119.024416
8. Debaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. *Blood Advances*. 2020;4(8):1554-1588. doi:10.1182/bloodadvances.2019001142
9. Osgood M, Budman E, Carandang R, Goddeau JRP, Henninger N. Prevalence of Pelvic Vein Pathology in Patients with Cryptogenic Stroke and Patent Foramen Ovale Undergoing MRV Pelvis. *Cerebrovascular Diseases*. 2015;39(3-4):216-223. doi:10.1159/000376613
10. Messé SR, Gronseth GS, Kent DM, et al. Practice advisory update summary: Patent foramen ovale and secondary stroke prevention. *Neurology*. 2020;94(20):876-885. doi:10.1212/wnl.0000000000009443
11. Demeestere J, Wouters A, Christensen S, Lemmens R, Lansberg MG. Review of Perfusion Imaging in Acute Ischemic Stroke. *Stroke*. 2020;51(3):1017-1024. doi:10.1161/strokeaha.119.028337
12. Latchaw RE, Yonas H, Hunter GJ, et al. Guidelines and recommendations for perfusion imaging in cerebral ischemia: A scientific statement for healthcare professionals by the writing group on perfusion imaging, from the Council on Cardiovascular Radiology of the American Heart Association. *Stroke*. 2003;34(4):1084-1104. doi:10.1161/01.STR.0000064840.99271.9E
13. Belani P, Schefflein J, Kihira S, et al. COVID-19 Is an Independent Risk Factor for Acute Ischemic Stroke. *American Journal of Neuroradiology*. 2020. doi:10.3174/ajnr.a6650
14. Merkler AE, Parikh NS, Mir S, et al. Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza. *JAMA Neurology*. 2020. doi:10.1001/jamaneurol.2020.2730
15. Guzik A, Bushnell C. Stroke Epidemiology and Risk Factor Management. *CONTINUUM: Lifelong Learning in Neurology*. 2017;23(1):15-39. doi:10.1212/con.0000000000000416
16. Tsvigoulis G, Alexandrov AV. Ultrasound in Neurology. *CONTINUUM: Lifelong Learning in Neurology*. 2016;22(5):1655-1677. doi:10.1212/con.0000000000000374
17. Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the Primary Prevention of Stroke. *Stroke*. 2014;45(12):3754-3832. doi:10.1161/str.0000000000000046
18. Lawton MT and Vates GE. Subarachnoid Hemorrhage. *N Engl J Med*. 2017;377:257-66. doi: 10.1056/NEJMcp1605827
19. American College of Radiology. ACR–AIUM–SPR–SRU Practice Parameter for the performance of an ultrasound examination of the extracranial cerebrovascular system. 2021; Available at: <https://gravitas.acr.org/PPTS/>
20. American College of Radiology. ACR–ASNR–SPR Practice Parameter for the performance of Computed Tomography (CT) of the extracranial head and neck. 2021; Available at: <https://gravitas.acr.org/PPTS/>

21. Kamel, H, et al. Tailoring the Approach to Embolic Stroke of Undetermined Source. A Review. *JAMA Neurol*;76(7):855-861. doi:10.1001/jamaneurol.2019.0591
22. Navi BB and Iadecola C. Ischemic Stroke in Cancer Patients: A Review of an Underappreciated Pathology. *Ann Neurol*. 2018 May ; 83(5): 873–883. doi:10.1002/ana.25227
23. Saver, JL. Cryptogenic Stroke. *NEngl J Med*. 2016;374:2065-74. doi:10.1056/NEJMcp1503946
24. Schwarzbach CJ, et al. Stroke and Cancer. The Importance of Cancer-Associated Hypercoagulation as a Possible Stroke Etiology. *Stroke*. 2012;43:3029-3034. doi: 10.1161/STROKEAHA.112.658625
25. Mangla A, Navi BB, Layton K, Kamel H. Transient global amnesia and the risk of ischemic stroke. *Stroke*. 2014;45(2):389-393. doi:10.1161/STROKEAHA.113.003916
26. Spiegel DR, Smith J, Wade RR, et al. Transient global amnesia: current perspectives. *Neuropsychiatric Disease and Treatment*. 2017;Volume 13:2691-2703. doi:10.2147/ndt.s130710
27. Chandra A, Stone CR, Du X, et al. The cerebral circulation and cerebrovascular disease III: Stroke.
28. . 2017;3(2):66-77. doi:10.4103/bc.bc_12_17
29. Hakimi R, Sivakumar S. Imaging of Carotid Dissection. *Current Pain and Headache Reports*. 2019;23(1). doi:10.1007/s11916-019-0741-9
30. Ghoneim A, Straiton J, Pollard C, Macdonald K, Jampana R. Imaging of cerebral venous thrombosis. *Clinical Radiology*. 2020;75(4):254-264. doi:10.1016/j.crad.2019.12.009
31. Dmytriw AA, Song JSA, Yu E, Poon CS. Cerebral venous thrombosis: state of the art diagnosis and management. *Neuroradiology*. 2018;60(7):669-685. doi:10.1007/s00234-018-2032-2
32. American College of Radiology. ACR-ASNR-SIR-SNIS Practice Parameter for the Performance of diagnostic cervicocerebral catheter angiography in adults. 2021; Available at: <https://gravitas.acr.org/PPTS/>
33. McCarter SJ, Lesnick TG, Lowe V et al. Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid- β PET Signal. *Neurology*. 2021;97 (18) :e1799-e1808. doi:10.1212/WNL.0000000000012770
34. Baron JC, Farid K, Dolan E, et al. Diagnostic utility of amyloid PET in cerebral amyloid angiopathy-related symptomatic intracerebral hemorrhage. *J Cereb Blood Flow Metab*. 2014;34(5):753-758. doi:10.1038/jcbfm.2014.43
35. American College of Radiology. ACR–ASNR–SPR Practice Parameter for the performance of computed tomography (CT) perfusion in neuroradiologic imaging. 2022; Available at: <https://gravitas.acr.org/PPTS/>
36. Han C, Feng H, Han YQ, et al. Prospective screening of family members with moyamoya disease patients. *PLoS One*. 2014;9(2):e88765. Published 2014 Feb 19. doi:10.1371/journal.pone.0088765
37. Kim JS. Moyamoya Disease: Epidemiology, Clinical Features, and Diagnosis. *J Stroke*. 2016;18(1):2-11. doi:10.5853/jos.2015.01627
38. Choudhri A, Zaza A, Auschwitz T, Mossa-Basha M. Noninvasive vascular imaging of moyamoya: Diagnosis, followup, and surgical planning. *Journal of Pediatric Neuroradiology*. 3 (2014) 13–20. doi:10.3233/PNR-14082
39. Expert Panel on Neurological Imaging, Ledbetter LN, Burns J, et al. ACR Appropriateness Criteria® Cerebrovascular Diseases-Aneurysm, Vascular Malformation, and Subarachnoid Hemorrhage. *J Am Coll Radiol*. 2021;18(11S):S283-S304. doi:10.1016/j.jacr.2021.08.012
40. Szidonya L, Nickerson JP. Cerebral Amyloid Angiopathy. *Radiol Clin North Am*. 2023;61(3):551-562. doi:10.1016/j.rcl.2023.01.009
41. Ropper AH. Transient Global Amnesia. *N Engl J Med*. 2023;388(7):635-640. doi:10.1056/NEJMra2213867
42. Berry JA, Cortez V, Toor H, Saini H, Siddiqi J. Moyamoya: An Update and Review. *Cureus*. 2020;12(10):e10994. Published 2020 Oct 16. doi:10.7759/cureus.10994
43. Mertens R, Graupera M, Gerhardt H, et al. The Genetic Basis of Moyamoya Disease. *Transl Stroke Res*. 2022;13(1):25-45. doi:10.1007/s12975-021-00940-2
44. Krishnamurti L. Hematopoietic Cell Transplantation for Sickle Cell Disease. *Front Pediatr*. 2021;8:551170. Published 2021 Jan 5. doi:10.3389/fped.2020.551170
45. Roeder HJ, Lopez JR, Miller EC. Ischemic stroke and cerebral venous sinus thrombosis in pregnancy. *Handb Clin Neurol*. 2020;172:3-31. doi:10.1016/B978-0-444-64240-0.00001-5
46. Kanter J, Liem RI, Bernaudin F, et al. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation. *Blood Adv*. 2021;5(18):3668-3689. doi:10.1182/bloodadvances.2021004394C
47. Jordan LC, Kassim AA, Wilkerson KL, Lee CA, Waddle SL, Donahue MJ. Using novel magnetic resonance imaging methods to predict stroke risk in individuals with sickle cell anemia. *Hematol Oncol Stem Cell Ther*. 2020;13(2):76-84. doi:10.1016/j.hemonc.2019.12.009

48. Hirtz D, Kirkham FJ. Sickle Cell Disease and Stroke. *Pediatr Neurol*. 2019;95:34-41. doi:10.1016/j.pediatrneurol.2019.02.018
49. Bernaudin F, Verlhac S, Arnaud C, et al. Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities. *Blood*. 2016;127(14):1814-1822. doi:10.1182/blood-2015-10-675231.
50. Kirkham FJ, Lagunju IA. Epidemiology of Stroke in Sickle Cell Disease. *J Clin Med*. 2021;10(18):4232. Published 2021 Sep 18. doi:10.3390/jcm10184232
51. Regalado ES, Mellor-Crummey L, De Backer J, et al. Clinical history and management recommendations of the smooth muscle dysfunction syndrome due to ACTA2 arginine 179 alterations. *Genet Med*. 2018;20(10):1206-1215. doi:10.1038/gim.2017.245
52. Cuoco JA, Busch CM, Klein BJ, et al. ACTA2 Cerebral Arteriopathy: Not Just a Puff of Smoke. *Cerebrovasc Dis*. 2018;46(3-4):161-171. doi:10.1159/000493863.
53. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance of intracranial magnetic resonance perfusion imaging. 2022; Available at: <https://gravitas.acr.org/PPTS/>
54. Nickel RS, Kamani NR. Ethical Challenges in Hematopoietic Cell Transplantation for Sickle Cell Disease. *Biol Blood Marrow Transplant*. 2018;24(2):219-227. doi:10.1016/j.bbmt.2017.08.034
55. Duvekot MHC, van Es ACGM, Venema E, et al. Accuracy of CTA evaluations in daily clinical practice for large and medium vessel occlusion detection in suspected stroke patients. *Eur Stroke J*. 2021;6(4):357-366. doi:10.1177/23969873211058576
56. de Oliveira EP, Fiebach JB, Vagal A, Schaefer PW, Aviv RI. Controversies in Imaging of Patients With Acute Ischemic Stroke: AJR Expert Panel Narrative Review. *AJR Am J Roentgenol*. 2021;217(5):1027-1037. doi:10.2214/AJR.21.25846
57. Chalela JA, Kidwell CS, Nentwich LM, et al. Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. *Lancet*. 2007;369(9558):293-298. doi:10.1016/S0140-6736(07)60151-2
58. Mullins ME, Schaefer PW, Sorensen AG, et al. CT and conventional and diffusion-weighted MR imaging in acute stroke: study in 691 patients at presentation to the emergency department. *Radiology*. 2002;224(2):353-360. doi:10.1148/radiol.2242010873
59. Wintermark M, Sanelli PC, Albers GW, et al. Imaging recommendations for acute stroke and transient ischemic attack patients: A joint statement by the American Society of Neuroradiology, the American College of Radiology, and the Society of NeuroInterventional Surgery. *AJNR Am J Neuroradiol*. 2013;34(11):E117-E127. doi:10.3174/ajnr.A3690
60. American Medical Association. CPT—Current Procedural Terminology. American Medical Association. Published 2026. Copyright 1995 – 2026

Cerebral Vasculitis (HD-22)

Guideline	Page
Cerebral Vasculitis (HD-22.1).....	254
References (HD-22).....	256

Cerebral Vasculitis (HD-22.1)

HD.CV.0022.1.A

v2.0.2026

- When CNS vasculitis is suspected, MRI Brain without and with contrast (CPT[®] 70553) is medically necessary
 - MRA Head (CPT[®] 70544, CPT[®] 70545, or CPT[®] 70546) **AND/OR**
 - MRA Neck (CPT[®] 70547, CPT[®] 70548, or CPT[®] 70549); **OR**
 - CTA Head (CPT[®] 70496) **AND/OR**
 - CTA Neck (CPT[®] 70498) **OR**
 - CTA Head and Neck (CPT[®] 70471) if performed during the same session
 - The above studies are medically necessary concurrently with brain imaging
- Primary CNS vasculitis includes Giant Cell Arteritis also known as Temporal Arteritis (see **New Headache Onset Older than Age 50 (HD-11.7)**)
- If initial vascular imaging is suspicious for vasculitis, 3D rendering (CPT[®] 76377 or CPT[®] 76376) with cervicocerebral angiography/arteriography (see **General Guidelines- Other Imaging Situations (HD-1.7)**)
- Transcranial Doppler Studies for individuals with documented vasculitis or concern for vasospasm (see **Transcranial Doppler (CPT[®] 93886) (HD-24.8)**)
- FDG-PET/CT Brain (CPT[®] 78608) is not supported due to lack of peer reviewed literature or expert consensus supporting the study for vasculitis.
- For extra-cranial giant cell arteritis evaluation (see **Giant Cell Arteritis (PVD-6.9.2)**)

Background and Supporting Information

The diagnosis of primary central nervous system vasculitis is challenging because of its nonspecific and varied symptoms. Central nervous system vasculitis typically presents with headache, followed by encephalopathy and behavioral changes. Focal neurologic deficits, including but not limited to, visual loss, unilateral weakness, language impairment, sensory loss, incoordination, occurs in 20% to 30% of individuals. Seizures and intracranial hemorrhage may also occur. With a strong clinical suspicion, brain imaging is important for supporting the diagnostic process and directing biopsy.

Classification of vasculitides based on vessel size adapted from Younger. MRA and CTA are useful for the evaluation of the large proximal arteries; evaluation of a possible small vessel vasculitis may be beyond the resolution of routine MRA and CTA Head. However, other abnormalities, such as atherosclerotic disease, arterial dissection, Moyamoya disease, or reversible cerebral vasoconstriction may be demonstrated. Conventional angiogram is superior to MRA and CTA in demonstrating abnormalities in smaller vessels and is considered the "gold standard" in the evaluation of primary small vessel CNS vasculitis.

Dominant Vessel Involved	Primary	Secondary
Large arteries	- Giant cell arteritis - Takayasu's arteritis	Aortitis with rheumatoid disease; Infection (e.g., syphilis)
Medium arteries	- Classical polyarteritis nodosa - Kawasaki disease	Infection (e.g., hepatitis B)
Small vessels and medium arteries	- Wegener's granulomatosis - Churg–Strauss syndrome - Microscopic polyangiitis	Vasculitis with rheumatoid disease, systemic lupus erythematosus (lupus cerebritis), Sjögren's syndrome, drugs, infection (e.g., HIV)
Small vessels	- Henoch-Schönlein purpura - Essential cryoglobulinemia - Cutaneous leukocytoclastic vasculitis	Drugs (e.g., sulphonamides, etc.) Infection (e.g., hepatitis C)

Evidence Discussion (HD-22)

- Non-invasive neuroimaging modalities play a role in the diagnostic evaluation of central nervous vasculitis by providing supportive imaging findings and guiding biopsy.^{3,6} The preferred modality for the evaluation of central nervous system vasculitis is MRI, which provides superior soft-tissue resolution.⁶ MRI Brain is abnormal in >95% of individuals with CNS vasculitis.⁸ MRI Brain shows infarcts in up to 50% of cases and white matter hyperintensities in 42% of cases.^{3,6}
- MRA head was found to be abnormal in 81% of individuals with angiographic findings of vasculitis and normal in 100% of individuals with a normal angiogram.⁶
- CT Angiography is an alternative non-invasive modality that also provides visualization of blood vessels.^{3,6,8}
- FDG-PET/CT brain is not supported due to the high physiologic FDG uptake in the brain and limited resolution of the camera system. Atherosclerosis may also interfere with the FDG-PET interpretation.

References (HD-22)

v2.0.2026

1. Younger DS. Epidemiology of Neurovasculitis. *Neurologic Clinics*. 2016;34(4):887-917. doi:10.1016/j.ncl.2016.06.006
2. Soun JE, Song JW, Romero JM, Schaefer PW. Central Nervous System Vasculopathies. *Radiologic Clinics of North America*. 2019;57(6):1117-1131. doi:10.1016/j.rcl.2019.07.005
3. Salmela MB, Mortazavi S, Jagadeesan BD, et al. ACR Appropriateness Criteria® Cerebrovascular Disease. *Journal of the American College of Radiology*. 2017;14(5). doi:10.1016/j.jacr.2017.01.051
4. Okazaki T, Shinagawa S, Mikage H. Vasculitis syndrome-diagnosis and therapy. *Journal of General and Family Medicine*. 2017;18(2):72-78. doi:10.1002/jgf2.4
5. Ikeda T, Furukawa F, Kawakami T, et al. Outline of guidelines for the management of vasculitis and vascular disorders in Japan, 2016 revised edition. *The Journal of Dermatology*. 2017;45(2):122-127. doi:10.1111/1346-8138.14086
6. Expert Panel on Neurological Imaging, Ledbetter LN, Burns J, et al. ACR Appropriateness Criteria® Cerebrovascular Diseases-Aneurysm, Vascular Malformation, and Subarachnoid Hemorrhage. *J Am Coll Radiol*. 2021;18(11S):S283-S304. doi:10.1016/j.jacr.2021.08.012
7. Slart RHJA; Writing group; Reviewer group; FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. *Eur J Nucl Med Mol Imaging*. 2018;45(7):1250-1269. doi:10.1007/s00259-018-3973-8
8. Wahed LA, Cho TA. Imaging of Central Nervous System Autoimmune, Paraneoplastic, and Neuro-rheumatologic Disorders. *Continuum (Minneap Minn)*. 2023;29(1):255-291. doi:10.1212/CON.0000000000001244

Dizziness, Vertigo and Syncope (HD-23)

Guideline	Page
Dizziness/Vertigo (HD-23.1).....	258
Syncope (HD-23.2).....	265
References (HD-23).....	267

Dizziness/Vertigo (HD-23.1)

HD.DZ.0023.1.A

v2.0.2026

Indications	Medically Necessary Imaging
Red Flags: - History of malignancy - Associated symptoms: - Headache - Hearing loss - Unilateral tinnitus - Visual disturbances - Drop attacks - Vestibular migraine - Weakness - Duration of episode: - Episodes lasting hour(s) or continuous - Exam findings: - Inconclusive positional testing or equivocal or unusual nystagmus findings (Negative Dix-Hallpike) - Visual disturbances including loss and diplopia - Hearing loss - Abnormal cranial nerve findings - Ataxia - Positive Romberg sign - Absent head thrust sign - Focal neurologic deficits - Dysarthria - Weakness, including unilateral or hemibody weakness - Failed treatment: - Failure to respond to vestibular therapy or unable to participate due to clinical condition - Abnormal test results: - ENG/VNG results support central cause	- MRI Brain without contrast (CPT 70551) OR - MRI Brain without and with contrast (CPT 70553) OR - CT Head without contrast (CPT 70450) If MRI contraindicated: - CT Head without contrast (CPT 70450) OR - CT Head without and with contrast (CPT 70470) See also: <u>Headaches with Red Flags (HD-11.2)</u> <u>Multiple Sclerosis and Related Conditions (HD-16)</u> <u>Brain Metastases (ONC-31.3)</u>

Indications	Medically Necessary Imaging
Stroke/TIA	See <u>Stroke/TIA (HD-21.1)</u>
Acoustic Neuroma/Vestibular Schwannoma	• MRI Brain without and with contrast (with IAC views) (CPT[®] 70553) OR without contrast (CPT[®] 70551) • Limited MRI of the internal auditory canals (CPT[®] 70540, CPT[®] 70542, OR CPT[®] 70543) when requested by the provider in place of a complete MRI Brain See also • <u>Acoustic Neuroma (HD-33.1)</u> • <u>Peripheral Nerve Sheath Tumors (PN-9.1)</u>
Head trauma/Temporal Bone Fracture/ Post-traumatic vertigo	• CT Head without contrast (CPT[®] 70450) ◦ See <u>Head Trauma (HD-13.1)</u> AND/OR • CT Orbit/Temporal bone without contrast (CPT[®] 70480)

Indications	Medically Necessary Imaging
Vertebrobasilar disease/ Vertebrobasilar Insufficiency/ Dissection	• CTA Head (CPT® 70496 AND/OR • CTA Neck (CPT® 70498) OR • CTA Head and Neck (CPT® 70471) if performed during the same session OR • MRA Head (CPT® 70544, CPT® 70545, OR CPT® 70546) AND/OR • MRA Neck (CPT® 70547, CPT® 70548, or CPT® 70549) See also: • <u>General Guidelines - CT and MR Angiography (CTA/CTV and MRA/MRV) (HD-1.5)</u> • <u>Headache and Suspected Vascular Dissection (HD-11.1)</u> • <u>Intracranial Cerebral Aneurysms (HD-12.1)</u>
Semicircular canal dehiscence	• CT Orbit/Temporal bone without contrast (CPT® 70480)

Indications	Medically Necessary Imaging
Meniere's Disease	• MRI Brain without and with contrast (with IAC views) (CPT[®] 70553) OR without contrast (CPT[®] 70551) • Limited MRI of the internal auditory canals (CPT[®] 70540, CPT[®] 70542, OR CPT[®] 70543) when requested by the provider in place of a complete MRI Brain

Background and Supporting Information

- Dizziness, a common complaint, with benign and dangerous causes, may be continuous, triggered, or spontaneous.
- For the continuously dizzy individual with nystagmus at the time of evaluation, a head impulse test and a test of skew should be performed to determine if dizziness is due to a peripheral cause or a posterior circulation stroke. Abnormalities on exam may be indications for imaging as detailed in the guideline.
- For triggered dizziness, positional testing such as the Dix-Hallpike maneuver, and/or orthostatic blood pressure measurements, should be performed. If symptoms are reproduced on examination, triggered dizziness is confirmed.
- Spontaneous dizziness may be due to vestibular migraine, TIA, or Meniere's disease, among other causes. A detailed neurologic examination should be performed, and imaging as detailed in the guideline.
- The Dix-Hallpike maneuver should be performed or the individual should be referred to a clinician who could perform the procedure if Benign Paroxysmal Positional Vertigo (BPPV) is suspected.
- The Head Impulse Test (HIT) is also known as the Head thrust test. It is designed to evaluate the vestibular-ocular reflex in an individual with concern for a peripheral vestibulopathy due to ACUTE spontaneous vertigo. The individual is instructed to look at the examiner during the entire test. The individual's head is then quickly turned or rotated to one side and then the other. If normal, the individual's eyes should remain locked on the examiner. If abnormal, the eyes will move in the direction of the head rotation and then quickly correct. This saccade indicates peripheral vestibular hypofunction on the side of the direction that the head is turned. The HIT test is

abnormal in individuals with vestibular neuronitis, and normal in individuals with a posterior circulation stroke.

- Posterior Canal BPPV (85%-95% of BPPV cases) is defined as:
 - Individual reports repeated episodes of vertigo with changes in head position relative to gravity.
 - Each of the following criteria is fulfilled on physical exam:
 - Vertigo associated with torsional (rotatory), upbeat (toward the forehead) nystagmus is provoked by the Dix-Hallpike test.
 - There is a latency period between the completion of the Dix-Hallpike maneuver and the onset of vertigo and nystagmus.
 - The provoked vertigo and nystagmus increase and then resolve within 60 seconds from the onset of the nystagmus.
- Lateral or Horizontal Canal BPPV (5%-15% of BPPV cases) will have horizontal or no nystagmus to which a supine roll test assesses for this condition.
- Exclusions for Dix-Hallpike maneuver
 - Individual previously diagnosed with BPPV and who on date of encounter in calendar year does not have positional dizziness or vertigo consistent with active BPPV
 - Individual has declined Dix-Hallpike maneuver
 - Individual has cervical spinal disease (i.e., cervical stenosis, severe kyphoscoliosis, limited cervical range of motion, Down's syndrome, severe rheumatoid arthritis, cervical radiculopathies, Paget's disease, ankylosing spondylitis, low back dysfunction, spinal cord injuries, spinal fractures)
 - Individual unable to lay flat (i.e., severe heart disease)
 - Individual has severe atherosclerotic disease or recent dissection involving the anterior or posterior cerebral circulation
 - Unable to be seated in exam chair (i.e., morbidly obese), or maneuver cannot be safely performed given morbid obesity
 - Ehlers Danlos/Marfans/Connective tissue disorder due to risk of cranio spinal instability/dissection
- Triggered episodic vestibular syndrome (t-EVS) usually last seconds to minutes with the most common triggers (vs. exacerbating factors) are head motion or change in body position. In the Emergency Department, benign paroxysmal positional vertigo (BPPV) is the second most common cause of t-EVS after orthostatic hypotension. Far lateral rotation of the neck leads to mechanical occlusion of one or both vertebral arteries causing temporary symptoms of vertigo and nystagmus when this position is maintained and may occur with the individual upright.
- Diagnoses or conditions associated with orthostatic hypotension (OH) or nOH include: Parkinson Disease (PD), Multiple System Atrophy (MSA), Pure Autonomic

Failure (PAF) or Dementia with Lewy Bodies (DLB), unexplained fall or syncope, peripheral neuropathies secondary to diabetes, amyloidosis and HIV), individuals ≥ 70 years of age and frail and on multiple medications and individuals with postural (orthostatic) dizziness or nonspecific symptoms that occur when standing. Symptoms may include: lightheadedness or dizziness, the sensation of blacking out, cognitive dysfunction, mental dulling, generalized weakness, neck pain or discomfort in the suboccipital and paracervical region (coat hanger) or platypnea (dyspnea while standing).

- Secondary or advanced laboratory testing is considered for use in select individuals for paraneoplastic syndromes (paraneoplastic panel) and serum and urine protein electrophoresis for monoclonal gammopathy for peripheral neuropathy.
 - See **Polyneuropathy (PN-3.1)** in the Peripheral Nerve and Neuromuscular Disorders Imaging Guidelines, **Multiple Myeloma and Plasmacytomas (ONC-25)** in the Oncology Imaging Guidelines, and **Paraneoplastic Syndromes (ONC-30.3)** in the Oncology Imaging Guidelines.
- Semicircular canal dehiscence (SCD) is a rare syndrome caused by dehiscence in the bony covering of the affected superior, posterior or lateral semicircular canal. When present, it can result in vestibular symptoms of vertigo associated with auditory symptoms including oscillopsia evoked by noise and conductive hearing loss. The vestibular symptoms in SCD can be debilitating. Individuals may note that loud noises cause them to see things moving or that they experience a similar sensation when they cough, sneeze, or strain to lift something heavy. The signs of vestibular abnormalities in SCD relate directly to the effect of the dehiscence which has created a third mobile window of the inner ear. Some individuals have a conductive hearing loss for low-frequency sounds that can resemble the pattern in otosclerosis.
- Occlusive carotid artery disease does not cause fainting but rather causes focal neurologic deficits such as unilateral weakness. Thus, carotid imaging will not identify the cause of the fainting and increases cost. Fainting is a frequent complaint, affecting 40% of people during their lifetime.

Evidence Discussion (HD-23.1)

- MRI Brain is the preferred initial imaging modality for evaluation of persistent vertigo, vertigo associated with an abnormal neurologic exam, and vertigo due to a suspected central cause.^{24,25}
- CT Head is not recommended for the initial evaluation of dizziness due to inferior soft tissue resolution when compared to MRI Brain. In addition, MRI Brain provides better visualization of the cerebellum and posterior fossa and is more sensitive for the detection of posterior fossa infarcts. For suspected superior semicircular canal dehiscence, CT Temporal bone is the appropriate initial imaging study.²⁴

- In the evaluation of dizziness or vertigo in the emergency department, the positivity rate of CT Head was 2%, for MRI Brain 4%, with the diagnostic yield increasing to 12% for MRI Brain if neurologic findings were present.²⁴
- For dizziness due to suspected vertebral-basilar insufficiency, MRA sensitivity reaches 97% when performed with contrast-enhancement.²⁴
- For suspected vertebral artery dissection, CTA had the highest sensitivity 100%, followed by MRA 77%, and Doppler ultrasound at 71%.²⁴
- Vascular imaging should include the entire vertebral artery from the origin at the aortic arch to the basilar artery.²⁴

Syncope (HD-23.2)

HD.DZ.0023.2.A

v2.0.2026

Indications	Medically Necessary Imaging
Syncope with focal signs of a neurologic deficit OR Syncope without focal signs of a neurological deficit AND negative or inconclusive Electrocardiogram (EKG)	- MRI Brain without contrast (CPT[®] 70551) OR - MRI Brain without and with contrast (CPT[®] 70553) OR - CT Head without contrast (CPT[®] 70450) AND/OR - CTA Head (CPT[®] 70496) OR - MRA Head (CPT[®] 70544, CPT[®] 70545, or CPT[®] 70546) AND/OR - CTA Neck (CPT[®] 70498) OR - MRA Neck (CPT[®] 70547, CPT[®] 70548, or CPT[®] 70549) - CTA Head and Neck (CPT[®] 70471) must be substituted if performed during the same session
Recurrent syncope with risk of head injury or head trauma related to syncope	See Head Trauma (HD-13.1)
Situational syncope, including precipitating factors to syncope such as coughing, defecation, eating, laughing, or urination Myoclonic jerks without symptoms or signs associated with seizure, including but not limited to prolonged amnesia/confusion, tongue biting.	Advanced imaging is not medically necessary

Indications	Medically Necessary Imaging
Loss of consciousness with other symptoms or signs of seizure, including but not limited to, prolonged amnesia/confusion, tongue biting, and/or urinary incontinence.	See <u>Epilepsy/Seizure (HD-9.1)</u>

Evidence Discussion (HD-23.2)

- The Choosing Wisely Campaign Best Practices, supported by the American College of Emergency Physicians, American College of Physicians, and the American Academy of Neurology recommended against neuroimaging in the evaluation of simple syncope and a normal neurologic evaluation.^{1,15}
- The initial evaluation for individuals with syncope includes a detailed history, physical exam, and electrocardiography.^{1,6,15,26,29} Neuroimaging has a low diagnostic yield of 5% to 6.4% of an acute abnormality on CT Head.^{1,15,27} Clinical factors associated with abnormal scans include head trauma or a focal neurologic deficit on exam.^{1,15,27}
- In select cases when neuroimaging is medically necessary, structural brain imaging with either CT Head or MRI Brain may be useful, along with vascular imaging, depending on the suspected underlying pathology.^{15,29}
- Inappropriate imaging studies may identify incidental findings, incorrectly assumed to be the cause of syncope, leading to further delay in the identification of the true cause and risk additional unnecessary procedures.²⁶
- Situational syncope does not require advanced imaging.^{3,6,28}

References (HD-23)

v2.0.2026

1. Runser LA, Gauer RL and Houser A. Syncope: Evaluation and Differential Diagnosis. *Am Fam Physician*. 2017;95(5):303-312
2. Expert Panel on Neurologic Imaging; Sharma A, Kirsch CFE, et al. ACR Appropriateness Criteria® Hearing Loss and/or Vertigo. *J Am Coll Radiol*. 2018;15(11S):S321-S331. doi:10.1016/j.jacr.2018.09.020
3. Cheshire WP. Syncope. *CONTINUUM: Lifelong Learning in Neurology*. 2017;23(2):335-358. doi:10.1212/con.0000000000000444
4. Bhattacharyya N, Gubbels SP, Schwartz SR, et al. Clinical Practice Guideline: Benign Paroxysmal Positional Vertigo (Update). *Otolaryngology–Head and Neck Surgery*. 2017;156(3_suppl). doi:10.1177/0194599816689667
5. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance of Computed Tomography (CT) of the extracranial head and neck. 2021; Available at: <https://gravitas.acr.org/PPTS/>
6. Shen W-K, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation*. 2017;136(5). doi:10.1161/cir.0000000000000499
7. Basura GJ, Adams ME, Monfared A, et al. Clinical Practice Guideline: Ménière's Disease. *Otolaryngology–Head and Neck Surgery*. 2020;162(2_suppl). doi:10.1177/0194599820909438
8. Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. *Journal of Neurology*. 2017;264(8):1567-1582. doi:10.1007/s00415-016-8375-x
9. Choosing Wisely. An initiative of the ABIM Foundation. *American Academy of Neurology*. Released February 21, 2013; Last reviewed 2019
10. Choosing Wisely. An initiative of the ABIM Foundation. *American College of Emergency Physicians*. October 27, 2014
11. Scott JW, Schwartz AL, Gates JD, Gerhard-Herman M, Havens JM. Choosing Wisely for Syncope: Low-Value Carotid Ultrasound Use. *Journal of the American Heart Association*. 2014;3(4). doi:10.1161/jaha.114.001063
12. Dix-Hallpike maneuver performed for patients with BPPV. www.aan.com. <https://www.aan.com/policy-and-guidelines/quality/quality-measures2/quality-measures/other/dix-hallpike-maneuver-performed-for-patients-with-BPPV>
13. Baloh RW. Vestibular Migraine I: Mechanisms, Diagnosis, and Clinical Features. *Seminars in Neurology*. 2020;40(01):076-082. doi:10.1055/s-0039-3402735
14. Tehrani ASS, Kattah JC, Kerber KA, et al. Diagnosing Stroke in Acute Dizziness and Vertigo. *Stroke*. 2018;49(3):788-795. doi:10.1161/strokeaha.117.016979
15. Expert Panels on Cardiac Imaging and Neurological Imaging, Kligerman SJ, Bykowski J, et al. ACR Appropriateness Criteria® Syncope. *J Am Coll Radiol*. 2021;18(5S):S229-S238. doi:10.1016/j.jacr.2021.02.021
16. Shmueli S, et al. Differentiating Motor Phenomena in Tilt-Induced Syncope and Convulsive Seizures. *Neurology*. 2018;90:e1339-e1346. doi:10.1212/WNL.0000000000005301
17. Henderson FC Sr, Austin C, Benzel E, et al. Neurological and spinal manifestations of the Ehlers-Danlos syndromes. *Am J Med Genet C Semin Med Genet*. 2017;175(1):195-211. doi:10.1002/ajmg.c.31549
18. Edlow JA, Gurley KL, Newman-Toker DE. A New Diagnostic Approach to the Adult Patient with Acute Dizziness. *The Journal of Emergency Medicine*. 2018;54(4):469-483. doi:10.1016/j.jemermed.2017.12.024
19. Edlow JA. The timing-and-triggers approach to the patient with acute dizziness. *Emerg Med Pract*. 2019 Dec;21(12):1-24. Epub 2019 Dec 1. PMID: 31765116
20. Krishnan K, Bassilious K, Eriksen E, et al. Posterior circulation stroke diagnosis using HINTS in patients presenting with acute vestibular syndrome: A systematic review. *European Stroke Journal*. Published online April 10, 2019;239698731984370. doi:10.1177/2396987319843701
21. Fife TD. Approach to the History and Evaluation of Vertigo and Dizziness. *CONTINUUM: Lifelong Learning in Neurology*. 2021;27(2):306-329. doi:10.1212/con.0000000000000938

22. Hain TC, Cherchi M. Vestibular Testing. *CONTINUUM: Lifelong Learning in Neurology*. 2021;27(2):330-347. doi:10.1212/con.0000000000000978
23. Steenerson KK. Acute Vestibular Syndrome. *CONTINUUM: Lifelong Learning in Neurology*. 2021;27(2):402-419. doi:10.1212/con.0000000000000958
24. Wang LL, Thompson TA, Shih RY, et al. ACR Appropriateness Criteria® Dizziness and Ataxia. Available at <https://acsearch.acr.org/docs/69477/Narrative/>. American College of Radiology. Revised 2023.
25. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance and interpretation of Magnetic Resonance Imaging (MRI) of the brain. 2024; Available at: <https://gravitas.acr.org/PPTS/>
26. Langer-Gould AM, Anderson WE, Armstrong MJ, et al. The American Academy of Neurology's top five choosing wisely recommendations. *Neurology*. 2013;81(11):1004-1011. doi:10.1212/WNL.0b013e31828aab14
27. Mitsunaga MM, Yoon HC. Journal Club: Head CT scans in the emergency department for syncope and dizziness. *AJR Am J Roentgenol*. 2015;204(1):24-28. doi:10.2214/AJR.14.12993
28. Cutsforth-Gregory JK. Postural Tachycardia Syndrome and Neurally Mediated Syncope. *Continuum (Minneapolis)*. 2020;26(1):93-115. doi:10.1212/CON.0000000000000818
29. Bayard M, Gerayli F, Holt J. Syncope: Evaluation and Differential Diagnosis. *Am Fam Physician*. 2023;108(5):454-463

Other Imaging Studies (HD-24)

Guideline	Page
Transcranial Magnetic Stimulation (TMS) (HD-24.1).....	270
Functional MRI (fMRI) (HD-24.2).....	271
Magnetic Resonance Spectroscopy (MRS) (HD-24.3)	272
CSF Flow Imaging (HD-24.4).....	273
CT or MRI Perfusion (HD-24.5).....	274
Magnetic Resonance Neurography (MRN) (HD-24.6)	276
Cone Beam Computed Tomography (CBCT) (HD-24.7).....	277
Transcranial Doppler (CPT®93886) (HD-24.8).....	278
Evidence Discussion (HD-24).....	281
References (HD-24).....	282

Transcranial Magnetic Stimulation (TMS) (HD-24.1)

HD.OI.0024.1.A

v2.0.2026

In TMS, an electromagnetic coil placed on the surface of the skull overlying the motor cortex depolarizes the motor axons, creating a motor evoked potential (MEP), which is recorded via superficial skin electrodes as it passes through the upper and lower motor pathways to an innervated muscle.

TMS is typically utilized for behavioral health purposes.

Functional MRI (fMRI) (HD-24.2)

HD.OI.0024.2.A

v2.0.2026

- fMRI is useful in pre-operative scenarios to define the “eloquent” areas of brain
 - The ordering physician must be a neurologist, neurosurgeon or radiation oncologist or any provider in consultation with one of these specialists.
- Primary medically necessary indications for fMRI include, but are not limited to, the following:
 - Assessment of intracranial neoplasm and other targeted lesions
 - Pre-surgical planning and operative risk assessment
 - Assessment of eloquent cortex (e.g., language, sensory, motor, visual centers) in relation to a tumor or another focal lesion
 - Surgical planning (biopsy or resection)
 - Therapeutic follow-up, as a one-time, post-operative, follow- up study
 - Evaluation of preserved eloquent cortex
 - Assessment of eloquent cortex for epilepsy surgery
 - Assessment of radiation treatment planning and post-treatment evaluation of eloquent cortex
- fMRI is medically necessary with PET Brain in epilepsy surgery planning
- Procedure codes for functional MRI:
 - CPT[®] 70554 MRI Brain, functional MRI, including test selection and administration of repetitive body part movement and/or visual stimulation, not requiring physician or psychologist administration
 - CPT[®] 70555 MRI Brain, functional MRI; requiring physician or psychologist administration of entire neurofunctional testing
 - If MRA Head (CPT[®] 70544) is medically necessary but Functional MRI (CPT[®] 70554 or CPT[®] 70555) was erroneously ordered, then CPT[®] 70544 may be substituted when appropriate
- MRI Brain (CPT[®] 70551 or CPT[®] 70553) and/or fMRI (CPT[®] 70554 or CPT[®] 70555) are medically necessary concurrently
 - See **Unlisted Procedures/Therapy Treatment Planning (Preface-4.3)** in the Preface Imaging Guidelines if MRI Unlisted is requested for surgical planning

Magnetic Resonance Spectroscopy (MRS) (HD-24.3)

HD.OI.0024.3.A

v2.0.2026

- MRS (CPT[®] 76390) involves analysis of the levels of certain chemicals in a pre-selected voxels (small regions) on an MRI scan done at the same time.
- When conventional imaging by magnetic resonance imaging (MRI) or computed tomography (CT) provides limited information regarding specific clinical questions, indications for MRS in adults and children include, but are not limited to, the following and are evaluated on a case-by-case basis:
 - Distinguish recurrent brain tumor from radiation necrosis as an alternative to PET (CPT[®] 78608)
 - Diagnosis of certain rare inborn errors of metabolism affecting the CNS (primarily pediatric individuals)
 - Evidence or suspicion of primary or secondary neoplasm (pre-treatment and post-treatment)
 - Grading of primary glial neoplasm, particularly high-grade versus low-grade glioma
 - Evidence or suspicion of brain infection, especially cerebral abscess (pre-treatment and post-treatment) and HIV-related infections
 - Seizures, especially temporal lobe epilepsy

Background and Supporting Information

- Evaluation of certain primary brain tumors where diagnostic accuracy has been established in peer-reviewed literature.
 - See **Primary Central Nervous System Tumors – General Considerations (ONC-2.1)**, **Low Grade Gliomas (ONC-2.2)**, and **High Grade Gliomas (ONC-2.3)** in the Oncology Imaging Guidelines

CSF Flow Imaging (HD-24.4)

HD.OI.0024.4.A

v2.0.2026

- Pulse-gated MRI imaging or MRI CINE is generally performed as a part of an MRI Brain study. It is not coded separately for pre-operative evaluation of hydrocephalus, Chiari syndromes, Normal Pressure Hydrocephalus, Idiopathic Intracranial Hypertension (also known as pseudotumor cerebri), and spontaneous intracranial hypotension.
- There is no specific or unique procedure code for this study; it is done as a special sequence of a routine MRI Brain without contrast (CPT[®] 70551).
- If not previously performed as part of recent study, a second study for the purpose of evaluating CSF flow is medically necessary.

CT or MRI Perfusion (HD-24.5)

HD.OI.0024.5.A

v2.0.2026

- Performed as part of a CT Head or MRI Brain examination in the evaluation of individuals with very new strokes or brain tumors.
- CT perfusion study is coded as either CPT® 70472 or CPT® 70473
- CPT® 70472, CT cerebral perfusion analysis with contrast material, including imaging postprocessing, performed with concurrent CT or CT angiography of the same anatomy, (use in conjunction with 70450, 70460, 70470, 70471, 70496).
- CPT® 70473, CT cerebral perfusion analysis with contrast, without concurrent CT or CTA of same anatomy, with postprocessing.
 - CTA Head and/or Neck is medically necessary in conjunction with the CT Perfusion study (CPT® 70472)
- CPT® 70472 or 70473 - “cerebral perfusion analysis using CT” is medically necessary for the following:
 - Evaluation of acute stroke (<24 hours) to help identify individuals with stroke-like symptoms and to help identify those most likely to benefit from thrombolysis or thrombectomy
 - Follow-up for acute cerebral ischemia or infarction and/or reperfusion in the subacute or chronic phase of recovery
 - To assist in planning and evaluating the effectiveness of therapy for cervical or intracranial arterial occlusive disease (as an isolated test or in combination with a cerebrovascular reserve challenge) and/or chronic cerebral ischemia
 - Identifying cerebral hyperperfusion syndrome following revascularization
 - Evaluation of the vascular status of solid tumors where MRI is degraded due to susceptibility artifact from air-containing spaces, surgical clips, or dental work
 - Follow-up of tumor response to therapy
- MRI Perfusion is obtained with MRI Brain (CPT® 70551 OR CPT® 70552 OR CPT® 70553).
 - No additional CPT® codes are medically necessary to perform MRI perfusion.
- Medically necessary indications for perfusion magnetic resonance imaging (MRI) MRI Perfusion (CPT® 70551 OR CPT® 70552 OR CPT® 70553)⁹ include the following:
 - Diagnosis and Characterization of Mass Lesions
 - Differential diagnosis (tumor versus tumor mimic)
 - Diagnosis of primary neoplasms (may include grading)
 - Surgical planning (biopsy or resection)
 - Targeting locations for biopsy
 - Guiding resection extent

- Therapeutic follow-up
 - Radiation necrosis versus recurrent or residual tumor
 - Chemonecrosis versus recurrent or residual tumor
 - Pseudoprogression and pseudoresponse
 - Monitor potential transformation of non-resectable low-grade neoplasms to higher grade
- Assessment of Neurovascular Disease
 - Acute stroke (assessment of ischemic penumbra)
 - Assessment of the hemodynamic significance of cervical or intracranial vascular stenosis
 - Assessment of cervical or intracranial revascularization efficacy
 - Assessment of vasospasm
- Other indications are usually regarded as not medically necessary.

Magnetic Resonance Neurography (MRN) (HD-24.6)

HD.OI.0024.6.A

v2.0.2026

- See **Magnetic Resonance Neurography (MRN) (PN-7.1)** in the Peripheral Nerve and Neuromuscular Disorders (PNND) Imaging Guidelines.

Cone Beam Computed Tomography (CBCT) (HD-24.7)

HD.OI.0024.7.A

v2.0.2026

- CPT® Codes: CPT® 70486, CPT® 70487, CPT® 70488, CPT® 70480, CPT® 70482 (No separate 3-D rendering codes should be reported)
- An alternative to traditional CT imaging is in-office cone beam testing and possible decreased radiation dosage. The indications for office-based CT imaging are the same as for traditional scanners, and they should not be used for diagnosing or managing uncomplicated acute bacterial rhinosinusitis (ABRS).
- See **Temporomandibular Joint Disease (TMJ) (HD-30.1)** and **Dental/Periodontal/Maxillofacial Imaging (HD-30.2)**

Transcranial Doppler (CPT[®] 93886) (HD-24.8)

HD.OI.0024.8.A
v2.0.2026

- Transcranial Doppler (TCD) is a non-invasive ultrasonic technique that measures local blood flow velocity and direction in the proximal portions of intracranial and extracranial arteries

CPT Code	Description	Additional Notes
93886	Transcranial Doppler study of the intracranial arteries; complete study	
93888	Transcranial Doppler study of the intracranial arteries; limited study	
93892	Transcranial Doppler study of the intracranial arteries; emboli detection without intravenous microbubble injection	
93893	Transcranial Doppler study of the intracranial arteries; venous-arterial detection with intravenous microbubble injection	Report 93893 if the study is performed with intravenous microbubble injection. Transcranial Doppler studies described as “with contrast” are performed with intravenous microbubble injection. The bubbles serve to enhance ultrasound thus enabling better visualization of the intracranial arteries.

- Transcranial Doppler studies are ordered either as a single complete or limited study or as a combination of the complete or limited study with additional studies for further evaluation of the condition being investigated.
- Evaluation of Stroke/TIA usually includes CPT[®] 93886 (Vasoreactivity study) and either CPT[®] 93892 or CPT[®] 93893 (Emboli detection).

- Examples include:
 - Evaluation of right to left cardiac shunts: Detection of microemboli in individuals with stroke or TIA. (CPT[®] 93892 or CPT[®] 93893 added to CPT[®] 93886)
 - Evaluation of intracranial occlusive disease in individuals with documented stroke or TIA
 - Evaluation of hemodynamic effects of known severe extra-cranial occlusive disease
- TCD studies are medically necessary for the following:
 - Evaluation of severe stenosis or occlusion of the extracranial ($\geq 60\%$ diameter reduction) and major basal intracranial arteries ($\geq 50\%$ diameter reduction)
 - Detection and serial evaluation of cerebral vasospasm in subarachnoid hemorrhage
 - Evaluation of cerebral embolization including in COVID-19 and refractory encephalopathy
 - Assessing the extent of collateral circulation in individuals with known regions of severe stenosis or occlusion
 - To detect residual right to left shunting after repair/closure of an intracardiac or intrapulmonary shunt
 - Evaluation of AVM both pre- and post-surgical intervention.
 - Periprocedural monitoring to detect cerebral thrombosis, embolization, hypoperfusion, and hyperperfusion
 - Assessing the stroke risk in children aged two to sixteen with homozygous sickle cell disease
 - Annual screening for individuals with Sickle Cell Anemia (Hb-SS) and Sickle Beta Thalassemia (S β) (CPT[®] 93886) up to the age of 16.
- TCD studies are not medically necessary for evaluation of:
 - Brain tumors
 - Familial and degenerative disease of the brain
 - Psychiatric disorders
 - Epilepsy
 - Migraine or other primary headache disorders
 - Infectious and inflammatory conditions

Background and Supporting Information

- Transcranial Doppler (TCD) ultrasound provides rapid, non-invasive, real-time measure of cerebrovascular function.
- TCD can be used to measure flow velocity in the proximal cerebral arteries to assess relative changes in flow, diagnose focal vascular stenosis, or to detect embolic signals within these arteries.

- TCD can be used to measure blood flow responses to changes in blood pressure (cerebral autoregulation), changes in end-tidal CO₂ (cerebral vasoreactivity), or cognitive and motor activation (neurovascular coupling or functional hyperemia).
- A technical limitation of TCD includes inadequate temporal bone acoustic windows due to a thickened skull which limits ultrasound penetration.
- Studies are ongoing regarding the use of TCD in the evaluation of dementia and psychiatric conditions such as depression.
- CPT® 93892 and CPT® 93893 represent add on services that require additional expertise, lab time, and equipment not included in the complete and limited codes. These additional codes may be appropriate during the same encounter if medical necessity is documented.
- CPT® 93892/CPT® 93893: Identification of right to left shunts (microembolic signals may be detected during TCD monitoring) and may indicate source of emboli in individuals with stroke or TIA. TCD bubble test is very sensitive and may be superior to transthoracic and transesophageal echocardiography in detection of right to left shunts.
- Transcranial Doppler (TCD) is considered not medically necessary for the following indications:
 - Assessing individuals with migraine;
 - Monitoring during cardiopulmonary bypass and other cerebrovascular and cardiovascular interventions, and surgical procedures (except during carotid endarterectomy, as noted above);
 - Evaluation of individuals with dilated vasculopathies such as fusiform aneurysms;
 - Assessing autoregulation, physiologic, and pharmacological responses of cerebral arteries; and/or
 - Evaluating children with various vasculopathies, such as moyamoya disease and neurofibromatosis.

Evidence Discussion (HD-24)

v2.0.2026

- Functional magnetic resonance imaging (fMRI) is useful for localizing eloquent cortex in relation to a focal brain lesion, for pre-surgical planning and therapeutic follow up.⁷ Overall functional MRI imaging sensitivity is 83% with a specificity of 82%, for mapping language and motor functions.²² Functional MRI is a useful tool for predicting post-operative outcomes in individuals with a single brain tumor.²³ Overall, fMRI studies are used in pre-operative decision making in 89% of tumor individuals and in 91% of epilepsy surgery individuals.^{24,25} In 63% of epilepsy individuals undergoing surgical evaluation, fMRI imaging results helped to avoid further studies, including the Wada test.²⁵
- For cases when conventional imaging by magnetic resonance imaging or computed tomography provides limited information regarding specific clinical questions, magnetic resonance spectroscopy (MRS) provides further characterization of brain tumors, radiation treatment changes, cerebral abscess, seizure disorders, and inherited metabolic disorders.^{8,27,28} MRS has a 90% sensitivity and 86% specificity in distinguishing tumoral tissue from non-tumoral tissue.²⁷
- Pulse-gated MRI imaging or MRI CINE is performed as part of an MRI Brain study and allows qualitative and quantitative analysis of oscillatory cerebrospinal fluid (CSF) movement in normal and abnormal conditions.^{11,21} This imaging technique is useful for evaluation of hydrocephalus, Chiari syndromes, Normal Pressure Hydrocephalus, intracranial hypertension, and spontaneous intracranial hypotension.^{10,11}
- MRI perfusion is useful for the diagnosis and characterization of mass lesions, surgical planning and therapeutic follow-up.^{9,30} MR perfusion allows localization of tumor for higher yield on stereotactic biopsy and non-invasive differentiation between radiation necrosis from recurrent tumor when conventional MR findings are equivocal.³⁰
- CT perfusion has multiple uses including in stroke diagnosis and treatment planning, characterization of neoplastic disease and response to treatment, and is alternative modality for those with contraindication to MRI-based perfusion imaging.^{2,29}
- The American Heart Association/American Stroke Association guidelines for acute stroke management recommended CT Perfusion for selecting candidates for mechanical thrombectomy within 24 hours after last known well.²⁹

References (HD-24)

v2.0.2026

1. Tsigoulis G, Alexandrov AV. Ultrasound in Neurology. *CONTINUUM: Lifelong Learning in Neurology*. 2016;22(5):1655-1677. doi:10.1212/con.0000000000000374
2. American College of Radiology. ACR–SPR–SSR practice parameter for the performance of computed tomography (CT) perfusion in neuroradiologic imaging. 2022; Available at: <https://gravitas.acr.org/PPTS/>
3. Connolly ES, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage. *Stroke*. 2012;43(6):1711-1737. doi:10.1161/str.0b013e3182587839
4. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance of Computed Tomography (CT) of the extracranial head and neck. 2021; Available at: <https://gravitas.acr.org/PPTS/>
5. Demeestere J, Wouters A, Christensen S, Lemmens R, Lansberg MG. Review of Perfusion Imaging in Acute Ischemic Stroke. *Stroke*. 2020;51(3):1017-1024. doi:10.1161/strokeaha.119.028337
6. American College of Radiology. ACR-AIUM-SPR-SRU practice parameter for the performance of transcranial doppler ultrasound. 2022; Available at: <https://gravitas.acr.org/PPTS/>
7. American College of Radiology. ACR–SPR–SSR practice parameter for the performance of functional magnetic resonance imaging (fMRI) of the brain. 2022; Available at: <https://gravitas.acr.org/PPTS/>
8. American College of Radiology. ACR–SPR–SSR practice parameter for the performance and interpretation of magnetic resonance spectroscopy of the central nervous system. 2024; Available at: <https://gravitas.acr.org/PPTS/>
9. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance of intracranial magnetic resonance perfusion imaging. 2022; Available at: <https://gravitas.acr.org/PPTS/>
10. Bradley WG. Magnetic Resonance Imaging of Normal Pressure Hydrocephalus. *Seminars in Ultrasound, CT and MRI*. 2016;37(2):120-128. doi:10.1053/j.sult.2016.01.005
11. Farb R, Rovira A. Chapter 2: Hydrocephalus and CSF Disorders. In: Hodler J, Kubik-Huch RA, von Schulthess GK, eds. *Hydrocephalus and CSF Disorders-- Diseases of the Brain, Head and Neck, Spine 2020–2023: Diagnostic Imaging*. 2020 Feb 15.
12. Antipova D, Eadie L, Macaden AS, Wilson P. Diagnostic value of transcranial ultrasonography for selecting subjects with large vessel occlusion: a systematic review. *The Ultrasound Journal*. 2019;11(1). doi:10.1186/s13089-019-0143-6
13. Batra A, Clark JR, LaHaye K, et al. Transcranial Doppler Ultrasound Evidence of Active Cerebral Embolization in COVID-19. *Journal of Stroke and Cerebrovascular Diseases*. 2021;30(3):105542. doi:10.1016/j.jstrokecerebrovasdis.2020.105542
14. Purkayastha S, Sorond F. Transcranial Doppler Ultrasound: Technique and Application. *Seminars in neurology*. 2012;32(4):411-420. doi:10.1055/s-0032-1331812
15. Feng Y, Su X, Zheng C, Lu Z. The Noninvasive Diagnostic Value of MRN for CIDP: A Research from Qualitative to Quantitative. *Spine*. 2020;45(21):1506-1512. doi:10.1097/brs.0000000000003599
16. AIUM Practice Guideline for the Performance of a Transcranial Doppler Ultrasound Examination for Adults and Children. *Journal of Ultrasound in Medicine*. 2012;31(9):1489-1500. doi:10.7863/jum.2012.31.9.1489
17. Expert Panel on Pediatric Imaging, Robertson RL, Palasis S, et al. ACR Appropriateness Criteria® Cerebrovascular Disease-Child. *J Am Coll Radiol*. 2020;17(5S):S36-S54. doi:10.1016/j.jacr.2020.01.036
18. McGirr A, Vila-Rodriguez F, Cole J, et al. Efficacy of Active vs Sham Intermittent Theta Burst Transcranial Magnetic Stimulation for Patients With Bipolar Depression. *JAMA Network Open*. 2021;4(3):e210963. doi:10.1001/jamanetworkopen.2021.0963
19. Lacomis D, Gooch C. Upper motor neuron assessment and early diagnosis in ALS. *Neurology*. 2019;92(6):255-256. doi:10.1212/wnl.00000000000006867
20. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical Practice Guideline (Update): Adult Sinusitis. *Otolaryngology–Head and Neck Surgery*. 2015;152(2_suppl):S1-S39. doi:10.1177/0194599815572097
- 21.
22. Bizzi A, Blasi V, Falini A, et al. Presurgical functional MR imaging of language and motor functions: validation with intraoperative electrocortical mapping. *Radiology*. 2008;248(2):579-589. doi:10.1148/radiol.2482071214

23. Kundu B, Penwarden A, Wood JM, et al. Association of functional magnetic resonance imaging indices with postoperative language outcomes in patients with primary brain tumors. *Neurosurg Focus*. 2013;34(4):E6. doi:10.3171/2013.2.FOCUS12413
24. Lee CC, Ward HA, Sharbrough FW, et al. Assessment of functional MR imaging in neurosurgical planning. *AJNR Am J Neuroradiol*. 1999;20(8):1511-1519.
25. Medina LS, Bernal B, Dunoyer C, et al. Seizure disorders: functional MR imaging for diagnostic evaluation and surgical treatment--prospective study. *Radiology*. 2005;236(1):247-253. doi:10.1148/radiol.2361040690
26. Castillo M, Kwock L, Scatliff J, Mukherji SK. Proton MR spectroscopy in neoplastic and non-neoplastic brain disorders. *Magn Reson Imaging Clin N Am*. 1998;6(1):1-20.
27. Law M. MR spectroscopy of brain tumors. *Top Magn Reson Imaging*. 2004;15(5):291-313. doi:10.1097/00002142-200410000-00003
28. Weinberg BD, Kuruva M, Shim H, Mullins ME. Clinical Applications of Magnetic Resonance Spectroscopy in Brain Tumors: From Diagnosis to Treatment. *Radiol Clin North Am*. 2021;59(3):349-362. doi:10.1016/j.rcl.2021.01.004
29. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*. 2019;50:e344-e418.
30. Petrella JR, Provenzale JM. MR perfusion imaging of the brain: techniques and applications. *AJR Am J Roentgenol*. 2000;175:207-19

Epistaxis (HD-25)

Guideline	Page
Epistaxis (HD-25.1).....	285
References (HD-25).....	287

Epistaxis (HD-25.1)

HD.EX.0025.1.A

v2.0.2026

- After initial nasal endoscopy by ENT, if there are findings suspicious for a mass lesion, the following imaging is medically necessary:
 - CT Maxillofacial without or with contrast (CPT® 70486 or CPT® 70487) **AND/OR**
 - MRI Orbit/Face/Neck without and with contrast (CPT® 70543)
- Individuals who have failed initial management with cauterization and packing and have persistent or recurrent epistaxis despite these primary interventions, should be referred to a clinician who can evaluate the individual for their candidacy for surgical ligation or endovascular embolization.
- Prior to embolization with surgical or endovascular technique, CT Maxillofacial without contrast (CPT® 70486) **OR** CT Maxillofacial with contrast (CPT® 70487) is medically necessary when requested by the clinician performing embolization or referring for embolization.
 - If endovascular embolization is planned, the following studies are medically necessary ahead of the interventional radiologic procedure:
 - CTA Head (CPT® 70496) **OR**
 - CTA Neck (CPT® 70498)
 - CTA Head and Neck (CPT® 70471) must be substituted if performed during the same session.

Background and Supporting Information

The American Academy of Otolaryngology Head and Neck Surgery recommended, in its most recent 2020 Clinical Practice Guidelines on Epistaxis, that the clinician should perform, or should refer to a clinician who can perform, nasal endoscopy to identify the site of bleeding and guide further management in individuals with recurrent nasal bleeding, despite prior treatment with packing or cautery, or with recurrent unilateral nasal bleeding. No recommendations for advanced imaging are outlined in this guideline without the exam findings (anterior rhinoscopy and/or nasal endoscopy) or the procedural needs of the individual indicating the need for such studies. If anterior rhinoscopy does not reveal the source of bleeding, it is recommended that the clinician perform nasal endoscopy or refer to a clinician who can perform nasal endoscopy, first.

Embolization procedures have shown an average nosebleed control rate of 87%, with minor transient complications in 20% (transient nasal ischemia, temporal-facial pain or numbness, headache, swelling, jaw claudication, trismus, and access site complications not requiring additional therapy) and major complications in up to 2.1% to 3.8% (skin/nasal necrosis, permanent facial nerve paralysis, monocular blindness, and stroke).

Detailed angiography, including internal and external carotid angiography, and precise embolization techniques are required. Despite use of meticulous techniques and knowledge of external carotid-internal carotid anastomoses, blindness and stroke are the most feared complications of endovascular embolization. These complications are rare but are more frequent than in individuals undergoing surgical arterial ligation. In one study, similar transient ischemic attacks are demonstrated across all groups but there is increased risk of stroke in the groups who underwent endovascular embolization alone (0.9%) or combined with surgical ligation (1.6%) as compared with surgical ligation alone (0.1%).

Evidence Discussion (HD-25)

- The American Academy of Otolaryngology - Head & Neck Surgery (AAO-HNS) recommends, in its most recent 2020 Clinical Practice Guidelines on Epistaxis, that the clinician should perform, or should refer to a clinician who can perform, nasal endoscopy to identify the site of bleeding and to guide further management in individuals with recurrent nasal bleeding despite prior treatment with packing or cautery, or with recurrent unilateral nasal bleeding. No recommendations for advanced imaging are outlined in this AAO-HNS Guideline without the exam findings (anterior rhinoscopy and/or nasal endoscopy) or the procedural needs of the individual, directing the need for such studies. If anterior rhinoscopy does not reveal the source of bleeding, it is recommended that the clinician perform nasal endoscopy or refer to a clinician who can perform nasal endoscopy.³
- Further characterization of any mass lesions suspected on initial nasal endoscopy may be evaluated with CT Maxillofacial, either with OR without contrast (CPT[®] 70487 or CPT[®] 70486), AND/OR MRI Orbit, Face, and/or Neck without and with contrast (CPT[®] 70543).^{1,2}
- Because of the risks involved in embolization procedures (blindness, stroke, and others), CT or MRI imaging is supported prior to any planned intervention.⁴
- Embolization procedures have shown an average nosebleed control rate of 87%, with minor transient complications in 20% (transient nasal ischemia, temporal-facial pain or numbness, headache, swelling, jaw claudication, trismus, and access site complications not requiring additional therapy) and major complications in up to 2.1% to 3.8% (skin/nasal necrosis, permanent facial nerve paralysis, monocular blindness, and stroke).^{4,5}

References (HD-25)

v2.0.2026

1. Expert Panel on Neurologic Imaging.; Kirsch CFE, Bykowski J, et al. ACR Appropriateness Criteria® Sinonasal Disease. *J Am Coll Radiol*. 2017;14(11S):S550-S559. doi:10.1016/j.jacr.2017.08.041
2. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance of Computed Tomography (CT) of the extracranial head and neck. 2021; Available at: <https://gravitas.acr.org/PPTS/>
3. Tunkel DE, Anne S, Payne SC, et al. Clinical Practice Guideline: Nosebleed (Epistaxis). *Otolaryngology–Head and Neck Surgery*. 2020;162(1_suppl). doi:10.1177/0194599819890327
4. Strach K, Schröck A, Wilhelm K, et al. Endovascular treatment of epistaxis: indications, management, and outcome. *Cardiovasc Intervent Radiol*. 2011;34(6):1190-1198. doi:10.1007/s00270-011-0155-5
5. Brinjikji W, Kallmes DF, Cloft HJ. Trends in epistaxis embolization in the United States: a study of the Nationwide Inpatient Sample 2003-2010. *J Vasc Interv Radiol*. 2013;24(7):969-973. doi:10.1016/j.jvir.2013.02.035
6. Kuan EC, Wang EW, Adappa ND, et al. International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors. *Int Forum Allergy Rhinol*. 2024;14(2):149-608. doi:10.1002/alr.23262

Mastoid Disease or Ear Pain (HD-26)

Guideline	Page
Mastoid Disease or Ear Pain (HD-26.1).....	289
References (HD-26).....	292

Mastoid Disease or Ear Pain (HD-26.1)

HD.MA.026.1.A

v2.0.2026

A pertinent clinical evaluation including a detailed history, physical examination (including otoscopic examination), must be performed on any individual with ear pain prior to considering advanced imaging. Common causes of ear pain include external and middle ear infections, dental problems, sinus infection, neck problems, tonsillitis, and pharyngitis.

Indications (Any one of the following)	Medically Necessary Imaging
- Persistent ear pain without obvious cause - Clinical suspicion for complicated or invasive infection such as mastoiditis - Clinical suspicion for complications from otitis media - Clinical suspicion of mass lesion causing ear pain - Significant trauma with concern for hematoma formation - Pre-operative planning (For additional imaging requirements for cholesteatoma surgery, see bullet below) (For skull base osteomyelitis, see Skull Base Osteomyelitis (SBO) (HD-20.2))	- CT Orbits/Temporal Bone without contrast (CPT[®] 70480) OR - CT Orbits/Temporal Bone without and with contrast (CPT[®] 70482) OR - MRI Brain without and with contrast with attention to internal auditory canals (CPT[®] 70553) OR - MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543)

- Advanced imaging is not medically necessary in the overwhelming majority of individuals with ear pain.
- The following imaging is medically necessary for **pre-operative evaluation** for cholesteatoma surgery when ordered by an otolaryngologist or in consultation with the otolaryngologist:

- CT Orbits/Temporal Bone without contrast (CPT[®] 70480) **OR**
- CT Orbits/Temporal Bone without and with contrast (CPT[®] 70482)

AND/OR

- MRI Brain without and with contrast with attention to internal auditory canals (CPT[®] 70553) **OR**

- MRI Internal Auditory Canal: (IAC) MRI can be reported as a limited study with one code from the set (CPT[®] 70540, CPT[®] 70542, or CPT[®] 70543), but should not be used in conjunction with MRI Brain codes (CPT[®] 70551, CPT[®] 70552, or CPT[®] 70553) if IAC views are performed as part of the brain
- The following imaging is medically necessary one time **post-operatively** to exclude residual or regrown cholesteatoma to avoid the need for a second-look surgery when ordered by an otolaryngologist or in consultation with the otolaryngologist:
 - CT Orbits/Temporal Bone without contrast (CPT[®] 70480) **AND/OR**
 - MRI Brain without and with contrast with attention to internal auditory canals (CPT[®] 70553), **OR**
 - MRI Internal Auditory Canal: (IAC) MRI can be reported as a limited study with one code from the set (CPT[®] 70540, CPT[®] 70542, or CPT[®] 70543), but should not be used in conjunction with MRI Brain codes (CPT[®] 70551, CPT[®] 70552, or CPT[®] 70553) if IAC views are performed as part of the brain
- Eustachian Tube Dilation: (endoscopic balloon dilatation of the Eustachian Tube, to treat persistent Eustachian tube dysfunction)
 - CT Orbit/Temporal Bone without contrast (CPT[®] 70480) is medically necessary for pre-operative evaluation of possible aberrant carotid.
- Concern for petrous apex lesions when requested by the otolaryngologist or in consultation with the otolaryngologist, the following are medically necessary:
 - CT Orbit/Temporal bone without contrast (CPT[®] 70480) **OR**
 - CT Orbit/Temporal bone without and with contrast (CPT[®] 70482) **AND/OR**
 - MRI Brain without and with contrast (CPT[®] 70553) **OR**
 - MRI Internal Auditory Canal: (IAC) MRI can be reported as a limited study with one code from the set (CPT[®] 70540, CPT[®] 70542, or CPT[®] 70543), but should not be used in conjunction with MRI Brain codes (CPT[®] 70551, CPT[®] 70552, or CPT[®] 70553) if IAC views are performed as part of the brain
- For concern related to non-resolving otalgia with chronic otorrhea:
 - See **Skull Base Osteomyelitis (SBO) (HD-20.2)**

Background and Supporting Information

- Common causes of ear pain include external and middle ear infections, dental problems, sinus infection, neck problems, and referred pain from the oral pharynx.
- Clinical suspicion for complications from otitis media such as coalescent mastoiditis, resulting in: subperiosteal abscess formation/Bezold's abscess, acute facial nerve paralysis, and intracranial abscess formation.
- Cholesteatomas are expansive cysts of the middle ear filled with cellular debris. They can be congenital or arise from recurrent middle ear infections or trauma to the tympanic membrane. Hearing loss is usually conductive, although if the lesion is

large enough combined conductive and sensorineural hearing loss may be present. Otoscopic exam findings and symptoms may include a white mass in the middle ear cleft, painless drainage from the ear or chronic/recurrent ear infections.

- Petrous apex lesions/infections may include: cholesteatoma, cephalocele, mucocoele, and cholesterol granuloma and can present with symptoms of pain, hearing loss, headache, vertigo, and Cranial nerve insults (including CN V VI, VII, IX, X, XI).

Evidence Discussion (HD-26)

- Contrast enhanced CT is commonly used for evaluation of head and neck infections due to its accessibility and short examination time. MRI provides better sensitivity of soft tissue infections in the setting of cholesteatoma, when there is concern for abscess formation or intracranial complications.⁷

References (HD-26)

v2.0.2026

1. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance of Computed Tomography (CT) of the extracranial head and neck. 2021; Available at: <https://gravitas.acr.org/PPTS/>
2. Rosenfeld RM, Shin JJ, Schwartz SR, et al. Clinical Practice Guideline: Otitis Media with Effusion (Update). *Otolaryngology–Head and Neck Surgery*. 2016;154(1_suppl):S1-S41. doi:10.1177/0194599815623467
3. Micucci S, Keschner DB, Liang J. Eustachian Tube Balloon Dilation: Emerging Practice Patterns for a Novel Procedure. *Ann Otol Rhinol Laryngol*. 2018 Nov;127(11):848-855. doi: 10.1177/0003489418798858.
4. Tucci DL, McCoul ED, Rosenfeld RM, Tunkel DE, Batra PS, Chandrasekhar SS, Cordes SR, Eshraghi AA, Kaylie D, Lal D, Lee J, Setzen M, Sindwani R, Syms CA 3rd, Bishop C, Poe DS, Corrigan M, Lambie E. Clinical Consensus Statement: Balloon Dilation of the Eustachian Tube. *Otolaryngol Head Neck Surg*. 2019 Jul;161(1):6-17. doi: 10.1177/0194599819848423.
5. Treviño González JL, Reyes Suárez LL, Hernández de León JE. Malignant otitis externa: An updated review. *Am J Otolaryngol*. 2021 Mar-Apr;42(2):102894. doi: 10.1016/j.amjoto.2020.102894. Epub. 2021 Jan 5. PMID: 33429178
6. Potter GM, Siripurapu R. Imaging of Petrous Apex Lesions. *Neuroimaging Clin N Am*. 2021;31(4):523-540. doi:10.1016/j.nic.2021.06.005
7. Baba A, Kurokawa R, Kurokawa M, Reifeiss S, Policeni BA, Ota Y, Srinivasan A. Advanced imaging of head and neck infections. *J Neuroimaging*. 2023 Jul-Aug;33(4):477-492. doi: 10.1111/jon.13099. Epub 2023 Mar 15. PMID: 36922159.
8. Agarwal M, Juliano AF, Hagiwara M, et al. ACR Appropriateness Criteria® Inflammatory Ear Disease. Available at <https://acsearch.acr.org/docs/3195157/Narrative/>. American College of Radiology. New 2024

Hearing Loss and Tinnitus (HD-27)

Guideline	Page
Hearing Loss (HD-27.1).....	294
Tinnitus (HD-27.2).....	296
References (HD-27).....	298

Hearing Loss (HD-27.1)

HD.HL.0027.1.A

v2.0.2026

- An initial evaluation including hearing tests, by bedside testing or by formal audiology, is necessary to determine whether an individual's hearing loss is conductive (external or middle ear structures) or sensorineural (inner ear structures, such as cochlea or auditory nerve) hearing loss. See **General Guidelines (HD-1.0)**
- CT Orbits/Temporal Bone without (CPT[®] 70480) **OR** MRI Brain without and with contrast (with IAC views) (CPT[®] 70553) **OR** MRI Brain without contrast (CPT[®] 70551) is medically necessary for the following:
 - Mixed conductive (MC)/Sensorineural (SN) hearing loss or any sensorineural hearing loss (MRI generally preferred for SN - See *Background and Supporting Information*)
 - Unilateral fluctuating or asymmetric hearing loss
 - Cholesteatoma (see **Mastoid Disease or Ear Pain (HD-26.1)**)
 - Congenital hearing loss
 - Surgical planning, including cochlear implants (both CT Temporal Bone and MRI Brain for surgical planning if requested by surgeon or any provider in consultation with the surgeon)
 - Hearing loss with vertigo (see **Dizziness/Vertigo (HD-23.1)**)
- CT Orbits/Temporal Bone without contrast (CPT[®] 70480) is medically necessary for the following:
 - Conductive hearing loss should have a CT Temporal Bone initially in the absence of an evident mass in the middle ear
- CT Orbits/Temporal Bone with contrast (CPT[®] 70481) is medically necessary for the following:
 - Glomus tumors or other vascular tumors of the middle ear, and/or surgical planning
 - Acquired sensorineural hearing loss if MRI unavailable or contraindicated
- Limited MRI of the internal auditory canals (CPT[®] 70540, CPT[®] 70542, or CPT[®] 70543) is medically necessary when requested by the provider in place of a complete MRI Brain. Note: Limited MRI codes should not be used in addition to MRI Brain codes; IAC views are performed as additional sequences as part of the brain study (see **General Guidelines – Anatomic Issues (HD-1.1)**)
- FIESTA protocol can be performed with MRI Brain without contrast (CPT[®] 70551) or limited MRI with attention to internal auditory canals.

Background and Supporting Information

- Sensorineural (SN) hearing loss – MRI is generally preferable to CT. CT Temporal bone is medically necessary in post-traumatic SN hearing loss, to evaluate for bony

remodeling of the IAC due to vestibular schwannoma and labyrinthine ossification resulting from prior infection and for consideration of otospongiosis, a common cause of MC and SN hearing loss.

Evidence Discussion (HD-27.1)

- A complete history and otologic exam should be performed prior to advanced imaging for the workup of hearing loss. Formal audiometric testing is also necessary to determine whether the hearing loss is conductive, sensorineural, or mixed.^{3,6}
- MRI brain is generally preferred for sensorineural and mixed hearing loss, particularly for unilateral hearing loss, congenital loss, or for surgical planning.^{1,4,5}
- CT orbits/temporal bone is preferred for cases of conductive hearing loss, trauma, or suspected bony or middle ear disorders.^{1,4,5}
- Both may be supported for surgical planning (cochlear implants, petrous apex disorders).^{1,4,5}
- 3D-Fast imaging employing steady state acquisition (3D-FIESTA) demonstrates significantly higher spatial resolution with superior imaging contrast between cranial nerves and CSF with a shorter acquisition time than conventional MRI scan.⁷

Tinnitus (HD-27.2)

HD.HL.0027.2.A

v2.0.2026

- A hearing evaluation is not required prior to imaging for tinnitus.
- The history in individuals with tinnitus should include a description of the tinnitus (episodic or constant, pulsatile or non-pulsatile, rhythmicity, pitch, quality of the sound), as well as inciting or alleviating factors. Continuous and pulsatile tinnitus are more concerning for an underlying and significant disorder. Audiometric assessment can be used as initial diagnostic testing particularly in individuals with tinnitus that is unilateral, persistent (>6 months) or associated with hearing difficulties (see **General Guidelines (HD-1.0)**)

Indications (Any one of the following)	Medically Necessary Imaging
• Clinical suspicion of mass lesion causing tinnitus • Asymmetric or unilateral non-pulsatile tinnitus (i.e., tinnitus that localizes to one ear) • Tinnitus associated with focal neurologic abnormalities, including asymmetric hearing loss • Persistent tinnitus after recent significant trauma. • Pulsatile tinnitus with or without concern for vascular lesion	• CT Orbits/Temporal Bone without contrast (CPT[®] 70480) OR • CT Orbits/Temporal Bone without and with contrast (CPT[®] 70482) OR • MRI Brain without and with contrast with attention to internal auditory canals (CPT[®] 70553) OR • MRI Brain without contrast with attention to internal auditory canals (CPT[®] 70551) OR • MRI Orbits/Face/Neck without contrast (CPT[®] 70540), with contrast CPT[®] 70542, or without and with contrast (CPT[®] 70543)
• Pulsatile tinnitus • Suspicion for vascular lesions	• MRA Head (CPT[®] 70544, CPT[®] 70545 OR CPT[®] 70546) OR • CTA Head (CPT[®] 70496) AND/OR • MRA Neck (CPT[®] 70547, CPT[®] 70548 or CPT[®] 70549) OR • CTA Neck (CPT[®] 70498) ◦ CTA Head and Neck (CPT[®] 70471) must be substituted if performed during the same session,

- Imaging is not medically necessary for bilateral non-pulsatile tinnitus without other neurologic signs or symptoms

- Limited MRI of the internal auditory canals (CPT[®] 70540, CPT[®] 70542, or CPT[®] 70543) is medically necessary when requested by the provider in place of a complete MRI Brain. Note: Limited MRI codes should not be used in addition to MRI Brain codes; IAC views are performed as additional sequences as part of the brain study (see **General Guidelines – Anatomic Issues (HD-1.1)**)
- CT and MR Venography (CTV and MRV) are reported with the same codes as the CTA/MRA counterpart. If arterial and venous CT or MR studies are both performed in the same session, only one CPT[®] code should be used to report both procedures.

Background and Supporting Information

- Non-pulsatile tinnitus may be described as ringing, buzzing, or clicking sensations which is constant and non-synchronous.
- Pulsatile tinnitus is a repetitive sound coinciding with the individual's heartbeat. The symptom may be subjective or objective.

Evidence Discussion (HD-27.2)

- A targeted history and clinical examination should be performed as the initial evaluation of an individual with tinnitus and determination as to whether the tinnitus is bothersome or not should be made before any imaging is considered.^{3,6}
- Both MRI and CT have utility in diagnosing the etiology of tinnitus, particularly for concerns of mass lesions, or for tinnitus in conjunction with hearing loss or trauma.^{1,4,5}
- MRA or CTA of the head and neck are also useful in the workup of pulsatile tinnitus or for suspicion of a vascular lesion.^{1,4,5}

References (HD-27)

v2.0.2026

1. Expert Panel on Neurologic Imaging: Sharma A, Kirsch CFE, et al. ACR Appropriateness Criteria® Hearing Loss and/or Vertigo. *J Am Coll Radiol*. 2018;15(11S):S321-S331. doi:10.1016/j.jacr.2018.09.020
2. Isaacson J, Vora NM. Differential diagnosis and treatment of hearing loss. *American Family Physician*. 2003 Sep 15;68(6):1125-32
3. Chandrasekhar SS, Do BST, Schwartz SR, et al. Clinical Practice Guideline: Sudden Hearing Loss (Update). *Otolaryngology–Head and Neck Surgery*. 2019;161(1_suppl). doi:10.1177/0194599819859885
4. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance of Computed Tomography (CT) of the extracranial head and neck. 2021; Available at: <https://gravitas.acr.org/PPTS/>
5. Expert Panel on Neurologic Imaging: Jain, V, Policeni B, et al. ACR Appropriateness Criteria® Tinnitus. 2023 <https://acsearch.acr.org/docs/3094199/Narrative/>
6. Tunkel DE, Bauer CA, Sun GH, et al. Clinical practice guideline: tinnitus executive summary. *Otolaryngol Head Neck Surg*. 2014;151(4):533-541. doi:10.1177/0194599814547475
7. Zou J, Hirvonen T. "Wait and scan" management of patients with vestibular schwannoma and the relevance of non-contrast MRI in the follow-up. *Journal of Otology*. 2017;12(4):174-184. doi:10.1016/j.joto.2017.08.002

Neurosurgical Imaging (HD-28)

Guideline	Page
Neurosurgical Imaging (HD-28.1)	300
Neuronavigation (HD-28.2)	301
Post-Operative Imaging (HD-28.3)	302
Evidence Discussion (HD-28)	303
References (HD-28)	304

Neurosurgical Imaging (HD-28.1)

HD.NI.0028.1.A**v2.0.2026**

- Typically, advanced imaging for monitoring disease for mass lesions occurs after biopsy (histologic) confirmation. This ensures appropriate determination related to phase of oncology imaging and alignment to appropriate diagnosis-specified guideline section.
 - However, repeat imaging by neurosurgeons or others of the management team for areas of the central nervous system (CNS) where permanent neurologic damage would be excessive with even a limited biopsy attempt is medically necessary.
 - Examples would include, but are not exclusive to: medically fragile individual, and tumors of the brainstem, eloquent areas of the brain, deep gray matter areas of the brain (ex. thalamus), and cavernous sinus.
- Repeat diagnostic head imaging is medically necessary when:
 - previous diagnostic head imaging is determined to be inadequate or additional imaging sequences/protocols are required by the neurosurgeon or the treatment team
 - prior imaging is greater than 6 months old

Neuronavigation (HD-28.2)

HD.NI.0028.2.A

v2.0.2026

- Neurosurgical navigation is “image-based” meaning that the necessary pre-operative CT and MRI images are used for navigation in the operating room (image acquisition). Accurate registration (a process to match the pre-operative images to the individual position) of pre-operative images is necessary to guide surgery regardless of the navigation system that is used. Registration can be point-based or surface matched routines to allow the surgeon to view the overlapping data sets and the current situation to allow navigation.
- The process of registration for neuronavigation via the acquisition of pre-operative CT and MRI images does not require a radiologist interpretation.
 - Diagnostic imaging codes are not medically necessary for the purpose of registration for neuronavigation.
 - Can be referenced by proprietary brand systems such as Brainlab or Stealth imaging procedures
 - See **Unlisted Procedures/Therapy Treatment Planning (Preface-4.3)** in the Preface Imaging Guidelines and **Unlisted Procedure Codes (ONC-1.5)** in Oncology in the Oncology Imaging Guidelines
- Advanced imaging for neuronavigation (image acquisition for registration for surgery) is medically necessary with one of each of the following as unlisted codes apply:
 - Unlisted MRI procedure code (CPT[®] 76498)
 - Unlisted CT procedure code (CPT[®] 76497)
 - Due to variances with techniques currently available for neuronavigation, the following are medically necessary:
 - CTA Head without and with contrast (CPT[®] 70496) or MRA Head (CPT[®] 70544, CPT[®] 70545 or CPT[®] 70546) (to avoid arterial and venous structures)
 - 3D (CPT[®] 76377 or CPT[®] 76376) (see **General Guidelines – Other Imaging Situations (HD-1.7)**)
 - Diagnostic imaging codes are only medically necessary if radiological supervision and interpretation of imaging is necessary with supporting documentation
 - MRI Brain without contrast (CPT[®] 70551) **OR** MRI Brain with contrast (CPT[®] 70552) **OR** MRI Brain without and with contrast (CPT[®] 70553) (contrast as requested) **AND/OR** CT Head without contrast (CPT[®] 70450) **OR** CT Head with contrast (CPT[®] 70460) **OR** CT Head without and with contrast (CPT[®] 70470) (contrast as requested)

Post-Operative Imaging (HD-28.3)

HD.NI.0028.3.A

v2.0.2026

- Post-operative imaging including MRI Brain without contrast (CPT® 70551), or MRI Brain with contrast (CPT® 70552), or MRI Brain without and with contrast (CPT® 70553) (contrast as request) or CT Head without contrast (CPT® 70450), or CT Head with contrast (CPT® 70460), or CT Head without and with contrast (CPT® 70470) (contrast as request) is medically necessary per neurosurgeon's or in concert with management team's request that includes, but not exclusive to the following indications:
 - Within 24-72 hours following brain surgery including to document the need for repeat surgery or if adjuvant intervention is necessary, concern or rule out for complication(s), evaluation if incomplete resection vs. consideration for plan for gross resection
 - Signs or symptoms indicating concern of clinical deterioration
 - Development of new neurological signs or symptoms
 - Follow-up on blood products, edema, and/or concern of cerebrospinal fluid leak
 - Follow-up imaging per condition-based guideline
- See additional condition-based guidelines:
 - Pediatric Neurosurgeries
 - See **Special Imaging Studies in Evaluation for Epilepsy Surgery (PEDHD-6.3)** in the Pediatric Head Imaging Guidelines
 - See **Modality General Considerations (PEDONC-1.3)** and **Pediatric CNS Tumors (PEDONC-4)** in the Pediatric and Special Populations Oncology Guidelines
 - Epilepsy
 - See **Perioperative Evaluations for Drug-Resistant Epilepsy (HD-9.2)**
 - Movement Disorders
 - See **Movement Disorders (HD-15.1)**
 - Pituitary or Sella Surgery
 - See **Pituitary (HD-19.1)**
 - Acoustic Neuroma and Other Cerebellopontine Angle Tumors
 - See **Acoustic Neuroma and Other Cerebellopontine Angle Tumors (HD-33.1)**
 - Central Nervous System Tumors
 - See **Primary Central Nervous System Tumors (ONC-2)** and **Brain Metastases (ONC-31.3)** in the Oncology Imaging Guidelines

Evidence Discussion (HD-28)

v2.0.2026

- Imaging modalities for neurosurgical planning include MRI Brain and CT Head, along with vascular imaging.
- MRI Brain is the preferred modality for the evaluation of intracranial neoplasms and other conditions affecting the brain parenchyma, meninges or cranium, due to its superior soft tissue resolution when compared to CT Head.¹⁹
- CT Head is the preferred modality for evaluation of bony structures in the pre-operative setting.²²
- For localization of relevant vascular anatomy prior to surgery, MRI angiography (MRA) head and neck or CT angiography (CTA) head and neck, may be appropriate.^{20,21}
- Pre-surgical navigational imaging, whether by CT or MRI, allows a spatially accurate anatomical individual model for use in the treatment-planning process.^{1,18}
- The requirements for surgical planning images differ from the requirements for diagnostic images, especially regarding the spatial accuracy of the images in the stereotactic coordinates used for localization and targeting.^{1,18}
- Navigation based on an immediate pre-operative scan optimizes the accuracy of data used for initial surgical planning.¹ Navigation systems reduce length of surgery, lower incidence of wound infection and shorten length of post-operative hospital stay.²³
- For post-operative imaging, CT Head is also useful for follow-up of intracranial hemorrhage, edema, hydrocephalus, shunts, and general post-operative follow-up. CT Head has the benefit of providing rapid evaluation if a post-operative complication is suspected.¹⁹ Post-operative MRI Brain provides superior soft tissue resolution in less urgent scenarios.²²

References (HD-28)

v2.0.2026

1. Orringer DA, Golby A, Jolesz F. Neuronavigation in the surgical management of brain tumors: current and future trends. *Expert Review of Medical Devices*. 2012;9(5):491-500. doi:10.1586/erd.12.42
2. Rughani A, Schwalb JM, Sidiropoulos C, et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Subthalamic Nucleus and Globus Pallidus Internus Deep Brain Stimulation for the Treatment of Patients With Parkinson's Disease: Executive Summary. *Neurosurgery*. 2018;82(6):753-756. doi:10.1093/neuros/nyy037
3. Kotecha R, Sahgal A, Rubens M, et al. Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion. *Neuro-Oncology*. 2019;22(3):318-332. doi:10.1093/neuonc/noz225
4. Xiao Y, Lau JC, Hemachandra D, Gilmore G, Khan AR, Peters TM. Image Guidance in Deep Brain Stimulation Surgery to Treat Parkinson's Disease: A Comprehensive Review. *IEEE Transactions on Biomedical Engineering*. 2021;68(3):1024-1033. doi:10.1109/tbme.2020.3006765
5. Delev D, Quesada CM, Grote A, et al. A multimodal concept for invasive diagnostics and surgery based on neuronavigated voxel-based morphometric MRI postprocessing data in previously nonlesional epilepsy. *Journal of Neurosurgery*. 2018;128(4):1178-1186. doi:10.3171/2016.12.jns161676
6. Yang I, Udawatta M, Prashant GN, et al. Stereotactic Radiosurgery for Neurosurgical Patients: A Historical Review and Current Perspectives. *World Neurosurgery*. 2019;122:522-531. doi:10.1016/j.wneu.2018.10.193
7. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance of Computed Tomography (CT) of the extracranial head and neck. 2021; Available at: <https://gravitas.acr.org/PPTS/>
8. Fitzpatrick JM. The role of registration in accurate surgical guidance. *Proc Inst Mech Eng H*. 2010;224(5):607-622. doi:10.1243/09544119JEIM589
9. Maurer CR, Fitzpatrick JM, Wang MY, Galloway RL, Maciunas RJ, Allen GS. Registration of head volume images using implantable fiducial markers. *IEEE Transactions on Medical Imaging*. 1997;16(4):447-462. doi:10.1109/42.611354
10. Pfisterer WK, Papadopoulos S, Drumm DA, Smith K, Preul MC. Fiducial Versus Nonfiducial Neuronavigation Registration Assessment and Considerations of Accuracy. *Operative Neurosurgery*. 2008;62(suppl_1):ONS201-ONS208. doi:10.1227/01.neu.0000317394.14303.99
11. Gumprecht HK, Widenka DC, Lumenta CB. Brain Lab VectorVision Neuronavigation System: Technology and Clinical Experiences in 131 Cases. *Neurosurgery*. 1999;44(1):97-104. doi:10.1097/00006123-199901000-00056
12. Grunert P, Darabi K, Espinosa J, Filippi R. Computer-aided navigation in neurosurgery. *Neurosurgical Review*. 2003;26(2):73-99. doi:10.1007/s10143-003-0262-0
13. Mezger U, Jendrewski C, Bartels M. Navigation in surgery. *Langenbeck's Archives of Surgery*. 2013;398(4):501-514. doi:10.1007/s00423-013-1059-4
14. Omay SB, Barnett GH. Surgical navigation for meningioma surgery. *Journal of Neuro-Oncology*. 2010;99(3):357-364. doi:10.1007/s11060-010-0359-6
15. Maciunas R. Computer-assisted neurosurgery. *Clin Neurosurg*. 2006;(53):267-271
16. Kelly PJ, Kall BA, Goerss SJ. Results of Computed Tomography-based Computer-assisted Stereotactic Resection of Metastatic Intracranial Tumors. *Neurosurgery*. 1988;22(1):7-17. doi:10.1227/00006123-198801000-00002
17. Wang MY, Maurer CR, Fitzpatrick JM, Maciunas RJ. An automatic technique for finding and localizing externally attached markers in CT and MR volume images of the head. *IEEE Transactions on Biomedical Engineering*. 1996;43(6):627-637. doi:10.1109/10.495282
18. American College of Radiology. ACR-ARS practice parameter for the performance of brain stereotactic radiosurgery. 2021; Available at: <https://gravitas.acr.org/PPTS/>
19. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance and interpretation of Magnetic Resonance Imaging (MRI) of the brain. 2024; Available at: <https://gravitas.acr.org/PPTS/>
20. American College of Radiology. ACR-ASNR-SNIS-SPR Practice Parameter for the performance of cervicocerebral Magnetic Resonance Angiography (MRA). 2020; Available at: <https://gravitas.acr.org/PPTS/>

21. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance and interpretation of cervicocerebral Computed Tomography Angiography (CTA). 2020; Available at: <https://gravitas.acr.org/PPTS/>
22. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance of computed tomography (CT) of the Head. 2020; Available at: <https://gravitas.acr.org/>
23. Khoshnevisan A, Allahabadi NS. Neuronavigation: principles, clinical applications and potential pitfalls. *Iran J Psychiatry*. 2012;7(2):97-103.

Sinus and Facial Imaging (HD-29)

Guideline	Page
Sinus and Facial Imaging (HD-29.1)	307
Evidence Discussion (HD-29.1).....	311
References (HD-29).....	312

Sinus and Facial Imaging (HD-29.1)

HD.SI.0029.1.A

v2.0.2026

- CT Maxillofacial without contrast (CPT[®] 70486) or limited CT Sinus without contrast (CPT[®] 76380) is medically necessary for ANY of the following:
 - Acute sinusitis without resolution of symptoms after a minimum of 4 weeks of treatment (treatment can include an appropriate course and duration of empiric oral antibiotic, topical intranasal steroid, and/or nasal saline rinses.)
 - Concern for potential or suspected complicated sinusitis, which is sinusitis with actual or threatened orbital or intracranial extension
 - Recurrent sinusitis (4 or more episodes of acute bacterial rhinosinusitis within the past 12 months without symptoms or signs between episodes)
 - In practice, recurrent acute exacerbations of chronic rhinosinusitis are seen as well as recurrent acute rhinosinusitis with disease free intervals between the acute episodes. CT Maxillofacial without contrast (CPT[®] 70486) may still be medically necessary under chronic sinusitis definitions.
 - Suspicion of chronic sinusitis (**Note:** A trial of antibiotic therapy is not required prior to imaging if individual meets criteria for chronic sinusitis)
 - Chronic sinusitis is suspected when **BOTH** of the following are met:
 - At least two of the following on history and physical exam:
 - Mucopurulent drainage
 - Nasal obstruction or congestion
 - Facial pain, pressure, and/or fullness (may involve the anterior face, periorbital region, or manifest with headache that is localized or diffuse)
 - Decreased sense of smell (see **Taste and Smell Disorders (HD-2.1)** if anosmia, hyposmia, or dysosmia is an isolated symptom)
- AND**
 - The aforementioned findings on history and physical exam have been present for at least 12 weeks
 - Follow-up on incidentally noted sinus pathology (i.e., mucosal thickening, partial opacification of a sinus, or other indeterminate finding in incompletely visualized sinuses) on other imaging studies not performed for the purpose of evaluating sinus pathology, such as MRI Brain for headache, when requested by ENT for clinical correlation.
- Studies requested for the sole purpose of navigation for sinus surgery should be coded CPT[®] 77011 (CT guidance for stereotactic localization).

- It is not appropriate to report both CPT[®] 70486 and CPT[®] 77011 for the same CT stereotactic localization imaging session (see **CT-, MR-, or Ultrasound-Guided Procedures (Preface-4.2)** in the Preface Imaging Guidelines).
- For unexplained cough as the main symptom, and suspected Upper Airway Cough Syndrome (UACS) as the etiology, see **Cough (CH-3.1)** in the Chest Imaging Guidelines.
- For the immunocompromised individual with symptoms of sinusitis, the following are medically necessary:
 - CT Maxillofacial (contrast level as requested) when ordered by the surgeon or in consultation with the surgeon (i.e., ENT or ophthalmologist)
 - CT Maxillofacial with contrast (CPT[®] 70487) when there is suspicion for ANY of the following:
 - Orbital or facial cellulitis
 - Proptosis
 - Abnormal visual examination
 - Ophthalmoplegia
 - Fungal or vascular lesions visualized in nasal cavity
- CT Maxillofacial without contrast (CPT[®] 70486) **OR** CT Maxillofacial with contrast (CPT[®] 70487) **OR** MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543) is medically necessary for the conditions below. However, CT Maxillofacial without contrast (CPT[®] 70486) may also be requested with MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543) for surgical planning or osseous involvement.
 - Sinonasal obstruction, polyp, or suspected mass
 - Suspected orbital complication
 - Suspected invasive fungal sinusitis
 - Cystic fibrosis
 - Osteomyelitis and odontogenic infections, see **Skull Base Osteomyelitis (SBO) (HD-20.2)** and **Dental/Periodontal/Maxillofacial Imaging (HD-30.2)** for additional imaging modalities
- CT Maxillofacial without contrast (CPT[®] 70486) **AND** MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543) are medically necessary when ordered by the ENT/ specialist prior to planned biopsy of an intranasal mass — the extent and origin of which could not be determined by complete rhinologic exam alone
- MRI Brain without and with contrast (CPT[®] 70553) is medically necessary for suspected intracranial complication
- CT Orbits/Temporal bone without contrast (CPT[®] 70480) or CT Orbits/Temporal bone with contrast (CPT[®] 70481) is medically necessary performed alone or added to CT Maxillofacial for:
 - suspected orbital complications
- For skull base osteomyelitis (SBO), see **Skull Base Osteomyelitis (SBO) (HD-20.2)**

- Repeat imaging is medically necessary for ANY of the following scenarios:
 - An ENT specialist or any provider in consultation with an ENT specialist requests the imaging **and** ONE or more of the following:
 - There has been a follow-up visit since the previous imaging and there is no improvement after an additional 3 weeks of conservative treatment after initial imaging was completed:
 - The following imaging is medically necessary: CT Maxillofacial without contrast (CPT® 70486) **OR** limited CT Sinus without contrast (CPT® 76380)
 - There is a new abnormality on exam such as obstructing mass
 - The following imaging is medically necessary: CT Maxillofacial without contrast (CPT® 70486) **OR** CT Maxillofacial with contrast (CPT® 70487)
 - If sinus surgery is planned (including but not limited to Balloon Sinus Ostial Dilation or Functional Endoscopic Sinus Surgery) **AND** the most recent diagnostic CT Maxillofacial without contrast (CPT® 70486) is greater than 6 months old **OR** there is a change in clinical status as described above (i.e. interval completion of provider-prescribed medical management after the last CT was performed), a repeat diagnostic CT Maxillofacial without contrast (CPT® 70486) is supported for surgical planning.
 - Repeat CT Maxillofacial solely for the use of navigation during the sinus surgery (i.e., the most recent diagnostic CT Maxillofacial performed within the prior six months was only inadequate due to lacking anatomic landmarks or insufficient thinness of cuts) should be requested with CPT® 77011, not the diagnostic CPT® 70486.
 - 3D Rendering (CPT® 76376 or CPT® 76377) should not be reported in conjunction with CPT® 77011 (or CPT® 70486 if used). The procedure inherently generates a 3D dataset.
- Complications of ABRS (acute bacterial rhinosinusitis) are suspected based on:
 - Any constellation of symptoms worrisome for intracranial extension of infection or meningitis (i.e., severe headache, photophobia, fever, neck stiffness)
 - Severe headache
 - Facial Swelling
 - Cranial nerve palsies
 - Orbital signs (cellulitis, impaired extraocular motility, decrease in vision or proptosis)
- Complications of ABRS are best assessed using iodine contrast-enhanced CT Maxillofacial with contrast (CPT® 70487) **OR** gadolinium-based MR imaging (MRI Orbits/Face/Neck without and with contrast (CPT® 70543) to identify extra-sinus extension or involvement; thus, this imaging is medically necessary.

- CT Maxillofacial without contrast (CPT[®] 70486) may also be requested with MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543) for surgical planning or osseous involvement.
- Suspected complications are the only medically necessary indication for MR imaging of the paranasal sinuses in the setting of ABRs.

For additional medical necessity criteria for CT Maxillofacial, see Cone Beam Imaging, see **Cone Beam Computed Tomography (CBCT) (HD-24.7)** and **Dental/Peridontal/Maxillofacial Imaging (HD-30.2)**

Evaluation of potential candidates for Eustachian Tube balloon dilation procedure is with a one-time CT of the temporal bone without contrast (CPT[®] 70480). See medical necessity discussion in **Mastoid Disease or Ear Pain (HD-26.1)**. CT Sinus/Maxillofacial irrespective of contrast level is not supported if the sole indication for medical necessity is to evaluate a potential candidate for Eustachian Tube balloon dilation procedure, without meeting other HD-29.1 medical necessity criteria.

Background and Supporting Information

- Rhinosinusitis is defined as inflammation of the nasal cavity and adjacent paranasal sinuses. Acute sinusitis refers to symptom duration <4 weeks, subacute 4 to 12 weeks, and chronic >12 weeks. Complicated sinusitis refers to symptoms suggesting spread of disease into adjacent structures, including orbital or intracranial complications.
- There is no evidence to support advanced imaging of acute (<4 weeks) and subacute (4 to 12 weeks) uncomplicated rhinosinusitis.
- There is no evidence to support routine follow-up advanced imaging after treatment with clinical improvement of sinusitis.

Evidence Discussion (HD-29.1)

v2.0.2026

- The American Academy of Otolaryngology – Head & Neck Surgery (AAO-HNS) recommended that clinicians should not obtain radiographic imaging for individuals with suspected uncomplicated Acute Rhinosinusitis (ARS), with imaging reserved for cases with clinically suspected complication. ARS refers to inflammation of the nasal cavity and paranasal sinuses lasting <4 weeks' duration.¹
- Contrasted CT Maxillofacial is first line imaging for rhinosinusitis with suspected complications (orbital or intracranial). There is up to 91% accuracy with CT to detect orbital complications vs clinical exam alone. CT also is preferred for surgical planning. However, CT is often more useful for surgical planning and easier to perform. Non-contrasted CT sinus is not preferred but may be useful for surgical navigation. There is no relevant literature to support pre- and post-contrast CT imaging. MRI head or orbits/face/neck can be complementary with CT. MRI is more accurate than CT in the evaluation of soft tissues regarding intra-orbital and intracranial complications.^{3,4}
- Chronic rhinosinusitis, acute recurrent bacterial sinusitis, non-invasive fungal sinusitis, and/or sinonasal polyposis are best evaluated initially with non-contrast CT Maxillofacial. CT is critical for surgical planning. Contrast is not necessary unless complications are suspected. MRI is not useful as the first-line study because of the lack of bony detail. In select cases, evaluation with MRI without and with IV contrast may be helpful to differentiate fluid secretions from inflamed mucosa and exclude an underlying obstructing mass.^{3,4}
- Urgent CT Maxillofacial, either without or with IV contrast is first line imaging for any suspected invasive fungal sinusitis, as delay in diagnosis and surgical debridement could increase the already high risk of mortality. In cases of invasive fungal sinusitis, MRI without and with IV contrast of the head and/or orbits/face/neck is adjunctive to look for invasion into surrounding soft tissues as well as vascular complications.^{3,4}
- CT and MRI are considered complimentary imaging modalities in the evaluation of a sinonasal mass—localizing and characterizing the lesions to determine their extent for treatment planning. If an MRI is planned, the CT may be performed without IV contrast since the main purpose of the CT is to evaluate osseous involvement.^{3,4}

References (HD-29)

v2.0.2026

1. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical Practice Guideline (Update): *Adult Sinusitis*. Otolaryngology–Head and Neck Surgery. 2015;152(2_suppl):S1-S39. doi:10.1177/0194599815572097
2. Desrosiers M, Evans GA, Keith PK, et al. Canadian clinical practice guidelines for acute and chronic rhinosinusitis. *Allergy, Asthma & Clinical Immunology*. 2011;7(1). doi:10.1186/1710-1492-7-2
3. Expert Panel on Neurological Imaging, Hagiwara M, Policeni B, et al. ACR Appropriateness Criteria® Sinonasal Disease: 2021 Update. *J Am Coll Radiol*. 2022;19(5S):S175-S193. doi:10.1016/j.jacr.2022.02.011.
4. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance of Computed Tomography (CT) of the extracranial head and neck. 2021; Available at: <https://gravitas.acr.org/PPTS/>
5. Abdalkader M, Xie J, Cervantes-Arslanian A, Takahashi C, Mian AZ. Imaging of Intracranial Infections. *Seminars in Neurology*. 2019;39(03):322-333. doi:10.1055/s-0039-1693161
6. Wu D, Bleier B, Wei Y. Definition and characteristics of acute exacerbation in adult patients with chronic rhinosinusitis: a systematic review. *J Otolaryngol Head Neck Surg*. 2020;49(1):62. Published 2020 Aug 18. doi:10.1186/s40463-020-00459-w
7. Micucci S, Keschner DB, Liang J. Eustachian Tube Balloon Dilation: Emerging Practice Patterns for a Novel Procedure. *Ann Otol Rhinol Laryngol*. 2018 Nov;127(11):848-855. doi: 10.1177/0003489418798858.
8. Tucci DL, McCoul ED, Rosenfeld RM, et al. Clinical Consensus Statement: Balloon Dilation of the Eustachian Tube. *Otolaryngol Head Neck Surg*. 2019;161(1):6-17. doi:10.1177/0194599819848423
9. Kuan EC, Wang EW, Adappa ND, et al. International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors. *Int Forum Allergy Rhinol*. 2024;14(2):149-608. doi:10.1002/alr.23262

Temporomandibular Joint Disease (TMJ) and Dental/ Periodontal/Maxillofacial Imaging (HD-30)

Guideline	Page
Temporomandibular Joint Disease (TMJ) (HD-30.1)	314
Dental/Periodontal/Maxillofacial Imaging (HD-30.2)	316
References (HD-30)	318

Temporomandibular Joint Disease (TMJ) (HD-30.1)

HD.TJ.0030.1.A

v2.0.2026

- MRI TMJ (CPT[®] 70336) is the diagnostic study of choice and is medically necessary for those who fail a minimum of 6 weeks of non-surgical treatment **AND** who are actively being considered for TMJ surgery.
 - The exception to the conservative management and surgical consideration requirement above includes the need to evaluate a recent trauma, dislocation, severe malocclusion, dental infection, or abscess.
- CT Maxillofacial without contrast (CPT[®] 70486) or without and with contrast (CPT[®] 70488) when there is suspicion of bony involvement based on prior x-ray or MRI
- Ultrasound (CPT[®] 76536) is medically necessary to look for the presence of a joint effusion and to evaluate cartilage and disk displacement with open and closed mouth imaging and to guide injections
- For TMJ imaging in individuals with Juvenile Idiopathic Arthritis (see **Temporomandibular Joint (TMJ) Imaging in Children (PEDHD-25)** in the Pediatric Head Imaging Guidelines)
 - MRI TMJ (CPT[®] 70336) is medically necessary annually for detecting silent TMJ arthritis in children and young adults with juvenile idiopathic arthritis as requested by a rheumatologist and/or oral/maxillofacial surgeon (OMS) and/or any provider in consultation with a rheumatologist or OMS.
 - Repeat imaging with MRI TMJ (CPT[®] 70336) in individuals with JIA is medically necessary for any of the following:
 - Change in signs or symptoms suggesting progression of disease
 - To monitor the effects of treatment¹¹
 - Bone Scintigraphy/Bone Scan 3 Phase Study (CPT[®] 78315) in individuals over 12 years of age is medically necessary in anticipation or consideration of surgery.
- Jaw Asymmetry - Unilateral condylar hyperplasia is manifested by slow growth in areas of the mandible causing facial asymmetry. It is usually a self-limiting condition seen predominantly in individuals 12 to 30 years of age.
 - CPT[®] 78315 Bone Scan 3 Phase Study is medically necessary in anticipation or consideration of surgery.

Evidence Discussion (HD-30.1)

- MRI is preferred for evaluation of the temporomandibular joint (TMJ) due to its superior contrast resolution and its ability to acquire dynamic imaging for demonstration of the functionality of the joint.^{3,10}
- MRI is the imaging modality of choice for the diagnosis of internal derangement with an accuracy of 95% in assessing the disc position and form and 93% accuracy in assessing the osseous changes.³
- MRI is reserved for individuals with persistent symptoms in whom conservative measures have been ineffective, or in those with suspected internal joint derangement.^{2,8,9} Imaging the TMJ prematurely may lead to harms including unnecessary surgery.⁷
- CT is the alternative modality for evaluating bony anatomy of the TMJ, fractures, degenerative changes, erosions, infections, congenital anomalies, acute and chronic inflammatory conditions, pre-operative evaluation and follow-up after surgery.^{3,5,10}
- For pre-operative planning of unilateral condylar hyperplasia, bone scintigraphy is useful to predict ongoing condylar growth.¹⁶
- The diagnosis of chronic rheumatoid arthritis of the TMJ is established with contrast-enhanced MRI.¹¹ It is the preferred imaging study for diagnosis, disease progression, treatment monitoring and annual surveillance of TMJ arthritis in juvenile idiopathic arthritis (JIA).¹¹

Dental/Periodontal/Maxillofacial Imaging (HD-30.2)

HD.TJ.0030.2.A

v2.0.2026

- Initial imaging with plain x-rays/dental x-rays is required.
- Cone beam CT is required for surgical planning and is, therefore, medically necessary for the potential indications listed below.
- Potential indications include but are not limited to:
 - Osteomyelitis and odontogenic infections (x-ray **NOT** required)
 - Bisphosphonate-related osteonecrosis of the jaw (x-ray **NOT** required)
 - Impacted teeth
 - Supernumerary teeth
 - Dentoalveolar trauma
 - Root resorption
 - Foreign body
 - Odontogenic cysts, tumors, or other jaw pathology
 - Orthognathic surgery for dentofacial anomalies
 - Maxillofacial bone graft planning
 - Dental implants related to tooth loss from injury, trauma, or jaw pathology such as cysts, tumors, or cancer
 - Post-operative imaging, including dental implants
- Cone Beam CT: Report with CPT[®] Codes: CPT[®] 70486, CPT[®] 70487, CPT[®] 70488, CPT[®] 70480, CPT[®] 70482 (see **Cone Beam Computed Tomography (CBCT) (HD-24.7)**)
- 3-D rendering (CPT[®] 76376 or CPT[®] 76377) should **NOT** be reported separately
- Cone beam CT (CBCT) may also be called i-CAT scanner or mini-CAT scanner
- For cleft palate indications (see **Other Indications for Sinus Imaging (PEDHD-5.6)**)
- For salivary gland indications (see **Salivary Gland Disorders (Neck-11.1)**)

Background and Supporting Information

Dental x-rays include panoramic, periapical, and/or occlusal x-rays.

Evidence Discussion (HD-30.2)

- CT is the radiologic modality for evaluating the bony anatomy of the head, acute and chronic inflammatory conditions, paranasal sinuses, pre-operative evaluation and follow-up after surgery.^{1,5}

- Recommendations by the American Association of Endodontists and the American Academy of Oral and Maxillofacial Radiology supported the use of cone beam CT (CBCT) as a supplemental imaging technique when conventional radiography fails to answer the clinical question and for surgical planning.^{1,4,12}

References (HD-30)

v2.0.2026

1. De Vos W, Casselman J, Swennen GRJ. Cone-beam computerized tomography (CBCT) imaging of the oral and maxillofacial region: A systematic review of the literature. *International Journal of Oral and Maxillofacial Surgery*. 2009;38(6):609-625. doi:10.1016/j.ijom.2009.02.028
2. Scrivani SJ, Keith DA, Kaban LB. Temporomandibular Disorders. *New England Journal of Medicine*. 2008;359(25):2693-2705. doi:10.1056/nejmra0802472
3. Bag AK. Imaging of the temporomandibular joint: An update. *World Journal of Radiology*. 2014;6(8):567. doi:10.4329/wjr.v6.i8.567
4. Horner K, O'Malley L, Taylor K, Glenney A-M. Guidelines for clinical use of CBCT: a review. *Dentomaxillofacial Radiology*. 2015;44(1):20140225. doi:10.1259/dmfr.20140225
5. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance of Computed Tomography (CT) of the extracranial head and neck. 2021; Available at: <https://gravitas.acr.org/PPTS/>
6. Guidelines for Diagnosis and Management of Disorders Involving the Temporomandibular Joint and Related Musculoskeletal Structures. *Cranio*®. 2003;21(1):68-76. doi:10.1080/08869634.2003.11746234
7. Mercuri LG. Management of temporomandibular joint disorders. *Journal of Oral Biology and Craniofacial Research*. 2012;2(3):141-142. doi:10.1016/j.jobcr.2012.10.010
8. Gauer R, Semidey M. Diagnosis and Treatment of Temporomandibular Disorders. *Am Fam Physician*. 2015 Mar 15;91(6):378-386
9. National Academies of Sciences. Temporomandibular Disorders: Priorities for Research and Care. Priorities for Research and Care | The National Academies Press. <https://doi.org/10.17226/25652>. Published March 12, 2020
10. Whyte A, Boeddinghaus R, Bartley A, Vijayaendra R. Imaging of the temporomandibular joint. *Clin Radiol*. 2021 Jan;76(1):76.e21-76.e35. doi: 10.1016/j.crad.2020.06.020
11. Schmidt C, Ertel T, Arbogast M, et al. The Diagnosis and Treatment of Rheumatoid and Juvenile Idiopathic Arthritis of the Temporomandibular Joint. *Dtsch Arztebl Int*. 2022;119(4):47-54. doi:10.3238/arztebl.m2021.0388
12. Kim IH, Singer SR, Mupparapu M. Review of cone beam computed tomography guidelines in North America. *Quintessence Int*. 2019 Jan 25;50(2):136-145. doi: 10.3290/j.qi.a41332
13. Almeida FT, Pacheco-Pereira C, Flores-Mir C, Le LH, Jaremko JL, Major PW. Diagnostic ultrasound assessment of temporomandibular joints: a systematic review and meta-analysis. *Dentomaxillofac Radiol*. 2019 Feb;48(2):20180144. doi: 10.1259/dmfr.20180144 9
14. Weiss R 2nd, Read-Fuller A. Cone Beam Computed Tomography in Oral and Maxillofacial Surgery: An Evidence-Based Review. *Dent J (Basel)*. 2019;7(2):52. Published 2019 May 2. doi:10.3390/dj7020052
15. Jacobs R, Salmon B, Codari M, Hassan B, Bornstein MM. Cone beam computed tomography in implant dentistry: recommendations for clinical use. *BMC Oral Health*. 2018;18(1):88. Published 2018 May 15. doi:10.1186/s12903-018-0523-5
16. Liu P, Shi J. Growth trends analysis of unilateral condylar hyperplasia followed up with planar scintigraphy: Retrospective overview of 249 cases. *Medicine (Baltimore)*. 2021;100(51):e28226. doi:10.1097/MD.00000000000028226
17. Schulze R KW, Drage NA. Cone-beam computed tomography and its applications in dental and maxillofacial radiology. *Clin Radiol*. 2020;75(9):647-657. doi:10.1016/j.crad.2020.04.006
18. Tyndall DA, Price JB, Tetradis S, et al. Position statement of the American Academy of Oral and Maxillofacial Radiology on selection criteria for the use of radiology in dental implantology with emphasis on cone beam computed tomography. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2012;113(6):817-826. doi:10.1016/j.oooo.2012.03.005

Cranial Neuropathies

(HD-31)

Guideline	Page
Cranial Neuropathies (HD-31.1)	320
References (HD-31)	324

Cranial Neuropathies (HD-31.1)

HD.CN.0031.1.A

v2.0.2026

Cranial Neuropathies Imaging Indications

- MRI Brain without contrast (CPT® 70551) **OR** MRI Brain without and with contrast (CPT® 70553) is medically necessary for all individuals with new or worsening specific cranial nerve abnormalities.
- MRI Orbit/Face/Neck without contrast (CPT® 70540) **OR** MRI Orbit/Face/Neck without and with contrast (CPT® 70543) is also medically necessary for individuals with abnormalities in cranial nerves I, II, III, IV, V, VI, VII, IX, X, XI, or XII.
- CT Neck with contrast (CPT® 70491) is medically necessary for evaluation of abnormalities involving cranial nerves IX, X, XI, or XII.
- Imaging of the Brain and Orbit, Face and/or Neck is medically necessary concurrently when requested.
- For specific cranial neuropathies, see the corresponding guideline section listed below:
 - CN I: Olfactory nerve (see **Taste and Smell Disorders (HD-2.1)**)
 - CN II, III, IV, VI: Optic, Oculomotor, Trochlear and Abducens (see **Eye Disorders and Visual Loss (HD-32.1)**)
 - CN V: Trigeminal nerve (see **Trigeminal Neuralgia and other Centrally Mediated Facial Pain Syndromes (HD-10.1)**)
 - CN VII: Facial nerve (see **Facial Palsy (HD-6.1)**)
 - CN VIII: Vestibulocochlear nerve (see **Dizziness/Vertigo (HD-23.1)**, **Hearing Loss (HD-27.1)**, **Tinnitus (HD-27.2)**, **Acoustic Neuroma and Other Cerebellopontine Angle Tumors (HD-33.1)**). For isolated nystagmus (see **Eye Disorders and Visual Loss (HD-32.1)**)
 - CN IX: Glossopharyngeal nerve (see **Glossopharyngeal Neuralgia/ Glossopharyngeal Neuropathy (HD-10.2)**)
 - CN X: Vagal nerve, imaging as detailed above (see also **Recurrent Laryngeal Palsy/Vocal Cord Palsy (Neck-7.1)**)
 - CN XI: Spinal accessory nerve, imaging as indicated above
 - CN XII: Hypoglossal nerve, imaging as indicated above
- For cranial neuropathies, whether isolated or multiple, due to clinically suspected stroke and/or vascular dissection (see **General Guidelines - CT and MR Angiography (CTA/CTV and MRA/MRV) (HD-1.5)**, **Headache and Suspected Vascular Dissection (HD-11.1)** and **Stroke/TIA (HD-21.1)**)

Background and Supporting Information

If a detailed clinical evaluation is unable to localize the site of the lesion, imaging of the entire course of the relevant cranial nerve is required, as cranial neuropathy can result from pathology affecting the nerve fibers at any point along the course of the nerve, from the cranial nerve origin in the brainstem to the end organ supplied by the nerve, requiring multiple imaging modalities.

The spinal trigeminal tract and nucleus extend from the midpons caudally into the upper cervical cord at the C2-4 levels. For suspected lesions of the spinal trigeminal tract and nucleus, imaging the brain stem and cervical spinal cord is supported. See **Trigeminal Neuralgia and other Centrally Mediated Facial Pain Syndromes (HD-10.1)**.

Number	Cranial Nerve Name	Nerve dysfunction on exam	Guideline Section in HD
I	Olfactory (smell)	Anosmia, hyposmia, parosmia, phantosmia	2
II	Optic (vision)	Optic neuritis, disc edema, papilledema, afferent pupillary defect APD)	16, 17, 32
III	Oculomotor (eye and pupil movement)	Eye "down and out", +/- dilated pupil, ptosis, diplopia	32
IV	Trochlear (depresses the eye)	Inability to depress the eye, diplopia	32
V	Trigeminal (sensation, mastication, taste)	Pain, numbness, corneal reflex loss, jaw deviation, trigeminal neuralgia, loss of taste	10
VI	Abducens (lateral movement of the eye)	Eye turns medially, inability to abduct, lateral rectus palsy, diplopia	32

Number	Cranial Nerve Name	Nerve dysfunction on exam	Guideline Section in HD
VII	Facial (movement facial muscles, taste at 2/3, salivation/lacrimation)	Inability to close eyelid, smile, nasolabial fold flattening, hyperacusis, impaired taste, salivation, lacrimation	6
VIII	Auditory, Vestibular, Vestibulochochlear (hearing and balance)	Hearing loss, tinnitus, vertigo, nystagmus, abnormal gait/balance, sway on Romberg	23, 27, 33
IX	Glossopharyngeal (swallow, sensation, pharynx, posterior 1/3 tongue, parotid salivary gland)	Depressed gag reflex and palate, dysphagia, uvula deviation, throat pain	10, 2
X	Vagus (swallow, speech, parasympathetic to heart, lungs, GI tract)	Vocal cord paralysis, recurrent laryngeal nerve palsy, spasmodic dysphonia	7.1, 1.1
XI	Spinal Accessory (motor function neck/shoulder)	Sternocleidomastoid (SCM) weakness when turning head opposite, shoulder elevation, winging scapula	1.1
XII	Hypoglossal (tongue movement)	Tongue deviation, atrophy, fasciculation	1.1

Number	Cranial Nerve Name	Nerve dysfunction on exam	Guideline Section in HD
INO	Internuclear Ophthalmoplegia (lesion of medial longitudinal fasciculus, CN III, CN VI)	Impaired adduction of ipsilateral eye with nystagmus of abducting eye	16, 21, 22
Horner Syndrome	Disruption of sympathetic innervation to eye and face	Ptosis, miosis (constricted pupil), facial anhidrosis (absence of sweating)	32.2, 11.3

Evidence Discussion (HD-31.1)

- Imaging of each body section along the entire course of the relevant cranial nerve may be medically necessary if detailed clinical evaluation is unable to localize the site of the lesion. Cranial neuropathy can result from pathology affecting the nerve fibers at any point along the course of the nerve, from the cranial nerve origin in the brainstem to the end organ supplied by the nerve, indicating need to image multiple body sections.^{1,2} MRI Brain, Orbits, Face, Neck, or any combination may be necessary depending on the clinical need.^{1,2}
- MRI is the standard modality for imaging the cranial nerves.^{2,3}
- CT Neck is useful to exclude neck masses when evaluating either isolated or multiple lower cranial neuropathies.² CT may be complementary to MRI in characterizing skull base erosions, calcifications, and skull base foramina.²

References (HD-31)

v2.0.2026

1. Expert Panel on Neurologic Imaging; Kennedy TA, Corey AS, et al. ACR Appropriateness Criteria® Orbits Vision and Visual Loss. *J Am Coll Radiol*. 2018;15(5S):S116-S131. doi:10.1016/j.jacr.2018.03.023
2. Expert Panel on Neurological Imaging, Rath TJ, Policeni B, et al. ACR Appropriateness Criteria® Cranial Neuropathy: 2022 Update. *J Am Coll Radiol*. 2022;19(11S):S266-S303. doi:10.1016/j.jacr.2022.09.021
3. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance and interpretation of Magnetic Resonance Imaging (MRI) of the brain. 2024; Available at: <https://gravitas.acr.org/PPTS/>

Eye Disorders and Visual Loss (HD-32)

Guideline	Page
Eye Disorders and Visual Loss (HD-32.1).....	326
Pupillary Abnormalities Including Horner’s Syndrome (HD-32.2).....	334
References (HD-32).....	336

Eye Disorders and Visual Loss (HD-32.1)

HD.VL.0032.1.A

v2.0.2026

- For specific conditions - See **Background and Supporting Information** that include table of abbreviations
- For eye pain, also refer to **Trigeminal Neuralgia/Trigeminal Neuropathy (HD-10.1)** and/or **Multiple Sclerosis and Related Conditions (HD-16)**
- Examination of ocular complaints and visual loss may include evaluation of pupillary responses, extraocular motility, visual acuity, visual field testing, intraocular pressures, external examination, slit lamp examination, and/or fundoscopic exam of retinae. An exam performed by a neuro-ophthalmologist, ophthalmologist, neurologist, or an optometrist meets this requirement.
- MRI Orbits/Face/Neck without contrast (CPT[®] 70540) **OR** MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543) **OR** CT Orbits/Temporal bone with contrast (CPT[®] 70481) **OR** CT Orbits/Temporal bone without contrast (CPT[®] 70480) **AND/OR** MRI Brain without contrast (CPT[®] 70551) **OR** MRI Brain without and with contrast (CPT[®] 70553) is medically necessary for:
 - unexplained vision loss
 - optic atrophy (cranial nerve II)
 - optic neuropathy (cranial nerve II)
 - papilledema/optic disc swelling (cranial nerve II) (see **Cranial Neuropathies (HD-31.1)** and **Papilledema/Pseudotumor Cerebri (HD-17.1)**)
 - Afferent Pupillary Defect (APD) or Relative Afferent Pupillary Defect (RAPD)
 - chiasmal symptoms/signs (including bitemporal field deficit)
 - ophthalmoplegia, diplopia, and/or cranial nerve palsy (specifically CN III, IV, and VI, see **Cranial Neuropathies (HD-31.1)**)
 - nystagmus
- For optic disc edema/papilledema, CT Head without contrast (CPT[®] 70450) is medically necessary to assess for space-occupying processes such as intracranial hemorrhage, mass effect and hydrocephalus.
- For suspected optic neuritis, MRI is the preferred modality (see **Multiple Sclerosis (MS) (HD-16.1)** and **Neuromyelitis Optica Spectrum Disorders (HD-16.2)**)
- Visual field defects are associated with retrochiasmal pathology (see **Stroke/TIA (HD-21.1)** or **Primary Central Nervous System Tumors (ONC-2)** in the Oncology Imaging Guidelines or **Brain Metastasis (ONC- 31.3)** in the Oncology Imaging Guidelines)
- MRI Orbits/Face/Neck without contrast (CPT[®] 70540) or MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543) or CT Orbits/Temporal bone with contrast (CPT[®] 70481) is medically necessary for:

- exophthalmos (including thyroid eye disease), enophthalmos or non-traumatic orbital asymmetry
- suspected orbital cellulitis or atypical pre-septal cellulitis, uveitis, or scleritis
- orbital mass or metastasis
- orbital inflammatory syndrome (orbital pseudotumor) and dacryocystitis or dacryoadenitis
- CT Orbits/Temporal bone without contrast (CPT[®] 70480) and/or CT Head without contrast (CPT[®] 70450) is/are medically necessary for:
 - orbital trauma with visual defect
 - exophthalmos (including thyroid eye disease)
- CT Orbits/Temporal bone without contrast (CPT[®] 70480) or CT Orbits/Temporal bone with contrast (CPT[®] 70481) or CT Orbits/Temporal bone without and with contrast (CPT[®] 70482) or CT Maxillofacial without contrast (CPT[®] 70486) or CT Maxillofacial with contrast (CPT[®] 70487) or CT Maxillofacial without and with contrast (CPT[®] 70488) is medically necessary for:
 - pre-operative planning for procedures including dacryocystorhinostomy (DCR) to correct nasolacrimal duct obstruction (NLDO)
- When requested by the surgeon or in consultation with surgeon, contrast level as requested is medically necessary. This includes requests from ophthalmologists and oculoplastic surgeons. Contrast level preference may vary per institutional protocol.
- MRA Head (CPT[®] 70544, CPT[®] 70545, or CPT[®] 70546) or CTA Head (CPT[®] 70496) is medically necessary for suspicion of intracranial aneurysm, including third nerve palsy with pupillary involvement (see **Cerebral Aneurysms (HD-12.1)**)
- MRA Head (CPT[®] 70544, CPT[®] 70545, or CPT[®] 70546) or CTA Head (CPT[®] 70496) **AND/OR** MRA Neck (CPT[®] 70547, CPT[®] 70548, or CPT[®] 70549) or CTA Neck (CPT[®] 70498) is medically necessary for evaluation of diplopia due to suspected stroke or TIA (see **Cerebral Aneurysms (HD-12.1)**)
 - CTA Head and Neck (CPT[®] 70471) must be substituted for CTA Head (CPT[®] 70496) and CTA Neck (CPT[®] 70498) if performed during the same session.
- Amaurosis Fugax (see **Stroke/TIA (HD-21.1)**)
 - Individuals describe a transient darkening or loss of vision, typically monocular
- Central Retinal Artery Occlusion, Branch Retinal Artery Occlusion, and Ophthalmic Artery Occlusion (see **Stroke/TIA (HD-21.1)**)
 - Individuals describe a sudden monocular loss of vision or visual field. Etiology is usually embolic and is considered a stroke to the retina
- There is currently no data to support advanced imaging while on Tepezza[®] (teprotumumab). However, advanced imaging is medically necessary for any of the following concerns:
 - Neurologic symptoms or ophthalmologic symptoms

- To reassess compressive optic neuropathy (symptoms/signs of compressive optic neuropathy include APD, decreased visual acuity, and/ or visual field defects)
- For non-response to Tepezza® (teprotumumab) or relapses, worsening proptosis, diplopia, lid retraction, or optic neuropathy
- For surgical planning for orbital decompression, strabismus surgery, or lid surgery
 - When any of the above concerns are present, **ONE** of the following modalities is medically necessary:
 - MRI Orbits/Face/Neck without contrast (CPT® 70540)
 - MRI Orbits/Face/Neck without and with contrast (CPT® 70543)
 - CT Orbits/Temporal bone with contrast (CPT® 70481)
 - CT Orbits/Temporal bone without contrast (CPT® 70480)
 - CT head without contrast (CPT® 70450)
- Autoimmune Retinopathy
 - Suspicion for CAR (Cancer associated retinopathy) or MAR (melanoma associated retinopathy) syndromes (see **Paraneoplastic Syndromes (ONC-30.3)** in the Oncology Imaging Guidelines)
- Oncologic conditions
 - Retinoblastoma (see **Retinoblastoma (PEDONC-12)** in the Pediatric and Special Populations Oncology Imaging Guidelines)
 - Uveal (choroidal) melanoma (see **Ocular Melanoma (ONC-5.9)** in the Oncology Imaging Guidelines)
 - Biopsy results are not required before initial staging
- Vasculitis including Temporal Arteritis (Giant Cell Arteritis) (see **Cerebral Vasculitis (HD-22.1)**)

Background and Supporting Information

- Imaging Non-Indications
 - Imaging is not necessary if visual loss or ocular symptom/sign is due to known intrinsic eye disease, such as refractive errors, amblyopia, pterygium, subconjunctival hemorrhage, conjunctivitis, cataracts, macular degeneration, central serous retinopathy, retinal vein occlusion, retinal detachment, etc. Monocular diplopia is not an indication for imaging. Physiologic anisocoria and surgically distorted pupils are not indications for imaging. Anisocoria may be physiologic or non-physiologic when the difference in pupil diameter between the two eyes is up to 2 mm.
 - Imaging is not typically necessary in cases of ptosis without concern for Horner's or 3rd nerve palsy
- Advanced imaging of the brain and orbit are not routinely paired.
 - Suspicion for disorders involving both regions is needed to image both regions.

- Orbital imaging alone may be sufficient unless other signs or symptoms suggest brain involvement.
- Thyroid function and iodine contrast: thyroid dysfunction can occur in susceptible individuals after iodine exposure.

List of Abbreviations and Meanings:

Abbreviation	Meaning
AC	anterior chamber
APD	afferent pupillary defect (see RAPD)
BCVA	best-corrected visual acuity
C3F8	gas bubble injected into vitreous cavity during retina surgery
cc	with correction (current new or old glasses or contact lenses)
CP	color plates
C/S	conjunctiva/sclera
CSME	clinically significant macular edema
CVF	confrontation visual field (testing of gross field of view)
D	disc, optic nerve head
DBH	dot blot hemorrhages
DCR	dacryocystorhinostomy
DFE	dilated fundus exam
E	esophoria at distance
E'	esophoria at near
EOM	extraocular movements
ERM	epiretinal membrane
ET	esotropia at distance

Abbreviation	Meaning
E(T)	intermittent esotropia at distance
ET'	esotropia at near
E(T)'	intermittent esotropia at near
GVF	Goldmann visual field test
HT	hypertropia
HVF	Humphrey visual field test (automated perimetry)
I	iris
Ishihara	commonly used color plates
IOP	intraocular pressure
K	cornea
LF	levator function
LFH	lid fissure height
LLL	lids, lashes, lacrimal gland
M	macula
ME	macular edema
MH	macular hole
MP	membrane peel
MRD1	margin-reflex distance from upper lid margin to pupillary light reflex
MRx	manifest refraction
NI	no improvement
NLDO	nasolacrimal duct obstruction
NSC or NS	nuclear sclerotic cataract
OD	right eye

Abbreviation	Meaning
OS	left eye
ortho	eyes are aligned on the same target
OCT	optical coherence tomography
P	periphery
PD	prism diopter
ph or PH	pinhole (crude assessment of best-corrected visual acuity)
PPV or PPVx	pars plana vitrectomy
PVD	posterior vitreous detachment
RAPD	relative afferent pupillary defect (see APD)
RD	retinal detachment
RT	retinal tear
SB	scleral buckle
sc	without correction
SF6	gas bubble injected into vitreous cavity during retina surgery
SLE	slit lamp examination
SO	silicone oil
SRF	subretinal fluid
Ta	applanation tonometry (intraocular pressure measurement)
Tp	tonopen tonometry (intraocular pressure measurement)
V	vessels
Va	visual acuity
VF	visual field testing (formal automated perimetry versus confrontation visual field testing)

Abbreviation	Meaning
X	exophoria at distance
X'	exophoria at near
XT	exotropia
X(T)	intermittent exotropia at distance
XT'	exotropia at near
X(T)'	intermittent exotropia at near

Evidence Discussion (HD-32.1)

- When evaluating suspected or known issues involving the eye, orbit, and/or brain, consideration must be given to:
 - whether or not imaging is required,
 - which body area should be imaged, i.e., brain, orbits, or both, and
 - which modality, MRI or CT, would best provide the information needed while exposing an individual to the least risk.
- The body area imaged should be reasonably expected to be potentially involved in the suspected condition. The angles of and distance between each view differ between brain imaging and orbital imaging. There are circumstances in which imaging of both the brain and orbits may be useful, as in conditions that can affect both locations or for which evaluation by the different techniques provides useful information.
- Soft tissue detail such as neural tissue is well-visualized by MRI.
- Calcification, bone, and hemorrhages are well-visualized by CT.
- MRI carries no risk of radiation exposure but is sensitive to motion, takes longer, and may require sedation or anesthesia for a longer duration than would be required for CT. Certain populations may have psychological or physical difficulty undergoing MRI scans, including children, those with obesity, movement disorders, anxiety, or claustrophobia.
- CT carries risk of radiation exposure but is less sensitive to motion and has a shorter duration than MRI. Imaging more than one body area increases the exposure dose. Certain populations may carry higher risk of detrimental effects from exposure, including children.
- Radiation exposure of the ocular lens contributes to cataract formation. Radiation doses vary between CT scans due to differences in scanning technique, number of images taken per CT, body area scanned, CT machines used, and facility protocols. The cancer risk of radiation exposure in diagnostic CT is considered extremely

low, and the benefit of an appropriately indicated CT examination far outweighs the potential risk.²⁵ Cataract formation is among the earliest radiation associated pathologies in the eye. The Beaver Dam Eye Study, a population-based study of common age-related eye diseases, found that nuclear sclerosis and posterior subcapsular opacity were significantly associated with CAT scans.²⁵

Pupillary Abnormalities Including Horner's Syndrome (HD-32.2)

HD.VL.0032.2.A

v2.0.2026

- Examination of ocular complaints may include evaluation of pupillary responses, extraocular motility, visual acuity, visual field testing, intraocular pressures, external examination, slit lamp examination and/or funduscopic exam of the retinae. An exam performed by a neuro-ophthalmologist, ophthalmologist, neurologist, or an optometrist meets this requirement.
- Anisocoria and Other Pupillary Disorders
 - Physiologic anisocoria (difference in pupil diameter between the two eyes of typically 2 mm or less) and surgically distorted pupils are not indications for advanced imaging.
 - Dilated pupil from suspected Third nerve palsy (see **Eye Disorders and Visual Loss (HD-32.1)**)
 - Horner's Syndrome (See below)
- Horner's Syndrome (anisocoria, ptosis, and ipsilateral anhidrosis) is caused by disruption of sympathetic innervation to the eye and face. Definitive diagnosis may be established by pharmacologic testing of the pupillary response with eye drops. Evaluation and imaging depends on determining whether the cause is a central lesion (brainstem or cervical spinal cord), pre-ganglionic lesion (spinal cord or sympathetic chain in the chest), or post-ganglionic lesion (neck or carotid artery).
- MRI Brain without contrast (CPT® 70551) or MRI Brain without and with contrast (CPT® 70553) is medically necessary for suspected intracranial or brainstem lesions
- MRI Cervical Spine without contrast (CPT® 72141) or MRI Cervical Spine without and with contrast (CPT® 72156) is medically necessary for suspected spinal cord abnormality
- MRI Brachial plexus for Horner syndrome with traction or trauma to the brachial plexus
 - Any **ONE** of the following are medically necessary:
 - MRI Upper Extremity other than joint without contrast (CPT® 73218)
 - MRI Upper Extremity other than joint without and with contrast (CPT® 73220)
 - MRI Chest without contrast (CPT® 71550)
 - MRI Chest without and with contrast (CPT® 71552)
 - MRI Neck without contrast (CPT® 70540)
 - MRI Neck without and with contrast (CPT® 70543)

- CT Chest with contrast (CPT[®] 71260) or MRI Chest without and with contrast (CPT[®] 71552) is medically necessary for suspected chest mass
- CT Neck with contrast (CPT[®] 70491) or MRI Face/Neck/Orbits without and with contrast (CPT[®] 70543) is medically necessary for suspected neck mass
- CTA Neck without and with contrast (CPT[®] 70498) or MRA Neck (CPT[®] 70547, CPT[®] 70548, or CPT[®] 70549) is medically necessary for suspected carotid injury or dissection
- MRI Orbits/Face/Neck without contrast (CPT[®] 70540), MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543) or CT Orbits/Temporal bone with contrast (CPT[®] 70481) is medically necessary for suspected orbital lesion or mass

Evidence Discussion (HD-32.2)

- In the evaluation of Horner Syndrome, if a detailed clinical evaluation is unable to localize the site of the lesion, imaging of the entire course of the relevant oculosympathetic pathway is required, as symptoms may result from pathology affecting the nerve fibers at any point along the course of the pathway, requiring multiple imaging modalities.³⁵ MRI Brain, MRI Orbits/Face/Neck, MRI Cervical Spine and/or MRI Brachial plexus studies may be necessary, depending on the clinical presentation.^{1,2,4,35}
- CT Neck is useful to exclude neck masses.^{2,35} CT may be complementary to MRI in characterizing skull base erosions, calcifications, and skull base foramina.³⁵
- For suspected lung masses associated with Horner syndrome, such as for evaluation of Pancoast tumors, chest imaging is recommended. A mass may be diagnosed on a CT Chest or an MRI Chest.^{2,4,24} CT scans provide 60% sensitivity, 65% specificity, and 63% accuracy in defining the local extent of tumor, in contrast to MRI with a sensitivity of 88%, a specificity of 100%, and an accuracy of 94%.²⁴ MRI of the chest is a more accurate pre-operative examination in identifying the local extent of a Pancoast tumor.²⁴
- For suspected carotid injury or dissection, vascular imaging with either CT Angiography (CTA) neck or MR Angiography (MRA) neck is medically necessary, depending on the individual's risk and benefit profile.^{2,4,6}

References (HD-32)

v2.0.2026

1. Expert Panel on Neurologic Imaging; Kennedy TA, Corey AS, et al. ACR Appropriateness Criteria® Orbits Vision and Visual Loss. *J Am Coll Radiol*. 2018;15(5S):S116-S131. doi:10.1016/j.jacr.2018.03.023
2. Lee JH, Lee HK, Lee DH, Choi CG, Kim SJ, Suh DC. Neuroimaging Strategies for Three Types of Horner Syndrome with Emphasis on Anatomic Location. *American Journal of Roentgenology*. 2007;188(1):W74-W81. doi:10.2214/ajr.05.1588
3. Szatmáry G. Imaging in Patients With Visual Symptoms. *CONTINUUM: Lifelong Learning in Neurology*. 2016;22(5):1499-1528. doi:10.1212/con.0000000000000375
4. Kawasaki AK. Diagnostic Approach to Pupillary Abnormalities. *CONTINUUM: Lifelong Learning in Neurology*. 2014;20:1008-1022. doi:10.1212/01.con.0000453306.42981.94
5. Prasad S. Diagnostic Neuroimaging in Neuro-ophthalmic Disorders. *CONTINUUM: Lifelong Learning in Neurology*. 2014;20:1023-1062. doi:10.1212/01.con.0000453305.65851.1c
6. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance of Computed Tomography (CT) of the extracranial head and neck. 2021; Available at: <https://gravitas.acr.org/PPTS/>
7. Tamhankar MA, Volpe NJ. Management of acute cranial nerve 3, 4 and 6 palsies: role of neuroimaging. *Curr Opin Ophthalmol*. 2015;26(6):464-468. doi:10.1097/ICU.0000000000000200
8. Tamhankar MA, Biousse V, Ying GS, et al. Isolated third, fourth, and sixth cranial nerve palsies from presumed microvascular versus other causes: a prospective study. *Ophthalmology*. 2013;120(11):2264-2269. doi:10.1016/j.ophtha.2013.04.009
9. Pineles SL, Velez FG. Isolated Ocular Motor Nerve Palsies. *J Binocul Vis Ocul Motil*. 2018;68(3):70-77. doi:10.1080/2576117X.2018.1481266
10. Flaxel CJ, Adelman RA, Bailey ST, et al. Retinal and Ophthalmic Artery Occlusions Preferred Practice Pattern®. *Ophthalmology*. 2020;127(2):P259-P287. doi:10.1016/j.ophtha.2019.09.028
11. Dagi LR, Velez FG, Archer SM, et al. Adult Strabismus Preferred Practice Pattern®. *Ophthalmology*. 2020;127(1):P182-P298. doi:10.1016/j.ophtha.2019.09.023
12. Sadaka A, Schockman SL, Golnik KC. Evaluation of Horner Syndrome in the MRI Era. *Journal of Neuro-Ophthalmology*. 2017;37(3):268-272. doi:10.1097/wno.0000000000000503
13. Glisson CC. Approach to Diplopia. *CONTINUUM: Lifelong Learning in Neurology*. 2019;25(5):1362-1375. doi:10.1212/con.0000000000000786
14. Gross JR, McClelland CM, Lee MS. An approach to anisocoria. *Current Opinion in Ophthalmology*. 2016;27(6):486-492. doi:10.1097/icu.0000000000000316
15. Costello F, Scott JN. Imaging in Neuro-ophthalmology. *CONTINUUM: Lifelong Learning in Neurology*. 2019;25(5):1438-1490. doi:10.1212/con.0000000000000783
16. Expert Panel on Neurologic Imaging, Whitehead MT, Cardenas AM, et al. ACR Appropriateness Criteria® Headache. *J Am Coll Radiol*. 2019;16(11S):S364-S377. doi:10.1016/j.jacr.2019.05.030
17. Lee SY, Rhee CM, Leung AM, Braverman LE, Brent GA, Pearce EN. A review: Radiographic iodinated contrast media-induced thyroid dysfunction. *J Clin Endocrinol Metab*. 2015;100(2):376-383. doi:10.1210/jc.2014-3292
18. van der Molen AJ, Thomsen HS, Morcos SK; Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Effect of iodinated contrast media on thyroid function in adults. *Eur Radiol*. 2004 May;14(5):902-7. doi: 10.1007/s00330-004-2238-z
19. Teo HM, Smith TJ, Joseph SS Efficacy and Safety of Teprotumumab in Thyroid Eye Disease. *Ther Clin Risk Manag*. 2021 17:1219-1230. doi: 10.2147/TCRM.S303057
20. Bednarczyk Z, Pearce, SH The knowns and unknowns of teprotumumab for thyroid eye disease. *Lancet Diabetes Endocrinol*. 2021 9:323-325. doi: 10.1016/S2213-8587(21)00076-0
21. Lee AG, Brazis PW. Localizing forms of nystagmus: symptoms, diagnosis, and treatment. *Curr Neurol Neurosci Rep*. 2006;6(5):414-420. doi:10.1007/s11910-996-0022-y
22. Freitag SK, Roos JC. Preoperative imaging should be performed prior to surgery in all cases of acquired nasolacrimal obstruction-Yes. *Eye (Lond)*. 2017;31(3):351-352. doi:10.1038/eye.2016.237

23. Choi SC, Lee S, Choi HS, Jang JW, Kim SJ, Lee JH. Preoperative Computed Tomography Findings for Patients with Nasolacrimal Duct Obstruction or Stenosis. *Korean J Ophthalmol*. 2016;30(4):243-250. doi:10.3341/kjo.2016.30.4.243
24. Panagopoulos N, Leivaditis V, Koletsis E, et al. Pancoast tumors: characteristics and preoperative assessment. *J Thorac Dis*. 2014;6 Suppl 1(Suppl 1):S108-S115. doi:10.3978/j.issn.2072-1439.2013.12.29
25. Watson RE, Yu L. Safety Considerations in MRI and CT. *Continuum (Minneap Minn)*. 2023 Feb 1;29(1):27-53. doi: 10.1212/CON.0000000000001213. PMID: 36795872.
26. Klein BE, Klein R, Linton KL, Franke T. Diagnostic x-ray exposure and lens opacities: the Beaver Dam Eye Study. *Am J Public Health*. 1993 Apr;83(4):588-90. doi: 10.2105/ajph.83.4.588. PMID: 8460743; PMCID: PMC1694473.
27. Poon R, Badawy MK. Radiation dose and risk to the lens of the eye during CT examinations of the brain. *J Med Imaging Radiat Oncol*. 2019 Dec;63(6):786-794. doi: 10.1111/1754-9485.12950. Epub 2019 Sep 13. PMID: 31520467.
28. Hopper KD, Neuman JD, King SH, Kunselman AR. Radioprotection to the eye during CT scanning. *AJNR Am J Neuroradiol*. 2001 Jun-Jul;22(6):1194-8. PMID: 11415918; PMCID: PMC7974781.
29. Lee AG, Hayman LA, Brazis PW. The evaluation of isolated third nerve palsy revisited: an update on the evolving role of magnetic resonance, computed tomography, and catheter angiography. *Surv Ophthalmol*. 2002;47(2):137-157.
30. Lee AG, Johnson MC, Policeni BA, Smoker WR. Imaging for neuro-ophthalmic and orbital disease – a review. *Clin Exp Ophthalmol*. 2009;37(1):30-53.
31. Lee AG, Brazis PW, Garrity JA, White M. Imaging for neuro-ophthalmic and orbital disease. *Am J Ophthalmol*. 2004;138(5):852-862.
32. American College of Radiology. ACR Appropriateness Criteria® Radiation Dose Assessment Introduction. <https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Appropriateness-Criteria>
33. Stewart F, Akleyev A, Hauer-Jensen M, et al. ICRP publication 118: ICRP statement on tissue reactions and early and late effects of radiation in normal tissues and organs—threshold doses for tissue reactions in a radiation protection context. *Ann ICRP*. 2012; 41: 1–322.
34. Hamada N, Fujimichi Y. Role of carcinogenesis related mechanisms in cataractogenesis and its implications for ionizing radiation cataractogenesis. *Cancer Lett*. 2015; 368: 262–74.
35. Expert Panel on Neurological Imaging, Rath TJ, Policeni B, et al. ACR Appropriateness Criteria® Cranial Neuropathy: 2022 Update. *J Am Coll Radiol*. 2022;19(11S):S266-S303. doi:10.1016/j.jacr.2022.09.021

Acoustic Neuroma and Other Cerebellopontine Angle Tumors (HD-33)

Guideline	Page
Acoustic Neuroma and Other Cerebellopontine Angle Tumors (HD-33.1).....	339
References (HD-33).....	341

Acoustic Neuroma and Other Cerebellopontine Angle Tumors (HD-33.1)

HD.AC.0033.1.A

v2.0.2026

- Acoustic neuroma and vestibular schwannoma may be used interchangeably
- Initial diagnosis is usually made during evaluation for asymmetric hearing loss and/or vertigo (see **Dizziness, Vertigo and Syncope (HD-23)** and **Hearing Loss and Tinnitus (HD-27)**) for evaluation of those problems)
- MRI Brain without and with contrast (CPT[®] 70553), which should be done with attention to the internal auditory canals, is medically necessary for initial diagnosis.
- MRI Brain without contrast (CPT[®] 70551) is medically necessary if performed with FIESTA protocol
- MRI Orbits/Face/Neck without and with contrast (CPT[®] 70543) with audiologic or clinical features of retrocochlear hearing loss and a negative MRI Brain and in the rare individual in whom a detailed search is medically necessary for both a lesion of the cerebellopontine angle **and** lesions of the cerebral hemispheres
- Repeat MRI Brain (contrast as requested) is medically necessary 6 months after diagnosis, then annually for 5 years and thereafter per neurologist, neurosurgeon, or otolaryngologist, or any provider in consultation with a neurologist, neurosurgeon, or otolaryngologist.
- MRI Brain without and with contrast with attention to the internal auditory canals (CPT[®] 70553) is medically necessary after surgical resection and following stereotactic radiation therapy at 6 to 12 months to document the completeness of tumor removal and to serve as a baseline for further follow-up. Additional follow-up is done annually for 5 years and every 2 years thereafter.
- Limited MRI of the internal auditory canals (CPT[®] 70540, CPT[®] 70542, or CPT[®] 70543) is medically necessary when requested by the provider in place of a complete MRI Brain. Note: Limited MRI codes should not be used in addition to MRI Brain codes; IAC views are performed as additional sequences as part of the brain study. (See **General Guidelines – Anatomic Issues (HD-1.1)**)
- See **Primary Central Nervous System Tumors- General Considerations (ONC-2.1)** in the Oncology Imaging Guidelines for additional imaging requests for surgery

Evidence Discussion (HD-33)

- MRI Brain is the preferred initial imaging modality for evaluation of persistent vertigo, vertigo associated with an abnormal neurologic exam, vertigo due to a suspected central cause, pulsatile or asymmetric tinnitus, and/or hearing loss.^{8,9}
- CT Head is not recommended for the initial evaluation of suspected acoustic neuroma due to inferior soft tissue resolution when compared to MRI Brain. In addition, MRI Brain provides better visualization of the cerebellum, posterior fossa, and cranial nerves.⁸
- MRI Brain, in this clinical scenario, is performed using specialized internal auditory canal (IAC) protocols, which include thin-section sequences to evaluate for vascular loops and small vestibular schwannomas.¹⁰
- MRI Brain can diagnose lesions in the cerebellopontine angle including schwannoma, meningioma, and other posterior fossa tumors.¹⁰
- 3D-Fast imaging employing steady state acquisition (3D-FIESTA) demonstrates significantly higher spatial resolution with superior imaging contrast between cranial nerves and CSF with a shorter acquisition time than conventional MRI scan.⁴
- Follow-up imaging is recommended 6 months after diagnosis to evaluate for rapid growth, then annually for 5 years.^{3,6,7} After 5 years, tumor growth that has remained stable is unlikely but may still occur, therefore, lifelong surveillance is advised with longer imaging intervals.⁷
- Follow-up imaging after surgical resection and/or stereotactic radiosurgery to assess residual tumor and treatment response is performed at 6-12 months with additional follow-up annually for 5 years and every 2 years thereafter.^{5,6}

References (HD-33)

v2.0.2026

1. Kesavadas C, Thomas B, Kapilamoorthy T, Hingwala D, Chatterjee S. Applications of 3D CISS sequence for problem solving in neuroimaging. *Indian Journal of Radiology and Imaging*. 2011;21(2):90. doi:10.4103/0971-3026.82283.
2. Camelio S, Schmid UD, Horsfield MA, et al. Visualization of cranial nerves I-XII: value of 3D CISS and T2-weighted FSE sequences. *European Radiology*. 2000;10(7):1061-1067. doi:10.1007/s003300000452.
3. Olson JJ, Kalkanis SN, Ryken TC. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Treatment of Adults With Vestibular Schwannomas: Executive Summary. *Neurosurgery*. 2017;82(2):129-134. doi:10.1093/neuros/nyx586.
4. Zou J, Hirvonen T. "Wait and scan" management of patients with vestibular schwannoma and the relevance of non-contrast MRI in the follow-up. *Journal of Otology*. 2017;12(4):174-184. doi:10.1016/j.joto.2017.08.002.
5. Lin EP, Crane BT. The Management and Imaging of Vestibular Schwannomas. *American Journal of Neuroradiology*. 2017;38(11):2034-2043. doi:10.3174/ajnr.a5213.
6. Goldbrunner R, Weller M, Regis J, et al. EANO guideline on the diagnosis and treatment of vestibular schwannoma. *Neuro-Oncology*. 2019;22(1):31-45. doi:10.1093/neuonc/noz153.
7. Somers T, Kania R, Waterval J, Havenbergh TV. What is the Required Frequency of MRI Scanning in the Wait and Scan Management? *J Int Adv Otol*. 2018; 14(1): 85-9. doi: 10.5152/iao.2018.5348.
8. Wang LL, Thompson TA, Shih RY, et al. ACR Appropriateness Criteria® Dizziness and Ataxia. Available at <https://acsearch.acr.org/docs/69477/Narrative/>. American College of Radiology. Revised 2023
9. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance and interpretation of Magnetic Resonance Imaging (MRI) of the brain. 2024; Available at: <https://gravitas.acr.org/PPTS/>
10. Expert Panel on Neurological Imaging, Jain V, Policeni B, et al. ACR Appropriateness Criteria® Tinnitus: 2023 Update. *J Am Coll Radiol*. 2023;20(11S):S574-S591. doi:10.1016/j.jacr.2023.08.017

Pineal/Colloid Cysts (HD-34)

Guideline	Page
Pineal/Colloid Cysts (HD-34.1).....	343
References (HD-34).....	344

Pineal/Colloid Cysts (HD-34.1)

HD.PT.0034.1.A

v2.0.2026

Pineal Cysts

Pineal cysts are generally discovered incidentally and do not require surgical intervention.

- MRI Brain without contrast (CPT[®] 70551) or MRI Brain without and with contrast (CPT[®] 70553) is medically necessary for initial evaluation of pineal cysts if not already completed.
- Repeat MRI Brain is not medically necessary for most individuals with pineal cysts, but MRI Brain without contrast (CPT[®] 70551) or MRI Brain without and with contrast (CPT[®] 70553) is medically necessary for the following:
 - New or worsening headache or focal neurologic deficits suggesting progression of cyst
 - Pre-operative planning

Colloid Cysts

- MRI Brain without contrast (CPT[®] 70551) or MRI Brain without and with contrast (CPT[®] 70553) is medically necessary for the initial evaluation of colloid cysts if not already completed.
- Repeat MRI Brain without contrast (CPT[®] 70551) or without and with contrast (CPT[®] 70553) is medically necessary for colloid cysts for the following:
 - In the presence of symptoms including syncope
 - Evaluation of CSF flow (CPT[®] 70551)
 - When requested by a neurologist or neurosurgeon or any provider in consultation with a neurologist or neurosurgeon

Evidence Discussion (HD-34)

- MRI Brain is the preferred modality for the evaluation of intracranial cysts, due to its superior soft tissue resolution when compared to CT Head.^{1,4}
- Follow-up imaging of pineal cysts is supported for new or worsening headaches, focal neurologic deficits, and/or for surgical planning, otherwise, routine follow up is not supported.^{2,3}
- In contrast to pineal cysts, colloid cysts may lead to sudden obstruction of cerebrospinal fluid flow at the foramen of Monro, resulting in neurologic symptoms, including syncope. Other than this scenario, follow-up imaging indications are similar to pineal cysts.^{1,5}

References (HD-34)

v2.0.2026

1. Ajtai B, Bertelson JA. Imaging of Intracranial Cysts. *CONTINUUM: Lifelong Learning in Neurology*. 2016;22(5):1553-1573. doi:10.1212/con.0000000000000372.
2. Tanaka T, Arnold L, Gabriela Mazuru D, Golzy M, Carr SB, Litofsky NS. Pineal cysts: Does anyone need long-term follow up? *Journal of Clinical Neuroscience*. 2021;83:146-151. doi:10.1016/j.jocn.2020.10.051.
3. Jussila M-P, Olsén P, Salokorpi N, Suo-Palosaari M. Follow-up of pineal cysts in children: is it necessary? *Neuroradiology*. 2017;59(12):1265-1273. doi:10.1007/s00234-017-1926-8.
4. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance and interpretation of Magnetic Resonance Imaging (MRI) of the brain. 2024; Available at: <https://gravitas.acr.org/PPTS/>
5. Velicu MA, Rossmann K, Vahedi A, et al. On Natural History and Management of Colloid Cysts: Time to Rethink? *World Neurosurg*. 2023;170:e188-e199. doi:10.1016/j.wneu.2022.10.094

Arachnoid Cysts (HD-35)

Guideline	Page
Arachnoid Cysts (HD-35.1).....	346
References (HD-35).....	347

Arachnoid Cysts (HD-35.1)

HD.AR.0035.1.A

v2.0.2026

Arachnoid cysts arise in the middle or posterior fossa, and the majority of lesions are discovered incidentally and do not require surgical intervention.

- MRI Brain without contrast (CPT[®] 70551) or MRI Brain without and with contrast (CPT[®] 70553) is medically necessary for initial evaluation of arachnoid cysts if not already completed.
- Repeat MRI Brain is not medically necessary for most individuals with arachnoid cysts, except in the following scenarios:
 - New or worsening headache or focal neurologic deficits suggesting progression of cyst
 - Pre-operative planning
 - When requested by a neurologist or neurosurgeon or any provider in consultation with a neurologist or neurosurgeon

Evidence Discussion (HD-35)

- MRI Brain is the preferred modality for evaluation and follow up of intracranial arachnoid cysts, due to its superior soft tissue resolution when compared to CT Head.^{1,3}
- Most intracranial arachnoid cysts remain asymptomatic and follow up imaging is not routinely supported. Surgical intervention is reserved for those with symptoms.^{1,2}

References (HD-35)

v2.0.2026

1. Ajtai B, Bertelson JA. Imaging of Intracranial Cysts. *CONTINUUM: Lifelong Learning in Neurology*. 2016;22(5):1553-1573. doi:10.1212/con.0000000000000372.
2. Hall S, Smedley A, Sparrow O, Mathad N, Waters R, Chakraborty A, Tsitouras V. Natural History of Intracranial Arachnoid Cysts. *World Neurosurg*. 2019 Jun;126:e1315-e1320. doi: 10.1016/j.wneu.2019.03.087.
3. American College of Radiology. ACR-ASNR-SPR Practice Parameter for the performance and interpretation of Magnetic Resonance Imaging (MRI) of the brain. 2024; Available at: <https://gravitas.acr.org/PPTS/>

Nuclear Medicine (HD-36)

Guideline	Page
Nuclear Medicine (HD-36.1).....	349
References (HD-36).....	351

Nuclear Medicine (HD-36.1)

HD.NM.0036.1.A

v2.0.2026

Nuclear medicine studies used in the evaluation of some head/brain disorders, and other rare indications as well.

- Brain Scintigraphy with or without vascular flow (any one of CPT[®] 78600, CPT[®] 78601, CPT[®] 78605, or CPT[®] 78606)
- Brain Imaging Radiopharmaceutical Localization SPECT (CPT[®] 78803)
 - Immunocompromised individuals with mass lesion detected on CT or MRI for differentiation between lymphoma and infection
 - In distinguishing recurrent brain tumor from radiation necrosis
 - Can be performed with vasodilating agent acetazolamide (Diamox) to assess functional reserve capacity to predict critically reduced perfusion in individuals with chronic cerebrovascular disease (for example, in Moya-Moya disease) and identify individuals who might benefit from an extracranial-to-intracranial (EC-IC) bypass to augment Cerebral Blood Flow, and to assess pre-operatively the potential for ischemia following carotid artery sacrifice. See **Moyamoya Syndrome/Disease (HD-21.5)**
- Brain Imaging Vascular Flow (CPT[®] 78610)
 - Cerebral ischemia
 - Establish brain death
- CSF Leakage Detection (CPT[®] 78650)
 - Evaluation of CSF rhinorrhea, otorrhea, or refractory post-lumbar puncture headache
 - Suspected normal pressure hydrocephalus with gait disturbance and either dementia or urinary incontinence
- Radiopharmaceutical Dacryocystography (CPT[®] 78660)
 - Suspected obstruction of nasolacrimal duct due to excessive tearing
- Cisternogram (CPT[®] 78630), see **Low-Pressure Headache and CSF Leak (HD-11.15)** and **Facial Trauma (HD-13.2)**
- Cerebrospinal Ventriculography (CPT[®] 78635) and Nuclear Medicine Shunt Evaluation (CPT[®] 78645) and CSF Flow SPECT (CPT[®] 78803), see **Hydrocephalus Shunts (HD-11.14)**
- DAT-SPECT OR Fluorodopa F (F-DOPA) PET Brain see **Lewy Body Dementia (LBD) – SPECT Brain Scan and PET (HD-8.3)** and **Movement Disorders (HD-15.1)**
- Jaw Asymmetry - see **Temporomandibular Joint Disease (HD-30.1)**

Evidence Discussion (HD-36)

- Nuclear medicine studies are adjunct, functional imaging modalities in the evaluation of a variety of neurologic conditions and are generally helpful when structural brain imaging modalities are unable to provide answers to complex clinical questions.
- The American Academy of Neurology practice guideline recommends brain SPECT to assist with prognostication in adults with traumatic brain injuries.⁴
- Single-photon emission CT (SPECT) is the most readily available nuclear medicine technique for assessment of cerebral hemodynamics.² Brain SPECT has also been validated for evaluation of cerebrovascular reactivity to acetazolamide (ACZ) challenge in individuals with various types of vaso-occlusive disease, including Moyamoya disease.^{2,7}
- Brain SPECT has been used in the evaluation of stroke, TIA, monitoring of medical or surgical therapy, assessment of cerebral blood flow reserve, and estimation of prognosis. The sensitivity of brain SPECT for acute stroke localization is 85.5% with a specificity of 97.6%.⁶
- Brain SPECT used with specific perfusion agents is useful in distinguishing radiation effects from residual or recurrent tumor, and/or for distinguishing cerebral lymphoma from infection, a distinction not always possible with CT or MRI.⁶
- Dacryocystography is supported to localize the lacrimal drainage system and evaluate for suspected obstruction in the nasolacrimal duct.⁹
- Radionuclide CSF shunt studies can evaluate shunt patency, differentiate proximal versus distal obstruction, and localize the site of obstruction. The combination of CT and radionuclide is more sensitive than CT alone in diagnosing shunt malfunction.⁸
- CT head cisternography in the evaluation of CSF leak has a sensitivity range between 85%-92%. This modality is particularly useful when there are multiple potential CSF leak sites. Radionuclide cisternography is useful for confirming the presence of a CSF leak.⁵

References (HD-36)

v2.0.2026

1. Bega D, Gonzalez-Latapi P, Zadikoff C, Spies W, Simuni T. Is There a Role for DAT-SPECT Imaging in a Specialty Movement Disorders Practice? *Neurodegenerative Diseases*. 2015;15(2):81-86. doi:10.1159/000370116
2. Vagal A, Leach J, Fernandez-Ulloa M, Zuccarello M. The Acetazolamide Challenge: Techniques and Applications in the Evaluation of Chronic Cerebral Ischemia. *American Journal of Neuroradiology*. 2009;30(5):876-884. doi:10.3174/ajnr.a1538
3. Subramaniam RM, Frey KA, Hunt CH, et al. ACR-ACNM Practice Parameter for the Performance of Dopamine Transporter (DaT) Single Photon Emission Computed Tomography (SPECT) Imaging for Movement Disorders. *Clinical Nuclear Medicine*. 2017;42(11):847-852. doi:10.1097/rlu.0000000000001815
4. Giacino JT, Katz DI, Schiff ND, et al. Practice guideline update recommendations summary: Disorders of consciousness. *Neurology*. 2018;91(10):450-460. doi:10.1212/wnl.0000000000005926
5. Expert Panel on Neurological Imaging, Shih RY, Burns J, et al. ACR Appropriateness Criteria® Head Trauma: 2021 Update. *J Am Coll Radiol*. 2021;18(5S):S13-S36. doi:10.1016/j.jacr.2021.01.006
6. Camargo EE. Brain SPECT in neurology and psychiatry. *J Nucl Med*. 2001;42(4):611-623.
7. Latchaw RE, Yonas H, Hunter GJ, et al. Guidelines and recommendations for perfusion imaging in cerebral ischemia: A scientific statement for healthcare professionals by the writing group on perfusion imaging, from the Council on Cardiovascular Radiology of the American Heart Association. *Stroke*. 2003;34(4):1084-1104. doi:10.1161/01.STR.0000064840.99271.9E
8. Wallace AN, McConathy J, Menias CO, Bhalla S, Wippold FJ 2nd. Imaging evaluation of CSF shunts. *AJR Am J Roentgenol*. 2014;202(1):38-53. doi:10.2214/AJR.12.10270
9. Singh S, Ali MJ, Paulsen F. Dacryocystography: From theory to current practice. *Ann Anat*. 2019;224:33-40. doi:10.1016/j.aanat.2019.03.009

Sleep-Related Imaging (HD-37)

Guideline	Page
General Guidelines Sleep-Related Imaging (HD-37.1).....	353
References (HD-37).....	355

General Guidelines Sleep-Related Imaging (HD-37.1)

HD.SL.0037.1.A

v2.0.2026

- Hypersomnolence:
 - When there are focal neurologic signs or suspicion for an inflammatory neurologic process as the etiology. Recognition and treatment of a comorbid sleep disorders is paramount, and a complete neurologic history and examination should precede any request for advanced imaging.
 - MRI Brain without and with contrast (CPT[®] 70553) **OR**
 - MRI Brain without contrast (CPT[®] 70551)
- Central Sleep Apnea:
 - For unexplained central sleep apnea syndrome when a primary CNS etiology is suspected, i.e., unassociated with CHF, COPD, or other potential etiology. Specific etiologies should be stated for imaging requests, including but not limited to, suspected Chiari malformation, stroke, CNS demyelinating disease, posterior fossa lesion, anoxia, or infection.
 - MRI Brain without and with contrast (CPT[®] 70553) **OR**
 - MRI Brain without contrast (CPT[®] 70551)
- Obstructive Sleep Apnea (OSA):
 - Advanced imaging is not medically necessary in the evaluation and management of obstructive sleep apnea.
 - The gold standard for OSA diagnosis, evaluation and management is a sleep study.
 - See **Initial Sleep Diagnostic and Treatment Testing (SL-2.1)**
- Oral Appliance:
 - There is a lack of published case-controlled clinical studies in Sleep literature validating the use of advanced imaging with respect to oral appliance therapy (pre-treatment assessment).
 - Previous literature has demonstrated support for cephalometric studies (x-ray) in predicting treatment success.
 - Nasoendoscopy (sedated and non-sedated with provocative maneuvers such as Mueller maneuver) has been helpful as well in this regard.
 - Routine use of advanced imaging is not medically necessary at this time.
- Upper Airway Surgery:

- There is a lack of published case-controlled clinical studies in sleep literature validating the use of advanced imaging for upper airway surgery (pre-treatment assessment).
 - Examples of upper airway surgery include, but are not limited to, hypoglossal nerve stimulation, uvulopalatopharyngoplasty (UPPP), turbinate reduction, and nasal septoplasty
- For congenital anomalies, see **Craniosynostosis Imaging (PEDHD-8.1)** and **Facial Anomalies (PEDHD-8.2)**
- For dentofacial abnormalities, see **Dental/Periodontal/Maxillofacial Imaging (HD-30.2)**
- Routine use of advanced imaging is not supported at this time.
- For suspected sleep-related seizure imaging (see **Epilepsy and Other Seizure Disorders (HD-9)**)

Evidence Discussion (HD-37.1)

- An individual's management is rarely impacted by structural brain imaging in the evaluation of unexplained hypersomnolence. Instead, a thorough evaluation can result in an accurate diagnosis while safeguarding individuals from unnecessary exposure to radiation and over-reliance on incidental imaging findings as potential contributors to the symptom(s).
- Literature supports use of drug-induced sleep endoscopy (DISE) to predict effectiveness of upper airway surgery, particularly in individuals seeking upper airway stimulation or maxillomandibular advancement.^{16,17}
- Studies have demonstrated how upper airway MRI and CT can be used to determine sites of collapse in OSA patients.^{14,15} Information from imaging could assist with determining which surgical interventions should be considered. Additionally, imaging may be helpful to determine why upper airway surgery is ineffective post-surgically.¹⁴ However, there are no large clinical trials that have shown improved surgical outcomes utilizing data from pre-treatment advanced imaging for OSA.
- The appropriate step in care for individuals with disordered sleep is to evaluate their breathing with polysomnography. Advanced imaging can lead to gaps in care and ineffective treatment of disordered sleep patterns. Instead, emphasis should be placed on holistic evaluation, including sleep history and sleep testing. Radiography (x-rays), 3D Advanced Imaging, or dynamic nasopharyngoscopy are not supported by evidence to being superior over polysomnography at this time.

References (HD-37)

v2.0.2026

1. Guarda-Nardini L, Manfredini D, Mion M, Heir G, Marchese-Ragona R. Anatomically Based Outcome Predictors of Treatment for Obstructive Sleep Apnea with Intraoral Splint Devices: A Systematic Review of Cephalometric Studies. *Journal of Clinical Sleep Medicine*. 2015;11(11):1327-1334. doi:10.5664/jcsm.5198
Guarda-Nardini L, Manfredini D, Mion M, Heir G, Marchese-Ragona R. Anatomically Based Outcome Predictors of Treatment for Obstructive Sleep Apnea with Intraoral Splint Devices: A Systematic Review of Cephalometric Studies. *Journal of Clinical Sleep Medicine*. 2015;11(11):1327-1334. doi:10.5664/jcsm.5198
2. Sutherland K, Vanderveken OM, Tsuda H, et al. Oral Appliance Treatment for Obstructive Sleep Apnea: An Update. *Journal of Clinical Sleep Medicine*. Published online February 15, 2014. doi:10.5664/jcsm.3460
3. Deak MC, Kirsch DB. Sleep-Disordered Breathing in Neurologic Conditions. *Clinics in Chest Medicine*. 2014;35(3):547-556. doi:10.1016/j.ccm.2014.06.009
4. Trotti LM, Bliwise DL. Brain MRI findings in patients with idiopathic hypersomnia. *Clin Neurol Neurosurg*. 2017;157:19-21. doi:10.1016/j.clineuro.2017.03.010
5. Kotula J, Kuc AE, Lis J, Kawala B, Sarul M. New Sagittal and Vertical Cephalometric Analysis Methods: A Systematic Review. *Diagnostics (Basel)*. 2022;12(7):1723. Published 2022 Jul 15. doi:10.3390/diagnostics12071723
6. Ramar K, Dort LC, Katz SG, et al. Clinical Practice Guideline for the Treatment of Obstructive Sleep Apnea and Snoring with Oral Appliance Therapy: An Update for 2015. *J Clin Sleep Med*. 2015;11(7):773-827. Published 2015 Jul 15. doi:10.5664/jcsm.4858
7. Chen H, Eckert DJ, van der Stelt PF, Guo J, Ge S, Emami E, Almeida FR, Huynh NT (2020) Phenotypes of responders to mandibular advancement device therapy in obstructive sleep apnea patients: a systematic review and meta-analysis. *Sleep Med Rev*. 49:101229
8. Lee CH, Ng WY, Hau W, Ho HH, Tai BC, Chan MY, Richards AM, Tan HC. Excessive daytime sleepiness is associated with longer culprit lesion and adverse outcomes in patients with coronary artery disease. *J Clin Sleep Med*. 2013 Dec 15;9(12):1267-72. doi: 10.5664/jcsm.3266. PMID: 24340288; PMCID: PMC3836337.
9. Murray BJ. A Practical Approach to Excessive Daytime Sleepiness: A Focused Review. *Can Respir J*. 2016;2016:4215938. doi: 10.1155/2016/4215938. Epub 2016 May 12. PMID: 27445538; PMCID: PMC4904525.
10. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. *N Engl J Med*. 2005 Nov 10;353(19):2034-41. doi: 10.1056/NEJMoa043104. PMID: 16282178.
11. Sahlin C, Sandberg O, Gustafson Y, Bucht G, Carlberg B, Stenlund H, Franklin KA. Obstructive sleep apnea is a risk factor for death in patients with stroke: a 10-year follow-up. *Arch Intern Med*. 2008 Feb 11;168(3):297-301. doi: 10.1001/archinternmed.2007.70. PMID: 18268171.
12. Dunietz GL, Chervin RD, Burke JF, Braley TJ. Obstructive sleep apnea treatment disparities among older adults with neurological disorders. *Sleep Health*. 2020 Aug;6(4):534-540. doi: 10.1016/j.sleh.2020.01.009. Epub 2020 Apr 21. PMID: 32331862; PMCID: PMC7529672.
13. Guarda-Nardini L, Manfredini D, Mion M, Heir G, Marchese-Ragona R. Anatomically Based Outcome Predictors of Treatment for Obstructive Sleep Apnea with Intraoral Splint Devices: A Systematic Review of Cephalometric Studies. *Journal of Clinical Sleep Medicine*. 2015;11(11):1327-1334. doi:10.5664/jcsm.5198
14. Volner K, Chao S, Camacho M. Dynamic sleep MRI in obstructive sleep apnea: a systematic review and meta-analysis. *Eur Arch Otorhinolaryngol*. 2022;279(2):595-607. doi:10.1007/s00405-021-06942-y
15. Li HY, Lo YL, Wang CJ, et al. Dynamic Drug-Induced Sleep Computed Tomography in Adults With Obstructive Sleep Apnea. *Sci Rep*. 2016;6:35849. Published 2016 Oct 20. doi:10.1038/srep35849
16. Chang JL, Goldberg AN, Alt JA, et al. International Consensus Statement on Obstructive Sleep Apnea. *Int Forum Allergy Rhinol*. 2023;13(7):1061-1482. doi:10.1002/alr.23079
17. Liu SY, Riley RW, Yu MS. Surgical Algorithm for Obstructive Sleep Apnea: An Update. *Clin Exp Otorhinolaryngol*. 2020;13(3):215-224. doi:10.21053/ceo.2020.01053
18. Inspire Upper Airway Stimulation (UAS). FDA label. Inspire Medical Systems, Inc.; 2023

19. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. *J Clin Sleep Med*. 2017;13(3):479-504. Published 2017 Mar 15. doi:10.5664/jcsm.6506
20. Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG. Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline. *J Clin Sleep Med*. 2019;15(2):335-343. Published 2019 Feb 15. doi:10.5664/jcsm.7640